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Abstract
Distribution coefficients, K - b i o o d  and K - t i s s u e s  ( o r  b io p h a s e ) ?  from the gas phase to 
blood and gas phase to tissues (plasma, brain, fat, heart, liver, lung, kidney, muscle, 
urine, saline and olive oil) have been collected for large number of volatile organic 
compounds (VOCs). For these datasets of VOCs, linear free energy relationships 
(LFERs) have been established and Abraham equations have successfully been 
constructed to predict these distributions. It has also been shown that human and rat 
data for the air to blood and air to tissue distribution of VOCs can be combined. The 
differences in the two data sets, for the common compounds are smaller than the 
estimated inter-laboratory experimental error. The combination of the log K t i SSu e  
values with values for air to blood yields distribution coefficients from blood to 
tissue, as log Ptissue- Equations have successfully been constructed to predict these 
distributions.
From a large amount of collected data on the distribution of drugs from blood, 
plasma or serum to tissue (brain, fat, heart, kidney, lung, liver, muscle and skin) at 
steady-state concentration in rats, it is shown that the three datasets of data can be 
combined. Predictive LFER equations for blood/plasma/serum to tissue for a large 
number of drugs, has been achieved and their predictive capability has been 
assessed. Finally, it has been shown that the in vitro data on VOCs and the in vivo 
data on drugs can be combined; LFERs on the total data yield correlative and 
predictive Abraham equations. Because the descriptors used in the LFERs can be 
calculated from structure, distribution coefficients for air to blood or tissue for VOCs 
and for blood/plasma/serum to tissue for VOCs and drugs can be predicted directly 
from the molecular structures of the VOCs and drugs.
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Introduction to the blood tissue distribution of 
volatile organic compounds (VOCs)
The solubility of gases and vapours in biological fluids (e.g. blood, plasma, 
serum and urine) and tissues (e.g. brain, muscle, lung, liver, kidney, heart, skin and 
fat) is of importance in areas such as anaestheology and environmental health 
especially with regard to indoor and outdoor air pollution.
The purpose of this work is to construct predictive equations for VOC 
distribution from air to tissue and from blood to tissue. This data will than be 
combined with drug data to give new Abraham equations for distribution of 
compounds between blood and various biological tissues.1 An extensive literature 
search has been be carried out in order to obtain the data that is needed for modelling 
of air to blood and blood to tissue distribution for various types of VOCs. The large 
amounts of data obtained from the literature are for compounds such as alcohols (e.g. 
1-hexanol), anaesthetics (e.g. halothane), agrochemicals (e.g. hexachlorobenzene), 
saturated alkanes (e.g. nonane),4 unsaturated alkenes (e.g. propylene)5 and many 
substituted cyclic alkanes (e.g. methylcyclohexane)6 and aromatic compounds (e.g. 
pentaflurobenzene).
The data obtained for VOCs is expressed as the Ostwald solubility coefficient 
(gas-liquid partition), K, for solutes in a biological phase (e.g. blood) at 310 K. This 
distribution data is obtained using analytical methods known as head-space 
chromatography.3 Scheme 1.0 outlines the importance of obtaining the direct Log K 
values from the literature to obtain air to blood and air to tissue distribution data. 
From this direct method, the log K tissue and log K blood values, lead to an indirect 
method for obtaining solute blood-tissue distribution data expressed as log P.
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Observed Observed
Calculated
Log P
Log Kblood Log Ktissue
Blood Tissue
VOCs in the Gas Phase
_ [cone, of solute in a tissue or blood] 
~ [conc. of solute in the gas phase]
Log P(bt) log Ktissue log Kbiood
Scheme 1.0. Determination of blood-tissue distribution for VOCs
Data for compounds that have been measured several times will then be 
combined in order to obtain an average log K value for any given set of compounds 
for air/blood and air/tissue distribution of VOCs. Human and rat log K data for 
VOCs shall than be compared for common compounds for air/blood and air/tissue, to 
see if there are similarities or differences between the two species.
Models will be made based on the Abraham equations for air/blood 
distribution as well as air/tissue distributions. Finally the difference in the two will 
give rise to log P, for distribution of compounds between blood and various 
biological tissues. Later, this data shall be gathered together with drug data to give 
rise to overall equations that can be used to predict log P values.
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Chapter
Volatile organic compounds (VOCs) in general 
and their environmental importance
There is a perception that many individuals believe that the risk associated 
with out door air pollution appears to be higher than for indoor air pollution. 
However, exposure to indoor air pollutants like volatile organic compounds (VOCs) 
appears to be a serious public health problem in a wide variety of non industrial 
settings, for example, residences, offices, schools and vehicles.1 Recent research 
conducted in the US and Europe shows that individual persons in industrialised 
nations spend 90% or more of their time indoors. The young, elderly and those 
with disability problems or suffering from diseases are most likely to spend their 
time at home. The experience of an individual who is exposed to VOCs is dependent 
upon the function of time and concentration involved.
Although a large deal of time and money has been spent on the interest of 
environmental pollution (i.e. the effects of outdoor air notably from traffic pollution), 
recently scientific interest on indoor pollution has been taken very seriously. The 
understanding on how VOCs affects human beings (and animals) is of prime 
importance in order to improve the quality of indoor air and reduce illnesses (and 
discomfort). Recent analysis of common 30 VOCs in Germany (belonging to the 
groups of alkanes, cycloalkanes, aromatics, volatile halogenated hydrocarbons and 
terpenes) have shown that the concentrations of VOCs in indoor air is, on average, 
10 times higher than outdoors.4 Attempts to reduce the exposure to VOCs have been 
proposed with strict guidelines on the standard levels that should be acceptable.
VOCs have a wide range of physical and chemical characteristics. The
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chemical groups typically include hydrocarbons, halogenated hydrocarbons, 
aromatic hydrocarbons, alcohols, esters, ketones and aldehydes. These compounds 
have a wide range of boiling points and have been classed as very volatile (<0 to 50- 
100°C), volatile (50-100 to 240-260°C) and semi-volatile (250-260 to 400°C).3 
According to a definition given by the European Communities the expression 
"volatile organic compounds" means any compound having at 293.15 K a vapour 
pressure of 0.01 kPa or more, or having a corresponding volatility under the 
particular condition of use.5
VOCs contribute to a broad scale of chemicals with production levels all over 
the world and widespread applications in industry, trade and private households. One 
of the most important industrial uses of the VOCs is their supply as solvents. In 
Table 2.0, sources and tonnage of VOCs found in air of the United Kingdom, in 
1995, are displayed. The identified numbers of VOCs present in ambient air has 
increased steadily in recent years, from 250 to more than 900 in 1989 and now 
currently over 1000.6 VOCs have been of increasing concern since the 1970s 
because of their potential to cause health effects similar to those reported in the sick 
building syndrome and to contribute to respiratory problems and other diseases 
including cancer.3
Source category
Estimated Emissions 
(thousand of tonnes)
% Total
Power station 5 -
Domestic 30 1.3
Commercial/public service 2 -
Refineries 2 -
Iron and steel 4 -
Other industrial combustion 9 0.4
Non-combustion sources 335 14.3
Extraction and distillation of fossil fuel 334 14.3
Solvent use 700 29.9
Road transport 690 29.5
Off road sources 96 4.1
Military 1 -
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Railways 8 0.3
Civil aircraft 4 -
Shipping 12 0.5
Waste treatment 26 1.1
Forest 80 3.4
Total 2338 100
Table 2.0. Sources of VOCs, excluding methane, in the outdoor air of UK during 
1995.3
The sources o f indoor air pollutant
There are number sources of indoor air pollution at home. This includes: 
combustion sources, such as oil, gas, kerosene, coal, wood, and tobacco products 
(e.g. benzene), a wide variety of building materials (e.g. toluene, xylenes, decane), 
cleaners, office products and machines, paints, and furnishings. Others come from 
bathing (e.g. chloroform is formed when chlorine interacts with organic substances 
found in hot water), cooking, cosmetics, hygienic products, plants, as well as human 
biological processes give rise to indoor air pollution.6 Table 2.1 gives examples of 
sources of VOCs known to contribute to indoor air pollution.3
Outdoor air may also contribute to indoor air contamination, particularly when 
air intakes are positioned near parking areas, roads, or other locations where 
contaminated air can be entered into the buildings. Example, car exhaust gases and 
particles can gain access into the homes, especially if windows remain open.1
Volatile organic compounds (VOCs) pose an air pollution hazard because of 
their potential for generating ozone. Some VOCs such as benzene, 1,3-butadiene, 
polycyclic aromatic hydrocarbons (PAH) and dioxins are hazardous in themselves to 
human health. Benzene comes mainly from petrol combustion, but some from 
cigarette smoke. There is an increased risk of leukaemia from occupational exposure 
but no evidence of risk below 25-30 ppm. 1, 3-butadiene comes mainly from vehicle 
exhausts, but cigarette smoke is a major source indoors. There is an increased risk of 
leukaemia and lymphoma from occupational exposure in the rubber production 
industry (around 1-10 ppm). Finally polycyclic aromatic hydrocarbons (PAHs)
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come mainly from incomplete combustion of vehicle emissions in urban areas and 
coal and coke burning elsewhere. Total PAH levels are around 10-150 ng/m3 in the 
UK. There is an increased risk of lung cancer from occupational exposure in coke- 
oven and coal gas workers (around 30 /x g/m3).7
VOCs Source
p-Dichlorobenzene Moth crystals and room deodorants.
Styrene Insulation, textiles, disinfectants, plastics and 
paints.
Benzyl chloride Vinyl tiles.
Benzene Smoking.
T etrachloroethylene Dry cleaned clothes.
Chloroform Chlorinated water.
1,1,1 -Trichloroethane Dry cleaned clothes, aerosol sprays and fabric 
protectors.
Carbon tetrachloride Industrial strength cleaners.
Aromatic hydrocarbons (toluene, xylenes, 
ethylbenzene, trimethylbenzenes)
Paints, adhesives, gasoline and combustion 
products.
Aliphatic hydrocarbons Paints, adhesives, gasoline and combustion 
products.
Terpenes Scented deodorisers, polishes, fabrics, fabric 
softeners, cigarettes and food.
Polyaromatic hydrocarbons (PAHs) Combustion products (smoking, wood- 
burning, kerosene heaters).
Alcohols Aerosols, window-cleaners, paints, paint 
thinning, cosmetics and adhesives.
Ketones Lacquers, varnishes, polish removers and 
adhesives.
Ethers Resin, paint, varnishes, lacquers, dyes, soaps 
and cosmetics.
Esters Plastics, resins, plasticizers, lacquer solvents, 
flavours and perfumes.
Table 2.1. Sources of indoor VOCs.3
33
Environmental tobacco smoke (ETS) is a source of particular concern because 
of the displeasure and irritation it can cause to many users of multi-occupied 
buildings and the risks of disease to those exposed long term smoke. Its complexity 
can be illustrated by the fact that some 4000 various components have been 
identified from tobacco smoke alone. The main VOCs released in side stream smoke 
in quantities exceeding 1 mg per cigarette are nicotine, acetaldehyde, acrolein, 
isoprene, and acetonitrile.16 Very few of the constituents are unique to ETS and this 
has caused difficulties in apportioning the contribution that ETS makes to 
concentrations of particular pollutants within buildings.3
There are three fundamental processes control the rate of VOC emissions from 
building sources: (1) evaporation; (2) desorption of absorbed compounds and (3) 
diffusion of a material. How fast the VOCs are produced depends on the process and 
the source characteristics. The sources can be divided into those with continuous
3 8emissions, and discontinuous emissions. ’ Some sources, such as building materials 
and furnishings release pollutants more or less continuously. The nature of emission 
and the variability of indoor spaces and ventilation conditions result in a dynamic
g
behaviour of air pollutants in indoor environment.
Measurement of volatile organic compounds in indoor air
A large range of sampling and analytical methods can be applied to determine 
the nature and concentration of many VOCs.10’12 The most common methods are 
based on collection using absorbents, e.g. Tenax TA, graphite carbon black and 
molecular carbon sieves contained in a sampling tubes or badge. These are used in 
multiple bed form to match targeted samples. The absorbent can be thermally 
desorbed and the VOCs can then be determined by gas chromatography coupled with 
various detection systems like mass spectrometry. Other absorbents are available and 
are chosen according to the polarity of the VOCs investigated.
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tubeAmbient air Adsorption tube
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Figure 2.0. Sampling with tube collection method.1012
Biological monitoring
The definition of biological monitoring (BM) by the International Union of
13Pure and Applied Chemistry (IUPAC), is a ‘systematic continuous or repeated 
measurement and assessment of workplace agents or their metabolites either in 
tissues secreta, excreta or any combination of these to evaluate exposure or health 
risk compared to appropriate reference’. Basically, BM allows one to assess the 
integrated exposure by different routes, including ingestion, inhalation, dermal 
absorption, blood, exhaled air and urine. The biological marker or biomarkers for 
exposure is an endogeneous substance or its metabolite or the product of interaction 
between a xenobiotic and some target molecule or cell that is measured in a
13compartment with an organism. The purpose of biomarkers are mainly focused on 
the amount of the pollutant penetrating into the organism. There are several 
biomarkers that are relevant to indoor air pollution: e.g. urinary excreted nicotine is 
used for exposure to ETS, the carboxyhaemoglobin level in blood is used to 
characterise exposure to CO, and the presence of VOCs in exhaled air breath is used 
to mark these compounds.14 Examples of the use of BM are available in the 
literature. Imbriani and co-workers15 developed a method for the BM of exposure to 
enflurane in operating room personnel, based on the measurement of the unchanged 
anaesthetic in urine. Jo and Pack16 employed a breath analysis for exposure to
17benzene associated with active smoking. Mathews et al. studied endogenous
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VOCs found in breath. Biological monitoring has extensively been applied in 
practical occupational medicine found in many developed countries. From this, as a 
result the biological threshold values have been evaluated in order to control the 
worker’s exposure.
The amount o f indoor air pollutants
The amount of indoor air pollutants depends on many factors. The amount
1 0
(levels) of indoor air pollutant are also dependent on human activity. Over recent 
years, the combination of reduced ventilation rates, warmer (temperature) and more 
humid conditions indoors, together with the greater use and diversity of materials, 
furnishing and consumer products, has resulted in accumulation of a wide range of 
pollutants occurring indoors at levels often exceeding those outdoors.1,3 The age of 
the buildings plays an important factor in concentration of pollutants. The US EPA 
studies have shown that a new building indicated to have eight of thirty-two target 
chemicals measured within days after completion of the building, was found to have 
100 fold higher levels compared to outdoor levels: xylenes, ethylbenzene, 
ethyltoluene, trimethylbenzene, decane and undecane.19 There are many VOCs that 
are commonly found as mixtures, with a mean concentration below 50 microgram
T 3per cubic meter (p.g.m' ) in established buildings, but much higher in new buildings.
Recently the EPA conducted a study on indoor and outdoor air concentrations
20of twenty-seven hazardous air pollutants. Indoor and outdoor exposures (i.e. 
concentrations breathed multiplied by duration of time breathed) was estimated from 
data of literature. The results that have emerged from this study showed that the 
indoor air concentration of these hazardous compounds are generally one to five 
times more than the outdoor concentration, and indoor exposures are ten to fifty 
times more than the outdoor exposures. The summary of results is shown in Table 
2 .2.20
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SOLUTE (VOCs) Typical concentration (a) Typical Daily Exposure (b)
NAME Indoor Outdoor I/O Ratio Indoor Outdoor
I/O
Ratio
Acetaldehyde (c) <10 <3 [5] <216 <7.2 [50]
Benzene (c) 5 5 [2] 108 12 [20]
1,2,3,6-Tetrahydro-
N(trichloromethylthio)-
phthalimide
<0.001 Na 10 <0.02 <0.0002 -100
Carbon tetrachloride(c) <5 1 [2] <108 2.4 [20]
1,2,4,5,6,7,8,8-Octachloro-
3a,4,7,7a-tetrahydro-4,7-endo-
methanoindan
0.2 0.01 20 4.32 0.024 200
Chloroform^0 1 0.2 [5] 21.6 0.48 [50]
Cumene 1 0.2 5 21.6 0.48 50
1,1 -dichloro-2,2-bis(4- 
chlorophenyl)ethylene
0.0005 <0.002 >0.2 0.0108 <0.005 >2
1,1 -dichloro-2-dimethoxyphos- 
phoryloxyethene
0.05 0.001 50 1.08 0.0024 400
Ethylbenzene 5 1 [3] 108 2.4 [30]
Formaldehyde 50 4 10 1080 9.6 100
Formaldehyde(c) 0.1 0.002 50 2.16 0.0048 400
Hexachlorobenzene 0.0005 0.0001 5 0.0108 0.00024 50
Hexane 5 4 [10] 108 9.6 [90]
2,2-bis(p-methoxyphenyl)- 
1,1,1 -trichloroethane
0.0001 0.00003 3 0.00216 0.000072 30
Methyl Ethyl Ketone 10 <1 [4] 216 <2.4 [40]
Methylene chloride 10 1 [10] 216 2.4 [90]
Naphthalene 1 1 [4] 21 2.4 [40]
Paradichlorobenzene 1 <0.05 [5] 21.6 <0.12 [50]
2-( 1 -methylethoxy)- 
phenylmethylcarbamate
0.1 0.01 10 2.16 0.024 90
Styrene (c) 2 0.6 [5] 43.2 1.44 [50]
T etrachloroethylene(c) 5 2 [3] 108 4.8 [30]
Toluene 20 5 [5] 432 12 [50]
Trichi oroethylene(c) 5 0.5 [3] 108 1.2 [50]
Xylenes (o+m+p) 15 10 [2] 324 24 [20]
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(a) Indoor and outdoor concentrations in pg.m"3. Typical values from the literature for U.S. locations. 
I/O ratios based on typical concentrations [or reported ratios as indicated by values in italics and 
brackets].
^  Exposure, in gg.m'3.h, based on assumption that the typical person spends 90% of the typical day 
indoors.
(c) Urban air toxic substances,(d) Radionuclides/ Rn in pCi.dm'3
Table 2.2. Summary of indoor and outdoor air concentrations and exposures for 
common air pollutants.20
The health effects of VOCs, both indoors and outdoors
The health effects from indoor air pollutants (IAP) may be experienced soon 
after exposure or possibly at a later time (years) to come. The most frequently 
reported health complaints include eye, nose, and throat irritation, headache, nausea, 
hoarseness, sore throat, cough, chest tightness, nasal congestion, palpitations, 
shortness of breath, stress, drowsiness, and alterations in mood found from single/ or 
continuous exposure of indoor air pollutants (includes VOCs).
Most of the immediate effects are usually short term and are treatable. The 
likelihood of immediate reactions to IAP depends on several factors. Age and any 
pre-existing medical conditions are two important influences. The effects on 
whether a person reacts to a pollutant depend on individual sensitivity, which varies 
from one individual to the next. Secondly, other health effects may show up only 
after long or repeated periods of exposure. These effects which include some
1 3 21 23respiratory diseases, heart disease, and cancer, can be more fatal. ’ ’
There are three distinct classes of insidious poison, all of which display what 
can be termed as “delayed effects.” They are carcinogens, mutagens, and teratogens. 
Chemical carcinogens are substances which induce cancer in humans and animals. 
Vinyl chloride has been identified as a causative agent in cancer of the liver. 
Mutagens are substances which are capable of altering the body’s genetic material
i.e. the genes and chromosomes of the cells. Ethylene-oxide, a non-carcinogen, has 
been found to have mutagenic properties. This mono-epoxide is used in the 
manufacture of numerous non-ionic surfactants. Examples of teratogens are 
phthalate-esters, frequently used as plasticizers in coating formulations. These 
agents can cause congenital defects in a developing embryo (or fetus).
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Toxic hazards can impact the human body either by affecting the respiratory 
system, the eyes and/or the skin; the respiratory system being the most significant 
route for poisonings as far as the paint industry is concerned.24 Substances used in 
the formulations of coatings, which can be inhaled, are primarily the vapours of 
volatile liquids and solids. Toxic vapours can be irritants, asphyxiants, anaesthetics 
and systemic poisons. Volatile irritants are capable of preferentially effecting 
specific areas of the respiratory system, such as the respiratory tract, the lung tissue 
of the terminal air passages and air sacs.
The most common eye disorder experienced in the handling of paint is 
undoubtedly eye irritation from volatile paint solvents. Sometimes, however, the 
irritation is primarily due to the presence of minor amounts of volatile chemicals, 
such as un-reacted monomers (e.g. acrylates) or pungent additives (e.g. allyl 
compounds). Formaldehyde is a very common indoor air contaminant. It is found in 
many products and materials; it has many uses. For instance, formaldehyde binds 
wood chips in particleboard, it is a solvent in dyes for cloth or paper, and it is used in 
wrinkle-resistant material and as a water-repellent in floor coverings. Among VOCs 
and their health effects, most is known concerning exposure to formaldehyde. 
Formaldehyde may cause a burning or tingling sensation in the eyes, nose and throat 
that goes away when the exposure is removed. It may trigger asthmatic symptoms in 
susceptible infants and children. Formaldehyde is the agent alleged to be responsible 
for blindness in methylated spirit drinkers. Methyl alcohol (methanol) taken 
internally is oxidized to formaldehyde and routed via the bloodstream to the optic 
nerve, which is ultimately destroyed. In table 2.3 is a summary of other selected 
VOCs and their various impacts on human beings.21,24
VOCs Health Effects
Benzene Carcinogen; respiratory tract irritant
Xylenes Narcotic; irritant; affects heart, liver, kidney, and nervous system
Toluene Narcotic; possible cause of anemia
Styrene Narcotic; affects control of nervous system; probable human 
carcinogen
Toluene di-isocyanate Sensitizer; probable human carcinogen
Trichloroethane Affects central nervous system
Ethyl benzene Severe irritation of eyes and respiratory tract; affects central nervous 
system
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Dichloromethane Narcotic; affects control of nervous system; probable human 
carcinogen
1,4-Dichlorobenzene Narcotic; eyes and respiratory tract irritant; affects heart, liver, 
kidney, and nervous system
Benzyl chloride Central nervous system irritant depressant, affects liver and kidney; 
eye and respiratory tract irritant
2-Butanone Irritant; central nervous system depressant
Petroleum distillate Affects central nervous system, liver and kidneys
4-Phenycyclohexene Eye and respiratory tract irritant; central nervous system effects
Sources adapted from ref. US EPA ‘introduction to IAQ’ report no. EPA/400/3-91/003, Washington, 
DC, 1991.
Table 2.3. Health effects of selected volatile organic compounds21,24
VOCs that acts as anaesthetic vapours
The solubility of an inhalation anaesthetic determines how fast it works and 
how fast it wears off. The more insoluble a drug (i.e. VOCs) is in blood, the quicker 
it works. If one breathes in a highly soluble anaesthetic vapour, such as ether, as 
soon as it arrives in the alveoli it dissolves into the bloodstream and ends up in 
muscle, fat, bone -  everywhere, and so, very little ether arrives in the brain. 
Consequently it takes “all day” to go to sleep and wake up. Solubility is related to, 
and described by, the blood-gas partition coefficient (BGPC). The amount of solute 
(VOCs) that dissolves in a biological fluid is related to the Ostwald solubility 
coefficient (K or L) for that substance, and, for blood it is known as the blood-gas 
partition coefficient.
The oil-gas partition coefficient
Many volatile agents are highly lipophilic, and there is a lot of lipid in cell 
membranes. Meyer and Overton hypothesised, at the beginning of the century, that 
anaesthetic agents acted at the level of the lipid membrane and, consequently 
potency is related to lipophilicity. Halothane is highly lipid soluble, isoflurane less 
so, and nitrous oxide is comparatively insoluble in fat. Lipid solubility is 
represented by the oil-gas partition coefficient (OGPC): again, the larger the number,
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the higher the solubility. An ideal anaesthetic would act extremely quickly (be 
highly insoluble in blood: have a low blood gas partition coefficient), and achieve 
anaesthesia at very low concentrations (be very potent-highly soluble in fat [brain]: 
have a high oil gas partition coefficient.25)
What determines how quickly an anaesthetic wears off?
The blood-gas partition coefficient (BGPC) is important, as once the drug is in 
the blood, the lower the BGPC, the quicker the drug is excreted through the lungs. 
However, every tissue in the body has its own blood-tissue partition coefficient and 
as the tissues act as a reservoir for anaesthetic gas, the rate at which the anaesthetic 
diffuses back from the tissues ultimately determines how quickly the patient wakes 
up.
TISSUE ISOFLURANE SEVOFLURANE HALOTHANE
FAT 44.90 47.50 51.10
MUSCLE 2.92 3.13 3.38
Table 2.4. Blood-tissue partition coefficients (P).
The combination of the blood-tissue and gas-blood partition coefficients determines 
how quickly the patient wakes up. One can imagine that a patient wakes up very 
quickly from isoflurane, and quite slowly from halothane. Sevoflurane is quicker 
than halothane because of its much lower blood-tissue partition coefficient. Finally, 
volatile agents dissolve much better in fat than in any other tissue. The more fat, the 
longer the wash out time: obese patients wake up much more slowly.26
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Chapter
3
Air to blood and air to tissue distribution of 
volatile organic compounds (VOCs)
The solubility of gases and vapours in biological fluids (plasma, blood and 
urine) and tissues (brain, muscle, lung, liver, kidney, heart and fat) is important in 
areas of research such as toxicology, environmental health and medicine especially 
anaesthetics. Knowledge of the distribution of VOCs in various body compartments 
is valuable and contributes to the understanding of the risk of toxic effects.
BRAIN
BRAINMUSCLE
MUSCLEMUSCLE
LUNGSLUNGS
HEARTHEART
LIVER
LIVER
KIDNEYS
KIDNEYS
Scheme 3.0. Identifies the important compartments in human body where VOCs 
may distribute to and from the blood
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Reported experimental values can be obtained from various journal articles in 
the literature. The distribution of VOCs from air to blood and air to tissue for a 
given temperature (310 K) is referred to as a partition coefficient (K or L). The 
partition coefficient can be calculated by dividing the concentration of solute in the 
tissue (or blood) phase over the concentration of solute in the gas phase at 
equilibrium (see scheme 1.0, chapter 1). The measure of K has units of gas volume, 
measured at ambient temperature and at 1 ATA partial pressure, which dissolves in a 
unit volume (V) of fluid. Other common units for concentration of the solute in the 
tissue phase is represented by pmol/kg.1
This distribution constant K (or L) is known as the Ostwald solubility 
coefficient. In scheme 1.0, chapter 1, the Kb and Kl are the gas-to-blood or gas-to- 
tissue partition coefficients, and P is the blood-to-tissue partition coefficient. Most 
air to blood distributions have been determined by the technique of headspace vial- 
equilibrium, which shall be discussed latter in this chapter. '
Data for air to olive oil and air to saline (9% salt concentration) have been 
obtained in order to construct models that resemble membrane permeability. The 
tissue partitioning of volatile organic compounds (VOCs) is due to lipophilic and 
hydrophilic interactions with tissue components, and empirical relations have been 
established between olive oil (Koji:ajr), saline ( K s a i m e : a i r ) ,  and tissue partition 
coefficients ( K t i Ss u e : a i r )  for human and rat tissues.
The literature sources for air to blood (or air-tissue) distribution are from the 
following authors: Abraham and Weathersby,2 Meulenberg,3 Krishnan,4'5 Poulin,5 
Gargas,6"7 Fiserova-Bergerova,8’9 Filser,10 Pezzagno,11 Zahlsen,12 Balaz13 and 
Zhang.14 Various model (equations) have been formulated to correlate air-to-tissue 
distribution, and are summarised in table 3.0. Meulenberg has obtained a 
reasonable amount of data in his training set as shown in table 3.0; this model has no 
test sets to verify predictions. Gargas et al have also produced models for air to 
blood and air tissue distribution of VOCs.6'7 Unfortunately their training set does 
not include standard deviations and also statistical information is not provided about 
the test set. From table 3.0 it appears that none of the models have any test sets to 
verify predictions. As shown by this table, it appears that the number of compounds 
is small for the majority of tissues studied and it seems that standard deviations are 
absent for some of the training sets.
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An improvement can be made on air to blood (or air to tissue) distribution by 
using training sets and test sets containing a large number of compounds. It would 
be very interesting to see if the diversity of compounds helps to improve models that 
are currently available. Most of the models found in table 3.0 are outdated and new 
measurements have been made for VOCs, which should improve the standard 
deviation and the square of the correlation coefficient for the training sets.
AIR-TISSUE DISTRIBUTION TRAINING SET TEST SET
Reference Tissue No. Var. r2 S.D. No. A. E.
Gargas, M. L et a l.7 Blood (Hum) 55 2 0.928 - - -
Gargas, M. L et a l.7 Blood (Hum) 36 2 0.875 - - -
Weathersby, P. K. and 
Abraham, M. H.2
Blood (Hum) 82 5 0.977 0.20
Meulenberg, C. J.W. and 
Vijverberg, H. P. M3
Blood (Rat) 92 2 0.930
Meulenberg, C. J.W. and 
Vijverberg, H. P. M3
Blood (Hum) 109 2 0.990
Weathersby, P. K. and 
Abraham, M. H.2
Plasma (Hum) 32 5 0.984 0.23
Weathersby, P. K. and 
Abraham, M. H.2
Brain (Hum) 41 5 0.968 0.27
Meulenberg, C. J.W. and 
Vijverberg, H. P. M3
Brain (Rat) 19 2 0.900
Meulenberg, C. J.W. and 
Vijverberg, H. P. M3
Brain (Hum) 35 2 0.980
Gargas, M. L et al.7 Liver (Rat) 55 2 0.903 - - -
Weathersby, P. K. and 
Abraham, M. H.2
Liver (Hum) 29 5 0.981 0.10
Meulenberg, C. J.W. and 
Vijverberg, H. P. M3
Liver (Rat) 77 2 0.920
Meulenberg, C. J.W. and 
Vijverberg, H. P. M3
Liver (Hum) 28 2 0.880
Gargas, M. L et al.7 Muscle (Rat) 55 2 0.879 - - -
Weathersby, P. K. and 
Abraham, M. H.2
Muscle (Hum) 41 5 0.966 0.26
Meulenberg, C. J.W. and 
Vijverberg, H. P. M3
Muscle (Rat) 76 2 0.820
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Meulenberg, C. J.W. and 
Vijverberg, H. P. M3
Muscle (Hum) 35 2 0.990 ” “
Gargas, M. L et a l/ Fat (Rat) 55 2 0.947 - - -
Weathersby, P. K. and 
Abraham, M. H.2
Fat (Hum) 36 5 0.988 0.12
Meulenberg, C. J.W. and 
Vijverberg, H. P. M3
Fat (Rat) 76 2 0.860
Meulenberg, C. J.W. and 
Vijverberg, H. P. M3
Fat (Hum) 41 2 0.920
Weathersby, P. K. and 
Abraham, M. H.2
Lung (Hum) 36 5 0.976 0.23
Weathersby, P. K. and 
Abraham, M. H.2
Kidney (Hum) 36 5 0.951 0.27
Meulenberg, C. J.W. and 
Vijverberg, H. P. M3
Kidney (Rat) 16 2 0.910
Meulenberg, C. J.W. and 
Vijverberg, H. P. M3
Kidney (Human) 34 2 0.980
Weathersby, P. K. and 
Abraham, M. H.2
Heart (Hum) 25 5 0.957 0.17
Weathersby, P. K. and 
Abraham, M. H.2
Urine (Hum) 40 5 0.876 0.40
No. = the number o f compounds used in the training set 
Var. = the number variables used in the training set
r2 = the overall square of the correlation coefficient (explained in detail from chapter 6)
S.D. = standard deviation (explained in detail from chapter 6)
A.E. = average error (explained in detail from chapter 6)
Hum = Human data only
Table 3.0. Literature survey on VOCs air-blood (or air to tissue) distribution
A number of equations have also been reported for the correlation of blood- 
tissue distribution of VOCs. These equations are summarised in table 3.1. From 
table 3.1., the number of compounds represented by the training sets can be seen to 
be very small. This may cause problems if one needs to predict the distribution of 
compounds between blood and tissue based on structural diversity. Unfortunately, 
as shown in table 3.1, there are no test sets to verify the model predictions and this 
would be very useful to incorporate into new models in the near future, especially 
with larger data sets. Nothing has been mentioned with regards to statistics to the
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test sets to verify the training equations used to predict solute blood to tissue 
distributions. There is no indication from the table that the VOCs and drug data can 
be combined to enable equations to predict the distribution for VOCs and drugs in 
general.
VOC BLOOD-TISSUE DISTRIBUTION TRAINING SET TEST SET
Reference Tissue No. Var. r2 S.D. No. A. E.
Fiserova-Bergerova, V. 
Diaz, M. L9
Brain (Hum) 35 1 0.940 0.78
Zhang, H.14 Brain (Hum) 35 2 0.920 0.12 - -
Balaz, S. and 
Lukacova, V 13
Brain (Hum) 35 7 0.956 0.08
Weathersby, P. K. and 
Abraham, M. H.2
Brain (Hum) 39 5 0.865 0.16
Fiserova-Bergerova, V. 
Diaz, M. L9
Kidney (Hum) 35 1 0.945 0.42
Zhang, H.14 Kidney (Hum) 34 2 0.897 0.11 - -
Balaz, S. and 
Lukacova, V 13
Kidney (Hum) 33 7 0.924 0.09
Weathersby, P. K. and 
Abraham, M. H.2
Kidney (Hum) 35 4 0.774 0.17
Fiserova-Bergerova, V. 
Diaz, M. L9
Liver (Hum) 27 1 0.920 1.00
Zhang, H .14 Liver (Hum) 29 2 0.872 0.13 - -
Balaz, S. and 
Lukacova, V 13
Liver (Hum) 28 5 0.931 0.10
Weathersby, P. K. and 
Abraham, M. H.2
Liver (Hum) 28 5 0.865 0.16
Fiserova-Bergerova, V. 
Diaz, M. L9
Lung (Hum) 30 1 0.541 3520
Zhang, H .14 Lung (Hum) 29 2 0.653 0.10 - -
Balaz, S. and 
Lukacova, V 13
Lung (Hum) 28 4 0.709 0.07
Weathersby, P. K. and 
Abraham, M. H.2
Lung (Hum) 35 2 0.389 0.14
Zhang, H .14 Muscle (Hum) 36 2 0.884 0.13 - -
Fiserova-Bergerova, V. 
Diaz, M. L9
Muscle (Hum) 34 1 0.927 0.70
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Balaz, S. and 
Lukacova, V 13
Muscle (Hum) 34 7 0.908 0.11
Weathersby, P. K. and 
Abraham, M. H.2
Muscle (Hum) 40 3 0.790 0.18
Zhang, H.14 Fat (Hum) 36 2 0.972 0.18 - -
Balaz, S. and 
Lukacova, V 13
Fat (Hum) 36 7 0.960 0.20
Weathersby, P. K. and 
Abraham, M. H.2
Fat (Hum) 35 5 0.967 0.19
Zhang, H .14 Heart (Hum) 16 2 0.599 0.20 - -
Balaz, S. and 
Lukacova, V 13
Heart (Hum) 14 3 0.701 0.08
Weathersby, P. K. and 
Abraham, M. H.2
Heart (Hum) 23 4 0.849 0.12
Weathersby, P. K. and 
Abraham, M. H.2
Plasma (Hum) 32 4 0.656 0.09
No. = the number o f compounds used in the training set 
Var. = the number variables used in the training set
r2 = the overall square o f the correlation coefficient (explained in detail from chapter 6)
S.D. = standard deviation (explained in detail from chapter 6)
A.E. = average error (explained in detail from chapter 6)
Hum = Human data only
Table 3.1. Literature survey on VOC blood to tissue distribution
The air to olive oil distribution model can also be incorporated in 
pharmacokinetic processes for predicting blood-tissue distribution of VOCs. 
Weathersby2, Fuchs15 and Klopman16 have made models to predict air to olive oil 
distribution (see table 3.2). It appears from his report, that Klopman16 has made his 
models based on training data sets containing both predictive and experimental 
values (see table 3.2). It would be better to devise a model based on true 
experimental values for solutes (VOCs) that have been accurately measured. So his 
overall equation may not be as valuable as one might expect in order to assess 
reliability for the predictions of air to olive oil distribution, for VOCs in general. 
Finally, this model shown in table 3.2 is outdated and new compounds have recently 
been measured. This can be used to devise new models based on larger training data
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sets. This would allow one to use larger test sets, which would be beneficial in 
determining how reliable the model is for such predictions.
AIR-SOLVENT DISTRIBUTION TRAINING SET TEST SET
Reference PHASE No. Var. r2 S.D. No. A. E.
Weathersby, P. K. and 
Abraham, M. H.2
Olive oil 88 4 0.997 0.08
Fuchs, R. and Abraham, M. 
H15
Olive oil 52 3 0.947 0.23
Klopman, G et al.,f> Olive oil 159a 23 0.938 0.29 36 0.271
Klopman, G et al.16 Olive oil 192a 26 0.968 0.21 - -
a Indicates that this data includes a large amount o f calculated data, as opposed to experimental data.
No. = the number o f compounds used in the training set
Var. = the number variables used in the training set
r2 = the overall square o f the correlation coefficient
S.D. = standard deviation (explained in detail from chapter 6)
A.E. = average error (explained in detail from chapter 6)
Table 3.2. Literature survey on VOCs air to olive oil distribution (310K)
Experimental methods for obtaining air to blood (or air to 
tissue) partition coefficient for rats and humans using head 
space chromatography
Measurements of air to blood distribution for VOCs in rats, has been studied
6 7 • *by many scientist including Michael Gargas and his team. ' His experiments 
involved using rats to measure the distribution of VOCs from air to blood (or tissue), 
using the method of head space chromatography. Three or more rats are contained 
in a glass chamber with oxygen being maintained at 21%. Carbon dioxide was 
removed by soda lime. Appropriate amounts of known VOC were injected until a 
suitable concentration was reached. The concentration of VOC in the gas phase was 
monitored over a period of time using gas chromatography (with flame ionization) 
until equilibrium had been reached. At various fixed times, the rats were 
anesthetised with carbon dioxide and blood was removed from the inferior vena
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cava, using a heparinised gas-tight syringe. Due to the volatility and rapid 
metabolism of VOCs, the removal of tissues was carefully timed. One-millilitre 
aliquots of blood were immediately transferred to chilled 5.5 ml vials sealed with 
Teflon lined septa. The blood samples were incubated, with shaking for 1 hour at 
37°C in a vortex evaporator and 1 ml aliquot of the headspace was analysed for VOC 
in blood. The concentrations of VOCs were then determined from the standard 
curves prepared in blood, under the condition described.
Immediately after blood sampling, the tissue e.g. liver of each rat was excised, 
a 4 g section transferred to chilled pre-weighed 20 ml vial containing buffer, the vial 
was capped and reweighed. The liver was than briefly homogenised (approx 10 
seconds) by using a Tissue-miser and 1 ml aliquots of the homogenates were 
transferred to chilled 5.5 ml vials. The vials were sealed immediately and incubated 
with shaking for 1 hour at 37°C in a vortex evaporator; equilibrium was established 
within an hour (between the liver homogenate and the headspace). Following the 
incubation, the VOC in the vial headspace was analysed by GC or by GC-mass 
spectrometry. The advantage of GC-MS is that it can used to determine the actual 
compound and also any metabolites formed from the sample. The GC injector, 
detector and oven temperatures were held at constant temperature. Helium was used 
as a carrier gas for this given sample. The concentrations of VOCs were then 
determined from standard curves prepared in liver under the condition described.
For human (or rat) subjects, the experimental method was the same but the dead 
tissue of the human (or rat) was homogenised and placed into air tight vial where the 
VOCs was injected and were allowed to equilibrate over period of time. Following 
incubation, the VOC in the vial headspace was analysed by GC or by GC-mass 
spectrometry.
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Chapter
4
Introduction to blood-tissue distribution of drugs
The single largest cause of attrition in drug development is drug absorption, 
distribution, metabolism and elimination (ADME).1
ADME: SINGLE LARGEST CAUSE OF ATTRITION IN DRUG DEVELOPMENT
Commercial Reason
□ 5%
Animal Toxicity □  11%
□ 39% 
Absorption 
Distribution 
Metabolism 
Elimination□ 30%
Lack of Efficacy
□ 10%
Adverse Effects in Man□ 5%Micellaneous
Fig. 4.0. Schematic representation of a pie chart displaying the biggest problems in 
drug development1
The purpose of drug therapy is to prevent, cure, or control many different 
disease states. To obtain this goal, sufficient drug doses must be delivered to the 
target tissues so that therapeutic and non-toxic levels are achieved. The clinician 
must be aware that four fundamental pathways control the speed of onset of drug 
action, the intensity of the drug’s effect, and the duration of the drug action. The 
four main steps involve the movement and the modification of the drug within the 
body (Figure 4.1).
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[11 ABSORPTION Drug in plasma/ 
bloodDrug at site of administration
[2] DISTRIBUTION
Drug in body tissues
[3] METABOLISM
Metabolitefs) in tissues
[ 4] ELIMINA TION
Drug and/or 
metabolite(s) in urine, 
faeces and bile.
Fig. 4.1. Schematic representation of drug absorption, distribution, metabolism and 
elimination (ADME).2
First, drug absorption from the site of administration authorises the entry of the 
therapeutic agent (either directly or indirectly) in to plasma or blood (input). Second, 
the drug may then reversibly leave the blood stream and distribute between the various 
body tissues. Third, the liver, kidney and body tissue help to metabolise the drug from 
the body. Finally, the drug and its metabolites are eliminated from the body (output) in 
the urine, bile, sweat or faeces.2
The aim of the present project is to concentrate on the second point (Figure 4.1) 
especially the distribution of drugs between blood, plasma and tissues. It is very 
important to know that ratio, and how it may be altered. For example Chadha and 
Abraham, showed that the change in functional group could alter the blood-brain ratio 
(BB). A non-polar functional group as a substituent, i.e. methyl or ethyl, would help a 
compound to distribute more to the brain than in the blood. Whereas polar groups 
containing OH or OMe would lead to distribution more in the blood than in the brain.3
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FUNCTIONAL GROUP X L O G B B (calculated)
H 0.42
Me 0.53
Et 0.67
Cl 0.54
OMe 0.35
n h 2 -0.11
OH -0.28
Table 4.0. Shows how log BB changes with the functional group X on an aromatic 
ring system.3
The majority of potent drugs that are administered to patients are 
pharmacologically active; i.e., they have the capability to bind to a specific receptor 
and produce their pharmacological effects. When absorbed into the circulation, the 
drug is distributed into various body tissues. This depends on the characteristic of the 
drug as it may bind to plasma proteins, accumulate in fat, adipose or other tissues and 
then bind specifically to the receptor site. The drug interaction with the receptor site is 
important in terms of the drug’s pharmacological effects.
The biochemical transformation of a drug into another substance by an organism 
is known as drug metabolism. Higher concentrations of drug-metabolising enzymes 
are found in many body tissues including the intestines, lungs, liver and the kidneys. 
Drug metabolites are usually more water-soluble and, consequently, more readily 
excreted from the body. The pharmacological activities for these metabolites are 
mostly reduced. The majority of drugs that are taken by patients are 
pharmacologically active in the administered form.3 Though, not all drugs that 
administered are pharmacologically active; some must be metabolically converted to 
the pharmacologically active form and these specialised drugs are known as prodrugs.5 
For example II is not readily transferred to the eye, but the prodrug I is more readily 
transferred. When it gets to the eye it is enzymatically converted to the active species 
II (Scheme 4.0).
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OXIME 
 ►
HYDROLASE
KETONE
REDUCTASEAr: Aromatic Entity
R i-Pr, t-Bu:
HQ
Scheme 4.0. Shows the sequential activation of oximes in the site and stereospecific 
delivery of a drug (e.g. alprenolol is a p blocker that has a protective effect after a 
heart attack by reducing high blood pressure) to the eye.6
Both of the above methods, which involve functional group interconversion, 
as shown in Table 4.0 and Scheme 4.0, are important to help the transport of drugs to 
the active site.
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Aim and plan
The present project involves the collection of drug distribution data obtained 
from a wide range of literature papers published by various types of journals. These 
published data will be analysed carefully in order to obtain values of the distribution 
coefficients of drugs between blood/plasma/serum and various tissues.
Once enough data for distribution to a given tissue have been collected, they 
will be used to obtain predictive equations using the Abraham solvation equation. A 
necessary requirement for this is the determination of descriptors for the drugs in 
question. These predictive methods using the Abraham equation may then be used 
in the first stages of drug design. These predictions can be made from structure 
before compounds are synthesised. Compounds with poor tissue distribution, can 
then be identified.
The drug distribution data will be collected into a database, and the descriptors 
for the compounds in the database will be found at a later stage. The drug 
distribution data and the descriptors will be combined into a multi-linear regression 
(statistical calculation) to give provisional solvation equations. These will then be 
evaluated to then give final predictive equations for drug blood/plasma/serum to 
tissue distribution. The basic steps are outlined by a flow diagram in Figure 4.2.
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Figure 4.2. Protocol used to obtain predicted equations.
Compound
Descriptors
Drug Tissue 
Distribution Data 
from literature
4
1
Multiple linear 
Regression 
Analysis
Solvation Equation
Predicted log TD
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How important is drug distribution data and how is this 
obtained
The prediction of the specific behaviour and effects which a solute (or drug) 
will demonstrate in a given biological environment, is desirable in a number of 
current research areas including: medicine (e.g. the study of anaesthetics), pharmacy 
(e.g. formulation for various drugs) and toxicology for the study of environmental 
toxicants (e.g. PCB’s) etc. There are many factors affecting the biological activity 
and availability, ranging from the chemical structure of the solute molecules (or 
drugs) themselves to the uptake process by which they distribute into various tissue 
sites. For example, in the pharmacokinetics of a drug molecule, it is important to 
quantify how much drug is being distributed to various body tissue sites.
The main workers’ in the field of drug distribution data for drug compounds 
are Patrick Poulin et al7"9 and Sven Bjorkman.10 The objectives of Poulin (et al) 
studies were to develop and validate mechanistic equations for predicting the rabbit, 
rat, and mouse Pt:p (ratio of drug tissue concentration over the drug plasma 
concentration at steady state) of non-adipose and non-excretory tissues (bone, brain, 
heart, intestine, lung, muscle, skin, spleen) for 65 structurally unrelated drugs and to
n
evaluate the adequacy of using Pp:t of muscle as predictors for Pp:t of other tissues. 
Bjorkman derived equations to predict volume of distribution based on data obtained 
from various literatures sources containing plasma-tissue coefficients (K values at 
steady state) of 43 drugs. His model has benefits for people who have interest 
primarily in pharmacokinetics where the predictive values for volume of distribution 
(Vd) based on drugs alone is important.10
The main workers in the field of drug blood-brain distribution are: Cabrera et 
al, 11 Rose et al, 12 Clark, 13 Keseru and Molnar, 14 Feher et al, 15 Lombardo et al16, 
Luco, 17 Norinder et al, 18 Lobell et al, 19 Platts et al,20 Kelder et al,21Chadha et al,22,23 
Hutter,24 Liu et al,26 Kaznessis et al,27 Ertl et al,28 Ooms et al,29 Salminen et al,30 
Kaliszan and Markuszewski,31 Kaliszan et al31 and Hou and Xu32,33 Although there 
has been a large number of reported work on blood to brain distribution for drugs (as 
summarised by table 4.1), but there still is a large scope of work to be done on drug 
blood to tissue distribution.
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Cabrera et al method of using TOPS MODE is complicated.11 This method 
involves calculating descriptors using a software (MODES labs) using spectral 
moment of each bond weight and number bonds in the molecules also considering 
reported influence of polar surface, atomic mass and hydrophobicity. Cabrera et al 
training set appears to have large data set with compounds containing drugs and 
VOCs.
DRUG BLOOD-BRAIN 
DISTRIBUTION
TRAINING SET TEST SET
Reference No. Var. r2 S.D. No. AAE.
Cabrera et al.11 114 2 0.697 0.422 28 0.33b
Cabrera et al.11 81 2 0.740 - 33 0.33b
Keseru and Molnar.14 55 1 0.723 0.370d 5, 25 0.14,° 0.37c
Clark13 55 2 0.787 0.354 5, 5 0.14, 0.24
Luco.17 58 18 0.850 0.318 12, 25 0.24,a 0.54,a
Feher et al.15 61 3 0.723 0.420 14,25 0.76, 0.80
Hutter.24 90 12 0.865 0.309d - -
Lombardo et al.16 55 1 0.670 0.410d 6 0.62
Norinder et al.18 56 14 0.834 0.312 6 0.52
Rose et al.12 106 3 - 0.450 20 0.47
Rose et al.12 102 3 0.660 - - -
Platts et al.20 148 6 0.745 0.343 - -
Platts et al.20 74 6 - 0.340 74 0.38
Lobell et al.19 48 5 0.837 0.260b 17 0.41b
Kelder et al.21 45 1 0.841 0.360 - -
Chadha et al.22’23 57 5 0.906 0.197 - -
Liu et al26 55 2 0.790 0.350 11 0.30c
Kaznessis et al2/ 76 5 0.941 0.173 4 0.48a
Ertl et al28 45 1 0.840 - - -
Ooms et al29 79 31 0.760 - - -
Salminen et al30 21 3 0.848 0.270 - -
Salminen et al30 23 3 0.848 0.320 - -
Kaliszan et al 20 2 0.642 0.486d - -
Kaliszan et al31 20 2 0.845 0.321d - -
Kaliszan et al31 20 2 0.889 0.271d - -
-- ry
Kaliszan et al 20 2 0.897 0.126d - -
Hou and Xu32 72 3 0.785 0.358 35 0.41°
Hou and Xu33 78 3 0.743 0.375 35 0.44°
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a is the root mean square value
L
is the mean absolute error 
c is the standard deviation 
d is the standard error
Table 4.1. Summary of models for blood to brain distribution of drugs and VOCs
This training set appeared to have relative large standard deviations (S.D. 0.422) 
compared to other models shown in table 4.1. 11 Cabrera et al’s correlation 
coefficient appears to be reasonable, although, there have better reported models 
with larger data sets for example; Platts et al.20 and Rose et al12 also have a large data 
set for drug blood brain distribution model. Rose et al’s equation unfortunately does 
not have a very good correlation coefficient (r2 = 0 .6 6 ) for the large data set in the 
training equation. It appears that for this blood to brain model that the training set 
has the largest standard deviation, as compared to other models shown in table 4.1. 
The number of compounds used in the test sets by Rose (et al), are too small.12
With regards to the drug blood-brain model, new models would be of interest 
to pharmaceuticals industry and the environmental health providing that the model 
consist of larger data sets along with bigger test sets for the validation of predictive 
model.
The present work expands on the diversity of the drugs and also includes other 
small solutes (mostly general anaesthetics) to enable the construction of more 
general predictive equations.
The purpose of this project is to collect large amounts of data from various 
sources for blood: tissue distribution coefficients (either directly or indirectly) for 
drugs (or small solutes) to facilitate the use of physiological-based pharmacokinetic 
models (PBPK) in drug discovery used to estimate the disposition of drugs in 
various species under steady state condition. Until now, the use of PBPK models in 
early stages of the drug discovery processes has not been possible, since the 
estimation of P blood: tissue (or P plasma: tissue and P serum: tissue) of* new drug candidates 
by using conventional in vitro and /or in vivo methods is too time and cost intensive 
especially with animal testing. The objectives of the present study are to develop 
and validate mechanistic equations for predicting the disposition of solutes (drugs) 
for various species (including rats, pregnant rats, rabbits, mouse and most
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importantly humans) and to see if there are any similarities for drug distribution data. 
If so, then data for two or more species may be combined to generate one general 
equation for predicting drug blood to tissue distribution. The different tissues 
considered in this study when validating P b io o d : t is s u e  (P p la sm a : t is s u e  & P b lo o d :  t i s s u e )  are 
adrenal, adipose, brain (including various brain compartments), bile, bone, 
cerebrospinal fluid, fat, gut, gastrointestinal tract, heart, kidney, lung, muscle, ovary, 
placenta, pancreas, spinal fluid, skin, spleen, testes, trachea, large intestine and small 
intestines. Ultimately the data for drug blood to tissue distribution for various 
tissues will be compared by statistical methods to assess if there are any similarities 
between the different types of data of the same solutes (or drugs). The drug blood to 
tissue distribution between two phases, at steady-state, can be calculated from the 
following equation:
P = Total drug concentration in tissue/ Total drug concentration in blood Equation 4.0
Equilibrium Distribution
Blood and Body Tissues
LIVER
BLOOD
wgggm
B LO O D Tissues e.g. LIVER
DR U G
Figure 4.3. Diagram for drug blood to tissue distribution at steady state 
(equilibrium)
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Careful interpretation of various recorded data has to be done in order to 
collect reliable data for drug blood to tissue distribution. Some pharmacokinetic 
models for drug disposition only produce data for the concentration of drug blood to 
tissue distribution versus time (Table 4.2) without displaying any direct results for 
any drug blood to tissue partition between various tissues.
TISSUE 5 MIN 15 MIN 30 MIN 60 MIN 90 MIN
Blood 0.13 0.09 0.06 0.03 0.05
Plasma 0.19 0.13 0.08 0.07 0.07
Heart 0.26 0.15 0.09 0.04 0.04
Trachea 0.17 0 .1 2 0.09 0.04 0.03
Table 4.2. Concentration of drug (adenosine) versus time.25
From the data in Table 4.2, a table of results for drug to tissue distribution 
data can be obtained by using equation 4.0 and this ratio is summarised by table 4.3. 
This can then be used to plot graphs to determine the drug blood to tissue 
distribution at steady state before finally adding this data to the database. Note the 
data for drug blood to tissue distribution can only be obtained if the drug remains at 
a constant equilibrium over a period of time as shown by Figures 4.4, 4.5 and 4.6. 
This would allow consistent comparison to be made with other tissue distribution 
values at steady state. The squared points from the graph indicate where the values 
can be averaged for the steady state equilibrium. The diamond plots indicate where 
the concentration of drug has changed over a period of time and the drug does not 
appear to be at steady state equilibrium (these values are ignored).
TISSUE 5 MIN 15 MIN 30 MIN 60 MIN 90 MIN
Plasma 1.46 1.44 1.33 2.33 1.40
Heart 2 .0 0 1.67 1.50 1.33 0.80
Trachea 1.31 1.33 1.50 1.33 0.60
25Table 4.3. Ratio for drug blood to tissue distribution obtained from data in Table 
4.2.
63
Ratio of plasma/blood
2.50
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Figure 4.4. Graph showing the blood to plasma ratio vs time,25 from Table 4.3.
Ratio of heart/blood
2.50
2.00
1.50
1.00
0.50
0.00
1008040 60200
Time(mins)
Figure 4.5. Graph showing the blood to heart ratio vs time,25 from Table 4.3.
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Ratio of trachea/blood
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Figure 4.6. Graph showing the blood to trachea ratio vs time,25 from Table 4.3.
From figures 4.4, 4.5, and 4.6 it is possible to obtain steady state distribution 
from the data corresponding to the blue square (■  ) points. These are summarised in 
Table 4.4.
TISSUE SAMPLES BLOOD TO TISSUE RATIO TAKEN
Plasma 1.60
Heart 1.42
Trachea 1.37
Table 4.4. Ratio of blood to tissue at steady state distribution
Data from literature for drugs that do not give a steady state for blood to tissue 
distribution has to be avoided, as this data would not be reliable for comparisons
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with other tissues at steady state (see Figure 4.7). It is important to ensure that plots 
are constructed before adding data to the database. In the case of Figure 4.7, this 
data can not be used for drug blood to tissue distribution, as no steady state is 
reached.
When collecting drug distribution data, it is very important to separate out data 
within one species. For example, the drug blood to tissue distribution data for one 
particular drug within rats and pregnant rats cannot be compared as they may have 
different distribution profiles. Later, comparison will be made to see if the overall 
data for several drugs are the same or different. Post mortem data for human 
subjects should also be kept separate from data on living human beings.
Ratio of striatum/blood
6.00
5.00
4.00
o'5re 3.00
2.00
1.00
0.00
100806020 400
Time(mins)
Figure 4.7. Graph showing the corpus blood to striatum (region of the brain) ratio 
vs time.25
66
References
1. Hill, S. A. (Review 2001) Modem medicinal chemistry. 1-4.
2. Mycek, M. J., Harvey, R. A. and Champe, C. P. (1997) Pharmacology. 
Lippincott illiams & Wilkins. 1-15.
3. Abraham, M. H. and Harpreet, S. C. (1994). Bioorganic & Medicinal Chemistry 
Letters. 4, 2511-2516.
4. Backes, W. L. (2001). Clinical Journal of Oncology Nursing. 5, 35-38.
5. Neal, M. J. (1993) Medical pharmacology at a glance. Blackwell scientific 
publications. 14-15.
6 . Bodor, N. and Buchwald, P. (1997). Pharmacology. Ther. 76, 1-27.
7. Poulin, P. and Theil, F. P. (2000). J. Pharm. Sci, 89, 16-35.
8 . Poulin, P., Schoenlein, K. and Theil, F. P. (2001). J. Pharm. Sci, 90, 436-447.
9. Poulin, P. and Theil, F. P. (2002). J. Pharm. Sci, 91, 1358-1367.
10. Bjorkman, S (2002). J. Pharmacy and Pharmacology, 54, 1237-1245.
11. Cabrera, M. A., Bermejo, M., Perez, M. and Ramos, R (2004). Journal of 
Pharm. Sci., 93, 1701-1717.
12. Rose, K., Hall, L. H. and Kier, L (2002). J. Chem. Inf. Comput. Sci., 42, 651- 
666 .
13. Clark, D, E (1999). J. Pharm. Sci., 8 8 , 815-821.
14. Kerseru, G. M. and Molnar, L (2001). J. Chem. Inf. Comput. Sci., 41, 120-128.
15. Fehur, M., Sourial, E. and Schimidt, J. H (2000). Int. J. Pharm., 201, 239-247.
16. Lombardo, F., Blake, J. F. and Curatolo, W. J (1996). J. Med. Chem., 39, 4750- 
4755.
17. Luco, J. M (1999). J. Chem. Inf. Comput. Sci., 39, 396-404.
18. Norinder, U., Sjoberg, P., Osterberg, T (1998). J. Pharm. Sci., 87, 952-959.
19. Lobell, M., Molnar, L. and Kesem, G. M (2003). J. Pharm Sci., 92, 360-370.
20. Platts, J. A., Abraham, M. H., Zhao, Y. H., Hersey, A., Ijaz, L. and Butina, D 
(2001). Eur. J. Med. Chem., 36, 719-730.
21.Kelder, J., Grootenhuis, P. D. J., Bayada, D. M., Deibressine, L. P. C. and 
Ploeman, J. P (1999). Pharm. Res., 16, 1514-1519.
22. Abraham, M. H., Chadha, H. S. and Mitchell, R. C (1994). J. Pharm. Sci., 83, 
1257-1268.
67
23. Abraham, M. H., Chadha, H. S., Martins, Filomena, M., Mitchell, R. C., 
Bradbury, M. W and Gratton, J. A (1999). Pesticide Sci., 55, 78-88.
24. Hutter, M. C (2003). J. Computer-Aided Molecular Design., 17, 415-433.
25. Fazio, F., Todde, S., Moresco, R. M., Simonelli, P., Baraldi, P. G., Cacciari, B., 
Spalluto, G., Varani, K., Monopoli, A., Matarrese, M., Carpinelli, A., Magni, F., 
Kienle, G. K. (2000). J. Med. Chem., 43, 4359-4362.
26. Liu, R., Sun, H. and So, S-S (2001). J. Chem. Inf. Comput. Sci., 41, 1623-1632.
27. Kaznessis, Y. N., Snow, M. E. and Blankley, C. J (2001). J. Computer-Aided 
Molecular Design, 15, 697-708.
28. Ertl, P., Rohde, B. and Selzer, P (2000). J. Med. Chem., 43, 3714-3717.
29. Ooms, F., Weber, P., Carrupt, P-A. and Testa, B (2002). Biochimica et 
Biophysica Acta, 1587, 118-125.
30. Salminen, T., Pulli, A. and Taskinen, J (1997). J. Pharmaceutical and 
Biochemical Analysis, 15, 469-477.
31. Kaliszan, R. and Markuszewski (1996). International Journal of Pharmaceutics, 
145, 9-16.
32. Hou, T. J. and Xu, X. J (2003). ADME evaluation in drug discovery. 3. 
Modelling blood-brain barrier partitioning using simple molecular descriptors. J. 
Chem. Inf. Comput. Sci., 43, 2137-2152.
33. Hou, T. J. and Xu, X. J (2004). ADME evaluation in drug discovery. 3. 
Modelling blood-brain barrier partitioning using simple molecular descriptors. J. 
Chem. Inf. Comput. Sci., 44, 766-770.
68
Chapter
Introduction to physicochemical considerations
The physicochemical properties (e.g. lipophilicity, solubility) of a drug compound 
may be related directly or indirectly to its biological properties. Thus, by understanding 
the relationship between chemical structure and biological activity it is possible to gain 
knowledge on what is needed to attempt to predict biological properties, such as 
transport and the activity of new possible compounds. This chapter will outline a 
number of relevant physiochemical properties of compounds.
Brensted acidity and basicity
To be able to appreciate the biological activity of a compound it is important to 
understand the transport processes of a compound to the site of action (i.e. body tissues) 
and also the binding of the compound to its target site (i.e. drug receptor). The acidity 
and basicity properties of a compound are important in order to control the transport and 
binding mechanism of that compound. It is important to notice the difference in 
Bronsted acidity and basicity, which refers to the loss or gain of a proton, and hydrogen- 
bond acidity and basicity, which refers to the tendency of a compound to donate or to 
receive a hydrogen bond. For protonic (Bronsted) acids and bases the following 
equations apply.
R C O O H ^ = ^  RCOO' + H+ Equation 5.0
[RCOO'][H+]
K =    Equation 5.1
[RCOOH]
Here Ka is the acid dissociation constant for an acidic solute. Note the stronger the acid 
the greater the tendency for the solute to give up its proton. For a typical Bronsted base, 
the base denotes constant, Kb can be expressed as,
RNH2 + H20  b » RNH3+ + OH- Equation 5.2
[RNH3+][OH]
----------------------  Equation 5.3
[RNH2]
Very often, values of Ka for the conjugate acid are given and defined as,
RNH3+ .  RNH2 + H+ Equation 5.4
[RNH2][H+]
Ka--------------—  Equation 5.5
[RNHj|
From equations 5.3 and 5.5,
Ka x Kb = [H+][HO'] = 10'14 in water Equation 5.6
Then pKa + p/Tb = 14 in water at 25°C.
The pH of a solution indicates the concentration of positively charged hydrogen 
ions in the solution (concentration is expressed as [H+]). The definition of pH is:
pH = -log [H+] = aH+ Equation 5.7
For convenience, the strength of an acid is generally indicated by its p ^ a value rather
than its Ka value. Then for a Bronsted acid, the concentration of neutral and ionised
forms is given by the following equation.
pKa = pH + log ([HA]/[A-]) Equation 5.8
pKa = -log K& Equation 5.9
For acidic solute the smaller the pK&, the stronger is the acid.
Very strong acids pKa < 1
Moderately strong acids pKa =1-5
Weak acids ipKa = 5-15
Extremely weak acids pKa >15
For a Bronsted base, the concentration of ionised and neutral forms is given by the 
following equation. 1 Here the concentration is taken as an approximation of activity. 
Note it is the ionisation that has the potential to limit the passage through membranes.
pKa = pH + log[RNH3+] - log[RNH2] Equation 5.10
For basic solute the smaller the p/Tb, the stronger is the conjugate base.
Very strong bases pKa > 9 pKt < 5
Moderately strong bases pKa = 8-5 pKb = 6-9
Weak bases pKa < 4 pKb >10
Henderson-Hasselbach equation
Whether a given acid will lose a proton in an aqueous solution depends on the pKa 
of the acid and the pH of the solution.1 The relationship between the two is given by the 
Henderson-Hasselbach equation. This is an extremely useful equation because it shows 
us whether a compound will exist in its acidic form (with its proton retained) or in its 
basic form (with its proton removed) at a particular pH.
An acid will exist primarily in its acidic form if the pH of the solution is less than 
its pATa. An acid will exist primarily in its basic form if the pH of the solution is greater 
than its p ^a- When pKa = pH then the concentration of HA and A' present are equal.
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Hydrophobic effect and the influence of lipophilicity
The original definition of the hydrophobic effect was defined as the tendency of 
non-polar molecules to dissolve in non-aqueous solvents by comparison to water as 
solvent. Recently this definition has been refined to lipophilicity. The measure of 
lipophilicity of any compound is found by measuring the water-solvent (e.g. octanol) 
partition coefficient, P, and is usually expressed as log P (as discussed latter).
Scheme 5.0. Decan-l-ol2
The partition coefficient is one of the physicochemical parameters influencing 
drug transport and distribution, because the drug must distribute between aqueous like 
phases (blood or plasma) and lipophilic like phases (cell membranes of various tissues)
of a compound can be divided two parts, (a) a polar contribution that drives the 
compound into water and (b) a size effect that drives the compound into the organic 
phase. It is this latter effect that is now usually termed hydrophobicity. It should be 
noted that neither hydrophobicity nor lipophilicity is the same as the hydrophobic 
interaction, which is the tendency for nonpolar molecules to interact with each other (to 
associate) in water.2
Note that it is important to consider lipophilicity, as it is a key factor affecting 
how drug molecules are distributed in biological organisms. Often there is a correlation 
between compound (e.g. drugs) with high lipophilicity and increased biological activity, 
poorer aqueous solubility (expressed as the maximum amount of solute that dissolves in 
a given volume of solvent), increased detergency (the ability of a surfactant to remove 
particles from a surface)/ cell lysis, increased storage in tissues, more rapid metabolism
N on-polar (lipophilic) 
hydocarbon chain
^  v  OH
Polar (hydrophilic group)
to be absorbed and reached the sites of action. Following Testa et al.,3 the lipophilicity
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and elimination, increased rate of onset of action and also sometimes a case of shorter 
duration of action.
Hydrogen bonding
Most short-range interaction are caused by hydrogen bonds, this is important in 
biological systems and responsible for maintaining the tertiary structure of proteins (e.g. 
enzyme receptors) .4 Besides other weak interaction, hydrogen bonds are dependent on 
directional component and the hydrogen bonding strength decreases as the geometry 
becomes less optimal. The majority of the hydrogen bond donors are in general are: 
OH, SH (aromatic), NH, and activated CH groups while hydrogen bond acceptors are 
electronegative groups that contains of nitrogen, oxygen, sulphur and fluorine.5
Index of lipophilicity from partition coefficients
The partition coefficient (P) is a measure of the affinity of a molecule for a 
solvent phase versus that for water. This can be obtained by dividing the equilibrium 
concentration of a solute species in the solvent phase by the equilibrium concentration 
of the same solute species in the water phase. Note that it important to relate partition 
coefficient (P) to a particular species, because a solute may exist in more than one form 
in either the organic phase or in water, or even in both phases. For example carboxylic 
acids may be dimerised in organic phases, but remain monomeric in the water phase 
(see scheme 5.1). Thus, in order to calculate a partition coefficient for the species in the 
monomeric form, the concentration of the monomer in the organic phase has to be 
determined; this will not be the same as the total (formal) concentration in the organic 
phase. Partition coefficient is a dimension-less quantity (it is a ratio), and its logarithm 
(log P) is widely used to establish correlations with many biological and other 
physiological properties.
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3 H "= m olecular association
O O in the organic phase
§ II
h -o -c -c h ,
o
H 0 -C-CH 3
 1 -----------------------------------
o  o
H O -C-CH 3 = ^ H 3C -C -0  + H + 
ionic dissociation in the aqueous phase
Scheme 5.1. Partitioning coefficient affected by two processes
p  _ [C loha, Equation 5.11
[C]water
Original studies by Meyer and Overton used olive oil as the organic phase, but 
now octan-l-ol has been used as a standard solvent for the determination of partition and 
log P measurements.6'9
Decan-l-ol (Scheme 5.0) being like a lipid molecule has a long aliphatic alkyl 
chain, plus a polar functional group which gives rise to hydrogen bond accepting and 
donating characteristic due to the presence of lone pair electrons. Suppose P > 1 then 
the molecule is lipophilic. If P < 1 the molecule is hydrophilic. The log P measurement 
is directly carried out by the ‘shake flask’ method or the ‘stir flask’ method. 10
Even though log P values do not vary very greatly with temperature, it is still 
worthwhile to maintain a record of the temperature for the system.11 For compounds 
that are ionisable, the water (aqueous) phase must either be buffered to suppress 
ionisation, or an appropriate correction for pH can be made as shown later. If the solute 
associates in one or another phase, then an appropriate adjustment must be made to 
avoid this problem.
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H ow the effect o f  partition is affected by ionisation o f the 
solute
The measurement of the partition coefficient (P) at a certain pH is important, 
because for Bronsted acids and bases, the ionised form either does not partition into the 
organic phase, or partitions much less readily than the neutral form.
The equilibrium of compounds (i.e. drugs) between ionised and un-ionised form 
depends on the ambient pH and pKa of the drug compound (i.e. drug). When pH is less 
than pKa, the protonated forms HA and BPT predominate. When pH is greater than 
pKa, the depronated forms A' and B predominate. When pH = pKa then [HA] = [A ] 
and [BH+]= [B] .12
UNIONISED
K
LIPID
P*a A
IONISED
N t /X
\
UNIONISED
P*L
AQUEOUS
A
IONISED
Figure 5.0. A diagram showing that lipophilicity depends on the degree of ionisation.11
It is important to take note of the degree of ionisation. The effective or net lipophilicity 
of a compound at a given stated pH is defined using the distribution coefficient log D. If 
the ionised form does not partition at all, then for a neutral compound (AH) will.
AH
D =
H+ + A'
[AH]org
Equation 5.12 
Equation 5.13
[AH]aq + [A-]aq
and for an organic base (BH+).
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BH ---------  H + B Equation 5.14
^  _ [B]org Equation 5.15
~ [B]aq + [BH+]aq
The pH partition diagram for weak acids is shown by a simple curve.
50 % neutral
50 % ionised
90% ionised
P=[HA]org/ [HA]aq
.'V// - V - V " ;
0 =  [HAJorg / [HA]aq+[A ]aq
Figure 5.1.9 The graph showing log D vs pH and the % neutral (un-ionised) form of an 
acidic compound of log P = 3.2 and p^a = 2
If, as in the case of monoacids, only the neutral form partitions, the distribution 
coefficient and the partition coefficient are related through,
Log D = log P - log( 1 + 10pH pKa) Equation 5.16
and for a mono-base where only the neutral form partitions.
Log D = log P - log( 1 +10 pH+pKa) Equation 5.17
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The partitioning of the charged species into the organic phase is restricted because the 
solute species possesses a charge.13
Very often log D values are carefully measured at the standard ‘physiological’ pH 
of 7.4 and are not corrected to log P values. If log P value is required, the larger the 
difference pH - pKa, the larger will be the correction factor. The partitioning of 
zwitterions appears to be more complex. The concentrations of the anionic (-ve), the 
cationic (+ve), and the zwitterionic (- /+ ve) forms will depend on the pH, but it is the 
electronically neutral species, which co-exists with the zwitterions (- / + ve), that has the 
greatest lipophilicity.14
OH
H2N
HN
H O
CH
pKabasic = 9.38acidic _ y
Figure 5.2. The structure of drug labetalol (beta blocker) that exists as a zwitterion. 14
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Linear free-energy relationships (LFERs)
Many case studies have been carried out on the relationship between changes 
in reaction conditions and the result they have on rates of chemical reactions, and on 
chemical equilibrium. It has been found that if a series of changes in conditions or 
reactant structure affects the rate or equilibrium of a second reaction in a similar way 
to the way it affected the first reaction, there exists a linear free-energy relationship 
(LFER) between the two sets of data. This type of relationship is known as linear 
free-energy because at constant temperature the rate of reaction is related to the free 
energy of activation and the equilibrium constant is related to the standard free 
energy change. When relationships like this exist, they can be useful in helping to 
elucidate mechanism, in predicting reaction rates and the extent of a reaction at 
equilibrium. The best-known example of LFERs is the Hammett equation. When 
applied to solvation processes, LFERs are sometimes denoted as linear solvation 
energy relationships (LSERs).1,2
Quantitative structure-activity relationships (QSAR)
The enormous cost involved in synthesising and testing thousands of modified 
compounds in an attempt to find an active drug led scientists to develop a more 
rational approach-called rational drug design of biologically active molecules. 
Scientists realised that if a physical or chemical property of a series of compounds 
could be correlated with biological activity, they would know what property of the 
drug was related to that particular activity. With this wealth of knowledge, scientists 
could design compounds that would have a good chance of exhibiting the desired
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activity. This strategy would be a great improvement over the random approach to 
molecular modification that traditionally had been employed.
The first hint that a physical property of a drug could be related to biological 
activity, appeared almost 100  years ago, when scientists recognised that chloroform 
(CHCI3), diethyl ether, cyclopropropane and nitrous oxide (N20 ) were all useful 
general anesthetics. Clearly, the chemical structures of these diverse compounds 
could not account for their similar pharmacological effects. Instead, some physical 
property must explain the similarity of their biological activities.
In the early 1960s, Cowin Hansch3 postulated that the biological activity of a 
drug depended on two processes. The first is distribution: A drug must be able to get 
from the point where it enters the body to the receptor where it exerts its effects. For 
example, an anaesthetic must be able to cross the aqueous milieu (blood) and 
penetrate the lipid barrier of nerve cell membranes. The second process is binding: 
When a drug reaches its receptor, it must interact properly with it.
Various types of solutes can be used to see how they would distribute between 
water and octanol phases (for e.g. anaesthetics like chloroform, diethyl ether and 
cyclopropane). Octanol properties include a hydrophobic long chain and a 
hydrophilic polar head group. The water/octanol system is used as a model of a 
biological membrane in general. The anaesthetics above appear to have similar 
distribution coefficients (the ratio of the amount dissolving in octanol to the amount 
dissolving in water). In other words, the distribution coefficient could be related to 
biological activity. Drug compounds with lower distribution coefficients appear to 
have more polar properties and therefore could not penetrate the cell membrane. 
Whereas drug compounds with greater distribution coefficients appear to have non 
polar properties and therefore can penetrate cell membranes. The distribution 
coefficient of a compound could be used to determine whether a compound should 
be tested in vivo and could indicate the transport property of the drug. The technique 
of relating a property of a series of drug compounds to biological activity is known 
as a quantitative structure-activity relationship (QSAR).3
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Multiple linear regression analysis (MLRA)
Abraham and co-workers used the traditional multiple linear regression analysis 
to generate coefficients in various equations. This is a frequent technique used in 
statistics where the dependent variable (y) is linearly correlated to two or more 
independent variables to produce equation coefficients specific to the data set under 
analysis. When the coefficients are obtained, it is very desirable to predict values of y 
based on an independent (test) set of values of the dependent variable. The reliability 
of the predicted y variable is dependent on the degree of scatter (or spread) in the data. 
The least square method is usually used for determining the best fit for the linear line 
through the data.
When a multiple linear regression analysis output is obtainable, it is important to 
assess how reliable the relationship is. The statistical methods used to do this include 
the standard deviation, (sd), correlation coefficient (r), t-test and the Fisher F-statistic 
(F).
Statistics
The standard deviation, sd
The standard deviation, (sd), is defined as the square root of the sample variance 
(sum of squares of deviations of individual results from the mean, divided by (n-p-1), 
where n is the number of data points, and p is the number of independent variables, as 
shown by Equation 6.0. For a simple comparison of two sets of data, p = 0, and (n-p-1) 
reduces to (n-1):
sd = ( I ( y ,  -  y)2 / ( n - p -  1 ) ) l/2 Equation6.0
The property being measured has the same units as the standard deviation. The 
standard deviation measures the spread of distribution of data around the mean. A 
small standard deviation suggests a low spread of data with a good relationship, and a 
large standard deviation suggests a high spread of data with a poor relationship, thus 
not favourable for multi-linear relationship analysis.
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Average Absolute Error, AAE
The average absolute error is sometimes used, and is a measure of the average 
absolute difference between predicted and measured responses. It is always smaller 
than the corresponding sd value, and is defined as
( A \
AAE  = I y  i -  y t
V J
/ n Equation 6 .1
y. is the calculated (or predicted) value and y. is the observed value (experimental 
data).
Root Mean Square Error, RMSE
The RMSE is the square root of the average of the squared differences 
between predicted and measured responses and is another measure of the prediction 
error of the model given in the same units.
1 / 2
y -  T/
RMSE = Equation 6.2
A
y t is the calculated (or predicted) value and y. is the observed value (experimental 
data).
Average error, AE
Average error gives an indication of whether an equation is biased i.e. whether 
it systematically over- or under- predicts the desired response variable. The nearer 
the average error is to zero, the more unbiased is the model.
X
A E  = v
n Equation 6.3
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Ay x is the calculated (or predicted) value and y. is the observed value (experimental 
data).
The correlation coefficient, r
The ‘r ’ term is defined as the correlation coefficient, and gives a measure of the 
success of the correlation of the dependent variable y against the independent variables 
x. Equation 6.4 shows how the correlation coefficient can be calculated:
Where y  is the mean observed value whereas y,- is the predicted values. The 
correlation coefficient (r) determines how closely the data set fits the relationship given
value of zero means there is no relationship at all between the data set and the analysis 
for multiple linear regression. A negative regression coefficient can sometimes often 
be interpreted as a poor correlation by an inexperienced eye so more often than not it is
linear regressions.
The standard deviation (sd) and correlation coefficient (r) do not provide any 
mathematical evidence that any relationship observed between the dependent variable 
and the independent variables does not occur by chance alone. The statistical tests that 
can be used study the significance of the regression coefficients are the Fischer F- 
statistic (F) and t-test.
A normal distribution of errors is assumed by a t-test calculation that consist of a 
set of confidence levels, usually 95 or 99%. This allows a range of values acceptable at 
a specific confidence limit. T-test is performed on each every individual variable in the 
multiple linear regression analysis to test their significance. Occasionally not all the 
variables are necessary and this would be indicated by the level of significance, and so 
may be eliminated.
Z{(y, ->0O, - y ) }
r = Equation 6.4
by the multi-linear regression analysis and can range from -1 to 1. The ‘r’ value of-1 
or 1 indicates that the data set is clarified by the correlation equation perfectly,6 while a
r2 (square of the overall correlation coefficient) that is quoted in relation to multiple
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The Fisher’s F-statistic, F
The F-statistic gives an indication of the quality of the regression, the higher 
value of F, the more significant it will be for given degrees of freedom and the better is 
the regression:
F = r2 (n - v -1) / (1 -  r^v Equation 6.5
The r2 is the square of the overall correlation coefficient; n is the number of data 
points and v is the number of degrees of freedom (v = p - 1, where p is the number of 
variables). From equation 6.5 it is clear that as the number of data points and the 
correlation coefficient increases, so does the F value, and the larger the F the better 
the regression.4’7
The limitations of MLRA
In a multiple regression if two or more of the explanatory variables are nearly 
linear combinations of each other, the variables are multicollinear. The existence of 
such dependence implies that it is almost impossible to vary one of these variables 
while holding the others constant. Multicollinearity can make the regression equation 
unstable. Although, it may be possible to find a good multiple linear fit for the Y 
variable, the values of the individual coefficients may be highly variable in that 
unexpectedly large estimated standard errors for the coefficients of the independent 
variables may be produced. Thus, Y may be predicted with reasonable accuracy, but it 
would not be possible to draw any reliable conclusions about the coefficients. 
Furthermore, fitted coefficients could vary widely from sample to sample of the data, or 
if a single independent variable is added or deleted from the equation.
In terms of the data used for multiple linear regression analysis, both the quality 
and quantity needs to be taken into account. To obtain meaningful and statistically 
significant coefficients, a wide spread of explanatory variables is required. 
Furthermore, as a rule of thumb, there should be no more than one descriptor per 5 
compounds in the regression. If more descriptors are used, the predictive capability of
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the model is liable to be significantly affected since the extra descriptors are more likely 
to be describing random error in the Y variable.
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Chapter
The method of Abraham
The Abraham method is mainly concerned with transport-related properties of 
solutes.1 These processes are defined as either equilibrium transfer (K or P) or the 
rate of transfer of a solute (k) between two phases. In Scheme 7.0, Kw and Ks are 
the gas-to-water or gas-to-solvent partition coefficients, and P is the water-to-solvent 
partition coefficient.
Log P
LogP = LogKs - LogKw
Scheme 7.0. The relationship between log K (air to solvent and air to water) to give 
the calculated value for partition of a solute between water and the solvent phase.
A large number of transport-related processes are of importance in 
pharmaceutical and environmental chemistry. Equilibrium transfer is controlled by
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the standard Gibbs free energy of the compound in the two phases, which in turn is 
related to the Gibbs free energy of solvation, AG°s and AG°w, in a solvent and water 
(Equation 7.0).
AGS = -i?rinATsand AGW = -R T  In K w Equation 7.0
From Equation 7.0 (where K or L is the gas-liquid partition coefficient or so 
called Ostwald solubility coefficient) and from equation 7.1, the standard Gibbs free 
energy of transfer (AG°t) is found by subtracting AG°S from AG°W (Equation 7.2).
AGt = -R T \n P  Equation 7.1
AGt = AGs -  AGw Equation 7.2
Accordingly log P can be calculated by using the following equation.2
Log P = Log Ks -  Log Kw Equation 7.3
The general method of approach is based on the assumption that certain 
properties (or descriptors) of a given solute, will be important in solvation of the 
compound in different solvent phases. In addition, the solute properties will be 
important in determining the transfer of solute from one phase to another. Thus if the 
polarisability3 for example, of a compound is an important factor in solvation in 
ethanol, we expect it to be relevant as regards solvation in hexane, or 
dichlorobenzene, or other solvents. Naturally, a compound property such as acidity 
will influence solubility in basic solvents, but will be redundant in non-basic 
solvents.
It is suggested that similar solute properties will be of importance in the 
solvation of the solute, not just in one particular solvent phase, but in solvent phases 
in general, and therefore similar solute properties will be important factors in the 
transfer of a solute between two phases.
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The aim of Abraham and co-workers was to attempt to identify the general 
solute properties expected to be relevant to transport processes, and to identify a set 
of solute descriptors, that could be used in algorithms for transport processes. 
Hansch equations have been very important in this context, but they are restricted to 
sets of related solutes, whereas the Abraham equation should be applicable to varied 
sets of solutes (or compounds).
T he cavity  m odel o f  solvation
SOLUTE SOLUTE
SOLVENT SOLVENT
[1] [2] [3]
Figure 7.0. The cavity model of solvation involves three steps.
The Abraham solvation equation is based on a simple solvation model used by 
Abraham, Kamlet and Taft (AKT),4*8 see Figure 7.0. This model describes the 
solvation of a gaseous solute into a liquid solvent and can be broken down into the 
following stages:
1) A cavity of suitable size (i.e. same size as the solute) is made in the solvent, this
involves the endoergic breaking of solvent-solvent bonds and hence the Gibbs
free energy change will be positive (AG = +ve). This is energetically
unfavorable.
SOLUTE- SOLVENT 
INTERACTIONS
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2) The bulk solvent molecules are reorganised into their equilibrium position 
around the cavity, for which the Gibbs free energy change is assumed to be 
negligible.
3) The solute is inserted into the cavity, where various solute-solvent interactions all 
take place. This process is exoergic and liberates energy (AG = -ve). This is 
energetically favorable.
Note that that the solvent phase is constant. The only variable that changes is 
the solute and hence the process can be described by solute properties. The work 
involved in forming the cavity will be proportional to the solute volume, V. It 
appears that the general dispersion interaction in statement (3) is also proportional to 
V, and so the v.V term in the solvation equation includes both cavity effect and the 
general solvation effect. The various solute-solvent interactions are described by the 
terms in E, S, A and B.
With the introduction of a solute molecule into the solvent cavity, a number of 
solute-solvent interactions will occur. These interactions are exoergic and aid the 
processes of solution. Both the cavity term and the solute-solvent interaction term 
will depend on the properties of the solute and the solvent under consideration. 
Hence to describe these effects, for the general case of a number of solutes in a 
number of solvents, it is necessary to construct a linear free energy relationship 
(LFER) equation, that includes the relevant properties of both the solutes and the 
solvents. The Hammett equation9 is the best-known example of a LFER and his 
work has formed a sound basis for many other studies to be carried out involving 
LFERs. Considerable simplification is possible for the general case of a number of 
solutes in a number of solvents, by considering only one solvent, then the properties 
of the solvent remain constant, and it is necessary only to consider properties or the 
descriptors of the solute.
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The general solvation equation
Abraham, Kamlet and Taft pointed out the necessity to consider both non­
specific and specific solute/solvent interactions separately. Their equation has the 
following general form:
Solute Property = constant + cavity term + dipolarity/polarisabilty-
Equation 7.4
-term + hydrogen bonding term
As Kamlet-Taft solute parameters were partly based on the solvent properties, 
Abraham and co-workers developed a new dipolarity/polarisability scale, S and new 
hydrogen bond acidity and basicity parameters, A and B respectively.10"12 McGowan 
characteristic volume13,14 was also represented as symbol V. The newly devised 
descriptors were combined linearly to give the following equations.15
SP = c + e.E + s.S + a.A + b.B + v.V Equation 7.5
SP = c + e.E + s.S + a.A + b.B + l.L Equation 7.6
Important applications of the general solvation equation in drug design are discussed 
in latter chapters.
SP is a biological or chemical property of a series of solutes in a system, 
usually as log of some properties, although sometimes other dependent variables are 
used, for example, the % intestinal absorption of drugs.16 Mostly, however,
17  • •distribution or partition is considered as in blood-brain distribution or the partition 
of compounds in a particular water solvent system. The equation constant is defined 
by ‘c.’ The equation descriptor coefficients (i.e. e, s, a, b and v or 1) reflect on the 
properties of the system phase under investigation and are obtained by multiple 
linear regression using Microsoft excel program. The old and new notation for 
solute descriptors is shown Table 7.0.
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SYMBOL 
NEW OLD
;
SOLUTE DESCRIPTORS
.■ '" :U  v
The excess molar refraction in units o f  (cm3 m o l1) /10, which reflects
E r 2 solute polarisabilty. It provides a quantitative measure o f the ability o f  
a solute to interact with a solvent through n- and n -  electron pairs.
S * H2
The solute dipolar/ polarisabilty parameter. This measures the ability 
o f the solute to stabilise a charge or dipole.
A £ ocH2
The overall hydrogen bond acidity parameter. A measure o f  hydrogen 
bonding by the solute in a basic solvent.
B SPH2
The overall hydrogen bond basicity parameter. A  measure o f  the 
extent o f hydrogen bonding by the solute in an acidic solvent.
The logarithmic o f  the gas-hexadecane partition coefficient (or the
L lo g L 16 Ostwald solubility coefficient) at 298K. Accounts for cavity size and 
dispersion interactions.
V Vx
McGowan’s characteristic volume in units o f  (cm3 m o l1) /100 
Represents the three-dimensional space occupied by the solute.
Table 7.0. Abraham solute descriptors used today.18
T he excess m olar refraction , E (R 2)
The polarisability-correction descriptor (82) used by Kamlet and Taft is only 
an empirical factor limited to one of three values, 0.5 for halogenated aliphatics, 1.0 
for aromatics or 0.0 for all other compounds. A number of possible alternatives for 
82 were considered by Abraham,19 solute molar refraction (MRX) being one of them. 
This is latter defined as:
MRX = 10[(n2-l)/ (n2 + 2)] V Equation 7.7
Here n is the refractive index of a liquid solute taken at 293K with the sodium-D- 
line, and V is the McGowan’s characteristic volume in (cm3mol~VlII.13’14 For 
solids, the refractive index of the hypothetical liquid at 20°C can be also calculated 
by using the ACD software.20 The MRX parameter was found to be of little use.
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Because of the presence of the volume term in molar refraction, this latter always 
increases with increasing size, and is very co-linear with volume itself. The 
refractive index function itself is an indication of the polarisable electrons for a 
molecule that is either aromatic or halogenated aliphatic compounds. However, an 
excess molar refraction can be defined as the solute molar refraction less the molar 
refraction of an alkane of the same characteristic volume. The parameter E (10' 
1cm3mol'1) is given by;
E = MRx(observed) -  MRx(for alkane of the same V) Equation 7.8
The advantage of E is that it is almost independent of volume and also provides a
quantitative indication of polarisable n and JI electrons. E is an almost additive
quantity that can easily be estimated for solids and for structures in general (from
0 1molecular fragment or substructure values for any compound).
Solute dipolarity/polarisability scale S (TT2H)
Initially 712* was taken as the solvent parameter n\* for non-associated liquids 
set out by Kamlet and Taft.4,8 Where 7ii* is experimentally accessible only for 
compounds that are liquid at 298 K, values of 712* had to be estimated for associated 
compounds such as acids, phenols, alcohols and amides as well as gaseous and solid 
solutes. Also in addition, there is present the inherent idea that 711* is the same as 
7i2* for non-associated liquids, but this may not always be the situation. In addition, 
because of its spectroscopic origin, this parameter fails to be Gibbs energy related. It 
therefore seemed necessary to develop a method that would allow the determination 
of a dipolarity / polarisability scale, (7i2H), that would be free energy related and 
include all types of solute molecule.
Abraham and his co-workers constructed the new dipolar / polarisability 
parameter, 7i2H (or descriptor S as known now), from extensive sets of gas liquid 
chromatographic (GLC) data. This provided 7t2H (S) values for hundreds of solutes.
The 7i2H (S) values for halogenated or polyhalogenated solutes were again obtained
22by the same method using retention data for various other stationary phases.
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Hydrogen bond acidity of a solute, A
A new hydrogen bonding acidity scale (aH2)23 was set up by Abraham, using 
log Ki;i (equilibrium constants) for 1:1 complexation of a series of monomeric acids 
(e.g. pyridine) against a given reference base in tetrachloromethane (CCI4) at 298K. 
The use of equilibrium constants means the scale is Gibbs free energy related. If the 
acid and base are present in low concentrations, both will be in monomeric and non- 
associated forms and will undergo interactions as shown by Figure 7.1.
Figure 7.1. Hydrogen-bond complexation reaction.
Abraham and co-workers obtained forty-five equations in which log Ki:i is the 
dependent variable (see equation 7.9). The value of log KAH describes the acid, and 
Lb and Db characterise the base.
Log Ki;i (series of acids against reference base B) = Lb log KHA + Db Equation 7.9
The general hydrogen-bond acidity scale was set up by plotting a series of acid 
log K (against reference base) verses a series of log K (against any other reference
• • Hbase), to give rise to a series of straight lines, with an intersection point at log K A = 
log Kha = -1.1 (equilibrium constant expressed in molar concentration units). 
Different types of log Ki:i plots must show family-independent behaviour, so that it 
is possible to obtain the average hydrogen bond acidity (with some exceptions) for 
solutes in tetrachloromethane (CCI4), given as Log KHA. The origin was then shifted 
from -1.1 to 0 and compressed by converting Log KHA to oi2H in order that all 
compounds with zero hydrogen bond-acidity have a a2H value of zero.
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a 2H = (logKHA+ l.l)/4.636 Equation 7.10
The empirical value of 4.636 is used to compress the acidity scale into a suitable 
working range.
Within a bulk solvent the solute can form numerous hydrogen bonds with the 
neighbouring molecules, therefore the 1:1 complexation no longer applies and the 
ct2H values may not be relevant and a scale of solute overall or effective hydrogen- 
bond acidity descriptor (A) was needed. To obtain A values a initial version of 
equation 7.6 was set up, using 0C2H as the hydrogen-bond acid descriptor and was 
applied to various water-solvent partitions coefficient (log SP).24 The descriptor, CC2H 
was then tailored where necessary, in order to obtain the effective value, A. The new 
set of equations was then constructed, and the same process repeated until a self- 
consistent set of equations and A values was given. Whilst solvent molecules 
surround the solutes in the water-solvent partitions, the overall hydrogen-bond 
acidity scale is the actual scale required. It was observed that values of A were 
constant along any homologous series, except perhaps for the first one or two 
members, so once a few values are found, values for the remainder of the 
homologous series can be established. The multiple hydrogen bonding of solute 
gives rise to a higher A value than a 2H, obtained from a simple complexation 
constant.
Note that the work carried out to obtain on the whole A scale from the 1:1 0C2H 
scale proceeded side-by-side with the calculation of A that took place during the S 
calculation. This suggests that a regular check had to be made on the self- 
consistency of the derived A values. It is important to clarify that hydrogen bond 
acidity, which indicates the ability of a compound to donate a hydrogen bond is not 
related to Bronstead acidity of a compound, which refers to loss of a proton. Table 
7.1 indicates solutes with hydrogen bond donors. It can be seen from their A values 
that ethanol and pyrrole both have similar ability to participate in the hydrogen bond 
interaction.
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SOLUTE a 2H A
Alkanes 0 .0 0 0 .0 0
Triethylamine 0 .0 0 0 .0 0
Ethanol 0 .33 0 .37
Pyrrole 0.41 0.41
Water 0.35 0.82
Acetic Acid 0.55 0.61
Phenol 0.60 0.60
Table 7.1. The solute comparison between oi2H and A values.24
Hydrogen bond basicity for solute, B
Abraham, Kamlet and Taft8,25 were the first to propose the p2 descriptor (the 
solute basicity parameter), which was derived from solvent Pi values. The new p 2 
scale was established by Abraham et al,12,26 using 1:1 hydrogen-bond complexation 
constants in CCI4 (tetrachloromethane), pH2. The hydrogen-bond basicity scale was 
established by plotting log K values of series of bases (against a given reference 
acid) versus a series of bases (against other acids). These plots gave straight lines 
passing through log K = -1.1, and allowed the average hydrogen-bond basicity, log 
KHb for solutes in CCI4 to be obtained. These values were then converted into the B 
scale by applying equation.
PH2 = (log KbH + 1. l)/4.636 Equation 7.11
The empirical factor 4.636 was selected so that pH2 = 1.00 for the hydrogen bond 
base hexamethylphosphortriamide, and has no physical importance other than to 
serve as a suitable working range of B values.
As for the acidity term, there is no guarantee that pH2 is the suitable scale to 
use when a solute is surrounded by the solvent species.27 Though with few 
exceptions pH2 can be used as B for mono-bases. However, in the case of poly-bases,
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there seems to be no alternative than to calculate B by back-calculation. Table 7.2 
shows a comparison of pH2 and B values for some solutes.
An additional hydrogen bond basicity term was introduced by Abraham, SB0, 
for which solutes such as pyridines, anilines, sulfoxides, and some heterocyclic 
compounds in water/solvent partitioning systems, where the solvent phase is quite 
aqueous. The latter include n-octanol, diethyl ether, di-n-butyl ether, ethyl acetate 
and n-butyl acetate. Whereas, for non-aqueous phases such as benzene, alkanes, 
chloroform and the gas phase, the original B term can be used for all solutes.
Solute B
Alkanes (e.g. n-Hexane) 0.00 0.00
Dichloromethane 0.05 0.05
Benzene 0.15 0.14
Phenylcyanide 0.42 0.33
Diethyl ether 0.45 0.45
Ethanol 0.44 0.48
Pyridine 0.62 0.52
Dimethyl sulfoxide 0.78 0.88
Phenol 0.22 0.30
4-Methoxyaniline 0.45 0.65
Table 7.2. Comparison between pH2 and B values.24
Descriptor L or Log L
From the stage one in the cavity theory of solvation, the larger the solute the 
larger will be the cavity. However from stage 3, the larger the solute, the larger will 
be its tendency to take part in solute-solvent interactions of the general London 
dispersion type. A useful measure that includes a cavity effect and general London
dispersion effect which is related to the log L16 Ostwald solubility coefficient, which
28was defined as solute gas-hexadecane partition coefficient at 298K.
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Li6 = (Cone, o f  solute in hexadecane)/(Conc. o f solute in gas phase) Equation 7.12
Hexadecane was chosen by Abraham and co-workers,28 as a reference solvent, 
as it is a readily available non-polar liquid of well-defined structure. From this L can 
be readily obtained from GLC measurements. For volatile organic compounds, the 
L descriptor can be obtained by direct GLC measurements using packed columns 
coated with hexadecane at 298K and a number of n-alkanes used as standards. The 
L descriptor of a test solute can then be determined from its retention time.
The remaining four descriptors, E, S, A and B, can be regarded as measures of 
tendency of a solute to undergo various solute/ solvent interactions, all of which are 
energetically favourable, i.e. exoergic. Where as, L and V are both a measure of the 
size of a solute, so will be a measure of the cavity term. Additionally since the size 
of the solute is related to general dispersion interaction, both L and V describe
9 9solute/ solvent dispersion interactions.
The McGowan characteristic volume V (Vx)
9 1 19 9 8The cavity term V (in cm mof /100) ’ was chosen by Abraham because it is 
so straightforward to calculate by simple summation of bonds and atoms found in the 
molecule. The method chosen by Abraham has replaced Leahy’s computer program, 
which was used previously to calculate the intrinsic volume. The bonds in a solute 
are all considered equal, so that a double bond such as C =0 or C=C or a triple bond 
such as C=C are regarded as ‘one bond’. An algorithm proposed by Abraham13, 
allows the number of bonds in a molecule to be obtained simply;
B = N -  1 + R Equation 7.13
B represents the number of bonds, N is the total number of atoms and R is the total 
number of ring structures. V is defined as,
V = ( I  atom contributions -  (6.56 x B))/100 Equation 7.14
Values for atom contributions required for the calculation of V, are given in Table 
7.3.
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C =  16.35 P = 24.78 Se = 27.81
N =  14.39 S = 22.91 Br = 26.21
O = 12.43 Cl = 20.95 Sn = 39.35
F =  10.48 B = 18.32 Sb = 37.74
H = 8.71 Ge = 31.02 Te = 36.14
Si = 26.83 As = 29.42 I =34.35
Table 7.3. Atom contributions for calculation of V (in cm3 mol'1)
The coefficients used in Abraham equations
As the descriptors correspond to the solute effect from the various solute- 
solvent interactions, the coefficients encode the interaction properties of the solvent 
phase. For a transfer between two phases: the coefficients indicate the difference in 
interaction properties of the two phases (see table 7.4):
SYMBOL INTERPRETATION OF THE COEFFICIENTS
e Tendency o f the solvent to interact through n and a  electron pairs. The value of ‘e’ is 
usually positive but may be negative for phases that contain fluorine atoms.
s Tendency o f the phase to interact with polarisable/ dipolar solutes.
a Measure o f the hydrogen bond basicity of the phase (because acidic solutes will 
interact with basic phases).
b Measure o f the hydrogen bond acidity o f the phase (because basic solutes will interact 
with acidic phases).
1 Combination o f exoergic dispersion forces that make a positive contribution to the 1- 
coefflcient and an endoergic cavity term that makes a negative contribution. The 
dispersion interaction usually dominates, so that the 1-coefficient is positive, except 
for solution o f gases and vapours into water.
V Measure o f phase hydrophobicity, resultant o f dispersion and cavity effects.
Table 7.4. Interpretation of the coefficients used by the Abraham solvation 
equations.
99
In a gas-to-solution processes the s-, a- and b-coefficients must always be positive 
(or zero), because of the interactions between the phase and a solute will increase the 
solubility of a gaseous solute. Whereas this e-coefficient is an exception, because it 
is tied to hydrocarbons as a zero; hence fluoro compounds as phases may give rise to 
a negative e-constant. The coefficients in the solvation parameter equation are 
therefore not just fitting constants but must obey general chemical principles.
As an example of how the coefficient of the general equation can be used to 
define the system: SP = log Poct (octanol-water partition coefficient).18
Log Poet = 0.088 + 0.562E -  1.054S + 0.034A -  3.460B + 3.814V Equation 7.15 
n = 613, r2 = 0.9974, SD = 0.116 and F = 23162
The e-coefficient has a value of 0.562, although its effect will not be as significant as 
the other interactions, solutes with larger excess molar refraction value will slightly 
favour the organic phase. A negative value of s (-1.054), implies that the more polar 
the molecule, the more it will favour the aqueous phase. The hydrogen bond acidity 
of the compound (hydrogen bond basicity of octanol) does not influence the 
partitioning, however, hydrogen bond bases will strongly favour water (b = -3.46).
With a significant value of 3.814, the v coefficient shows that the larger the solute,
1 8the more it will be attracted to octanol.
OCTANOL
WATER
Figure 7.2. Properties of the octanol-water system
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Chapter
8
Methods of determination of descriptors
One of the major parts of the present work is the determination of descriptors 
for the variety of compounds, especially drugs, for which blood-tissue distribution 
are available. The Abraham descriptors E can be obtained from the refractive index 
in conjunction with structural information, as discussed before in chapter 7, and V 
can always be calculated. There are a number of ways of obtaining values for 
descriptors (S, A and B), whether there are experimental values available (i.e. log P 
for partition of a solute in a given solvent system) or not. The experimental methods 
include RP-HPLC measurements on various stationary phases, water/solvent
1 3partitions, and even solubility data. In recent studies, Valko " and co-workers have 
used a fast gradient elution RP-HPLC in order to obtain Abraham descriptors by a 
reasonably rapid procedure. Valko (et al) used 9 solvation equations for the different 
HPLC systems to obtain the Abraham descriptors. They have set up their method by 
choosing the most orthogonal HPLC systems by non-linear mapping.4 Zissimos et al 
have measured drug compounds to obtain log P values using the GlpKa instrument, 
utilising potentiometric methods developed by Sirius Analytical. This instrument 
used is designed specifically to determine ionisation constants (pKa) and partition 
coefficients (log P) of weak proton acids and bases in various water-solvent 
systems.5 The Abraham descriptors S, A and B were obtained by using the ‘Solver’ 
method for four equations corresponding to four water-solvent system. The systems 
were chosen so that the coefficients for the equations are as different as possible. 
The solvents used in Zissimo’s log P method are: octanol, chloroform, cyclohexane 
and toluene.
When no experimental data are available, methods based on a fragment 
addition approach (ABSOLV as developed by Pharma Algorithm6'7, UNIX based on
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structure developed by Platts8'9 and estimation by analogy) can give a quick 
estimation of a compound’s descriptors based on its 2D structure. Accurate 
estimation of descriptor values (S, A, B) can be obtained by using experimental data 
in a program called Solver (a function of Microsoft Excel). This chapter is an 
overview of the methods available to obtain descriptor value for small compounds 
like VOCs and large compounds such as drugs or pesticides.
Absolv
Absolv is a computer program that has been developed by Pharma Algorithms. 
The program calculates various solvation-associated properties from Abraham type 
equations and predicts Abraham’s solvation parameters necessary for such 
calculations. The parameters calculated are:
■ Excess molar refraction - E
■ Polarity/polarisability - S
■ Hydrogen bonding acidity parameter - A
■ Hydrogen bonding basicity parameter - B
■ McGowan volume - V
■ Partition coefficient between gaseous phase and hexadecane - L
These parameters have been discussed in detail in chapter 7 (the method of 
Abraham). The advantage of using Absolv is that for a given calculation for a given 
solute, it also lists up to 5 most similar structures from the Absolv database 
(experimental data for compounds found at UCL) along with their experimental 
values of the Abraham parameters and literature references. Absolv also allows one 
to calculate various solvent-solvent or gas-solvent partition coefficients from more 
than 100 predefined Abraham type equations, using predicted Abraham solvation 
parameters of a solute. The equation manager contained within the program allows 
one to define a new equation as well as view existing equations. Finally, Absolv has 
a fully searchable database, containing a list of more than 5000 compounds 
providing their names, CAS registry numbers, literature values of Abraham solvation
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parameters and references. This data compilation includes training and test sets used 
in building and evaluating Absolv predictive algorithms.6'7
Unix
The first fragmentation algorithm was devised by Platts et al8 who introduced 
an additive model (UNIX method) for the estimation of Abraham’s molecular 
descriptors E, S, A, B, and V. This model was developed from a set of 81 atomic 
and functional group fragments and intra-molecular interactions for which an 
evaluation of their contribution to each descriptor was carried out through a process 
of multiple linear regressions. They proceeded to apply this group contribution 
model to sets of molecules for which partitioning data was predicted using 
Abraham’s solvation equations.9 The method gives good results for predicting the 
molecular descriptors in question and also produces partitioning data for a number of 
compounds.
Abraham and Platts10 have set out characteristic parameters (sA and sB) for 
common functional groups, as given in Table 8.0 and 8.1. These are really fragment 
constants, but for functional groups, rather than the very small fragments considered 
by Platts et al. These ‘structural’ constants can be used very simply to estimate the 
effect of a substituent on overall A and B values. The main advantage of this 
method is that it can be set as a high throughput automated system, estimating 
descriptors for approximately 600 molecules per minute. The descriptors can be 
estimated from molecular structure entered as a SMILES string.9
Substituent sE sS sA sB sV
-H 0.00 0.00 0.00 0.00 0.0000
-F 0.03 0.35 0.00 0.10 0.0177
-Cl 0.22 0.40 0.00 0.10 0.1224
-Br 0.37 0.40 0.00 0.12 0.1750
-I 0.63 0.40 0.00 0.15 0.2582
-OMe 0.06 0.25 0.00 0.44 0.1996
-CHO 0.19 0.65 0.00 0.45 0.1566
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-CN 0.19 0.90 0.00 0.36 0.1547
-n h 2 0.23 0.35 0.16 0.61 0.0998
-n o 2 0.24 0.95 0.00 0.31 0.1742
-SH 0.39 0.35 0.00 0.24 0.1635
-OH(l°) 0.24 0.42 0.37 0.48 0.0587
-c o 2h 0.21 0.62 0.60 0.45 0.2153
c o n h 2 0.42 1.30 0.56 0.68 0.2564
3 Derived from propyl-H, where E = 0.(30, S= 0.00, A= 0.00, B= 0.00 and V=
0.5313.
Table 8.0. Aliphatic functional group structural constants3
Substituent sE sS sA sB sV
-H 0.00 0.00 0.00 0.00 0.0000
-Me -0.01 0.00 0.00 0.00 0.1409
-F -0.13 0.05 0.00 -0.04 0.0177
-Cl 0.11 0.13 0.00 -0.07 0.1224
-Br 0.27 0.21 0.00 -0.05 0.1750
-I 0.58 0.30 0.00 -0.02 0.2582
-OMe 0.10 0.23 0.00 0.15 0.1996
-CHO 0.21 0.48 0.00 0.25 0.1566
-CN 0.13 0.59 0.00 0.19 0.1547
-n h 2 0.35 0.44 0.00 0.27 0.0998
-n o 2 0.26 0.59 0.00 0.14 0.1742
-SH 0.39 0.28 0.09 0.02 0.1635
-OH(l°) 0.20 0.37 0.60 0.16 0.0587
-c o 2h 0.12 0.38 0.59 0.26 0.2153
s o 2n h 2 0.52 1.03 0.55 0.66 0.3807
c o n h 2 0.38 0.98 0.35 -0.05 0.9728
3 Derived from phenyl-H (benzene), where E = 0.61, S= 0.52, A= 0.00, B= 0.14 and 
V= 0.7164.
Table 8.1. Aromatic functional group structural constants3
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Estimation of descriptors based on the analogy method
The descriptors S, A and B are approximately constant for a given functional 
group (see table 8.0/8.1). They can be estimated by comparison with known 
descriptors of similar compounds. In addition, S, A and B are usually constant along 
a homologous series. This method can provide a rapid estimation of the descriptor 
values but is more time consuming than automatic programs like Absolv and UNIX. 
However, both the latter methods do not take into account all intra-molecular 
interactions such as hydrogen bonding. Hence, estimating the descriptors manually 
by analogy may lead to more reliable values.
Solver descriptor calculation
Solver is a tool in Microsoft Excel, which can be used to determine the 
maximum or minimum value of one cell by changing other cells. The LFER 
equations are entered in a Microsoft Excel spreadsheet, as well as the corresponding 
measured/literature data. Solver minimises the sum of squares on the required 
equations to fit the targeted cells S, A and B and the values are accepted when the 
overall sum of squares reaches a minimum. Solver uses the Generalised Reduced 
Gradient (GRG2) non-linear optimisation code developed by Leon Lasdon, 
University of Texas at Austin, and Allan Waren, Cleveland State University.
As an example, the descriptors for fluorescein S, A and B can be calculated by 
using the Excel program called Solver. The descriptor E and V can be calculated by 
using a VR calculator program based on equations discussed in chapter 7. From 
table 8.2, S, A and B for fluorescein can be calculated based on seven experimental 
values for log P measured by Ricardo Sanchez at UCL. It was found that the system 
containing 7 equations of different water/solvent system could be used to minimise 
and optimise the three Abraham descriptors accurately, without any other 
combinations. This is why it is necessary to use as many systems as possible. In 
addition, the system coefficients have to be as different as possible, in order to obtain 
good fits by the solver method. In the present case, it was found that calculated 
values for log P were very close to experimental values, that suggest the fits for 
descriptor S, A and B are the best values for fluorescein. The descriptors for
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fluoroscein are: S = 3.28, A = 1.41 and B = 1.00. The standard deviation between 
observed and calculated log P is 0.172. Finally, I would like to thank Ricardo 
Sanchez for the permission to use his results.
^  0
Log P values
Solvent Observed values Calculated values
Octanol 3.367a 3.333
Dichloromethane 1.4723 1.224
T richloromethane 0.977a 0.925
1,2-Dichloroethane 1.535a 1.569
Toluene 0.409a 0.344
Chlorobenzene 0.647a 0.544
Bromobenzene 0.6523 0.962
Solver descriptors E=2.75 S=3.28 A=1 
Standard dev
1.41 B=1.00 V=2.25 
iation = 0.172
aDirect experimental values for log P obtained for fluorescein (Ricardo Sanchez, UCL)
Table 8.2. Calculated values for fluorescein obtained from solver.
Descriptor calculation for terbinafine (via the analogy 
method)
The descriptors S, A and B are constant values for a given functional groups. 
They can also be estimated by comparison with known descriptors of similar 
compounds, for which the descriptors are already known. In this case, the fragments 
for terbinafine are shown in table 8.3. The descriptors obtained for the fragments are 
added up to give an estimated value for the compound as a whole. For terbinafine, E 
was obtained from the hypothetical refractive index, which was calculated using 
ACD Chemsketch, version 6.0. Descriptor V, is obtained by molecular formula, the
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number of rings present within the compound structure and the chemical formula as 
discussed in detail from chapter 7. From table 8.4, it seems that the calculated value 
for water/octanol partition agrees with the observed value, which suggests that the 
descriptors are good as one can get for this drug compound.
TERBINAFINE (C2iH25N) DATA Vr Calculator
CH,
C H 3
Number of rings = 2 
n20=1.5 86  (ACD) 
C21H25N
E = 1.8910 
V = 2.6061
ADDING THE VARIOUS 
FRAGMENTS
S A B
Napthalene
0.92 0 .0 0 0 .2 0
c h 3
N
H3C CH3 Trimethylamine
0 .2 0 0 .0 0 0.67
Ethylene
0 .1 0 0 .0 0 0.07
JJt3CH3
c h 3
0.23 0 .1 2 0 .1 0
E s A B V
Estimated descriptors: 1.89 1.45 0 . 1 2 1.04 2.61
bThe descriptor E and V were calculated by using a VR calculator program based on equations 
discussed in chapter 7
Table 8.3. Estimated descriptors for terbinafine
Log P values
Solvent Observed values Calculated values
Octanol 6 .0 0a 
, ,0 , 1 . , 'i i
6 .02
aLog P star (octanol/water) obtained from the MedChem database
Table 8.4. Calculated values for terbinafine obtained from Solver.
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Descriptor calculation for erythromycin (via the analogy 
method)
From the literature it was possible to obtain two partition coefficients for this 
compound. From this data one can check by using solver if the estimated descriptors 
are good or not. The descriptors S, A and B are estimated by adding fragments with 
known descriptors, of similar compounds of which the descriptors are already 
known. In this case, the fragments for erythromycin are shown in table 8.5. 
Descriptors E and V were calculated in the same way as previously described for 
terbinafine. From table 8 .6 , it seems that the calculated values for the partition for 
water/octanol and water/trichloromethane do not agree with the observed value. 
This suggests that the descriptors obtained by analogy method are not very good. 
The estimation for descriptors may be improved by using the Pharma Alogorithm 
method.
ERYTHROMYCIN (C37H67N1O13) DATA Vr Calculator
0
CHa^ ^ CH3 
OH OH C^ '!
CH3'p '^ O H  HO N-CH3
A  \
CH3 ° --- \o '  o  \1 | CH3
CH3oA
Jr—0 
ch3 \  \1 ch3 ch3
oh
Number of rings = 3 
n20=1.535 (ACD) 
C37H67N 1O13
E = 2.150 
V = 5.773
ADDING THE VARIOUS 
FRAGMENTS
s A B
/ ° \ X \
OH 2-Methoxyethanol
0.50 0.30 0.84
/  v  \  Dimethoxymethane
0.46 0 .0 0 0.52
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0/ v / \O Ethyl acetate
0.62 0.00 0.45
K
H<3 OH Propan-1,2-diol
0.90 0.58 0.80
0
Pentan-3-one
0.66 0.00 0.51
ch3
h3c — c — ch3
OH
2-Methylpropanol-2-ol
0.30 0.31 0.60
/ ° x / 0 \
/  \  Dimethoxymethane
0.46 0.00 0.52
OH
CH
H3C CH3 propan_2-ol
0.36 0.33 0.56
ch3
/ N\
h3c ch3
0.20 0.00 0.67
E s A B V
Estimated descriptors: 2.15 4.46 1.52 5.47 5.77
Table 8.5. Estimated descriptors for erythromycin
It appears that when the analogy method is used to estimate descriptors (S, A 
and B) for erythromycin, the two equations used to calculate log P for octanol and 
trichloromethane give values that differ greatly from the observed values. The 
Pharma Algorithm’s5 method for obtaining estimated descriptors for erythromycin,
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gives more accurate predictions for S, A and B than the analogy method. From 
analysis of the two equations used by Solver to calculate S, A and B it appears that 
there many possible combinations of descriptors, because there are two equations but 
three unknowns. To limit this problem, three Solver calculations were obtained 
based on descriptors estimated for S, A and B from the Pharma Algorithm. For 
Solver (1) calculations, B was fixed and descriptors S and A were minimised until a 
suitable fit was obtained. For Solver (2) calculations, A was fixed and descriptors S 
and B were minimised until a suitable fit was obtained. Finally, S was fixed and 
descriptors A and B were minimised until a suitable fit was obtained based on the 
two equations mentioned earlier. The averages of descriptor values S, A and B 
obtained using solver (1 and 3) were taken, are shown in table 8.6. This average data 
for Solver supported by the Pharma Algorithms method gives log P values closer to 
the observed values, which suggests that using Solver in conjunction with the 
Pharma Algorithm calculated values is the best method for obtaining descriptors 
when only two equations are involved. If more equations are available, then there is 
only one combination to obtain descriptors, that can be found from Solver itself.
METHODS S A B
OCTA
LO<
JVOL
S P
TRICHLORC
LO<
)METHANE
CALC OBSa CALC OBSb
ANALOGY 4.46 1.52 5.47 -0.26 2.54 -0.54 2.46
PHARMA
ALGORITHM
3.80 1.16 4.88 2.46 2.54 2.90 2.46
SOLVER (1) 3.73 1.31 4.88 2.54 2.54 2.45 2.46
SOLVER (2) 3.02 1.16 5.10 2.53 2.54 2.45 2.46
SOLVER (3) 3.80 1.32 4.86 2.54 2.54 2.46 2.46
AVERAGE
TAKEN
3.77 1.31 4.87 2.54 2.54 2.47 2.46
CALC = calculated values obtained from Solver 
OBS = observed values
aLog P star (octanol/water) obtained from the MedChem database10 
bLog P star (trichloromethane/water) obtained from the MedChem database1
Table 8.6. Comparison of the calculated descriptors obtained from the three 
methods for erythromycin.
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Combining Rat and Human 
Log K data for VOCs
There has been a large number of sources of VOC data reported by various 
authors, on air to blood and air to tissue distribution.1'38 The reported data have been 
obtained by measurements on known volatile organic compounds at steady state 
equilibrium (37°C) using a head space chromatography technique. Within this 
reported literature data there are two important groups of species: humans and rats.
The purpose of this work is firstly to collect literature data for air to blood 
distribution for humans and rats and secondly to collect VOC data for air to tissue 
partition and then to filter the log K data into these two main classes. If any new 
reported literature data is obtained for the same compound, this can then be averaged 
with the current data to give rise to an average value for log K. These constructed 
sets can then be used to make a direct comparison between human and rat values for 
both blood and tissue data. Tables are displayed for air to blood and air to tissue 
distribution for humans and rats as table 9.0 and 9.1. The tables show data that are 
common compounds to both species and also other non common compounds for 
humans and rats. Human and rat log K data for VOCs will then be compared for 
common compounds for air/blood and air/tissue distribution to see if there are 
similarities or differences between species. Table 9.0 (see appendix) is the up to date 
literature data for air to blood distribution for VOCs in general. Finally, table 9.1 
(see appendix) is the up to date literature data for air to tissue (brain, fat, kidney, 
liver, lung, muscle and plasma) distribution for VOCs (see appendix).
114
Air to blood distribution in humans and rats
Gargas et al6 made an attempt to look at the similarities between human and 
rat air to blood distribution for a group of VOCs. He compared 36 common 
compounds between both species to see if the air to blood distribution (blood:air) is 
the same or not.6 His table of 36 common compounds contained blood log K values 
for human and rat that are not averaged literature values. From his table he plotted 
human blood:air versus rat blood air to reveal that rat values tend to be 1.5 to 2.0 
times higher than the corresponding human values in some instances (equation for 
his plot, see table 9.2).
MODEL
GRADIENT
Em]
STD 
ERROR [m]
INTERCEPT
[c] .:e ;v
STD 
ERROR [c]
REG 
COEFF [r2] n RMSE
THIS WORK 
(2004)a 1.00 0.028 -0.12 0.047 0.94 86 0.279
GARGAS
(1989)b,e 1.01 0.037 -0.23 0.051 0.96 36 0.132
Straight line equation obtained from a logarithmic scale plot 
b Straight line equation obtained from a numerical scale plot
Table 9.2. Plot for the common compounds between rat and human log K blood
RMSE = 0.279
0.210
AE (rat-hum) = 0.124
SD (n«1) = 0.280
86
Table 9.3. Statistics on common compounds between rat and human log K blood, 
this work
From his equation, the gradient is 1.01 and the intercept is -0.23 which suggest 
there is a direct linear relationship between the two sets of data for both species. The 
intercept is close to zero and Gargas et al suggest that rat and human log K values 
are not the same and they cannot be combined. In Table 9.3., this shows that with
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larger data sets of common compounds, the average absolute error to be 0.21 for the 
two sets of data. The standard deviation of 0.28 also indicates that there very little 
difference between the two groups of species.
This model takes this method further where the average values for log K blood 
are obtained for humans and rats. The model has 86 common compounds for VOCs 
and also the model has greater structural diversity than was used by Gargas. Using 
the 86 common compounds it is important to find out if there are similarities or 
differences between humans and rats. A plot was made for the 86 common 
compounds (see the human verses rat plots) and obtained a straight line equation 
(equation for the plot, see table 9.2). From this equation, the gradient is 1.00 and 
intercept of -0.12 which suggest there is a direct linear relationship between the two 
sets of data for both species. The intercept is very close to zero. This equation 
supports the conclusion of Gargas that there is a slight variation in data between both 
species, but this is extremely small as compared with the Gargas model; it appears 
from the plot that rat and human data are the same
Experimental error for three different VOCs
Fiserova-Bergerova et al was one of the first to report large discrepancies in 
air to blood partition. She found that the values for gas to blood partition for acetone 
and 2-butanone appeared different from the other investigators using methods based 
on the same principle as used in her study. She had no explanation for this
discrepancy, and suggested that it is possibly experimental error in the
measurements.5 It is important to find out what is the experimental error in obtaining 
VOC air to blood (or air to tissue) distribution at several laboratories. From table 9.4 
(acetone), 9.5 (chloroform) and 9.6 (trichloroethylene) the partition coefficient 
appears to vary among the five to six independent laboratories. The standard 
deviation has been calculated for each of these three compounds, to gain some 
insight into what is the experimental error for these VOCs. The smallest
experimental error is observed for trichloroethylene (standard deviation = 0.06),
whilst the highest is for acetone (standard deviation = 0.34). There are many reasons 
why this variation of partition coefficients (air to blood) for VOC can take place. 
For example: not enough time to allow steady state concentration to be achieved
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before measurements are taken, error measurement of sample of sample, error in the 
preparation sample, variation in the blood sample (or tissue sample), and many more.
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REFERENCE Measurements Acetone (propan-2-one)
[26] 1 1.68
[4] 2 2 .50
[5] 3 2 .27
[34] 4 2 .39
[35] 5 2.50
Standard deviation (n-1) 0.34
Table 9.4. Experimental data for air to blood distribution for acetone in humans
REFERENCE Measurements
Chloroform
(trichloromethane)
[4] 1 1.09
[36] 2 0.91
[32] 3 1.03
[37] 4 1.01
[6] 5 0.84
[39] 6 0.93
Standard deviation (n-1) 0.09
Table 9.5. Experimental data for air to blood distribution for chloroform in humans
REFERENCE Measurements Trichloroethylene
[38] 1 1.08
[4] 2 0.94
[36] 3 0.95
[37] 4 0.98
[6] 5 0.91
[39] 6 0.96
Standard deviation (n-1) 0.06
Table 9.6. Experimental data for air to blood distribution for Trichloroethylene in 
humans
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Compound name Standard deviation (n-1)
A cetone 0.34
Chloroform 0.09
Trichloroethylene 0.06
Average standard deviation (n-1) 0.16
Table 9.7. Average standard deviation for three VOCs (air to blood in human)
The average standard deviation for the three compounds can be taken, to gain a 
better idea of what is the average experimental error obtained. In this case from 
Table 9.7, the average standard deviation is found to be 0.16, which could represents 
the average experimental error for air to blood (or air tissue to tissue) distribution for 
VOCs in general.
Total regression of blood log K for humans and rats
In table 9.0, a full list of blood K data is given from various literature sources. 
Here it can be seen that there is a large data set of solutes for air to blood distribution 
for humans and rats. It is important to compare both of the Abraham equations for 
humans and rats for air to blood distributions, to verify if the equations for both 
species are the same. From table 9.8 the two equations have been obtained by multi 
linear regression analysis. By comparing the standard errors for each of the 
coefficients in the equations in table 9.8, it can be seen that the coefficients e, s, a, b 
and 1 are same within the standard error (see Table 9.9) at 95% confidence interval.
Species v. c  iM. S n r* SD (n-1) F
HUMAN -1.18 0.39 0.97 3.80 2.69 0.41 155 0.94 0.34 474.00
RAT -0.75 0.56 1.06 3.64 2.41 0.29 127 0.91 0.29 241.63
Table 9.8. Human and Rat log K blood (blood log K verses descriptors)
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Coefficients
HUMAN 
95% limits
HUMAN
SD
RAT 
95% limits
RAT
SD
c -1.29 to 1.06 0.06 -0.93 to -0.58 0.09
e 0.17 to 0.62 0.11 0.29 to 0.84 0.14
s 0.71 to 1.24 0.13 0.78 to 1.33 0.14
a 3.24 to 4.36 0.28 3.08 to 4.19 0.28
b 2.38 to 3.00 0.16 2.07 to 2.76 0.17
1 0.36 to 0.46 0.03 0.23 to 0.35 0.03
Table 9.9. The range for the standard error (95% confidence interval) of the 
coefficient
The coefficient c is just outside this range. However, it can be concluded that rat and 
human air to blood tissue distribution are the same for both species (see the plots for 
rats and humans verses Abraham’s descriptors over the next two pages).
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Air to tissue distribution for hum ans and rats
It is important to determine if human and rat VOCs air to tissue distribution 
are the same or not. Table 9.1 contains a list of data for log K air to tissue 
distribution for humans and rats. The tissue data where log K have been compiled 
for both species are: brain, fat, kidney, liver, lung, muscle and plasma. From this 
data set an overall list for air to tissue distribution for 108 compounds that is 
common to both humans and rats has been compiled. From this list a plot (humans 
verses rat tissues log K) was constructed to see if there is a similarity between both 
species. From table 9.10 that the straight line equation for the plot suggests that 
there is a direct linear relationship between both humans and rats. The intercept is 
almost 0, the square of the overall correlation coefficient is almost 1 and the gradient 
is almost 1 which suggest that they are the same. The standard deviation is small 
suggesting there is very little difference between the two sets of data (see plot of air 
to tissue distribution for humans verses rats).
MODEL
GRADIENT
[m]
STD 
ERROR [m]
INTERCEPT
[c]
STD 
ERROR [c]
REG 
COEFF [r2] n RMSE
THIS WORK 
(2004) 0.91 0.019 0.10 0.037 0.96 108 0.27
Table 9.10. Equation for the common compounds between rat and human tissue log 
K (brain, fat, kidney, liver, lung, muscle and plasma)
RMSE = 0.265
AAE = 0.193
AE (rat-hum) = 0.030
SD (n-1) = 0.266
n = 108
Table 9.11. Statistics on the log K values for the common compounds between rat 
and human tissues.
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Table 9.11 the average absolute error of 0.19 for the two sets of data for human and 
rats is small and suggest that the two sets are almost the same. The standard 
deviation 0.27 also indicates that there very little difference between the errors for 
the means of the two groups of species.
It is also finally important again to verify if the data on both species are the 
same for air to tissue distribution by comparing the tissue equations. In this case fat 
has the largest data set of any tissues for the equations to be constructed for humans 
and rats. From table 9.12 the two equations have been obtained for fat by multi 
linear regression analysis. By comparing the standard error for the coefficients of 
the equations, the coefficients c, e, s, a, b and 1 are same within the standard error 
(see Table 9.13) at 95% confidence interval. The plots are shown in figure 9.0 for 
humans and figure 9.1 for rats. This suggests again that rat and human air to tissue 
distributions are the same for both species.
Species c e S a b 1 n r2 SD (n-1) F
HUMAN -0.03 0.02 0.70 2.14 0.04 0.77 30 0.97 0.15 153.53
RAT 0.09 0.03 0.53 2.15 0.20 0.74 30 0.97 0.14 145.17
Table 9.12. Human and Rat log K tissue (fat log K verses descriptors)
Coefficients
HUMAN 
Lower 95%
HUMAN 
Upper 95%
RAT 
Lower 95%
RAT 
Upper 95%
c -0.24 0.18 -0.12 0.30
e -0.32 0.36 -0.30 0.36
s 0.33 1.06 0.18 0.89
a 1.60 2.67 1.63 2.67
b -0.36 0.44 -0.19 0.60
1 0.69 0.85 0.66 0.81
Table 9.13. The range for the standard error (95% confidence interval) of the 
coefficient (for fat log K)
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C onclusion
Both the equations and plots show that human and rat air to blood (and air to 
tissue) distributions are the same within the experimental error. Human and rat log 
K data for air to blood and air to tissue distribution can be combined and averages 
taken where necessary to develop new Abraham equations to predict distribution for 
VOCs.
Calculated log K verses observed log K for human fat
OBSERVED LOG K
Figure 9.0. Graph showing calculated log K verses observed log K for human blood
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Figure 9.1. Graph showing calculated log K verses observed log K for rat blood
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Chapter
Air to blood distribution for VOCs 
(rat and human average data)
The solubility of VOCs in biological fluids like blood is of importance in 
anaesthesiology, toxicology and environmental health. There has been a large 
number of reported log K data for air to blood distribution and their references are 
cited in chapter 9 of this thesis. Several cited papers, where models have been used 
to predict air to blood distribution in humans, rats or for both species shall be 
discussed. The purpose of this work is to add new literature data to the existing data 
set of Abrahams and to make an attempt to construct a new equation to predict these 
processes. Correlative and predictive equations shall be constructed based on 
datasets that represent average human and rat data combined. The complete list of 
the VOC log K data for these averages, are shown in table 10.0 (see chapter 9 how 
this data is obtained). The reported literature models for the correlation of air to 
blood distribution for VOCs are found for the following authors: Gargas (et al)1, 
Weathersby (et al)2 and Meulenberg (et al).3
Gargas et al, determined log K values (air to blood distribution) for 55 low 
molecular weight, volatile compounds in humans. From this data set he successfully 
modelled human air to blood distribution in terms of contribution from air to oil and 
air to saline values using linear regression techniques as shown below.1
Log ( K n u m a n  b l o o d )  = 0.553(±0.030)log(Koil) + 0.351(±0.025)log(Ksal) - Equation 10.0
0.286(±0.080)
r2= 0.957 RMSE = 0.179 n = 55
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Gargas also obtained 36 log K (air to blood distribution) values, common to rats and 
humans. From this data set he used the rat log K in the equations to predict human 
air to blood distribution (see below for equation). Unfortunately his model doesn’t 
have a test set, thus any predictions cannot be assessed.1
Log ( K n u m a n  b l o o d )  = 1.014(±0.037) log ( K R a t  b i o o d ) - 0 . 2 3 2 ( ± 0 . 0 5 1 )  Equation 1 0 . 1
0.957 RMSE = 0.132 n=36
Weathersby compiled a dataset of 86 solutes in his model to correlate air to 
blood distribution for humans. Most of the data is compiled from previous literature 
reviews and new data have been added to update any current models in air to blood 
distribution. Weathersby used the Abraham solvation equation to correlate the log K 
data (Ostwald solubility coefficient at 31 OK) for air to blood with the five Abraham 
descriptors (E, S, A, B and L). The Abraham equation used for this model is shown 
in equation 10.2.2
Log K ( a i r b i o o d )  = -1.269 + 0.612E + 0.916S + 3.614A + 3.381B + 0.362L Equation 10.2
1^  = 0.977 S.D = 0.203 n = 82
Meulenberg obtained a reasonable amount of data in his training set to produce 
two correlative equations for air to blood distribution in rats and humans. He found 
that the partition coefficients of VOCs in human (or rat) blood are well described by 
a linear combination of Kair:oii and Kair:Saiine with specific regression coefficient for the 
biological sample i.e. blood. The partition (K) data for air to blood distribution are 
averaged values from literature sources and have been used for the bilinear 
regression. This method is very much similar to the method employed by Gargas et 
al.1 Equations 10.3 and 10.4 shows how Kajr:biood is described as a bilinear function of 
Kair;oiive oil and Kajr;Saiine- The coefficients a0ii and asaiine of both equations represents 
the tissue-specific contributions of the lipophilic and hydrophilic interactions to the 
solubility of the VOCs in blood. The c constant has no specific physical meaning 
but it was required by Meulenberg to compensate for systematic errors in blood, oil, 
or saline partition coefficients.
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Human equation
K a i r : b l o o d =  0 . 0 0 7 2 K a ir : o l iv e  o i l  +  0 . 8 9 8 K a ir : s a lin e  +  0 . 0 3  
r2 = 0 . 9 9  SD = n/a n = 1 0 9
Equation 10.3
Rat equation
K - a in b lo o d  0 . 0 0 5 4 K a ir :o ]jv e  0 j | +  0 . 9 3  l K - a ir : s a l i n e  1 * 1 6  
r2 = 0 . 9 3  SD = n/a n = 9 2
Equation 10.3
It appears that none of the three models have any test sets that includes statistical 
information that can be used to verify their predictions. It was very unfortunate that 
Meulenberg did not calculate the fits (i.e. standard deviation) for his training set used 
for his correlation.
An improvement can be made on air to blood distribution by using training 
sets and test sets containing a large number of compounds (including statistical 
information). It would be very interesting to see if the diversity of compounds helps 
to improve models that are currently available. Most of the models discussed before 
are outdated and many new measurements have been made for VOCs which will be 
included into the new training sets (see appendix table 10.0).
Discussion on air to blood distribution for VOCs in human 
and rat combined
The Abraham solvation equations can successfully be employed to correlate 
VOC air to blood distribution (see table 10.1). Considering that this model has now 
got 196 compounds in the dataset, the fits for this new equation appear to very good 
(S.D = 0.324 and r2 = 0.938). This work is the most up to date model for VOC air to 
blood distribution, it appears this is the most general model yet reported for both 
species (humans and rats).
There were two outliers observed from this training set: CFH2CH2CFH2 and 
cyclopentadiene. The residual for these two compounds are approximately 1 log unit 
and may result from being an experimental error. Other possibilities can arise as 
these compounds may bind irreversibly to proteins contained in blood or interact and 
bind to hydrophobic pockets in haemoglobin.
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All the log K equations for air to tissue distribution are based on the same model, 
given by:
Log K = c + e.E + s.S + a.A + b.B + l.L
In the present case, if the two outliers are included in the model, this gives the 
following equation.
Log K (air:blood) = -1.049 + 0.450E + 1.088S + 3.720A + 2.565B + 0.373L 
N = 198 r2 = 0.932 SD = 0.338 F = 523.776 D = 5
The statistics of the equation with n = 198 are very close to those of the equal with n 
= 196 (as shown in table 10.1). The coefficients and statistics for both of the 
equations are very much the same. This model shown above is used throughout the 
thesis for VOCs.
EQUATIONS N r2 SD F D
FULL SET-AVERAGED
Log K (airiblood) = - 1.069 + 0.456E + 1.083S + 
3.738A + 2.580B + 0.376L
196 0.938 0.324 572.751 5
FULL SET-COMBINED (NOT AVERAGED)
Log K (airiblood) = - 1.062 + 0.460E + 1.067S + 
3.777A + 2.556B + 0.375L
282 0.927 0.330 699.100 5
TRAINING SET
Log K (airiblood) = - 0.978 + 0.596E + 1.000S + 
3.494A + 2.914B + 0.329L
TEST SET
N = 98 RMSE= 0.326 AAE = 0.255 
AE = 0.043 SD (n-l) = 0.327
98 0.933 0.338 257.339 5
N = number o f compounds used in the training set 
r2 = is the overall square o f the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number o f descriptors used in the model
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RMSE = the root mean square error 
AAE = absolute average error 
AE = average error
Table 10.1. Summary of the equations for VOC air to blood distributions and 
statistics for test sets of 98 solutes
The inter-correlations of descriptors used for VOC air to blood distribution are 
shown in table 10.2. The largest r value for E versus L descriptor is 0.37. It appears 
that there is no strong inter-correlation between the set of descriptors used in this 
model.
The Abraham solvation equation has successfully been employed to predict air 
to blood distribution for VOCs provided the solute is within the given descriptor 
range of the training set to make the correlative equations. To test the predictability 
of the model it was necessary to split the full data into training and test set using a 
random data set generator. A new model is developed using only those data in the 
training set, which is then used to predict values for the test set. The full data set of 
196 compounds in two sets of 98, using the first set to construct equation similar to 
the first equation from table 10.1 and predicting 96 log K values (air to blood 
distribution of VOCs) for the second set. The regression yielded similar training 
equation and statistics to the first equation in table 10.1. The test of 96 compounds 
shows the average absolute error to be 0.255 for the two sets of data (observed and 
predicted log K). The root mean square error of 0.326 also indicates that there very 
little difference between the observed value and predicted data for air to blood 
distribution for VOCs. The average error of 0.043 indicates that the equation of the 
model is not biased, as it is close 0.
r E S A B L
E 1.00
S 0.54 1.00
A -0.09 0.08 1.00
B 0.05 0.41 0.42 1.00
L 0.61 0.44 -0.06 0.21 1.00
Table 10.2. The inter-correlation of descriptors for 196 solutes using descriptors E, 
S, A, B and L.
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The positive e- and 1-coefficients in the air to blood equation (10.1) indicate 
that increasing molecular size, cavity effects, London dispersion interaction and the 
presence of n- and 11-electrons pairs can push VOCS out of air and into the blood 
phase. The coefficients of the ‘polar’ descriptors S, A, and B are all positive, 
indicating that polarity and hydrogen-bond donor and acceptor ability is stronger in 
the blood phase than in gas phase. The solutes are pushed out of the air and into the 
blood phase. Finally, the Abraham equation can successfully be used to make 
predictions for air to blood distribution for a diverse range of solutes (VOCs) as 
shown before.
We can also use the data on human blood and rat blood without averaging the 
Kbiood(human) and Kbi00d(rat) values. This leads to 282 data points and the 
corresponding equation is shown in blue in table 10.1. The coefficients in the 
combined equation and the average equation (table 10.1) are almost identical. The r 
value in the combined equation is a little less than that in the average equation, but 
the F-statistic is much better, simply reflecting the larger number of data points.
The statistics for this model is very good, as indicated by the large spread of 
data shown from the plot. It is found to be possible to construct an equation capable 
of predicting further values of log Kbi00d to around 0.3 log units. This equation is 
one of the soundest equations for predicting log K values for air to blood distribution 
of VOCs.
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Chapter
Air to plasma, air to blood and plasma to blood 
distribution for VOCs
In this chapter the Abraham solvation equation shall be used for models that 
include: air to plasma distribution for VOCS and air to blood (blood and plasma data 
combined) distribution for VOCs. A comparison between plasma and blood log K 
data for VOCs and blood to plasma distribution (log P) for VOCs shall be discussed.
Air to plasma distribution for VOCs
The distribution of VOCs from air to plasma is of importance in clinical 
medicine, toxicology and environmental sciences. There has been only been one 
reported model for air to plasma distribution.1 The purpose of this work is to add 
new literature data to the existing data set of previous authors and to make an 
attempt to construct a new equation to predict these processes. The correlative 
equations of Abraham shall be constructed based on datasets that represent average 
human and rat data combined. The complete list of the VOC log K data for these 
literature averages is shown in table 11.0. The reported literature models for the 
correlation of air to plasma distribution for VOCs are found only from Weathersby 
and Abraham.1
Weathersby and Abraham compiled a dataset of 32 VOCs in their model to 
predict air to plasma distribution for humans. Most of their data is compiled from 
previous literature reviews and new data have been added to update any current 
models in air to plasma distribution.1 Weathersby used the Abraham solvation
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equation to correlate the log K  data (Ostwald solubility coefficient at 31 OK) for air to 
plasma with the five Abraham descriptors (E , S , A , B and L ). The Abraham 
equation used for this model is shown in equation 11.0.1
Log K  (air:piasma) = -1-480 + 0.490E + 2.047S + 3.507A + 3.91 IB + 0.157L Equation 11.0 
1^  = 0.984 S.D = 0.232 n = 32
The equation above is the only literature model for air to plasma distribution 
of VOCs. A small improvement can be made by adding new data to that of 
Weathersby and Abraham for air to plasma distribution of VOCs to see if the new 
equation for the full set has better fits than the above model. Table 11.0 (see 
appendix) is the up to date literature data for air to plasma distribution for VOCs in 
general.
Discussion on air to plasma distribution for VOCs
The solvation equation of Abraham can successfully be employed to correlate 
VOC air to plasma distribution (see table 11.1). Considering that this model has 
now got 36 compounds in the dataset, the fits for this new equation appear to very 
good (S.D = 0.249 and r2 = 0.979). This work is the most up to date model for VOC 
air to plasma distribution; it appears this is the most general model yet reported for 
both species (humans and rats). There were no outliers observed from this full set.
The inter-correlations of descriptors used for VOC air to plasma distribution 
are shown in table 11.2. The largest r2 value for S versus L descriptor is 0.45. It 
appears that there is no strong inter-correlation between the set of descriptors used in 
this model.
EQUATIONS N r2 SD F D
FULL SET
Log K (air:plasma) = -1.435 + 0.543E + 1.677S +
3.518A + 3.982B + 0.192L
36 0.979 0.249 285.359 5
N = number o f compounds used in the model
r2 = is the overall square of the correlation coefficient
SD = the standard deviation
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F = F-statistic
D = the number o f descriptors used in the model
Table 11.1. Summary of the equations for VOC air to plasma distributions
r E S A B L
E 1.00
S 0.39 1.00
A 0.20 0.37 1.00
B 0.26 0.60 0.66 1.00
L 0.43 0.67 0.34 0.54 1.00
Table 11.2. The inter-correlation of descriptors for 36 solutes using descriptors E,
S, A, B and L.
The Abraham solvation equation has successfully been employed to correlate 
air to plasma distribution for VOCs. No training and test sets were used as the 
number of compounds was too small. The positive e- and 1-coefficients in the air to 
plasma equation (11.1) indicate that increasing molecular size, London dispersion 
interaction and the presence of n- and Fl-electrons pairs can push VOCS out of air 
and into the plasma tissue phase. The coefficients of the ‘polar’ descriptors S, A, 
and B are all positive, indicating that polarity and hydrogen-bond donor and acceptor 
ability is stronger in the plasma phase than in gas phase. The solutes are pushed out 
of the air and into the plasma phase.
The statistics for this correlative model (air-plasma distribution) is good, as 
indicated by the even spread of data shown from the plot. The air to plasma model is 
comparable to the air to blood model, as blood and plasma behave very similar to 
other especially when they interact with VOCs.
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Air to blood and plasma distribution for VOCs
It is now important to find out whether the air to plasma equation for VOC is 
the same as the equation for air to blood distribution. One way of investigating this 
is to combine the dataset for air to blood distribution with the data set of air plasma 
distribution and then construct an equation of Abraham solvation based on the full 
data set combined. This equation can then be compared to the original air to blood 
equation for VOCs to see if the two equations are the same or not. Correlative and 
predictive equations of Abraham for the combined dataset (i.e. air to plasma and air 
to blood) shall be constructed. The complete list of the VOC log K data is obtained 
by combining the air to blood (chapter 10, table 10.0) with air to plasma (table 11.0) 
distribution data, to give a total set of 232 VOCs.
Discussion on air to blood and plasma distribution for 
VOCs
The air to blood and plasma solvation equations can successfully be employed 
to correlate VOC air to blood and plasma distribution with the Abraham descriptors 
(see table 11.3). Considering that this model has now got 232 compounds in the 
dataset, the fits for this new equation appear to be very good (S.D = 0.332 and r2 = 
0.943). In fact, this equation for full set has an improved fit (r = 0.943) over the 
current air to blood equation (1^=0.938, in chapter 10, table 10.1). The coefficients 
for the combined data set (air to blood and air to plasma) equation for the 232 
solutes, are more or less the same as in the air to blood equation. This suggest that 
air to plasma log K data for VOCs can be combined together with the air to blood 
log K data, as they do not appear to be different from each other.
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EQUATIONS N r* SD F D
FULL SET
Log K (airisample) = - 1.154 + 0.446E + 1.130S 
+ 3.844A + 2.673B + 0.386L 
Log K (air.blood) = - 1.069 + 0.456E + 1.083S 
+ 3.738A + 2.580B + 0.376L
232
(196+36)
196
0.943
0.938
0.332
0.324
741.611
572.751
5
5
TRAINING SET
Log K (airisample) = - 0.997 + 0.629E + 1.015S 
+ 3.517A + 2.769B + 0.337L
TEST SET
N = 116 RMSE = 0.352 AAE = 0.288 
AE =0.082 SD(n-l)= 0.353
116 0.933 0.332 308.020 5
Sample = blood and plasma data combined 
N = number of compounds used in the training set 
r2 = is the overall square of the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model 
RMSE = the root mean square error 
AAE = absolute average error 
AE = average error
Table 11.3. Summary of the equations for VOC air to blood and plasma 
distributions and statistics for training sets and test sets of 116 solutes
The Abraham solvation equation has successfully been employed to predict air 
to blood and plasma distribution for VOCs provided the solute is within the given 
descriptor range of the training set to make the correlative equations. To test the 
predictivity of the model it was necessary to split the full data into training and test 
set using a random data set generator. A new model is developed using only those 
data in the training set, which is then used to predict values for the test set. The full 
data set of 232 compounds is divided into two sets of 116, using the first set to 
construct an equation similar to the first equation from table 11.3 and then 116 log K 
values are predicted for the second set. The regression yielded a similar training 
equation and statistics to the first equation in table 11.3. The test of 116 compounds
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shows the average absolute error to be 0.288 for the two sets of data (observed and 
predicted log K). The root mean square error of 0.352 also indicates that there is a 
reasonable predictive capability for the equations shown in table 11.3. The average 
error of 0.082 indicates that the equation of the model is not biased, as it is just over 
zero. The plot on page 147, indicates visually that there is no difference between the 
blood and plasma observed data points.
The coefficients for the air to blood and plasma equation are the same as the 
coefficients as in the air to blood equation (shown in blue in table 11.3).
The inter-correlations of descriptors used for VOC air to blood and plasma
'y
distribution are shown in table 11.4. The largest r for E versus L descriptor is 0.36. 
It appears that there is no strong inter-correlation between the set of descriptors used 
in this model.
r E S A B L
E 1.00
S 0.53 1.00
A -0.06 0.11 1.00
B 0.07 0.43 0.46 1.00
L 0.60 0.49 -0.02 0.24 1.00
Table 11.4. The inter-correlation of descriptors for 232 solutes using descriptors E, 
S, A, B and L.
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Comparison between air to plasma and air to blood
distribution data for common VOCs
In table 11.5 (see appendix), the data for 35 VOCs common to air to plasma 
and air to blood distribution are shown. For these common compounds it important 
to see again if there are any statistical differences between these two data sets. Table
11.6 shows the average absolute error to be -0.116 for the two sets of data. The 
standard deviation of 0.174 also indicates that there is very little difference between 
the air to plasma and air to blood distribution for VOCs. The reason for this is that 
average error (log KpiaSma-log Kbi00d) of -0.116 log units is smaller than experimental 
error and is statistically not significant. This is a very important result, because it 
means that data on log Kpiasma and log Kbi00d can be combined in any correlative 
analysis if needed.
RMSE = 0.172
SD (n-1) = 0.174
AAE = 0.127
AE ( p la s m a -b lo o d )  = -0.116
n = 35
Table 11.6 Statistics used to compare the common compounds (found in table 11.5) 
for log K between air to plasma and air to blood distribution.
A comparison of the various coefficients is in Table 11.7. The coefficients (c, 
s, b and 1) for the air to plasma equation are not the same as those in the air to blood 
equation. Although, there are only 36 compounds in the air to plasma equation, this 
is not representative size to compare to the 196 compounds used make the air to 
blood equation. This contradicts the analysis of the 35 compounds, but is probably 
due to the small number of VOCs in the plasma equation.
The combined data set for air to blood and plasma equation, has very much the 
same coefficients as the air to blood equation. This also suggests that air to blood
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and air to plasma data for VOCs are the same, although the compound numbers for 
blood and plasma are not the same.
MODEL N c e s a b 1
Air to blood 196 -1.069 0.456 1.083 3.738 2.580 0.376
Air to plasma 36 -1.435 0.543 1.677 3.518 3.982 0.192
Air to blood and plasma 232 -1.154 0.446 1.130 3.844 2.673 0.386
Table 11.7 The comparison of the various coefficients
Now it was important to see if the air to blood equation for VOC from table
11.7 can be used to predict the 35 VOCs for air to plasma distribution as shown from 
table 11.8. If the average error of 0.04 for the test set of the air to blood equation is 
combined (from table 10.1) with the experimental error of 0.163, a combined error of 
0.203 is found. The average error for this test set 0.18 (table 11.8) is found to be less 
than the combined error of 0.203. This concludes that blood and plasma log K data 
for VOCs are the within the given error.
RMSE = 0.390
SD (n-1) = 0.396
AAE = 0.334
AE = 0.179
n = 35
Table 11.8 Statistics used to compare the difference between observed and predicted 
values for plasma log K; the predicted values are from the air to blood equation.
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Blood to plasma distribution for VOCs
It is also important to find out whether there is correlation between the blood 
to plasma distribution for VOCs and the Abraham descriptors. The log P data for 
blood to plasma distribution for VOCs can be obtained by combining the log KpiaSma 
data with log Kbiood VOC data.
Weathersby and Abraham compiled a dataset of 32 VOCs in his model to 
predict blood to plasma distribution for humans. Most of their data is compiled from 
previous literature reviews and new data have been added to update any current 
models in air to plasma distribution. Weathersby used the Abraham solvation 
equation to correlate the log P data for blood to plasma with the four Abraham 
descriptors (E, S, B and V). The Abraham equation obtained by Weathersby and 
Abraham is shown as 11.1.1 Note the ‘aA’ was left out as appeared to be not 
significant in the equation.
Log P (biood to plasma) = -0.049 - 0.298E + 0.422S + 0.340B - 0.344V Equation 11.1
0.660 S.D = 0.086 n = 32
There have been no other reports in the literature, where models have been 
constructed for blood to plasma distribution for humans or rats. The correlative 
equation shall be constructed based on datasets that represent average human and rat 
data combined. The complete list of the VOC log P data for these averages, are 
shown in table 11.5.
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Discussion on blood to plasma distribution for VOCs
The correlation for blood to plasma distribution for VOCs can be successfully 
constructed by using the Abraham solvation equation (see table 11.9). This model 
has 35 compounds in the dataset, but the fits for this new equation appear to be very 
poor (S.D = 0.119 and r2 = 0.270). The reason for this, as suggested before, is that 
there is a very little difference between the experimental values of blood log K and 
of plasma log K for VOCs. This means that the spread of log P values is very small,
0.6 log units and this is only 3 times the standard error. This explains why the 
correlation between the two biological samples is poor. There were no outliers 
observed in the correlation. The equation for log P blood to plasma, with a very poor 
r2 value and very small coefficients suggests that there is little difference between the 
two sets of data, air and into the plasma phase. The plot for this blood to plasma 
model also indicates that the data has not got an even spread and most VOC data is 
too cluttered in the middle of the graph (see page 153). This model is poor when 
compared to other good models like blood to brain distribution for VOCs, where 
there is an even spread of data (as shown from the plots in chapter 12). Although 
Weathersby and Abrahams model has a better fit for humans, the present model 
takes into account average log K data for air to plasma and air to blood (humans and 
rats combined). The final conclusion is that the air to blood and air to plasma 
distribution data can be combined for VOCs.
EQUATIONS N r 2 SD F D
FULL SET
Log P (blood:plasma) = -0.056 -  0.227E + 0.103S
- 0.268A + 0.303B -  0.201V
35 0.270 0.119 2.145 5
N = number of compounds used in the training set 
r2 = is the overall square of the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number o f descriptors used in the model
Table 11.9. Summary of the equations for VOC blood to plasma distributions
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The inter-correlations of descriptors used for VOC blood to plasma 
distribution are shown in table 11.10. It appears that there is no strong inter­
correlation between the set of descriptors used in this model.
r E S A B V
E 1.00
S 0.39 1.00
A 0.20 0.38 1.00
B 0.25 0.61 0.66 1.00
V 0.05 0.57 0.20 0.39 1.00
Table 11.10. The inter-correlation of descriptors for 35 solutes using descriptors E, 
S, A, B and V.
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Chapter
Air to brain, blood to brain and plasma to brain 
distribution (rat and human) for VOCs
In this chapter the Abraham solvation equation shall be used for models that 
include: air to brain distribution for VOCs, blood to brain distribution for VOCs and 
plasma to brain distribution for VOCs.
Air to brain distribution for VOCs
The distribution of VOCs from air to brain is of importance in medicine, 
toxicological sciences and environmental health. There has been a large amount of 
reported log K data for air to brain distribution.1’15 Several cited papers, where 
models have been suggested to predict air to brain distribution in humans, rats or for 
both species shall be discussed. The purpose of this work is to add new literature 
data to the existing data set of Abraham and to make an attempt to construct new 
equations to predict these processes. Correlative and predictive equations shall be 
constructed based on datasets that represent average human and rat data combined. 
The complete list of the VOC log K data for these averages, are shown in table 12.0 
(see appendix). The reported literature models for the correlation of air to brain 
distribution for VOCs are found from the following authors: Meulenberg and 
Vijverberg1 and Abraham and Weathersby3
Meulenberg and Vijverberg1 have obtained a reasonable amount of data used 
in a training set to produce two correlative equations for air to brain distribution in 
rats and humans. They found that the partition coefficients of VOCs in human (or
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rat) brain are well described by a linear combination of Kajr:0ii and Kajr:saiine with 
specific regression coefficients for the biological sample i.e. brain. The partition 
data (K) for air to brain distribution were averaged values from literature sources and 
were used for the bilinear regression. Equations 12.0 and 12.1 show how Kajr;brain is 
described as a bilinear function of Kair:oiive oil and Kajr;Saijne. The coefficients a0ii and 
(Xsaiine of both equations represents the tissue-specific contributions of the lipophilic 
and hydrophilic interactions to the solubility of the VOCs in brain.
Human equation Equation 12.0
K-air:brain — 0.020Kair:oiiVe oil 0.380Kajr:sa]jne + 0.94 
^  = 0.98 SD = n/a n = 35
Rat equation
K - a ir b r a in  0 . 0 5 4 K a jr :o l i v e  o i l  0 - 8 3 2 K a jr :s a i in e  
^= 0 .9 0  SD = n/a n = 1 9
Note. The c coefficient for the rat equation was 
Vijverberg.
Abraham and Weathersby3 compiled a dataset of 41 solutes to predict air to 
brain distribution for humans. Most of the data was compiled from previous 
literature. Abraham and Weathersby used the Abraham solvation equation to 
correlate the log K data (Ostwald solubility coefficient at 31 OK) for air to brain with 
the five Abraham descriptors (E, S, A, B and L). The Abraham equation used for 
this model is shown in equation 12.2.3
Log K (air:brain) = -1-074 + 0.427E + 0.286S + 2.781A + 2.787B + 0.609L Equation 12.2
r2 = 0.968 S.D = 0.240 n = 41
Neither of the two models have any test sets that include statistical information 
that can be used to verify their predictions. It is very unfortunate that Meulenberg 
and Vijverberg did not calculate the fits (i.e. standard deviation) for the training set 
used in the correlation.
An improvement can be made on air to brain distribution by using training sets 
and test sets containing a large number of compounds (including statistical
Equation 12.1
not determined by Meulenberg and
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information). It would be very interesting to see if the diversity of compounds helps 
to improve models that are currently available. The models discussed before are 
outdated and many new measurements have been made for VOCs which will be 
included in the new training sets (see appendix table 12.0).
Discussion on air to brain distribution for VOCs (humans 
and rats combined)
The Abraham solvation equation can successfully be employed to correlate 
VOC air to brain distribution (see table 12.1). Considering that this model has now 
81 compounds in the dataset, the fits for this new equation appear to be quite good 
(S.D = 0.346 and r2 = 0.923). This work is the most up to date model for VOC air to 
brain distribution; it appears that this is the most general model yet reported for both 
species (humans and rats).
There were two outliers observed from this training set: cyanoethylene oxide 
and methanol. The residual for these two compounds are approximately 1 log unit 
and may result from being an experimental error.
EQUATIONS N r2 SD F D
FULL SET
Log K (air:brain) = - 0.987 + 0.263E + 0.41 IS + 
3.358A + 2.025B + 0.591L
81 0.923 0.346 178.980 5
TRAINING SET
Log K (air:brain) = - 1.018 + 0.560E + 0.563S + 
3.440A + 2.240B + 0.521L
TEST SET
N = 40 RMSE = 0.404 AAE = 0.347 
AE = -0.136 SD (n-1) = 0.409
41 0.930 0.342 92.680 5
N = number of compounds used in the training set 
r2 = is the overall square o f the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model 
RMSE = the root mean square error 
AAE = absolute average error
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AE = average error 
SD = standard deviation
Table 12.1 Summary of the equations for VOC air to brain distributions and the 
statistics for test sets of 40 solutes
The inter-correlations of descriptors used for VOC air to brain distribution are 
shown in table 12.2. The largest r2 value for S versus B descriptor is 0.32. It 
appears that there is no strong inter-correlation between the set of descriptors used in 
this model.
r E S A B L
E 1.00
S 0.36 1.00
A 0.01 0.25 1.00
B 0.04 0.57 0.45 1.00
L 0.39 0.16 -0.08 0.10 1.00
Table 12.2. The inter-correlation of descriptors for 81 solutes using descriptors E, 
S, A, B and L.
The Abraham solvation equation has successfully been employed to predict air 
to brain distribution for VOCs provided the solute is within the given descriptor 
range of the training set to make the correlative equations. To test the predictivity of 
the model it was necessary to split the full data into training and test set using a 
random data set generator. A new model was developed using only those data in the 
training set, which was then used to predict values for the test set. The full data set 
of 81 compounds was divided into two sets, using the first set to construct an 
equation similar to the first equation from table 12.1 and then 40 log K values (air to 
brain distribution of VOCs) are predicted for the second set. The regression yielded 
a similar training equation and statistics to the first equation in table 12.1. The test 
set of 40 compounds shows the average absolute error to be 0.347 for the two sets of 
data (observed and predicted log K). The root mean square error of 0.404 also 
indicates that there is a reasonable predictive capability for the equations shown in
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table 12.1. The average error of -0.136 indicates that the equation of the model is 
not biased, as it is just below zero.
The e-coefficient (P = 0.15) and s-coefficient (P = 0.06) is not significant. The 
positive 1-coefficient in the air to brain equation (12.1) indicate that increasing 
molecular size and London dispersion interaction can push VOCS out of air and into 
the brain tissue phase. The coefficients of the descriptors A, and B are all positive, 
indicating that the hydrogen-bond donor and acceptor ability is stronger in the brain 
phase than in gas phase. The solutes are pushed out of the air and into the brain 
phase. Finally, the Abraham equation can successfully be used to make predictions 
for air to brain distribution for a diverse range of solutes (VOCs).
The statistics for this model is good, as indicated by the large spread of data 
shown from the plot. It is found that to be possible to construct an equation capable 
of predicting further values of log Kbrain to around 0.4 log units. This equation is not 
much better in terms of predictions when compared to the air to blood equation 
shown in chapter 10. This may be due to the fact there are fewer data points used in 
this model.
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Blood to brain distribution for VOCs
Zhang developed a non linear equation for blood to brain distribution of 
neutral compounds.16 He compiled a list of 35 different volatile organic compounds 
obtained from various literatures sources. The first two equations in 12.3, takes into 
account the biological interaction of the VOCs in the brain tissue phase, with regards 
to lipids and proteins. The product of the first two equations is used in the third 
equation (12.3) to make predictions for blood to brain distribution for VOCs. The 
descriptors used in equation 12.3 are, a is the molecular polarizability (used to 
characterise the steric bulk effeck), £Ca js the sum 0f H-bond factor values for all 
acceptor substructures in the molecule and £Q + is the sum of all positive partial 
atomic charges for all atoms in the molecule. His non-linear regression equations, 
was compared to the composition of the tissue (i.e. contents of lipids, proteins and 
water in brain and other tissues). Zhang concludes that his equations for blood to 
brain distribution are related to the tissue composition.
Log P(iipid) = 0.124a - 0.714£Ca Equation 12.3
LogP(protein) = 0.630ZQ+
Log P (blood » brain) = log( 10'°6P (lipid) + 1 + 1) - 0.642
r2 = 0.920 SD = 0.120 n = 35
Balaz and Lukacova compiled a list of 35 experimental data of non-ionisable 
chemicals from several literature sources.17 Their aim was to predict blood to brain 
distribution based on: membrane accumulation and protein binding. The equation 
for blood to brain distribution of VOCs takes into account the tissue composition of 
the brain (lipids, proteins and water) in humans and function of lipophilicity. The 
independent variable is Poct (the 1-octanol/water partition coefficient) and the 
adjustable parameters were A j ,  A b  and B for brain tissue and blood. P is the 
adjustable constants for series compounds binding to proteins in the bi-layer system) 
and I as the indicator variable. The fits for the blood to brain distribution model was 
good and this model had a better fit than other current published models.
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2
Log P(b,ood to brain) = P  X log Poct + log ( l  +  J ]  Ai'x Ii)-log(PP X Ab +  1)+B’
»=i Equation 12.4
r2 = 0.956 SD = 0.083 n = 35
The solvation equation obtained by Abraham and Weathersby was shown to 
be useful in order to predict blood to brain distribution for VOCs.3 Their 39 blood to 
brain distribution dataset was compiled from previous literature reviews for human 
subjects. The solvation equation was used to correlate the log K data (Ostwald 
solubility coefficient at 31 OK) for blood to brain with the five Abraham descriptors 
(E, S, A, B and V). The Abraham equation used for this model is shown in equation
12.5.3
Log P(biood:brain) = -0.166 + 0.239E - 0.626S - 0.368A - 0.615B + 1.072V Equation 12.5
1^  = 0.865 S.D = 0.154 n = 39
Fiserova-Bergerova and Diaz used the head space chromatography method to 
determine experimentally air to brain distribution for seven VOCs. They also 
compiled a literature survey of experimental values based on human subjects. Air to 
brain and air to blood partition coefficients were used to calculate blood to brain 
partition coefficients for VOCs. From the statistical analysis of Fiserova-Bergerova 
Diaz, it was found that there is a good inter-correlation between blood to brain 
partition coefficients and blood to fat partition coefficients as shown from a plot.
The intercept and the gradient of the straight line (linear) plots were included in the 
model to make a correlative equation to predict blood to brain distribution of VOCs 
(see equation 12.6). It appears that there is no test set for this model which limits the 
information with regards to its models predictability of VOCs partition. The 
standard deviation of this model is very large and suggests that the equation is of 
little use in prediction.2
P ( b i o o d  t o  b r a in )  = 0 . 0 3 7 2 P b iOo d  to  fa t  +  0 . 5 1 9 9  Equation 1 2 . 6
n = 3 5  r2 = 0 . 9 4 0  SD = 0 . 7 7 9  
P  denotes to the appropriate partition of the VOCs
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An improvement of the current models can be made on blood to brain 
distribution by using training sets and test sets containing a larger amount of data 
(including statistical information). It would be very interesting to see if the diversity 
of compounds helps to improve models that are currently available. Most of the 
models discussed before are outdated and many new measurements have been made 
recently and can be included in a new training set (see appendix table 12.3).
Discussion on blood to brain distribution for VOCs 
(humans and rats combined)
The solvation equation of Abraham can successfully be used to correlate VOC 
blood to brain distribution (see table 12.4). The model has 78 compounds in the 
dataset, and the fits for this new equation appear to be very good (S.D = 0.203 and r2 
= 0.725). This work is the most up to date model for VOC blood to brain 
distribution; it appears this is the most general model yet reported for both species 
(humans and rats).
There were two outliers observed from this training set: decane and 
cyclohexane. The residual for these two compounds are approximately between 0.5 
to 1 log units and may result from experimental error.
EQUATIONS N r2 SD F D
FULL SET
Log P (blood:brain) = - 0.057 + 0.017E - 0.536S - 
0.323A-0.335B +0.731V
78 0.725 0.203 37.908 5
TRAINING SET
Log P (blood:brain) = 0.009 + 0.053E - 0.584S - 
0.238A-0.338B +0.638V
TEST SET
N = 39 RMSE = 0.200 AAE = 0.155 
AE = -0.027 SD (n-1) = 0.203
39 0.657 0.215 12.654 5
N = number of compounds used in the training set 
r2 = is the overall square of the correlation coefficient 
SD = the standard deviation 
F = F-statistic
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D = the number o f descriptors used in the model 
RMSE = the root mean square error 
AAE = absolute average error 
AE = average error
Table 12.4 Summary of the equations for VOC blood to brain distributions and 
statistics for test sets of 39 solutes
The inter-correlations of descriptors used for VOC blood to brain distribution 
are shown in table 12.5. The largest r value for S versus B descriptor is 0.31. It 
appears that there is no strong inter-correlation between the set of descriptors used in 
this model.
r E S A B V
E 1.00
S 0.36 1.00
A 0.01 0.24 1.00
B 0.03 0.56 0.45 1.00
V 0.13 -0.04 -0.18 0.03 1.00
Table 12.5. The inter-correlation of descriptors for 78 solutes using descriptors E, 
S, A, B and V.
The Abraham solvation equation has successfully been employed to predict 
blood to brain distribution for VOCs, provided the solute is within the given 
descriptor range of the test set used to make the correlative equations. To test the 
predictivity of the model, it was necessary to split the full data into training and test 
set using a random data set generator. A new model is developed using only those 
data in the training set, which is then used to predict values for the test set. The full 
data set of 78 compounds is split into two sets of 39, using the first set to construct 
an equation similar to the first equation from table 12.4 and predicting 39 log K 
values (blood to brain distribution of VOCs) for the second set. The regression 
yielded similar training equation and statistics to the first equation in table 12.4. The 
test of 39 compounds shows the average absolute error to be 0.155 for the two sets of 
data (observed and predicted log K). The root mean square error of 0.200 also 
indicates that there is little difference between the observed value and predicted data
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for blood to brain distribution for VOCs. The average error of -0.027 indicates that 
the equation of the model is not biased, as it is very close to zero.
The e-coefficient (P = 0.87) and a-coefficient (P = 0.16) is not significant. 
The positive v-coefficients in the blood to brain equation (12.4) indicate that 
increasing molecular size and London dispersion interaction can push VOCS out of 
blood and into the brain tissue phase. The coefficients of the ‘polar’ descriptors S 
and B are negative, indicating that polarity and hydrogen-bond acceptor ability is 
stronger in the blood phase than in brain phase. The solutes are pushed out of the 
brain and into the blood phase. From this analysis the Abraham equation can 
successfully be employed to make predictions for blood to brain distribution as 
shown from table 12.4, for a wide range of VOCs.
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Plasma to brain distribution for VOCs
There have been no reported models for plasma to brain distribution for VOCs 
in humans and rats. From the literature survey, it was possible to obtain distribution 
data (air to plasma and air to brain) for a small number of solutes (21 VOCs in total). 
From this, the difference in the two distribution data for air to plasma and air to brain 
(for VOCs), would give rise to distribution coefficients for solutes between plasma 
and brain. Although there are fewer solute numbers than in the previous model 
mentioned earlier (blood to brain distribution of VOCs), it would be interesting to 
see if the equations for both of the models (blood to brain and plasma to brain 
distribution for VOCs) are similar or not. The equation and the statistical analysis 
for plasma to brain distribution for VOCs, was compiled from data shown in table
12.6 (see appendix).
Discussion on plasma to brain distribution for VOCs 
(humans and rats combined)
The solvation equation was applied to correlate the 21 plasma to brain 
distribution coefficients for VOCS, with the Abraham descriptors. From table 12.7., 
the fits for this equation are good (SD = 0.153 and r2 = 0.619), but coefficients of the 
equation are not comparable to the blood to brain distribution model of VOCs. The 
reason is that this data set is small (21 solutes only compared with 78) and is not a 
representative number for plasma to brain distribution of VOCs in general. This 
means that the spread of log P values is very small, 0.7 log units and this is only 3 
times the standard error. Therefore this explains why it is not possible to get a 
reasonable model. The plots for this plasma to brain model also indicate that the 
data has not got an even spread and most VOC data is cluttered in the middle of the 
graph (see page 169). That is why the correlation for this model is poor and this may 
be due to the fact that the model has a limited amount of data points as shown from 
the plot. Whereas, the plot for blood to brain distribution has an even spread of data 
for a larger number of solutes and gives rise to a better correlative model than that of 
the plasma to brain model. There were no outliers observed from this training set.
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No test sets have been used for this model as there are a limited number of 
compounds available.
EQUATIONS N r* SD F D
FULL SET
Log P (plasma:brain) = 0.049 + 0.037E - 0.21 IS + 
0.361A-0.829B +0.592V
21 0.619 0.153 4.881 5
N = number of compounds used in the training set 
r2 = is the overall square of the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model
Table 12.7 Summary of the equations for VOC plasma to brain distributions
Finally the inter-correlations of descriptors used for VOC plasma to brain 
distribution are shown in table 12.8. The largest r2 value for A versus B descriptor is 
0.42. It appears that there is no strong inter-correlation between these sets of 
descriptors used in this current model.
r E S A B V
E 1.00
S 0.47 1.00
A 0.40 0.36 1.00
B 0.50 0.64 0.65 1.00
V -0.02 0.64 0.17 0.38 1.00
Table 12.8 The inter-correlations of descriptors used for VOC plasma to brain 
distribution for 21 solutes
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Blood to brain combined with plasma to brain distribution 
data for VOCs
It is important to find out if the blood to brain equation for VOC is the same as 
the equation for plasma to brain distribution. Unfortunately, examination of 
coefficients can be very misleading because there are only data 21 data points in the 
plasma to brain equation. Another way of investigation is to combine the dataset for 
blood to brain distribution with the data set of plasma to brain distribution and then 
construct an equation for full data set combined. This equation can then be 
compared to the original blood to brain equation for VOCs to see if the two 
equations are the same or not. Correlative and predictive equations of Abraham for 
the combined dataset (i.e. blood to brain and plasma to brain) shall be constructed. 
The complete list of the VOC log K data, are shown in table 12.9 (see appendix).
Finally, to support this analysis, one can compare the common partition 
coefficients for plasma to brain and blood to brain distribution for 19 VOCs and see 
if it is possible to combine these two dataset for these processes (table 12.12).
Discussion on blood to brain and plasma to brain 
distribution for VOCs
The solvation equation can be employed to correlate VOC (blood and 
plasma) to brain distribution (see table 12.10). Considering that this model has now 
got 99 compounds in the dataset, the fits for this new equation appear to be very 
good (S.D = 0.196 and r = 0.703). In fact, this equation for full set has an improved 
fit (SD = 0.196) over the current blood to brain equation (SD = 0.203). Note the ‘e’ 
coefficient for the combined set appears to be not significant in this model, although 
it was still used in the equation. The coefficients for the combined data set, (blood 
and plasma to brain) equation for the 99 solutes, has more or less the same 
coefficients (c, e, s, b and v) as the blood to brain equation. There is one exception 
where the ‘a’ coefficient for the combined equation appeared to be smaller than in 
the blood to brain equation. This suggests that blood to brain log P data for VOCs 
can be combined together (if needed) with the plasma to brain log P data, as they do
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not appear to be different from each other (as shown by the coefficients of the 
equations and the values of r and SD).
EQUATIONS N r2 SD F D
FULL SET
Log P ((b+p):brain) = - 0.028 + 0.003E - 0.485S
- 0.117A-0.408B +0.703V 
Log P (blood:brain) = - 0.057 + 0.017E - 0.536S
-0.323A-0.335B +0.731V
99
78
0.703
0.725
0.197
0.203
44.062
37.908
5
5
TRAINING SET
Log P ((b+p):brain) = 0.023 + 0.074E - 0.655S
- 0.117A-0.283B +0.652V
TEST SET
N= 49 RMSE = 0.195 AAE = 0.151 
AE = -0.003 SD (n-l) = 0.197
50 0.700 0.206 20.495 5
N = number o f compounds used in the training set 
r2 = is the overall square of the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model 
RMSE = the root mean square error 
AAE = absolute average error 
AE = average error 
b = blood 
p = plasma
Table 12.10 Summary of the equations for VOC blood (and plasma) to brain 
distributions and statistics for test sets of 99 solutes
The Abraham solvation equation has been employed to predict blood and 
plasma to brain distribution for VOCs provided the solute is within the given 
descriptor range of the test set to make the correlative equations. Note that no 
outliers were found in this combined data set (blood to brain and plasma to brain). 
The values of the coefficients for the blood and plasma to brain equation are nearly 
the same as the coefficients in the blood to brain equation (shown in blue in table 
12.10).
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The inter-correlations of descriptors used for VOC blood and plasma to brain 
distribution are shown in table 12.11. The largest r value for S versus B descriptor 
is 0.34. It appears that there is no strong inter-correlation between the set of 
descriptors used in this model.
r E S A B V
E 1.00
S 0.37 1.00
A 0.07 0.27 1.00
B 0.11 0.58 0.50 1.00
V 0.15 0.05 -0.16 0.05 1.00
Table 12.11. The inter-correlation of descriptors for 99 solutes using descriptors E, 
S, A, B and V.
SOLUTE NAME Log.;P (plasma to brain)
Argon 0.09 0.03
Krypton -0.09 -0.16
Xenon 0.34 0.15
Nitrogen 0.07 0.03
Nitrous Oxide 0.03 0.03
Methane 0.20 0.03
Cyclopropane 0.53 0.11
CF3CBrCIH (Halothane) 0.31 0.14
Diethyl ether -0.02 -0.01
CHF20CHCICF3
(Isoflurane) 0.19 0.19
CF3CH20CH=CH2
(Fluomar/ Fluroxene) 0.24 0.14
Acetone
(Propan-2-one) -0.18 -0.17
Butan-2-one 
(Methyl ethyl ketone) -0.05 -0.17
Ethanol -0.01 -0.12
1-Propanol -0.01 -0.08
2-Propanol (Isopropanol) 0.00 -0.11
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2-Methyl-1 -propanol 
(Isobutanol) 0.01 -0.14
Sulphur hexafluride 0.57 0.39
CHF20CF2CHFCI
(Enflurane) 0.49 0.14
SD (n-1) = 0.168
RMSE = 0.164
AAE = 0.122
AE (plasma to brain - blood to brain) = 0.120
N = 19
Table 12.12. 19 common compounds, for plasma to brain and blood to brain 
distribution, which includes the statistics between the two columns of data.
From table 12.12, the 19 common compounds for plasma to brain and blood to brain 
distribution for VOCs appear to be slightly different. This is also supported by the 
plot shown page on page 174, where the plasma to brain distribution data appears to 
below the line of the regression for the whole plot.
The fact that the equation for blood to brain and plasma (plus blood) to brain 
are nearly the same is mostly due to the fact that they have 78 common compounds. 
The total data set used in the (plasma plus blood) to brain equations has the 78 blood 
to brain VOCs and only 21 plasma to brain VOCs. Therefore the best statistical 
parameter is the average error between the two partitions for the 19 data set. This is 
0.12 log unit and definitely indicates that plasma to brain and blood to brain 
distribution are not quite the same. However the SD in the blood to brain equation is
0.20 log unit, so that it may be justified to combine the two data sets, even though 
they are not quite the same.
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Chapter
13
Air to kidney and blood to kidney distribution for 
VOCs (human and rats)
In this chapter the Abraham solvation equation shall be used to construct 
models that include air to kidney and blood to kidney distribution for VOCs. This 
model will contain training and test sets for air to kidney distribution and blood to 
kidney distribution.
Air to kidney distribution for VOCs
The distribution of VOCs from air to kidney is of importance in environmental 
toxicology and health. There have been only a relatively small number of citations 
for air to kidney distribution data for VOCs.1'15 The aim of this work is to gather a 
set of existing data from literatures sources and to attempt to construct a new 
equation to predict these distribution processes. The correlative equations of 
Abraham shall be constructed based on datasets that represent average human and rat 
data combined. The complete list of the VOC log K data for these literature 
averages is shown in table 13.0 (see appendix). The reported literature models for 
the correlation of air to kidney distribution for VOCs are from Meulenberg & 
Vijverberg1 and Weathersby and Abraham.4
Meulenberg and Vijverberg have used a small amount of literature data in their 
training set to produce two correlative equations for air to kidney distribution in rats 
and humans.1 They found that the partition coefficients of VOCs in human (or rat) 
kidney are well described by a linear combination of Kair:oii and Kair:saiine with specific
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regression coefficient for the biological sample i.e. kidney. The partition data (K) 
for air to kidney distribution are averaged values from literature sources and have 
been used for the bilinear regression. The two equations 13.0 and 13.1 show how 
Kainkidney is described as a bilinear function of Kair:oiive oil and Kair:saiine- The 
coefficients a0ii and asaiine of both equations represents the tissue-specific 
contributions of the lipophilic and hydrophilic interactions to the solubility of the 
VOCs in kidney. The c constant has no specific physical meaning but it was 
required by Meulenberg and Vijverberg to compensate for systematic errors in 
kidney, oil, or saline partition coefficients. It appears that none of the two models 
have any test sets that includes statistical information that can be used to verify their 
predictions. It was very unfortunate that Meulenberg and Vijverberg did not 
calculate the fits (i.e. standard deviation) for the obtained correlation.1
Human equation Equation 13.0
K(ajr to kidney) 0.01 lKair:olive oil 0.400Kajr;sa]jne + 0.69 
R2 = 0.98 SD = n/a n = 34
Rat equation Equation 13.1
K(air to kidney) ~ 0.097Kair:oliveoil 0.826Kajr;sa]jne
R2 = 0.91 SD = n/a n = 16
Weathersby and Abraham compiled a dataset of 36 VOCs in order to correlate 
air to kidney distribution for humans.4 They used the Abraham solvation equation to 
correlate the log K data (31 OK) for air to kidney with the five Abraham descriptors 
(E, S, A, B and L). The Abraham equation used for this model is shown in equation
13.2.4
Log K ( a ir  t o  h u m a n  k i d n e y )  = -1.084 + 0.417E + 0.226S + 3.624A + 2.926B + Equation 13.2
0.534L
r2 = 0.951 S.D = 0.266 n = 36
It appears that both of the above models have not got any test sets that can be 
used to test predictions; this may be due to the limited number of compounds used in
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the air to kidney distribution model. It was very unfortunate that Meulenberg & 
Vijverberg did not calculate the fits (i.e. standard deviation) for the training set used 
in the correlation.
Some improvement to these models can be made by compiling new VOC data 
to see if the new equation for the full set has better fits than the published models. 
With larger data sets for air to kidney distribution, it would be possible to construct 
training sets and test sets. Table 13.0 (see appendix) contains the up to date literature 
data for air to kidney distribution for VOCs.115
Discussion on air to kidney distribution for VOCs (humans 
and rats combined)
The Abraham solvation equation has been employed to correlate VOC air to 
kidney distribution as shown in table 13.1.
EQUATIONS N r2 SD F D
FULL SET
Log K (air to kidney) = -1.154 + 0.208E + 0.382S 
+ 2.919A + 2.533B + 0.651L
76 0.923 0.327 167.846 5
TRAINING SET
Log K (air to kidney) = -1.223 + 0.390E + 0.408S 
+ 3.381A + 2.627B + 0.640L
TEST SET
N = 38 RMSE = 0.298 SD (n-1) = 0.302 
AAE = 0.238 AE = -0.022
38 0.907 0.380 62.741 5
N = number of compounds used in the training set 
r2 = is the overall square of the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model 
RMSE = root mean square error
Table 13.1. Summary of the equations for VOC air to kidney distributions for 
humans and rats.
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This model has now 76 compounds in the dataset, and the fits for the new 
equation appear to be good (S.D = 0.327 and r2 = 0.923), considering now there is a 
diverse range of VOCs. Although, the standard deviation is little larger than the 
earlier model of Abraham and Weathersby, this work is the most up to date model 
for VOC air to kidney distribution model yet reported for both species (humans and 
rats). There were two outliers observed from this full set: methanol and 
methylcyclohexane; the residuals for the two outliers are approximately 1 log unit.
r E S A B L
E 1.00
S 0.32 1.00
A 0.00 0.24 1.00
B -0.05 0.52 0.46 1.00
L 0.31 0.02 -0.15 -0.01 1.00
Table 13.2. The inter-correlation of descriptors for 76 solutes using descriptors E,
S, A, B and L for air to kidney distribution model.
The inter-correlations of the descriptors (E, S, A, B and L) used for VOC air 
to kidney distribution are shown in table 13.2. The largest r value for S versus B 
descriptor is 0.27. It appears that there is no strong inter-correlation between the set 
of descriptors used in this air to kidney distribution model.
The Abraham solvation equation has been employed to predict air to kidney 
distribution for VOCs, provided the solute is within the given descriptor range of the 
training set to make the correlative equations. To examine the predictive ability of 
the model, it was necessary to split the full data into training and test set using a 
random data set generator (Kennard-Stone). A new model was developed using only 
those data in the training set, which was then used to predict values for the test set. 
The regression yielded similar training equations and statistics to the first equation in 
table 13.1, although, the fits of the training set appeared to be littler poorer than the 
full set.
The test set of 38 compounds shows the average absolute error to be 0.238 for 
the two sets of data (observed and predicted log K). The root mean square error of
0.298 also indicates that there is a small difference between the observed value and
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predicted data for air to kidney distribution for VOCs. The average error o f -0.022 
indicates that the equation of the model is not biased, as it is very close to 0.
The statistics for this model is satisfactory, as this is indicated by the even 
spread of data shown from the plot. It is found that it is possible to construct an 
equation capable of predicting further values of log Kidney to around 0.3 log units. 
This equation is not much better in terms of predictions when compared to the air to 
saline or air to olive oil equation shown in chapter 18 and 19. This maybe due to the 
fact there are other processes like metabolism (cytochrome-p450 enzymes) and 
protein binding taking place within the kidney.
The e-coefficient (P = 0.24) and s-coefficient (P = 0.07) is not significant. The 
positive 1-coefficient in the air to kidney equation (13.1) indicates that increasing 
molecular size and London dispersion interaction can push VOCs out of air and into 
the kidney tissue phase. The coefficients of the descriptors A and B are all positive, 
indicating that the hydrogen-bond donor and acceptor ability is stronger in the 
kidney tissue phase than in the gas phase. The solutes are pushed out of the air and 
into the kidney phase. Finally, the Abraham equation can successfully be used to 
correlate and predict air to kidney distribution for humans and rats (see graph on 
page 181).
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Blood to kidney distribution for VOCs
Fiserova-Bergerova and Diaz used the head space chromatography method to 
determine experimentally air to kidney distribution for several VOCs.2 They also 
compiled a literature survey of experimental values based on human subjects. Air to 
kidney and air to blood partition coefficients were used to calculate blood to kidney 
partition coefficients for VOCs. From the statistical analysis of Fiserova-Bergerova 
Diaz, it was found that there is a good inter-correlation between blood to kidney 
partition coefficients and blood to fat partition coefficients as shown from a plot.
The intercept and the gradient of the straight line (linear) plots were used to make a 
correlative equation for blood to kidney distribution of VOCs (see equation 13.3). It 
appears that there is no test set for this model which limits the information with 
regards to the model’s predictability of VOCs partitioning. The standard deviation 
of this model is very large, so that the equation is poor by comparison to other 
models mentioned latter.
P ( b l o o d  t o  k i d n e y )  0.021 l P b i o o d  to  fa t  0.6442 Equation 13.3
n = 35 r2 = 0.945 SD = 0.421 
P  denotes to the appropriate partition of the VOCs
A solvation equation was obtained by Abraham and Weathersby for blood to 
kidney distribution for VOCs.4 Their 35 blood to kidney distribution dataset was 
compiled from previous literature reviews for human subjects. The Abraham 
equation used for this model is shown in equation 13.4.4
Log P ( b i o o d  to  k i d n e y )  = -0.188 + 0.226E -  0.559S -  0.433B + 0.832V Equation 13.4
r2 = 0.774 S.D = 0.168 n = 35
Balaz and Lukacova compiled a list of 33 experimental data of non-ionisable 
chemicals from several literature sources.16 Their aim was to predict blood to kidney 
distribution based on: membrane accumulation and protein binding. The equation 
for blood to kidney distribution of VOCs takes into account the tissue composition of 
the kidney (lipids, proteins and water) in humans and function of lipophilicity. The 
independent variable is P o c t (1-octanol/water partition coefficient) and the adjustable
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parameters were A j ,  A b  and B for tissue and blood. (3 is the adjustable constants for 
series compounds binding to proteins in the bi-layer system) and I as the indicator 
variable. Fits for the blood to kidney distribution model were very good and this 
model had a better fit than other published models.
2
Log P(blood to kidney) ~ P X log Poet lo g ( l+ X Ai’xIi)-
/ = 1
Equation 13.5
log(Ppx Ab + 1)+B’ 
r2 = 0.924 SD = 0.089 n = 33
Zhang developed a non linear equation for blood to kidney distribution of 
neutral compounds.17 He compiled a list of 34 different volatile organic compounds 
obtained from various literatures sources. The first two equations in 13.6, takes into 
account the biological interaction of the VOCs in the kidney tissue phase, with 
regard to lipids and proteins. The product of these two equations is used in the third 
equation (13.6), to make predictions for blood to kidney distribution for VOCs. The 
descriptors used in equation 13.6 are: a is the molecular polarizability (used to 
characterise the steric bulk effeck), Camax is the maximum H-bond acceptor 
descriptor in a molecule and £Q + is the sum of all positive partial atomic charges for 
all atoms in the molecule.
Log P(iipid) = 0.094a -  3.661Camax Equation 13.6
LogP(protein) = 0.637XQ+
LogP (b,cod,ok i d n e y )  = log( 10logP('ipid> + 10'0^ * '" *  + 1) - 0.562 
1^  = 0.897 SD = 0.110 n = 34
The aim of the current work was to construct an equation as part of a general 
method for ‘high-throughput’ prediction of equilibrium blood-kidney distribution 
based on structure using the Abraham descriptors (E, S, A, B and V). Table 13.3 
(see appendix) has the observed and calculated log P data for blood to kidney 
distribution of VOCs.
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Discussion on blood to kidney distribution for VOCs 
(humans and rats combined)
The Abraham solvation equation has been employed to correlate VOC blood 
to kidney distribution as shown in table 13.4.
EQUATIONS N r2 SD F D
FULL SET
Log P (blood to kidney) = -0.361 + 0.134E - 0.515S - 
0.823A + 0.273B + 0.981V
73 0.757 0.217 41.661 5
FULL SET TRAINING SET
Log P (blood to kidney) = -0.305 + 0.15IE - 0.45IS - 
0.797A + 0.195B +0.881V
TEST SET
N = 36 RMSE = 0.189 SD (n-1) = 0.192 
AAE = 0.153 AE = -0.036
37 0.678 0.253 13.003 5
N = number of compounds used in the training set 
r2 = is the overall square of the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model 
RMSE = root mean square error
Table 13.4. Summary of the equations for VOC blood to kidney distributions for 
humans and rats
The solvation equation of Abraham can be used to correlate VOC blood to 
kidney distribution (see table 13.4). This model has 73 compounds in total in the 
dataset and the fits for this new equation appear to be reasonably good (S.D = 0.217 
and r2 = 0.757). Although the fits for this model are poorer than the previous 
equations for the blood to kidney distribution, the present model is much more 
general. There were three outliers observed in the training set: 1,2-dimethylcyclo- 
hexane, decane and 1,2,4-trimethylcyclohexane. The residual for these three 
compounds are approximately 0.6-0.8 log units and may result from experimental 
error.
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r E S A B V
E 1.00
S 0.32 1.00
A 0.00 0.23 1.00
B -0.04 0.51 0.45 1.00
V 0.00 -0.18 -0.22 -0.02 1.00
Table 13.5. The inter-correlation of descriptors for 73 solutes using descriptors E,
S, A, B and V.
The inter-correlations of descriptors used for VOC blood to kidney 
distribution are shown in table 13.5. The largest r value for S versus B descriptor is
0.26. It appears that there is no strong inter-correlation between the set of 
descriptors used in this model.
The Abraham solvation equation has been employed to correlate blood to 
kidney distribution for VOCs. To test the predictiveness of the model it was 
necessary to split the full data into training and test set using a random data set 
generator. A new model was developed using only those data in the training set, 
which was then used to predict values for the test set. The regression yielded a 
similar training equation and statistics to the first equation in table 13.4. The test set 
of 36 compounds shows the average absolute error to be 0.153 for the observed and 
predicted log K. The root mean square error of 0.189 also indicates that there is a 
small difference between the observed value and predicted data for air to kidney 
distribution for VOCs. The average error of -0.036 indicates that the equation of the 
model is not biased, as it is very close to 0.
The e-coefficient (P = 0.23) and b-coefficient (P = 0.08) is not significant. 
The positive v-coefficients in the blood to kidney equation (13.4) indicate that 
increasing molecular size and London dispersion interaction can push VOCs out of 
blood and into the kidney tissue phase. The coefficients of the ‘polar’ descriptors S 
and A are all negative, indicating that polarity and hydrogen-bond donor is stronger 
in the blood phase than in the kidney tissue phase. The solutes are pushed out of the 
kidney and into the blood phase. Finally the Abraham equation can successfully be 
used to correlate and predict blood to kidney distribution for humans and rats (see 
graph on page 186).
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Chapter
Air to fat and blood to fat distribution for VOCs 
(human and rats)
In this chapter the Abraham solvation equation shall be used to construct 
models that include air to fat and blood to fat distribution for VOCs.
Air to fat distribution for VOCs
The distribution of VOCs from air to fat is of importance in pharmaceuticals, 
and in environmental toxicology. There have been a number of citations for air to fat
1 9 ^distribution data for VOCs. ' The purpose of this work is to gather a set of existing 
data from the literature of previous authors and to attempt to construct a new 
equation to predict these distribution processes. The correlative equations of 
Abraham shall be constructed based on datasets that represent average human and rat 
data combined. The complete list of the VOC log K data for these literature 
averages is shown in table 14.0 (see appendix). The reported literature models for 
the correlation of air to fat distribution for VOCs were made by Meulenberg & 
Vijverberg,1 Gargas et a l3 and Weathersby and Abraham.4
Meulenberg & Vijverberg have obtained a reasonable amount of data in their 
training set to produce two correlative equations for air to fat distribution in rats 
(equation 14.0) and humans (equation 14.1). They found that the partition 
coefficients of VOCs in human (or rat) fat are well described by a linear combination 
of Kairoii and Kairsaiine with specific regression coefficients for the biological sample
i.e. fat. The partition data (K) for air to fat distribution are averaged values from 
literature sources and have been used for the bilinear regression (note K is used in
188
the equations, and not log K). This method is very similar to the method employed 
by Gargas et al.3 Equations (14.0 and 14.1) show how K a jr:f a t  is described as a 
bilinear function of Kajr;oiive oil and Kajr;saiine- The coefficients a0ii and asaiine of both 
equations represents the tissue-specific contributions of the lipophilic and
hydrophilic interactions to the solubility of the VOCs in fat. The c constant has no 
specific physical meaning but was required by Meulenberg & Vijverberg to 
compensate for systematic errors in fat, oil, or saline partition coefficients.1 Note
that the standard deviation and test sets are absent in this model.
Human equation Equation 14.0
K ( a i r  t o  f a t )  —  0 ‘4 4 7 K a jr :o ]jVe  o i l  0 - 0 7 5 K a ir :sa ]jn e  6 . 5 9
r2 = 0.92 SD = n/a n = 41
Rat equation Equation 1 4 . 1
K ( a i r  to  f a t )  =  0 . 5 9 4 K a ir : o l iv e  o i l  0 . 0 8 5 K a ir :sa i i n e +  9 . 4 0  
tL =  0 . 8 6  SD = n/a n = 7 6
Gargas et al, obtained 55 air to oil partition (log K) data; this was used to
model VOC air to fat distribution for rats. For this data set they used the air to oil
log K data in equations to estimate rat air to fat distribution for VOCs (see below for 
the equation). Unfortunately the model doesn’t have a test set, thus the predictive
'i
capability cannot be assessed.
Log K(air t o  f a t )  = 0.920(±0.030)log(Kair:Oii) + 0.136(±0.083) Equation 14.2
i  ^= 0.946 RMSE = 0.187 n=55
Gargas also modelled VOC air to rat fat distribution in terms of contribution 
from air to oil and air to saline values using linear regression techniques as shown 
below. With this combination there was very little improvement on the fits.
Log K(air to  f a t )  = 0.927(±0.03 l)log(Kair;oii) - 0.032(±0.026)log(Kair:sai) Equation 14.3
+ 0.120(±0.083) 
r2 = 0.947 RMSE = 0.186 n = 55
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Abraham and Weathersby4 compiled a dataset of 3 6  VOCs to model air to fat 
distribution in humans. Most of their data was collected from previous literature 
reviews. They used the Abraham solvation equation to correlate the log K data 
( 3 1  OK) for air to fat with the five Abraham descriptors ( E ,  S ,  A ,  B and L ) .  The 
Abraham equation used for this model is shown in equation 14.4.4
Log K (a ir  t o  h u m a n f a t )  =  - 0 . 2 9 4  -  0 . 1 7 2 E  +  0 . 7 2 9 S  +  1 . 7 4 7 A  +  0 . 2 1 9B + 0 . 8 9 5 L  Equation 1 4 . 4  
r2 = 0.988 S . D  = 0.118 n = 3 6
It appears that none of the three models have any test sets that include 
statistical information that can be used to test predictions. It was very unfortunate 
that Meulenberg & Vijverberg did not calculate the fits (i.e. standard deviation) for 
the training set equation they constructed.
Some improvement to these models can be made by adding new VOC data to 
see if the new equation for the full set has better fits than the published models.
Table 14.0 (see appendix) contains the up to date literature data for air to fat 
distribution for VOCs.1'25
Discussion on air to fat distribution for VOCs (humans and 
rats combined)
The Abraham solvation equation has successfully been employed to correlate 
VOC air to fat distribution as shown in table 14.1. This model has now got 129 
compounds in the dataset, and the fits for this new equation appear to be quite good 
(S.D = 0.194 and r2 = 0.958), considering now there is a diverse range of VOCs.
This work is the most up to date model for VOC air to fat distribution; it appears that 
this is the most general model yet reported for both species (humans and rats). There 
were no outliers observed in this full set.
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EQUATIONS N r2 SD F D
FULL SET
Log K (air to fat) = -0.052 + 0.05IE + 0.728S + 
1.783A + 0.332B + 0.743L
129 0.958 0.194 562.789 5
TRAINING SET
Log K (air to fat) = -0.138 + 0.067E + 0.770S + 
1.965A + 0.356B + 0.756L
TEST SET
N = 64 RMSE = 0.177 SD(n-l) = 0.178 
AAE = 0.142 AE = -0.036
65 0.962 0.217 298.023 5
N = number o f compounds used in the training set 
r2 = is the overall square of the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model 
RMSE = root mean square error
Table 14.1. Summary of the equations for VOC air to fat distributions for rats and 
humans.
The inter-correlations of the descriptors (E, S, A, B and L) used for VOC air to 
fat distribution are shown in table 14.2. The largest r2 value for E versus S is 0.25. 
It appears that there is no strong inter-correlation between the set of descriptors used 
in this current model.
r E S A B L
E 1.00
S 0.50 1.00
A -0.06 0.11 1.00
B -0.07 0.39 0.34 1.00
L 0.48 0.16 -0.18 0.00 1.00
Table 14.2. The inter-correlation of descriptors for 129 solutes using descriptors E, 
S, A, B and L for air to fat distribution model.
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The Abraham solvation equation has successfully been employed to correlate 
air to fat distribution for VOCs. To test the predictive ability of the model it was 
necessary to split the full data into training and test set using a random data set 
generator (Kennard-Stone). A new model was developed using only those data in 
the training set, which was then used to predict values for the test set. The regression 
yielded similar training equations and statistics to the first equation in table 14.1. 
The test set of 64 compounds leads to an average absolute error of 0.142 for the two 
sets of data (observed and predicted log K) and a root mean square error of 0.177, 
which indicates that the predictive capability of the training equation is very good. 
The average error of -0.036 indicates that the equation of the model is not biased, as 
it is very close to zero. The statistics for this model is the best out of all the air to 
tissue distribution models for VOCs. This is indicated by the large spread of data 
shown from the plot (page 194) giving rise to strong correlative fits.
The e-coefficient is not significant (P = 0.56). The positive 1-coefficient in the 
air to fat equation (14.1) indicate that increasing molecular size and London 
dispersion interaction can push VOCS out of air and into the fat tissue phase. The 
coefficients of the ‘polar’ descriptors S, A, and B are all positive, indicating that 
polarity and hydrogen-bond donor and acceptor ability is stronger in the fat tissue 
phase than in gas phase. The solutes are pushed out of the air and into the fat phase. 
Finally the Abraham equation can successfully be used to correlate and predict air to 
fat distribution for humans and rats (see graph on page 194).
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Blood to fat distribution for VOCs
The solvation equation obtained by Abraham and Weathersby was shown to 
be useful in order to correlate blood to fat distribution for VOCs.4 Their 35 blood to 
fat distribution dataset was compiled from previous literature reviews for human 
subjects. The solvation equation was used to correlate the log P data for blood to fat 
distribution with the five Abraham descriptors (E, S, A, B and V). The Abraham 
equation obtained is shown as equation 14.5.4
Log P (blood to fat) = 0.168 + 0.198E + 0.130S -  1.211A -  3.267B + 2.275V Equation 14.5 
r2 = 0.967 S.D = 0.188 n = 35
Balaz and Lukacova compiled a list of 36 experimental data from several
9 Aliterature sources. Their objective was to predict blood to fat distribution based on: 
membrane accumulation and protein binding. The equation 14.6 for blood to fat 
distribution of VOCs takes into account the tissue composition of the fat (lipids, 
proteins and water) in humans and function of lipophilicity. The independent 
variable was the Poct (1-octanol/water partition coefficient) and the adjustable 
parameters were Aj, Ab and B for tissue and blood, p is the adjustable constant for 
series compounds binding to proteins in the bi-layer system) and I is an indicator 
variable.
The fits for the correlation of blood to fat distribution model were very good 
and had similar statistics to equation 14.5, although the Abraham & Weathersby 
model was slightly better.
2
Log P (blood to fat) ~  P X log Poct i ° g ( i + Z Ai' xIi)-
/=1
Equation 14.6
log(Ppx Ab+ 1)+B’ 
r2 = 0.960 SD = 0.20 n = 36
Zhang developed a non linear equation for blood to fat distribution of neutral 
compounds.27 He compiled a list of 36 different volatile organic compounds 
obtained from various literatures sources. The first two equations in 14.7 takes into
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account the biological interaction of the VOCs in the fat tissue phase, with regards to 
lipids and water. Note here, that protein contribution in this equation (14.7) was not 
taken into account for fat tissue, as it found to be the lowest in weight out of all the 
tissues used by Zhang. The product of these two equations is used in the third 
equation (14.7), to make predictions for blood to fat distribution for VOCs. The 
descriptors used in equation 14.7 are: a is the molecular polarizability (used to 
characterise the steric bulk effeck), £Q + is the sum of all positive partial atomic 
charges for all atoms in the molecule, Camax is the maximum H-bond acceptor 
descriptor in a molecule and £Cd is the sum of the H-bond factor values for all the 
donor atoms in the molecule. His non-linear regression equations, was compared to 
the composition of the tissue (i.e. contents of lipids and water in fat and other 
tissues). Zhang concludes that his equations for blood to fat distribution are related 
to the tissue composition.
Log P(iipid) = 0.123a + 0.868£Q+- 0.849Camax + 0.621£Cd + 0.419 Equation 14.7
Log P ( w a t e r )  =-0.318a
Log P  ( b lo o d  t0  f a t )  = log(10'°gP (lip'd) + 10^ P(Water)+ 1) 
r2 = 0.972 SD = 0.178 n = 36
The aim of the current work was to construct an equation as part of a general 
method for prediction of equilibrium blood-fat distribution based on structure, using 
the Abraham descriptors ( E ,  S ,  A ,  B and V ) .  It would be interesting to see if the new 
literature for VOC air to fat distribution (humans and rats combined), leads to better 
statistics than the previous models. Table 14.3 (see appendix) lists the observed log 
P  data for blood to fat distribution of VOCs.
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Discussion on blood to fat distribution for VOCs (humans 
and rats combined)
The solvation equation of Abraham can be used to correlate VOC blood to fat 
distribution (see table 14.4). This model has 126 compounds in total in the dataset 
and the fits for this new equation appear to be reasonably good (S.D = 0.304 and r =
0.847). This work is the most up to date model for VOC blood to fat distribution; it 
appears this is the most general model with the largest dataset yet reported for both 
species (humans and rats).
There were three outliers observed from this training set: nonane, decane and 
2-nitropropane. The residual for these three compounds are approximately 0.82-1.12 
log units and may result from experimental error.
EQUATIONS N r2 SD F D
FULL SET
Log P (blood to fat) = 0.473 + 0.017E - 0.003S - 
1.577A-2.246B+ 1.560V
126 0.847 0.304 132.700 5
TRAINING SET
Log P (blood to fat) = 0.419 - 0.006E - 0.016S - 
1.245A - 2.240B + 1.587V
TEST SET
N = 63 RMSE = 0.303 SD (n-1) = 0.305 
AAE = 0.249 AE = -0.047
63 0.835 0.311 57.739 5
N = number of compounds used in the training set 
r2 = is the overall square o f the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number o f descriptors used in the model 
RMSE -  root mean square error
Table 14.4. Summary of the equations for VOC blood to fat distributions
The inter-correlations of descriptors used for VOC blood to fat distribution are 
shown in table 14.5. The largest r2 value for E versus S is 0.26. It appears that there 
is no strong inter-correlation between the set of descriptors used in this model.
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r E S A B V
E 1.00
S 0.51 1.00
A -0.07 0.11 1.00
B -0.08 0.37 0.34 1.00
V 0.12 -0.17 -0.24 0.00 1.00
Table 14.5. The inter-correlation of descriptors for 126 solutes using descriptors E, 
S, A, B and V
The Abraham solvation equation has been employed to correlate blood to fat 
distribution for VOCs. To test the predictiveness of the model it was necessary to 
split the full data into training and test set using a random data set generator. A new 
model was developed using only those data in the training set, which was then used 
to predict values for the test set. The regression yielded similar training equation and 
statistics to the first equation in table 14.4. The test of 63 compounds shows the 
average absolute error to be 0.249 for the two sets of data (observed and predicted 
log K). The root mean square error of 0.303 also indicates that there is reasonable 
predictive capability. The average error of -0.047 indicates that the equation of the 
model is not biased, as it is very close to zero. The blood to fat model is the best 
statistical model reported for blood to tissue distribution of VOCs in the thesis.
The e-coefficient (P = 0.90) and s-coefficient (P = 0.98) is not significant. The 
positive v-coefficient in the blood to fat equation (14.4) indicate that increasing 
molecular size and London dispersion interaction can push VOCS out of blood and 
into the fat tissue phase. The coefficients of the descriptors A and B are all negative, 
indicating that the hydrogen-bond donor and acceptor ability is stronger in the blood 
phase than in fat tissue phase. The solutes are pushed out of the fat and into the 
blood phase. The Abraham equation can therefore successfully be used to correlate 
and predict blood to fat distribution for humans and rats (see graph on page 198).
197
CA
LC
UL
AT
ED
 
LO
G 
P
Calculated log P versus observed log P for blood to fat distribution for VOCs
______
OBSERVED LOG P
198
R eferences
1. Meulenberg, C. J. W. and Vijverberg, H. P. M (2000). Toxicology and 
Applied Pharmacology, 165, 206-216.
2. Fiserova-Bergerova, V. and Diaz, M. L (1986). International Archives of 
Occupational and Environmental Health, 58, 75-87.
3. Gargas, M. L., Burgess, R. J., Voisard, D. E., Cason, G. H. and Anderson, 
M. E (1989). Toxicology and Applied Pharmacology, 98, 87-99.
4. Abraham, M. H. and Weathersby, P. K (1994). J. Pharm. Sci, 83, 1450- 
1455.
5. Zahlsen, K., Eide, I., Nilsen, A. M. and Nisen, O. G (1993). 
Pharmacology & Toxicology, 73, 163-168.
6. Zahlsen, K., Eide, I., Nilsen, A. M. and Nisen, O. G (1992). 
Pharmacology & Toxicology, 71, 144-149.
7. Gargas, M. L., Anderson, M. E., Teo, S. K. O., Batra, R., Fennell, T. R. 
and Kedderis, G. L (1995). Toxicology and Applied Pharmacology, 134, 
185-194.
8. Sweeney, L. M., Himmelstein, M. W. and Gargas, M. L. Chemical- 
Biological Interactions, 135-136, 303-322.
9. Kaneko, T., Wang, P-Y. and Sato, A (2000). J. Occup. Health, 42, 86- 
87.
10. Filser, J. G., Schmidbauer, R., Rampf, F., Baur, C. M., Putz, C. and 
Csanady, G. A (2000). Toxicology and Applied Pharmacology, 169, 40- 
51.
11. Kedderis, G. L., Carfagna, M. A., Held, S. D., Batra, R., Murphy, J. E. 
and Gargas, M. L (1993). Toxicology and Applied Pharmacology, 123, 
274-282.
12. Nussbaum, E. and Hursh, J. B (1957). Science, 125, 552-553.
13. Knaak, J. B. and Smith, L. W (1998). Inhalation Toxicology, 10, 65-85.
14. Medinsky, M. A., Bechtold, W. E., Bimbaum, L. S., Chico, D. M., 
Gerlach, R. F. and Henderson, R. F (1988). Fundamental and Applied 
Toxicology, 11, 250-260.
199
15. Loizou, G. D. and Anders, M.W (1993). Drug Metabolism and 
Disposition, 21, 634-639.
16. Loizou, G. D. Urban, G. Dekant, W. and Anders, M.W (1994). Drug 
Metabolism and Disposition, 22, 511-517.
17. Filser, J. G., Csanady, GY. A., Hartmann, M., Denk, B., Kauffmann, A., 
Kessler, W., Kreuzer, P. E., Putz, C., Shen,J. H. and Stei, P (1996). 
Toxicology, 113, 278-287.
18. Zahlsen, K. and Eide, I (1996). Arch. Toxicol, 70, 397-404.
19. Simmons, J. E., Boyes, W. K., Bushnell, P. J., Raymer, J. H., Limsakun, 
T., McDonald, A., Sey, Y. M. and Evans, M. V (2002). Toxicological 
Sciences, 69, 3-15.
20. Krishnan, K., Gargas, M. L., Fennell, T. R. and Anderson, M. E (1992). 
Toxicol. Indust. Health, 8, 121-140.
21. Csanady, Gy. A., Denk, B., Putz, C., Kreuzer, P. E., Kessler, W., Baur, 
C., Gargas, M. L. and Filser, J. G (2000). Toxicology and Applied 
Pharmacology, 165, 1-26.
22. Reitz, R. H., Gargas, M. L., Anderson, M. E., Provan, W. M. and Green, 
T. L (1996). Toxicology and Applied Pharmacology, 137, 253-267.
23. Lilly, P. D., Anderson, M. E., Ross, T. M. and Pegram, R. A (1997). 
Toxicology, 124, 141-152.
24. Csanady, Gy. A., Kreuzer, P. E., Baur, C. and Filser, J. G (1996). 
Toxicology, 113, 300-305
25. Borghoff, S. J., Murphy, J. E. and Medinsky, M. A (1996). Fundamental 
and Applied Toxicology, 30, 264-275.
26. Balaz, S and Lukacova, V (1999). Quant. Struct.-Act. Relat., 18, 361- 
368.
27. Zhang, H (2004). J. Pharmaceutical Sciences, 93, 1595-1604.
200
Chapter
15
Air to liver and blood to liver 
distribution for VOCs
In this chapter, the Abraham solvation equation shall be used to construct 
models that include air to liver and blood to liver distribution for VOCs.
Air to liver distribution for VOCs
The partition of VOCs from air to liver is of importance in medical and 
environmental sciences. There have been a number of citations for air to liver 
distribution data for VOCs.1'24 The purpose of this work is to gather a set of existing 
data from the literature of previous authors and to attempt to construct a new 
equation to predict these distribution processes. The correlative equations of 
Abraham shall be constructed based on datasets that represent average human and rat 
data combined. The complete list of the VOC log K data for these literature 
averages is shown in table 15.0 (see appendix). The reported literature models for 
the correlation of air to liver distribution for VOCs were made by Meulenberg and 
Vijverberg,1 Gargas et a l.3 and Weathersby and Abraham.4
Meulenberg and Vijverberg have obtained a small number of literature data in 
his training set to produce two correlative equations for air to liver distribution in rats 
and humans.1 They found that the partition coefficients of VOCs in human (or rat) 
liver are well described by a linear combination of K a ir:o i i  and K a jr :sa i in e  with a specific 
regression coefficient for the biological sample i.e. liver. The partition ( K )  data for 
air to liver distribution were averaged values from literature sources and were used
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for the bilinear regression. The two equations 15.0 and 15.1 shows how Kajr;ijVer is 
described as a bilinear function of Kair:0iive oil and Kair;saiine. The coefficients a0ii and 
opaline of both equations represents the tissue-specific contributions of the lipophilic 
and hydrophilic interactions to the solubility of the VOCs in liver. The c constant 
has no specific physical meaning but it was required by Meulenberg and Vijverberg 
to compensate for systematic errors in liver, oil, or saline partition coefficients. It 
appears that neither of the two models have any test sets that includes statistical 
information that can be used to verify their predictions. It was very unfortunate that 
Meulenberg and Vijverberg did not calculate the fits (i.e. standard deviation) for the 
obtained correlations.1
Human equation Equation 15.0
K(ajr to liver) — 0.028Kajr;oijVe oil 0.79 
r2 = 0.88 SD = n/a n = 28
Note K air to saline was not determined for the human air to liver equation. K is not log
of K for air to liver partition.
Rat equ ation Equation 15.1
K(ajr to liver) — 0.026Kajr:o|jVe oil 0.878Kajr:saijne + 2.36 
r2 = 0.92 SD = n/a n = 77
Gargas et al. also modelled VOC air to rat liver distribution in terms of
contribution from air to oil and air to saline values using linear regression techniques 
as shown below. With this combination reasonable fits were obtained. 
Unfortunately the model does not have a test set.
Log K(ratair t0 liver) = 0.730(±0.036)log(Kair;oii) + 0.128(±0.030)log(Kair:sai) Equation 15.2
- 0.550(±0.097) 
r2 = 0.903 RMSE = 0.217 n = 55
Weathersby and Abraham compiled a small dataset of 29 VOCs in order to 
model air to liver distribution for humans. Most of their data was compiled from 
previous literature reviews, and they used the Abraham solvation equation to 
correlate with the log K data (31 OK) for air to liver distribution with the five
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Abraham descriptors (E, S, A, B and L). The Abraham equation used for this model 
is shown in equation 15.3.4
Log K ( a i r  t o  h u m a n  l i v e r )  = -1.031 +0.059E + 0.774S+ 0.593A + 1.049B+ Equation 15.3
0.654L
r2 = 0.981 S.D = 0.101 n = 29
None of the three above models have any test sets that include statistical 
information that can be used to test predictions. It was very unfortunate that 
Meulenberg and Vijverberg did not calculate the fits (i.e. standard deviation) for the 
training set equation they constructed. This also makes it very difficult to compare 
the training equations for the three authors based on the fits.
Some improvement to these models can possibly be made by adding new VOC 
data, to see if the new equation has better fits than the published models mentioned. 
Table 15.0 (see appendix) contains up to date literature data for air to liver 
distribution for VOCs.1'25
Discussion on air to liver distribution for VOCs (humans 
and rats combined)
The Abraham solvation equation has been employed to correlate VOC air to 
liver distribution as shown in table 15.1. This model has now 124 compounds in the 
data set, and the fits for this new equation appear to be good (S.D = 0.285 and r2 = 
0.909), considering that there is a diverse range of VOCs. This work is the most up 
to date model for VOC air to liver distribution; it appears that this is the most general 
model yet reported for both species (humans and rats). There were four outliers 
observed (0.75 to 1.04 log units difference in observed and calculated values) in this 
full set: methanol, ethanol, allyl chloride and 1, 2, 4-trimethylbenzene. There is no 
direct explanation to why these compounds are outliers, but it may be due 
experimental errors.
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EQUATIONS N r2 SD F D
FULL SET
Log K (air to liver) = -0.919 + 0.083E + 0.768S 
+ 2.796A + 2.090B + 0.560L
124 0.909 0.285 236.684 5
TRAINING SET
Log K (air to liver) = -0.846 + 0.249E + 0.835S 
+ 2.594A + 2.196B + 0.504L
TEST SET
N = 62 RMSE = 0.271 SD (n-1) = 0.273 
AAE = 0.223 AE = 0.000
62 0.905 0.315 106.502 5
N = number of compounds used in the training set 
r2 = is the overall square of the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model 
RMSE = root mean square error
Table 15.1. Summary of the equations for VOC air to liver distributions
The inter-correlations of the descriptors (E, S, A, B and L) used for VOC air to
•y
liver distribution are shown in table 15.2. The largest r value for E versus S 
descriptor is 0.23. It appears that there is no strong inter-correlation between the set 
of descriptors used in this current model.
r E S A B L
E 1 . 0 0
S 0 . 4 8 1 . 0 0
A - 0 . 0 6 0 . 1 2 1 . 0 0
B - 0 . 1 0 0 . 3 9 0 . 3 0 1 . 0 0
L 0 . 4 6 0 . 1 3 - 0 . 1 4 0 . 0 1 1 . 0 0
Table 15.2. The inter-correlation of descriptors for 124 solutes using descriptors E, 
S, A, B and L for air to liver distribution model.
The Abraham solvation equation has effectively been employed to correlate air 
to liver distribution for VOCs. To test the predictive ability of the model it was
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necessary to split the full data into training and test set using a random data set 
generator (Kennard-Stone). A new model was developed using only those data in 
the training set, which was then used to predict values for the test set. The regression 
yielded similar training equations and statistics to the first equation in table 15.1, 
although the full set has a better fit than the training equation. Note also the e 
coefficient in the full set is slightly different from that in the training equation. The 
test set of 62 compounds leads to an average absolute error of 0.223 for the two sets 
of data (observed and predicted log K) and a root mean square error of 0.271, which 
indicates that the predictive capability of the training equation is good. The average 
error of 0.0 indicates that the equation of the model is not biased, as it is zero.
The e-coefficient is not significant (P = 0.51). The positive 1-coefficients in 
the air to liver equation (15.1) indicate that increasing molecular size and London 
dispersion interaction can push VOCS out of air and into the liver tissue phase. The 
coefficients of the ‘polar’ descriptors S, A, and B are all positive, indicating that 
polarity and hydrogen-bond donor and acceptor ability is stronger in the liver tissue 
phase than in gas phase. The solutes are pushed out of the air and into the liver 
tissue phase. Finally the Abraham equation can successfully be used to correlate and 
predict air to liver distribution for humans and rats (see graph on page 206).
The performance of this model is satisfactory, as this is indicated by the even 
spread of data shown from the plot. It is found that it is possible to construct an 
equation capable of predicting further values of log Kijver to around 0.3 log units. 
This equation is not much better in terms of predictions when compared to the air to 
fat equation shown in chapter 14. This may be due to the fact there are other 
processes like metabolism (cytochrome-p450 enzymes) and protein binding taking 
part within the liver.
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Blood to liver distribution for VOCs
The purpose of this work is to combine the VOC liver data (log K ti SSu e )  with 
blood data (log K b i o o d )  to give blood to liver distribution for VOCs (log P b i o o d  to  l i v e r )  at 
31 O K .  The correlative equations of Abraham can be constructed based on datasets 
that represent average human and rat data combined for blood to liver distribution.
The complete list of the VOC log P data is shown in table 15.3 (see appendix). The 
reported literature models for the correlation of blood to liver distribution for VOCs 
were made by Weathersby and Abraham,4 Balaz and Lukacova,25 Zhang26 and 
Fiserova-Bergerova and Diaz.
The solvation equation obtained by Abraham and Weathersby was shown to 
be useful in order to correlate blood to liver distribution for VOCs.4 Their 28 blood 
to liver distribution dataset was compiled from previous literature reviews on human 
subjects. The solvation equation was used to correlate the log P data (31 OK) for
blood to liver with the five Abraham descriptors (E, S, A, B and V). The Abraham
equation used for this model is shown in equation 15.4.4
Log P  ( b l o o d  t o  l i v e r )  = -0.270 + 0.233E - 0.375S-1.004A - 1.118B + 1.241V Equation 15.4
r2 = 0.865 S.D = 0.155 n = 28
Balaz and Lukacova compiled a list of 28 experimental data of non-ionisable 
chemicals from several literature sources.25 Their aim was to predict blood to liver 
distribution based on: membrane accumulation and protein binding. The equation 
for blood to liver distribution of VOCs takes into account the tissue composition of 
the liver (lipids, proteins and water) in humans and function of lipophilicity. The 
independent variable is P o c t (the 1-octanol/water partition coefficient) and the 
adjustable parameters were A j ,  A b  and B for tissue and blood. (3 is the adjustable 
constants for series compounds binding to proteins in the bi-layer system and I as the 
indicator variable. The fits for the blood to liver distribution model were good and 
this model had a better fit than previous published models.
2
Log P  ( b l o o d  to  l i v e r )  —  P X log P o c t + log Ai X I j ) -
1=1 Equation 15.5
log(Ppx Ab + 1)+B’
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r2 = 0.931 SD = 0.095 n = 28
Zhang developed a non linear equation for blood to liver distribution of neutral 
compounds. He compiled a list of 29 different volatile organic compounds 
obtained from various literatures sources. The first two equations in 15.6, takes into 
account the biological interaction of the VOCs in the liver tissue phase, with regards 
to lipids and proteins. The product of the first two equations is used in the third 
equation (15.6) to make predictions for blood to liver distribution for VOCs. The 
descriptors used in equation 15.6 are, a is the molecular polarizability (used to 
characterise the steric bulk effeck), £Ca [s the sum 0f H-bond factor values for all 
acceptor substructures in the molecule and £Q + is the sum of all positive partial 
atomic charges for all atoms in the molecule. Zhang concludes that his equations for 
blood to liver distribution are related to the tissue composition.
Log P(iipid) = 0.130a - 0.668£Ca Equation 15.6
LogP(protein) = 0.843IQ+
Log P(bl00d t o  l i v e r )  =  log( 10logP <Iipid) + 101<>8P<P™«i")+ 1).0.658 
r2 = 0.872 S D  = 0.134 n = 29
Fiserova-Bergerova and Diaz used the head space chromatography method to 
determine experimentally air to liver distribution for several VOCs. They also 
compiled a literature survey of experimental values based on human subjects. Air to 
liver and air to blood partition coefficients were used to calculate blood to liver 
partition coefficients for VOCs. From the statistical analysis of Fiserova-Bergerova 
Diaz, it was found that there is a good inter-correlation between blood to liver 
partition coefficients and blood to fat partition coefficients as shown from a plot.
The intercept and the gradient of the straight line (linear) plots were included in the 
model to make a correlative equation for blood to liver distribution of VOCs (see 
equation 15.7). The standard deviation of this model is very large compared to other 
models mentioned earlier and this suggests that the equation is poor in terms of 
correlation in contrast to other models mentioned earlier.
P ( b i o o d  to  liver) =  0 . 0 4 2 5 P b iOo d  to  fa t  + 0 . 5 7 7 0  Equation 15.7
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n = 27 r2 = 0.919 SD = 0.997 
P denotes to the appropriate partition of the VOCs
The aim of the current work was to construct an equation for prediction of 
equilibrium blood-liver distribution based on structure using the Abraham 
descriptors (E, S, A, B and V). Now it would be interesting to see if the new data for 
VOC blood to liver distribution (humans and rats combined) makes a difference in 
the fits to the previous blood to liver distribution models as mentioned. Table 15.3 
(see appendix) lists the observed log P (blood to liver) data for blood to liver distribution 
of VOCs. Note all of the work is for blood and not blood or plasma.
Discussion on blood to liver distribution for VOCs (humans 
and rats combined)
The solvation equation of Abraham can be used to correlate VOC blood to 
liver distribution (see table 15.4). This model has 120 compounds in total in the 
dataset. The fits for this new equation appear to be not as good (S.D = 0.211 and r = 
0.648), compared to other models constructed previously by other authors. Although 
the standard deviation is good (SD= 0.211) and even better than the model by 
Fiserova-Bergerova and Diaz (SD = 0.997), the overall square of the correlation is 
poorer (r2 = 0.648). This work is the most up to date model for VOC blood to liver 
distribution; it appears this is the most general model with the largest dataset yet 
reported for both species (humans and rats).
There were four outliers observed from this training set: nonane, decane, t- 
butylcyclohexane and 1,1-difluoroethylene. The residual for these four compounds 
are approximately 0.60-0.90 log units and may result from experimental error.
EQUATIONS N r2 SD F D
FULL SET
Log P (blood to liver) = -0.202 - 0.048E - 0.295S -
0.213A-0.359B +0.876V
120 0.648 0.211 42.012 5
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TRAINING SET
Log P (blood to liver) = -0.213 - 0.002E - 0.253S - 60 0.693 0.193 24.389 5
0.236A - 0.522B + 0.879V
TEST SET
N = 60 RMSE = 0.233 SD (n-1) = 0.235 
AAE = 0.184 AE = -0.018
N = number of compounds used the in training set 
r2 = is the overall square of the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model 
RMSE = root mean square error
Table 15.4. Summary of the equations for VOC blood to liver distributions
The inter-correlations of descriptors used for VOC blood to liver distribution 
are shown in table 15.5. The largest r value for E versus S descriptor is 0.21. It 
appears that there is no strong inter-correlation between the set of descriptors used in 
this model.
r E S A B V
E 1.00
S 0.46 1.00
A -0.07 0.11 1.00
B -0.13 0.37 0.30 1.00
V 0.05 -0.20 -0.18 0.02 1.00
Table 15.5. The inter-correlation of descriptors for 120 solutes using descriptors E, 
S, A, B and V.
The Abraham solvation equation has been employed to correlate blood to liver 
distribution for VOCs. To test the predictiveness of the model it was necessary to 
split the full data into training and test set using a random data set generator. A new 
model was developed using only those data in the training set, which was then used 
to predict values for the test set. The regression yielded similar training equation, 
although the training set had a slightly better fit than the first full equation in table
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15.4. The test of 60 compounds shows the average absolute error to be 0.184 for the 
two sets of data (observed and predicted log K). The root mean square error of 0.233 
also indicates that there is reasonable predictive capability. The average error of -
0.018 indicates that the equation of the model is not biased, as it is very close to zero.
The e-coefficient (P = 0.58) and a-coefficient (P = 0.33) is not significant. 
The positive v-coefficients in the blood to liver equation (15.4) indicate that 
increasing molecular size can push VOCS out of blood and into the liver tissue 
phase. The coefficients of the ‘polar’ descriptors S and B are all negative, indicating 
that polarity and hydrogen-bond acceptor ability is stronger in the blood phase than 
in liver tissue phase. The solutes are pushed out of the liver and into the blood 
phase. The Abraham equation can therefore successfully be used to correlate and 
predict blood to liver distribution for humans and rats (see graph on page 212).
It appears that this up to date model has a poorer fit than the current models 
already published by Weathersby and Abraham,4 Balaz and Lukacova,25 Zhang26 
and Fiserova-Bergerova and Diaz.2 Although this model has a poorer fit, it 
represents a larger dataset of compounds for blood to liver distribution for VOCs. 
Previous published models have a limited number of compounds (27-28 compounds) 
in the data set and this may well not be a total representation of VOC blood to liver 
distribution. In addition, the smaller number of data points per descriptor, the better 
will the fit be in terms of the correlation coefficient and SD (but not in terms of F). 
The published models above have small data sets, and this is probably the reason for 
the good fits. The present model has a much larger and more varied data set and 
should represent a better coverage of chemical space.
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Chapter
16
Air to muscle and blood to muscle 
distribution for VOCs
In this chapter the Abraham solvation equation shall be used to construct 
predictive equations that include air to muscle and blood to muscle distribution for 
VOCs.
Air to muscle distribution for VOCs
The distribution of VOCs from air to muscle is of importance in 
environmental and toxicological sciences. There have been a few citations for air to 
muscle distribution data for VOCs.1'17 The purpose of this work is to gather a set of 
existing data from the literature of previous authors and to attempt to construct a new 
equation to predict these distribution processes. The Abraham equation used in the 
correlation shall be constructed based on datasets that represent average human and 
rat data combined. The complete list of the VOC log K data for these literature 
averages is shown in table 16.0 (see appendix). The reported literature models for 
the correlation of air to muscle distribution for VOCs are found from Meulenberg & 
Vijverberg,1 Gargas et a l3 and Weathersby and Abraham.4
Meulenberg and Vijverberg have used a small amount of literature data in 
training sets to produce two correlative equations for air to muscle distribution in rats 
and humans.1 They found that the partition coefficients of VOCs in human (or rat) 
kidney are well described by a linear combination of Kair:oii and Kajr:saiine with specific
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regression coefficient for the biological sample i.e. muscle. The partition (K) data 
for air to muscle distribution are averaged values from literature sources and have 
been used for the bilinear regression. The two equations 16.0 and 16.1 shows how 
Kainmuscie is described as a bilinear function of Kair:oiive oil and Kair;saiine- The 
coefficients a 0ii and a saiine of both equations represents the tissue-specific 
contributions of the lipophilic and hydrophilic interactions to the solubility of the 
VOCs in muscle. The c constant has no specific physical meaning but it was 
required by Meulenberg and Vijverberg to compensate for systematic errors in 
muscle, oil, or saline partition coefficients. Neither of the two models have any test 
sets that can be used to assess predictions. It is very unfortunate that Meulenberg 
and Vijverberg did not calculate the fits (i.e. standard deviation) for the obtained 
correlations.1
Human equation
K-(air to muscle) — 0-014JC.ajr:oiiVe oil 0.384Kajr:saijne + 0.94 
r2 = 0.99 SD = n/a n = 35
Note K is not the log o f  K for air to muscle distribution
Rat equation
K(air to muscle) — 0.010Kair:olive oil 0.772Kajr;sa]jne + 0.29 
1^  = 0.82 SD = n/a n = 76
Gargas et al. also modelled VOC air to rat muscle distribution in terms of 
contribution from air to oil and air to saline values using linear regression techniques 
as shown below. With this combination they achieved reasonable fits. 
Unfortunately the model again does not have a test set.
Log K(air to muscle) = 0.644(±0.038)log(Kair:Oii) + 0.180(±0.032)log(Kair:sai) Equation 16.2
- 0.725(±0.104)
1^  = 0.879 RMSE = 0.233 n = 55
Weathersby and Abraham compiled a dataset of 41 VOCs in order to correlate 
air to muscle distribution for humans. Their data is compiled from previous 
literature reviews.4 They used the Abraham solvation equation to correlate the log K
Equation 16.0
Equation 16.1
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data (31 OK) for air to muscle with the five Abraham descriptors (E, S, A, B and L).
The Abraham equation used for this model is shown in equation 16.3.4
Log K (a ir  to human m uscle) = -1.140 + 0.544E + 0.216S + 3.471 A + 2.924B + Equation 16.3
0.578L
r2 = 0.966 S.D = 0.262 n = 41
None of the three above models have any test sets that include statistical 
information that can be used to assess predictions. It is disappointing that 
Meulenberg and Vijverberg did not calculate the fits (i.e. standard deviation) for the 
training set equation they have constructed.
Some improvement to these models can be made by adding new VOC data to 
see if the new equation for the full set has better fits than the published models. 
Table 16.0 (see appendix) contains up to date literature data for air to muscle 
distribution for VOCs.1'17
Discussion on air to muscle distribution for VOCs (humans 
and rats combined)
The solvation equation of Abraham is used to correlate and predict VOC air to 
muscle distribution as shown in table 16.1. This model has now got 114 compounds 
in the dataset, and the fits for this new equation appear to be quite good (S.D = 0.267 
and r2 = 0.944), for a diverse range of VOCs. This work is the most up to date model 
for VOC air to muscle distribution (humans and rats). Although this model has the 
largest data set ever reported; the fits for the full set (table 16.1) appear to be not too 
far off compared to other models mentioned earlier. There were three outliers 
observed from this training set: tricyclo[5.2.1.0]-decane (JP10), methanol and 4- 
chlorobenzotrifluoride The residual for these three compounds are approximately 
0.78-0.97 log units and may result from experimental error.
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EQUATIONS N r2 SD F D
FULL SET
Log K (air to muscle) = -1.039 + 0.207E + 0.723S 
+ 3.242A + 2.469B + 0.463L
114 0.944 0.267 362.966 5
TRAINING SET
Log K (air to muscle) = -1.061 + 0.427E + 0.982S 
+ 3.328A + 2.557B + 0.387L
TEST SET
N = 57 RMSE = 0.304 SD (n-1) = 0.306 
AAE = 0.236 AE = -0.043
57 0.947 0.262 180.787 5
N = number of compounds used in the training set 
r2 = is the overall square o f the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model 
RMSE = root mean square error
Table 16.1. Summary of the equations for VOC air to muscle distributions for 
humans and rats combined.
The inter-correlations of the descriptors (E, S, A, B and L) used for VOC air to 
muscle distribution are shown in table 16.2. The largest r2 value for E versus L 
descriptor is 0.34. It appears that there is no strong inter-correlation between the set 
of descriptors used in this current model.
r E S A B L
E 1.00
S 0.57 1.00
A -0.03 0.10 1.00
B -0.05 0.35 0.31 1.00
L 0.58 0.49 -0.01 0.24 1.00
Table 16.2. The inter-correlation of descriptors for 114 solutes using descriptors E, 
S, A, B and L for air to muscle distribution model.
The Abraham solvation equation has successfully been employed to correlate 
air to muscle distribution for VOCs provided the solute is within the given descriptor
2 1 8
range of the training set to make the correlative equations. To test the predictive 
ability of the model it was necessary to split the full data into training and test set 
using a random data set generator (Kennard-Stone). A new model was developed 
using only those data in the training set, which was then used to predict values for 
the test set. The regression yielded similar training equations and statistics to the 
first equation in table 16.1, except for the e coefficient, which appeared to be slightly 
different. The test set of 57 compounds leads to an average absolute error of 0.236 
for the two sets of data (observed and predicted log K) and a root mean square error 
of 0.304, which indicates that the predictive capability of the training equation is 
good. The average error of -0.043 indicates that the equation of the model is not 
biased, as it is very close to zero. The statistics for this model is very good, as 
indicated by the even spread of data shown from the plot. It is found that it is 
possible to construct an equation capable of predicting further values of log Kmuscie 
to around 0.3 log units. The fits for this equation are little better than that of the air 
to blood model mentioned earlier in chapter 10.
The e-coefficient is not significant (P = 0.11). The positive I-coefficients in 
the air to muscle equation (16.1) indicate that increasing molecular size and London 
dispersion interaction can push VOCS out of air and into the muscle tissue phase. 
The coefficients of the ‘polar’ descriptors S, A, and B are all positive, indicating that 
polarity and hydrogen-bond donor and acceptor ability is stronger in the muscle 
tissue phase than in gas phase. The solutes are pushed out of the air and into the 
muscle phase. Finally the Abraham equation can successfully be used to correlate 
and predict air to muscle distribution for humans and rats (see graph on page 220).
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Blood to muscle distribution for VOCs
The Abraham solvation equation obtained by Weathersby and Abraham was 
shown to correlate blood to muscle distribution for VOCs.4 Their 40 blood to 
muscle distribution dataset was compiled from previous literature reviews for human 
subjects. The solvation equation was used to correlate the log P data (31 OK) for 
blood to muscle with the Abraham descriptors. The Abraham equation used for this 
model is shown in equation 16.4.4
Log P (blood to m uscle) = -0.222 - 0.479S - 0.517B + 0.999V Equation 16.4
t L = 0.790 S.D = 0.176 n = 40
Balaz and Lukacova compiled a list of 34 experimental data of non-ionisable 
chemicals from several literature sources.18 Their aim was to predict blood to 
muscle distribution based on: membrane accumulation and protein binding. The 
equation for blood to muscle distribution of VOCs takes into account the tissue 
composition of the muscle (lipids, proteins and water) in humans and function of 
lipophilicity. The independent variable is Poct (1-octanol/water partition coefficient) 
and the adjustable parameters were A*, Ab and B for tissue and blood, p is the 
adjustable constants for series compounds binding to proteins in the bi-layer system 
and Ij as the indicator variable. The fits for the blood to muscle distribution model 
were good and this model had a better fit than other published models.
2
Log P (blood to m uscle) ~ P X log P0ct lo g ( l+ £ A i 'x I i) -
/=1
Equation 16.5
logtPoc, x Ab + 1)+B’ 
r2 = 0.908 SD = 0.108 n = 34
Zhang developed a non linear equation for blood to muscle distribution of 
neutral compounds.19 Lie compiled a list of 36 different volatile organic compounds 
obtained from various literatures sources. The first two equations in 16.6, take into 
account the biological interaction of the VOCs in the muscle tissue phase, with 
regards to lipids and proteins. The product of the first two equations is used in the 
third equation (16.6) to make predictions for blood to muscle distribution for VOCs.
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The descriptors used in equation 16.6 are, a is the molecular polarizability (used to 
characterise the steric bulk effeck), £Ca is the sum of H-bond factor values for all 
acceptor substructures in the molecule and £Q + is the sum of all positive partial 
atomic charges for all atoms in the molecule. His non-linear regression equations, 
was compared to the composition of the tissue (i.e. contents of lipids, proteins and 
water in muscle and other tissues). Zhang concludes that his equations for blood to 
muscle distribution are related to the tissue composition.
Log P(iipid) = 0.091a -  0.760£Ca + 0.600£Q+ Equation 16.6
Log P(protein) = 0.553XQ+
Log P(blood to muscle) = l0g( 10'°gP '^ + 10l‘*P«’ro“i"> +  1) - 0.617 
r2 = 0.884 SD = 0.133 n = 36
Fiserova-Bergerova and Diaz used the head space chromatography method to 
determine experimentally air to muscle distribution for several VOCs.2 They also 
compiled a literature survey of experimental values based on human subjects. Air to 
muscle and air to blood partition coefficients were used to calculate blood to muscle 
partition coefficients for VOCs. From the statistical analysis of Fiserova-Bergerova 
Diaz, it was found that there is a good inter-correlation between blood to muscle 
partition coefficients and blood to fat partition coefficients as shown from a plot.
The intercept and the gradient of the straight line (linear) plots were included in the 
model to make a correlative equation to predict blood to muscle distribution of 
VOCs (see equation 16.6). There is no test set for this model which limits the
information with regards to its predictability of VOCs partition. The standard
deviation of this model is very large compared to other models mentioned earlier, 
and so the equation is very poor in terms of correlation, in contrast to other models 
mentioned earlier.2
P(blood to muscle) 0.0326Pbiood to fat 0.4504 Equation 16.7
n = 34 r2 = 0.928 SD = 0.7022 
P denotes to the appropriate partition of the VOCs
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The aim of the current work was to construct an equation as part of a general 
method for prediction of equilibrium blood-muscle distribution based on structure 
using the Abraham descriptors (E, S, A, B and V). Now it would be interesting to 
see if the new data for VOC blood to muscle distribution (humans and rats 
combined) makes a difference in the fits to the previous blood to muscle distribution 
models as mentioned. Table 16.3 (see appendix) lists the observed log P (blood to 
muscle) data for blood to muscle distribution of VOCs. Note that all of the work is for 
blood and not blood or plasma.
Discussion on blood to muscle distribution for VOCs 
(humans and rats combined)
The Abraham solvation equation was used to correlate VOC blood to muscle 
distribution (see table 16.4). This model has 110 compounds in total in the dataset 
and the fits for this new equation appear to be poor (S.D = 0.207 and rz = 0.537), 
compared to other models by other authors. Although the standard deviation is good 
(SD= 0.207) and even better than the model by Fiserova-Bergerova and Diaz (SD = 
0. 702), the overall square of the correlation is poorer (r = 0.537). From the plot on 
page 226 most of the data is cluttered to the middle of the graph and that might 
explain why this model has a poor correlation for the full set and training set. This 
work is the most up to date model for VOC blood to muscle distribution reported for 
both species (humans and rats).
There were three outliers observed in this training set: 2,3,4-trimethylpentane, 
octane and 2,2,4-trimethylpentane (isooctane). The residual for these three 
compounds are approximately 0.35-0.56 log units and may result from experimental 
error.
EQUATIONS N r2 SD F D
FULL SET
Log P (blood to muscle) = -0.185 - 0.209E - 0.593S -
0.081A-0.168B +0.741V
110 0.537 0.207 24.125 5
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TRAINING SET
Log P (blood to muscle) = -0.057 - 0.13IE - 0.606S - 55 0.481 0.214 9.087 5
0.230A-0.218B +0.594V
TEST SET
N = 55 RMSE = 0.213 SD (n-1) = 0.215 
AAE = 0.169 AE = 0.037
N = number of compounds used in the training set 
r2 = is the overall square of the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model 
RMSE = root mean square error
Table 16.4. Summary of the equations for VOC blood to muscle distributions for 
humans and rats combined.
The inter-correlations of descriptors used for VOC blood to muscle 
distribution are shown in table 16.5. The largest r2 value for E versus S descriptor is
0.31. It appears that there is no strong inter-correlation between the set of 
descriptors used in this model.
r E S A B V
E 1.00
S 0.56 1.00
A -0.03 0.08 1.00
B -0.07 0.32 0.32 1.00
V 0.25 0.27 -0.04 0.33 1.00
Table 16.5. The inter-correlation of descriptors for 110 solutes using descriptors E, 
S, A, B and V
The Abraham solvation equation has been employed to correlate blood to 
muscle distribution for VOCs. To test the predictiveness of the model it was 
necessary to split the full data into training and test set using a random data set 
generator. A new model was developed using only those data in the training set, 
which was then used to predict values for the test set. The regression yielded
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similar training equation and statistics to the first equation in table 16.4., except for 
the ‘a’ coefficient. The test set of 55 compounds shows the average absolute error to 
be 0.169 for the two sets of data (observed and predicted log P). The root mean 
square error of 0.213 also indicates that there is reasonable predictive capability. The 
average error of 0.037 indicates that the equation of the model is not biased, as it is 
very close to zero. The blood to muscle model is the poorest statistical model 
reported for blood to tissue distribution of VOCs in the thesis and is ranked the 
lowest. The data points are cluttered in the middle of the graph and give rise to poor 
correlations as shown from the plot on page 226. The reason is that the coefficients 
in the equations for blood to muscle distribution are harder to interpret than those in 
the air to muscle distributions. This is because the coefficients in the blood to 
muscle equations reflect the difference in interactions between VOCs and blood and 
VOCs and muscle. This will also give rise to larger percentage error in the blood to 
muscle equation than the air to muscle equation due to these cancellation effects.
The a-coefficient (P = 0.70) and b-coefficient (P = 0.19) is not significant. 
The positive v-coefficients in the blood to muscle equation (16.4) indicate that 
increasing molecular size, can push VOCS out of blood and into the muscle tissue 
phase. The negative e-coefficients in the blood to muscle equation (16.4) indicate 
that London dispersion interaction and the presence of n- and ll-electrons pairs can 
push VOCS out of muscle and into the blood tissue phase. The coefficient of the 
‘polar’ descriptor S, indicating that polarity is stronger in the blood phase than in 
muscle tissue phase. The solutes are pushed out of the muscle and into the blood 
phase. The Abraham equation can therefore successfully be used to correlate and 
predict blood to muscle distribution for humans and rats (see graph on page 226).
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Chapter
17
Air to urine distribution for VOCs (human only)
The solubility of volatile organic compounds in biological fluids and tissues is 
of importance in areas such as anaesthesiology and toxicology. Indeed, a 
quantitative knowledge of such solubility is needed in pharmacokinetic modelling 
for VOCs in human subjects. Air to urine distributions for VOCs (or the ability of a 
molecule to enter urine from the air), have not frequently been obtained. The normal 
healthy urine sample for humans contains many chemical components of which 
water is the most abundant substance (95%), see figure 17.0.
Urine
0.05% Ammonia 
0.18% Sulphate 
0.12% Phosphate 
0.6% Chloride 
0.01% Magnesium 
~ 0.015% Calcium
0.6% Potassium 
0.1% Sodium 
0.1% Creatinine
0.03% Uric acid 
2% Urea
95%  W ater
Figure 17.0. The chemical composition for normal healthy human urine
Abnormal urine has additional substances that include: glucose, ketones and 
various types of protein. Most of the reported published data for VOC distributions 
are for normal human urine samples (that does not affect binding of VOCs to
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proteins). The reported distribution data from the literature for VOCs is collected in 
table 17.0 (see appendix).
A few reviews are available in which partition data for VOCs into urine are 
available.1*4 The values for log K that were obtained from the literatures are 
displayed in Table 17.0 and they refer to the VOC distribution (air:urine) in humans. 
The solubility in urine for VOCs was first reported by Pezzagno (et al).1 They 
reported partitions of a number of VOCs in human urine at 310 K. Each of these 
data was expressed in terms of partition coefficient, K. Abraham then used this data 
to construct an equation for air to urine distribution for 34 solutes (see table 17.1)4 
The E descriptor in the equation appeared not to be significant in the correlation, so 
this was removed. Besides this review, there has not been any other reported model 
for air to urine distribution in humans (with any other data sets).
EQUATION N r2 SD F D
Log K (air:urine) = -0.314 + 0.854S + 3.445A + 
3.720B + 0.056L
34 0.951 0.263 140.10 4
Table 17.1. Equation for air to urine distribution for VOCS in humans.4
The aim of this work is attempt to correlate 50 log K (solutes in urine) values 
with the Abraham descriptors (E, S, A, B and L), to obtain equations to enable 
prediction of air to urine distribution (humans only). The human urine sample 
contains 95% water, so it would be very useful to also see if the second Abraham 
equation can be constructed using V as the fifth descriptor rather than L.
Discussion on air to urine distribution for VOCs in humans
The two Abraham solvation equations were used to correlate VOC air to urine 
distribution (see table 17.2). The fits for the first equation (s.d = 0.322) appear to be 
poorer than for the second equation (s.d = 0.306). This shows that V descriptor is a 
rather better descriptor than L in this distribution process (thus giving rise to 
correlation r2 = 0.936). There were six outliers observed for this set of 50 
compounds and they are: enflurane, sulphur hexafluoride, cyclopentadiene, 2,3-
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dimethylbutane, decane and nonane with residuals of 0.80-1.07 log units. The 
second model with the V descriptor has the same compounds as outliers as the first 
model, plus an additional compound that is ethane. The residuals for this second 
model for the seven outliers are 0.71-1.28 log units. Although there is no direct 
explanation to why these compounds are outliers, but it may be due experimental 
errors.
EQUATIONS N r2 SD F D
Log K (ainurine) = - 0.973 - 0.689E + 1.285S + 
4.451 A + 3.288B + 0.300L
44 0.936 0.322 111.825 5
Log K (ainurine) = - 0.716 - 0.322E + 1.320S + 
4.062A + 3.257B +0.643V
43 0.936 0.306 107.407 5
N = number of compounds used in the equation 
r2 = is the overall square of the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model
Table 17.2. Summary of the two equations for VOC air to urine distributions
'y
The inter-correlations of descriptors are shown in table 17.3. The largest r value for 
E versus S and E versus L descriptor is 0.30. It appears that there is no strong inter­
correlation between the sets of descriptors used in this model.
The Abraham solvation equation has been employed to correlate air to urine 
distribution for VOCs.. No test sets have been used for this model as there is a 
limited number of compounds available. The descriptors used in the equation reflect 
solute/solvent interactions. Therefore, one can interpret these coefficients in terms 
of effect that particular interactions have on the process under consideration.
The statistics for this model is good, as indicated by the even spread of data 
shown from the plot (see graph on page 233). This model is not much better in 
describing the VOC air to urine distribution process compared to the air to muscle 
model mentioned earlier in chapter 16. The reason could be due to the limited 
amount of data in the dataset and to the presence of other components in urine.
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r E S A B L
E 1.00
S 0.55 1.00
A -0.04 0.01 1.00
B -0.25 0.46 0.35 1.00
L 0.55 0.39 -0.38 -0.07 1.00
Table 17.3. The inter-correlation of descriptors for 44 solutes using descriptors E, 
S, A, B and L
EQUATIONS N r2 SD F D
Log K (air:water) = -1.271 + 0.822E + 2.743S 
+ 3.904A + 4.814B -0.213L
392 0.992 0.185 10229 5
Log K (air:water) = -0.994 + 0.577E + 2.549S 
+ 3.813A + 4.841B-0.869V
408 0.995 0.151 16810 5
Table 17.4. VOC air to water distributions for 408 solutes5
The positive 1-coefficient in the air to urine equation from table 17.2 indicates 
that increasing molecular size and London dispersion interaction can push VOCs out 
of air and into urine. The E-coefficient is not significant (P = 0.08). The 
coefficients of the ‘polar’ descriptors S, A, and B are all positive, indicates that 
polarity and hydrogen-bond donor and acceptor ability is stronger in the urine phase 
than in gas phase. The solutes are pushed out the air and into the urine phase. The 
positive S, A and B coefficients in this equation are also similar to the air to water 
equation (see table 17.4), although this equation has a larger training set of 408 
solutes.5 It is interesting that the v-coefficient for log K (airiurine) is positive (Table 
17.2), but for log K (airrwater) it is negative (table 17.4). The 5% components other 
than water in urine must have a considerable effect in making urine less hydrophilic 
than water.
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Calculated log K versus observed log K for air to urine distribution (using V
descriptor)
y = 0.9355X + 0.0856
= 0.9355
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Chapter
18
Air to olive oil distribution for VOCs
In this chapter, the Abraham solvation equation shall be used to construct 
models that include air to olive oil distribution for VOCs.
Air to olive oil d istribution for V O C s
The partition of VOCs from air to olive is of importance in the pharmaceutical 
industry, biochemical and environmental sciences. Air-saline (as discussed in 
chapter 19) and air-olive oil partition coefficients are used to predict various air- 
solvent or air-tissue partitions for VOCs. The differences in the air-tissue and air to 
blood partition can used to predict blood to tissue distributions for a large number of 
VOCs. There have been a number of citations for air to olive oil distribution data for
VOCs.1'11
Scheme 18.0. Bottles of pure olive oil
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The purpose of this work is to gather a set of data from the literature and to 
attempt to construct a new equation to predict the distribution of solutes from air to 
olive oil. The correlative equations of Abraham shall be constructed based on the 
obtained dataset at a temperature of 31 OK. The complete list of the VOC log K data 
is shown in table 18.0 (appendix). Various models for the correlation of air to olive 
oil distribution for VOCs have been made by Weathersby and Abraham1, Klopman, 
et al.,4 and Fuchs and Abraham.5
Weathersby and Abraham compiled a dataset of 88 VOCs in their model to 
predict air to olive oil distribution at 310 K .  Most of their data was compiled from 
previous literature reviews. They used the Abraham solvation equation to correlate 
the log K  data for air to olive oil with the five Abraham descriptors ( E ,  S ,  A ,  B and 
L). The Abraham equation used for this model is shown in equation 18.0.1
Log K ( a i r  to  o l i v e  o i l )  = -0.240 - 0.018E + 0.806S + 1.469A +0.891L Equation 18.0
r2 = 0.997 S.D = 0.082 n = 88
Klopman et al modelled the air to olive oil distribution for VOCs based on a 
number of properties of solutes.4 The purpose of the work was to derive coefficients 
for the equation to predict air to olive oil distributions as surrogates for air to blood 
distribution, used for pharmacokinetic profiling for humans or rats. The Log K (a jr to  
o l i v e  o i l )  models were also derived from multivariate regression analysis, based on the 
basic sets of functional groups (L1.94) and correction factors obtained from the CASE 
computer program which calculates the intramolecular group interaction of VOCs.
The basic parameters for the functional groups (L1.94) are: OH, CHO, COOH, COO, 
CONH2, CONH, CON, CON=, CO, CS, NO, N 02, PO, SO, S02, NH2, NH, CN, SH, 
etc). The predictions for the first equation appear to be good.
T R A I N I N G  S E T  Equation 18.1
Log Ka(air t o  o l i v e  o , i )  = 0.9608 -  O.OOOlLt + 0.4706L2 + 0.7265L3 +
0 . 9 5 7 7 L 4 -  O . O I O I L 5 +  0 . 4 3 6 8 L 6  +  0 . 3 8 9 6 L n  +  0 . 4 2 8 4 L 1 4  +  0.9096Li5 -  
0 . 4 2 7 0 L , y  +  0 . 3 4 3 6 L 1 9  +  0 . 7 8 9 1 L 21  +  0 . 5 1 9 8 L 2 4  +  0 . 5 4 3 1 L 2 5  +  0 . 0 9 1 1 L 3 0  
+  0 . 8 8 4 4 L 3 4  +  0 . 9 1 2 1 L 4 0  +  0 . 0 9 1 4 L 5 5  -  0 . 3 4 8 5 L 6 8  +  0 . 1 1 2 8 L 7 3  -  
0 . 0 8 8 3 L 8 9  -  0 . 0 2 4 9 L 9 3  -  0 . 9 1 1 0 L 9 4
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n = 159 r2= 0.9377 SD = 0.2954
T E S T  S E T
n = 36 SD = 0.271
T O T A L  S E T  Equation 18.2
Log Kb(air to olive oil) = 0.2541 + 0.0057Li + 0.2399L2 + 0.3233L3 +
0.2153L4 -  0.0678L5 + 0.2688L6 + 0.0847L? + 0.2357Ln + 0.2598Li4 +
0 . 4 8 2 6 L i 5  -  0 . 4 5 3 9 L n  -  0.0329Li9 -  0.2673L2i +  0 . 6 3 3 1 L 2 4  +  0 . 3 2 9 7 L 5 5  
+  0 . 9 1 9 6 L 5 7  -  0 . 1 0 1 4 L 6 8  +  0 . 0 4 7 8 L 7 3  -  0 . 0 6 7 8 L 8 9  -  0 . 0 1 9 8 L 9 3  -  
0 . 4 8 2 8 L 9 4  +  0 . 1 6 7 5 L 9 5  
n = 1 9 2  r2 = 0 . 9 6 7 8  SD =  0 . 2 0 5 6
N O  T E S T  S E T
aEquation was derived from 119 experimental values and 40 calculated values for 
log K air to olive oil distribution. bEquation was derived from 192 calculated values 
for log K air to olive oil distribution
Klopman et al. found that the most important descriptor in the model for 
determining Log K air to olive oil distribution was the molecular weight (L9s). The 
fits for the second equation appears to be a little better because of this additional 
descriptor taking into account of the molecular weight of the VOC. Note that both 
equations include a large amount of calculated data as opposed to experimental 
data,4 and this may well lead to much better statistics than for the usual ‘observed’ 
values.
Abraham and Fuchs also modelled VOC air to olive distribution using a linear 
regression technique (olive oil at 31 OK).5 They achieved reasonable fits for the 
correlation of air to olive oil distribution for 52 VOCs (see equation 18.3).
Log K = 0.6468 -  0.0384V + 0.2233(MR) + 0.0869(p2) Equation 18.3
n = 52 SD = 0.233 r2 = 0.947
The endoergic work of creating a cavity in the solvent is given by vV, where V 
is a solute volume and the exoergic solute-solvent interactions are given by c(MR) 
and dp2, being dispersion and dipole-induced dipole (or dipole-dipole) effects,
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respectively; MR and p are the solute molar refraction and dipole moment. The air 
to olive oil distribution is denoted by log K at 310 K.5
It is found that two out of the three models do not have any test sets that 
include statistical information that can be used to test predictions. It is disappointing 
that Klopman et al. did not base their models fully on experimental data for the 
training set equations they have constructed. Some improvement to these models 
can be made by adding new VOC experimental data, to see if the new equation for 
the full set has better fits than the published models. Table 18.0 (see appendix) 
contains up to date literature data for air to olive distribution for VOCs.1'11
Discussion on air to olive oil distribution for VOCs
Abraham’s solvation equation has successfully been employed to correlate 
and predict VOC air to olive oil distribution as shown in table 18.1. This model 
contains 213 compounds in the dataset, and the fits for this new equation appear to 
be quite good (S.D = 0.197 and r2 = 0.981), for a diverse range of VOCs. This work 
is the most up to date model for VOC air to olive oil distribution. There were three 
outliers observed in the training set: CF2HCFHCH2CF2H, N-Methylimidazole and 
2-Methyl-1,3-butadiene (isoprene). The residuals for these three compounds are 
approximately 0.80-2.62 log units and may result from experimental error.
EQUATIONS N r2 SD F D
FULL SET
Log K (air to olive oil) = -0.159 - 0.277E + 0.903S 
+ 1.698A - 0.091B + 0.876L
213 0.981 0.197 2090.954 5
TRAINING SET
Log K (air to olive oil) = -0.124 - 0.266E + 0.830S 
+ 1.620A - 0.018B + 0.868L
TEST SET
N = 106 RMSE = 0.160 SD (n-1) = 0.161 
AAE = 0.105 AE = -0.004
107 0.973 0.232 739.167 5
N = number of compounds used in the training set
r2 = is the overall square of the correlation coefficient
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SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model 
RMSE = root mean square error
Table 18.1. Summary of the equations for VOC air to olive oil distributions
The inter-correlations of the descriptors (E, S, A, B and L) used for VOC air to 
olive oil distribution are shown in table 18.2. The largest r2 value for E versus S 
descriptor is 0.35. It appears that there is no strong inter-correlation between the set 
of descriptors used in this current model.
r E S A B L
E 1.00
S 0.59 1.00
A -0.01 0.11 1.00
B 0.12 0.52 0.30 1.00
L 0.52 0.30 -0.07 0.18 1.00
Table 18.2. The inter-correlation of descriptors for 213 solutes using descriptors E, 
S, A, B and L for air to olive oil distribution model
The Abraham solvation equation has successfully been employed to correlate 
air to olive oil distribution for VOCs. To test the predictive ability of the model it 
was necessary to split the full data into training and test set using a random data set 
generator (Kennard-Stone). A new model was developed using only those data in 
the training set, which was then used to predict values for the test set. The regression 
yielded similar training equations and statistics to the first equation in table 18.1., 
except for the b coefficient, which appeared to be slightly different. The test set of 
106 compounds leads to an average absolute error of 0.105 for the two sets of data 
(observed and predicted log K) and a root mean square error of 0.160, which 
indicates that the predictive capability of the training equation is good. The average 
error of -0.004 indicates that the equation of the model is not biased, as it is very 
close to zero.
The b-coefficient is not significant (P = 0.22). The positive 1-coefficients in 
the air to olive oil equation (18.1) indicate that increasing molecular size can push
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VOCs out of air and into the olive oil phase. The negative e-coefficients in the air to 
olive oil equation (18.1) indicate that London dispersion interaction and the presence 
of n- and 11-electrons pairs can push VOCs out of the olive oil phase and into the air. 
The coefficients of the ‘polar’ descriptors S and A are positive, indicating that 
polarity and hydrogen-bond acceptor ability is stronger in the olive oil tissue phase 
than in gas phase. The solutes are pushed out of the air and into the olive oil phase. 
Finally, the Abraham equation can successfully be used to correlate and predict air to 
olive oil distribution (see graph on page 242)
The statistics for this model is very good, as indicated by the large spread of 
data shown from the plot. It is found that it is possible to construct an equation 
capable of predicting further values of log K o i i v e  o i l  to around 0.2 log units. This 
equation is the best model for predicting log K values for air to olive oil distribution 
for VOCs and is far better in terms of fits than other models (air to tissue distribution 
of VOCs) reported earlier in this thesis
Although, now this model has the largest data set ever reported; the fits for the 
full set (table 18.1) appear to better than the models of Klopman et al., and of Fuchs 
and Abraham, but not as good as the fit found by Abraham and Weathersby. 
However, there is now a larger diversity of compounds in the data set than ever 
before, and on this basis the present equations are more soundly based than any of 
those previously published.
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Calculated log K versus observed log K for air to olive oil distribution for VOCs
0.9806x + 0.0478 
R2 = 0.9806
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Chapter
19
Air to saline and saline to olive oil 
distribution for VOCs
In this chapter, the Abraham solvation equation shall be used to construct 
models that include air to saline and saline to olive oil distribution for VOCs.
Air to saline distribution for VOCs
The air to saline distribution of VOCs, or the ability of a volatile organic 
molecule to enter the saline phase has become a subject of interest to the 
pharmaceutical industry, biochemical and environmental sciences. Air-saline and 
air-olive oil partition coefficients are used to predict various air-solvent or air-tissue 
partitions for VOCs. The differences in the air-tissue and air to blood partition can 
used to predict blood to tissue distributions for a large number of VOCs.
Most of the literature data compiled for saline is for 0.9% NaCl solution and 
this is indicated clearly in table 19.0 (see appendix). There have been a number of 
reported published data for air to saline distribution for VOCs.1'5 There have been 
no specific reviews reported yet that attempt to make models to predict air to saline 
distribution for VOCs. The present work consists of a large data set of 134 
compounds, which is all that has been published.1'5 The VOC data for air to saline 
distribution is at 310 K. The aim is to attempt to construct a model based on the 
Abraham equations to predict the distribution process. This equilibrium distribution 
for air to saline distribution will be the first reported model in this area. Since saline
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is so close to water, it would be useful to see if a second Abraham equation can be 
constructed using V as the fifth descriptor, rather than L, in correlating the 
distribution process.
The aim of this work is to construct an equation as part of a general method for 
‘high-throughput’ prediction of equilibrium air to saline distribution based on 
structure using the Abraham descriptors (E, S, A, B and L or V).6
Discussion on air to saline distribution for VOCs
The Abraham solvation equation has been employed to correlate and predict 
VOC air to saline distribution, as shown in table 19.1.
EQUATIONS N r2 SD F D
FULL SET
Log K (air to saline) = -1.254 + 0.653E + 2.447S 
+ 4.144A + 4.247B - 0.211L
134 0.961 0.302 625.836 5
TRAINING SET
Log K (air to saline) = -1.214 + 0.804E + 2.206S 
+ 3.978A + 4.274B - 0.200L
TEST SET
N = 67 RMSE = 0.259 SD (n-1) = 0.261 
AAE = 0.206 AE = -0.009
67 0.954 0.353 252.645 5
FULL SET (with V  coefficient)
Log K (air to saline) = -1.034 + 0.300E + 2.310S 
+ 4.079A + 4.21 IB-0.763V
133 0.966 0.284 714.153 5
TRAINING SET (with V  coefficient)
Log K (air to saline) = -1.083 + 0.345E + 2.277S 
+ 3.791A + 4.348B- 0.728V
TEST SET
N = 66 RMSE = 0.241 SD (n-1) = 0.243 
AAE = 0.178 AE = -0.033
67 0.960 0.329 291.539 5
N = number o f compounds used in the training set 
r2 = is the overall square of the correlation coefficient 
SD = the standard deviation 
F = F-statistic
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D = the number of descriptors used in the model 
RMSE = root mean square error
Table 19.1. Summary of the equations for VOC air to saline distributions
This model has 134 compounds in the dataset, and the fits for the first full equation 
appear to be good (S.D = 0.302 and r2 = 0.961), considering this data set contains a 
diverse range of VOCs. The fits for the second full equation (s.d = 0.284) appear to 
be slightly better than for the first equation (s.d = 0.302), although there were only 
133 compounds in this data set. The reason for this is that, a new set of outliers was 
observed in this regression when using the V descriptor. These outliers are: 1,3- 
difluoropropane, heptane, 2,2,4-trimethylpentane, 3-methylpentane and 
CF2HCFHCH2CF2H (residuals of 0.91-1.55 log units). This justifies the fact that V 
descriptor is a more important factor than the L descriptor in this distribution process 
(thus giving rise to better correlation r = 0.966). There were five outliers observed 
from this full set of the equation using the L-descriptor: 1,3-difluoropropane, 
heptane, 2,2,4-trimethylpentane, 3-methylpentane and CF2HCFHCH2CF2H; the 
residuals for the five outliers are approximately 0.91-1.55 log units.
The inter-correlations of the descriptors (E, S, A, B and L) used for VOC air to 
saline distribution are shown in table 19.2. The largest r2 value for E versus L 
descriptor is 0.50. It appears that there is no strong inter-correlation between the set 
of descriptors used in this current model.
r E S A B L
E 1.00
S 0.61 1.00
A -0.14 -0.04 1.00
B -0.04 0.28 0.46 1.00
L 0.71 0.47 -0.19 0.13 1.00
Table 19.2. The inter-correlation of descriptors for 134 solutes using descriptors E, 
S, A, B and L for air to saline distribution model
The Abraham solvation equation has been employed to predict air to saline 
distribution for VOCs. To examine the predictive ability of the model, it was
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necessary to split the full data into training and test set using a random data set 
generator (Kennard-Stone). A new model was developed using only those data in 
the training set, which was then used to predict values for the test set. The regression 
yielded similar training equations and statistics to the first equation in table 19.1., 
except for the e-coefficient, which appeared to be slightly different.
The test set of 67 compounds shows the average absolute error to be 0.206 for 
the two sets of data (observed and predicted log K). The root mean square error of 
0.259 also indicates that there is a small difference between the observed value and 
predicted data for air to saline distribution for VOCs. The average error of -0.009 
indicates that the equation of the model is not biased, as it is very close to 0.
The statistics for this model is good, as is indicated by the even spread of data 
shown from the plot. It is found that it is possible to construct an equation capable 
of predicting further values of log K saijne to around 0.2 log units. The reason why 
this model is better than other air to tissue models (VOCs) at steady-state is that the 
measurements for solvents (saline or olive oil) have less background noise than 
tissue samples.
The positive e-coefficients in the air to saline equation (19.1) indicates that 
increasing the presence of n- and II-electrons pairs can push VOCs out of air phase 
and into the saline phase. The negative 1-coefficients in the air to saline equation 
indicates that increasing molecular size and the London dispersion interaction this 
can push VOCs out of saline and into the air phase. The coefficients of the ‘polar’ 
descriptors S, A, and B are all positive, indicating that polarity and hydrogen-bond 
donor and acceptor ability is stronger in the saline phase than in the gas phase. The 
solutes are pushed out of the air and into the saline phase. Finally, the Abraham 
equation can successfully be used to correlate and predict air to saline distribution 
(see graph on page 248).
The general chemistry associated with the second equation, (containing the V 
coefficient in table 19.1), is similar to that of the first equation.
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Calculated log K versus observed log K for air to saline distribution for VOCs (using the L
descriptor)
0.9607X + 0.0202
Saline to olive oil distribution for VOCs
It is also important to find out whether there is a correlation between the saline 
to olive oil distribution for VOCs and the Abraham descriptors. The log P data for 
saline to olive oil distribution for VOCs can be obtained by combining the log Koiive 
oil data (chapter 18, table 18.0) with the log Ksaiine VOC data (chapter 19, table 19.0).
There have been no reports in the literature, where models have been 
constructed for saline to olive oil distribution. The correlative equation shall be 
constructed based on datasets that represent average literature values for distribution 
at 310 K. The complete list of the VOC log P data for these averages, are shown in 
table 19.3 (see appendix).
Discussion on saline to olive oil distribution for VOCs
The Abraham solvation equation has been used to correlate VOC saline to 
olive oil distribution as shown in table 19.4.
EQUATIONS N r2 SD F D
FULL SET
Log P (saline to olive oil)= 0.066 + 0.700E - 0.961 S
-2.152A-4.504B +4.068V
131 0.982 0.207 1370.563 5
TRAINING SET
Log P (saline to olive oil)= 0.006 + 0.695E - 0.959S
-2.035A-4.512B +4.172V
TEST SET
N = 65 RMSE = 0.162 SD (n-1) = 0.164 
AAE = 0.129 AE = 0.057
66 0.977 0.253 500.655 5
N = number o f compounds used in the training set 
r2 = is the overall square o f the correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number o f descriptors used in the model 
RMSE = root mean square error
Table 19.4 Summary of the equations for VOC saline to olive oil distributions
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This saline to olive oil model has a total of 131 compounds in the dataset, and 
the fits for the new equation appear to be good (SD = 0.207 and r2 = 0.982), 
considering now there is a diverse range of VOCs. There were two outliers observed 
from this full set: ethyl t-pentyl ether and hexaflurobenzene; the residuals for the two 
outliers are approximately 1.22-1.36 log unit. The inter-correlations of descriptors 
used for VOC saline to olive oil distribution are shown in table 19.5. The largest r2 
value for E versus S descriptor is 0.37. It appears that there is no strong inter­
correlation between the set of descriptors used in this model.
r E S A B V
E 1.00
S 0.61 1.00
A -0.15 -0.05 1.00
B -0.04 0.29 0.46 1.00
V 0.24 0.08 -0.23 0.13 1.00
Table 19.5. The inter-correlation of descriptors for 131 solutes using descriptors E, 
S, A, B and V
The solvation equation of Abraham has been employed to correlate saline to 
olive oil distribution for VOCs. To test the predictiveness of the model it was 
necessary to split the full data into a training set and a test set using a random data 
set generator. A new model was developed using only those data in the training set, 
which was then used to predict values for the test set. The regression yielded similar 
training equation and statistics to the first equation in table 19.4. The root mean 
square error of 0.162 also indicates that there is reasonable predictive capability. The 
average error of 0.057 indicates that the equation of the model is not biased, as it is 
very close to zero.
The positive e- and v-coefficients in the saline to olive oil equation (19.4) 
indicate that increasing molecular size, London dispersion interaction and the 
presence of n- and Il-electrons pairs can push VOCS out of saline and into the olive 
oil phase. The coefficients of the ‘polar’ descriptors S, A, and B are all negative, 
indicating that polarity and hydrogen-bond donor and acceptor ability is stronger in 
the saline phase than in olive oil phase. The solutes are pushed out of the olive oil
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phase and into the saline phase. The Abraham equation can therefore successfully be 
used to correlate and predict saline to olive oil distribution (see graph on page 252).
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Conclusion on air to tissue and blood to tissue 
distribution for VOCs
The equilibrium distribution models for: air to tissue, air to solvent, blood to 
tissue and blood to biophase distribution were successfully employed using the 
Abraham equations. The following tissues, biophases and solvents thus examined 
are blood, plasma, brain, kidney, fat, heart, liver, lung, muscle, urine, olive oil and 
saline. The coefficients for the equations are summarised in tables 20.0 and 20.1.
The partition coefficients, Kairtissues & Pbioodissues for volatile organic 
compounds, VOCs, from air to tissues and blood to tissues have been collected for a 
large number of compounds, measured in two different species, namely humans and 
rats. The general solvation equations from table 20.0 and 20.1 can be used to 
correlate the partitions of these VOCs as log K or log P values at 31 OK. The 
equations can be used to screen large numbers of compounds very quickly and to 
identify out-of-line log K or log P values that may be a result of experimental error 
or some specific effect.
It has been found that human and rat partition data are the same within a given 
experimental error of 0.16 log units (see chapter 9) and that these two sets of data 
can be combined for all the tissue models discussed earlier in this thesis.
Coefficients e, s, a, b and 1 versus the tissue composition for 
air to tissue distribution of VOCs
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An attempt was made to compare the coefficients (e, s, a, b, I and v) of the 
equations (table 20.0 and 20.1) with the composition of the tissues (weight fraction 
of lipid and water). It was not possible to construct mathematical connections, and 
so a useful visual comparison of plots (20.0-20.15) between the tissue equation 
coefficients and the tissue composition was made using the software program, 
MINIITAB.1
AIR:
TISSUE
e s a b I TISSUE COMPOSITION 
(WEIGHT FRACTIONS)2
LIPID PROTEIN WATER
OIL8 -0.277 0.903 1.698 -0.091 0.876 1.000 0.000 0.000
FAT 0.051 0.728 1.783 0.332 0.743 0.800 0.050 0.150
BRAIN 0.263 0.411 3.358 2.025 0.591 0.107 0.079 0.790
HEART 0.139 0.941 0.778 1.870 0.595 0.100 0.167 0.727
LIVER 0.083 0.768 2.796 2.090 0.560 0.070 0.180 0.720
KIDNEY 0.208 0.382 2.919 2.533 0.651 0.050 0.170 0.770
MUSCLE 0.207 0.723 3.242 2.469 0.463 0.020 0.170 0.790
LUNG 0.534 1.052 3.679 3.078 0.421 0.010 0.177 0.780
BLOOD 0.456 1.083 3.738 2.580 0.376 0.007 0.180 0.800
URINE -0.689 1.285 4.451 3.288 0.300 - - -
PLASMA 0.543 1.677 3.518 3.982 0.192 - - -
SALINE 0.653 2.447 4.144 4.247 -0.211 - - -
WATERb 0.822 2.743 3.904 4.814 -0.213 0.000 0.000 1.000
“Olive oil
bWater equation at 298K
Table 20.0. Summary of equations for air to tissue (or phase) distribution, and the
2
tissue composition (lipid, protein and water) in humans.
Due to small number of data found in the literature, the new equations have 
not been mentioned for air-lung and air-heart distribution. The new equations are 
not different to the current published produced by Weathersby and Abraham. The 
amount of data in the literature for air-lung and air-heart distribution was very small, 
being only for 43 and 26 compounds respectively. Hence these systems were not 
reported earlier in this work. The equations are given here for the completeness (see 
table 20.0).
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When the lipid fraction is increased in tissues (lung, blood, muscle, kidney, 
brain, heart, liver and fat) or solvents (water and olive oil), the ‘e’ coefficient for the 
equations appears to get smaller. This indicates that the London dispersion 
interaction is smaller for partition into lipids than into the more polar water and 
protein constituents. This is shown by the graph in scheme 20.0.
The s coefficient also becomes smaller when the lipid fraction is increased. 
Then dipole/dipole and dipole/induced dipole interactions are also smaller for 
partition into lipid than into the more polar water and protein constituents. This is 
displayed by the graph shown in scheme 20.1.
When the lipid fraction is increased in tissues or solvents, the ‘a and b ’ 
coefficients for the equations appear to get smaller. Again, the more polar 
constituents of the tissues, hydrogen bond better to VOCs that are themselves 
hydrogen bond acids or bases, see scheme 20.2 and 20.3. Note that the coefficients 
for the heart equation in scheme 20.2. do not follow this trend. This could be because 
the dataset does not represent the true chemical space for that particular tissue. This 
problem is discussed again later, with the blood to heart distribution equation. Note 
also that the a-coefficient in an equation will reflect an interaction between a 
hydrogen bond acidic VOC and a hydrogen bond basic tissue, so that a large a- 
coefficient means that the tissue is a strong hydrogen bond base.
Finally, as the lipid fraction is increased in tissues or solvents, the 1-coefficient 
for the equation increases and seems to reach a plateau. The 1-coefficient is a 
measure of the Tipophilicity’ of a phase. Thus for partition from the gas phase into 
hexadecane, 1 = 1, for partition into many organic solvents 1 is around 0.7 to 0.9, and 
for partition into saline, 1 = -0.21 (the only solvent phase for which 1 is negative). 
The trend shown in scheme 20.4 is exactly as expected, although the numerical value 
for 1 in water (at 298K) is also negative (1 = -0.21), this data is the same for that of 
saline at 31 OK.
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Scheme 20.0. Scatter plot for e coefficient versus the fraction of lipid for VOCs air 
to tissue distribution
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Scatterplot for a versus the fraction of lipid
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Scatterplot for I versus the fraction of lipid
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Scheme 20.4. Scatter plot for L coefficient versus the fraction of lipid for VOCs air 
to tissue distribution
Plots of the coefficients e, s, a, b and I versus the fraction of water are almost 
mirror images of the plots versus the fraction of lipid. The explanation is the same 
as that given above. The e, s, a and b-coefficients increase with water fraction 
because the coefficients refer to polar-type interactions. The 1-coefficient decreases 
with water content because it refers to essentially a non-polar type interaction. This 
can all be seen in the plots shown in schemes 20.5 to 20.9. The a-coefficient for the 
air to heart distribution is anomalous, just as it is for the plot of a versus the lipid 
content, but this is the only very large anomaly.
The conclusion is that the coefficients in the equations for air to tissue 
distribution are chemically reasonable. They reflect the chemical composition of the 
tissues, and are not just fitting coefficients in the multiple linear regression 
equations.
259
Scatterplot for e versus the fraction of water
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Scheme 20.5. Scatter plot for e coefficient versus the fraction of water for VOCs air 
to tissue distribution
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Scatterplot for a versus the fraction of water
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Scheme 20.7. Scatter plot for a coefficient versus the fraction of water for VOCs air 
to tissue distribution
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Scheme 20.8. Scatter plot for b coefficient versus the fraction o f water for VOCs air
to tissue distribution
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Scatterplot for I versus the fraction of water
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Scheme 20.9. Scatter plot for L coefficient versus the fraction of water for VOCs air 
to tissue distribution
Coefficients a, b and v versus the tissue composition for 
blood to tissue distribution of VOCs
The coefficients in the equations for blood to tissue distribution are harder to 
interpret than those in the air to tissue distributions. This is because the coefficients 
in the blood to tissue equations reflect the difference in interactions between VOCs 
and blood and VOCs and tissue. If blood and a given tissue have the same hydrogen 
bond basicity, for example, then the a-coefficient for the blood to tissue distribution 
will be zero, even though the a-coefficients in the air to blood and air to tissue 
equations might both be large. In addition, the coefficients in the blood to tissue 
equations are much smaller than those in the air to tissue equations, because of 
partial cancellation of effects. Then the percentage error in the blood to tissue 
coefficients will be much larger than the percentage error in the air to tissue 
coefficients. This is another factor that makes interpretation of the blood to tissue 
equation coefficients difficult.
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In Table 20.1 are given the equation coefficients for blood to tissue 
distribution of VOCs. Included is blood to blood, for which the coefficients are zero, 
by definition. For blood to muscle, the a-coefficient is very small at 0.081 units, 
even though the coefficient is very large for air to blood (3.738) and air to muscle 
(3.242). The latter two figures would suggest that the blood to muscle a-coefficient 
should be - 0.496 instead of 0.081, but this will only be the case if the exactly the 
same set of compounds is used in all three equations. As it is, the small a-coefficient 
in the blood to muscle equation shows that blood and muscle are have about the 
same hydrogen bond basicity -  the coefficients 3.738 (air to blood) and 3.242 (air to 
muscle) show that this hydrogen bond basicity is very large.
Plots involving the e- and s-coefficients are so scattered that little can be 
deduced. Plots of the equation coefficients a, b and v against the fraction of lipid are 
shown in schemes 20.10 to 20.12, and plots against the fraction of water are shown 
in schemes 20.13 to 20.15
BLOOD:
TISSUE
e s■' ' a b
. - . - 
v T'TCC
LIPID PROTEIN
SITION
riONS)
WATER
FAT 0.017 -0.003 1.577 -2.246 1.560 0.800 0.050 0.150
BRAIN 0.017 -0.536 0.323 -0.335 0.731 0.107 0.079 0.790
HEART 0.033 0.177 2.664 -0.749 0.923 0.100 0.167 0.727
LIVER -0.048 -0.295 0.213 -0.359 0.876 0.070 0.180 0.720
KIDNEY 0.134 -0.515 0.823 0.273 0.981 0.050 0.170 0.770
M USCLE -0.209 -0.593 0.081 -0.168 0.741 0.020 0.170 0.790
LUNG -0.193 0.004 -0.279 -0.206 0.256 0.010 0.177 0.780
BLOOD 0.000 0.000 0.000 0.000 0.000 0.007 0.180 0.800
PLASM A -0.227 0.103 -0.268 0.303 -0.201 - - -
Table 20.1. Summary of equations for blood to tissue distribution, and the tissue 
composition (lipid, protein and water) for humans.2
The plot of the a-coefficients against the lipid fraction is shown in scheme 
20.10, and appears to be quite anomalous. It would be expected that as the tissue 
gets less polar, so the a-coefficient should get less (the value for the blood to heart
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equation is again out of line). However, the a-coefficients get larger, for which there 
is no explanation. The plot of the a-coefficients against the fraction of lipid for the 
air to tissue equations shows that as the tissue gets less polar, the a-coefficient gets 
less, as expected, so the peculiar trend in scheme 20.10 might be due to errors in the 
coefficients.
If the lipid fraction is increased in tissues, the b-coefficient for the equations 
gets smaller, see scheme 20.11. This is reasonable, because the tissue becomes less 
polar, and less positive. Finally, as the lipid fraction is increased in tissues, the v- 
coefficient for the equations increases, scheme 20.12. This is also reasonable 
because the v-coefficient is also an indication of lipophilicity of a phase.
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Scheme 20.10. Scatter plot for a coefficient versus the fraction of lipid for VOCs 
blood to tissue distribution
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Scatterplot of b versus the fraction of lipid
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Scheme 20.11. Scatter plot for b coefficient versus the fraction of lipid for VOCs 
blood to tissue distribution
Scatterplot of v versus the fraction of lipid
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Scheme 20.12. Scatter plot for v coefficient versus the fraction o f lipid for VOCs
blood to tissue distribution
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The plots against the water fraction are almost mirror images of the plots 
against lipid fraction. The plot of the a-coefficients, scheme 20.13 is again 
completely anomalous. However, the plot for the b-coefficient, scheme 20.14, is 
sensible and shows that the b-coefficient increases as the tissue becomes more polar, 
and has more hydrogen bond acidity. Finally, as the water fraction is increased in 
tissues, the v- coefficient for the equations, appears to also gradually decrease. This 
demonstrates that the tissues with larger amounts water content are less lipophilic 
and less likely to accommodate larger solutes. This relationship is shown by a graph 
in scheme 20.15.
In conclusion, we show that for a large data set of air to tissue and blood to 
tissue partitions for VOCs, it is possible to construct statistically sound models and 
to assess the predictive capability of the model through selection of training and test 
sets of VOCs. A particular feature of the model is that the coefficients obtained are 
not just fitting parameters but encode chemical information about the nature of the 
process. This enables the air to tissue or blood to tissue distribution process to be 
compared in terms of the chemical interactions between the VOCs and blood and 
tissues.
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Scheme 20.13. Scatter plot for a coefficient versus the fraction of water for VOCs
blood to tissue distribution
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Scatterplot of b versus the fraction of water
KIDNEY*
BLOOD,
0.0 -
MUSCLE 
LUNG 4
BRAIN-0.5-
HEART,
- 1 . 0 --Q
-1.5-
- 2 .0 -
FAT
-2.5H
0.6 0.80.1 0.2 0.3 0.4 0.5 0.7
WATER
Average standard error for 7 biological samples
Scheme 20.14. Scatter plot for b coefficient versus the fraction of water for VOCs 
blood to tissue distribution
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Chapter
Blood/plasma/serum to brain distribution 
for drugs and VOCs combined
In this chapter the Abraham solvation equation shall be used for models that 
include: blood/plasma/serum to brain distribution for drugs and blood/plasma/serum 
to brain distribution for VOCs and drugs combined
Blood/plasma/serum to brain distribution for drugs
Brain uptake, or the ability of a molecule to enter the brain tissue, has been a 
subject of great interest to the pharmaceutical industry for over 35 years. There are 
two quite different methods used to obtain blood to brain distribution coefficients, 
denoted as BB values. In the first method, gas to blood and gas to brain partition 
coefficients are determined separately, using blood and brain samples from either 
humans or rats. Then the two partition coefficients can be combined to yield in vitro 
BB values. This method has invariably been used to obtain BB values for volatile 
organic compounds and some volatile inorganic compounds; the term VOC is used 
to cover both of these and has already been discussed in chapter 12 of this thesis.
The second method of obtaining blood/plasma/serum to brain distribution data 
for drugs in rats is by having the drug administered to the rat and the latter then 
being sacrificed after a given period of time. The drug concentration in 
blood/plasma/serum and in brain gives the blood/plasma/serum to brain ratio. The 
blood to brain distribution data {in vivo) for steady state is obtained by the following 
equation (21.0).
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log BB = (conc. of drug in the brain tissue)/(conc. of drug in the Equation 21.0
blood/ serum/plasma)
Literature values of the in vivo distribution of drugs from blood/plasma/serum 
to rat brain have been assembled for 120 compounds (152 data points), by far the 
largest data set ever reported.1'34 Several cited papers, where models have been 
suggested to predict blood to brain distribution in rats will be discussed. The 
purpose of this work is to add new literature data to the existing data sets and to 
make an attempt to construct new equations to predict blood to brain distribution. 
The complete list of drug log BB data is shown in table 21.0 (see appendix); where 
two or more results are reported for the same compound in the same system 
(blood/plasma/serum) they have been averaged.
The usual method of obtaining blood to brain distribution data is that of Young 
and Mitchell.11 A number of rats are sacrificed at given times and the 
blood/plasma/serum to brain ratios are examined to see if they reach a constant 
value. Quite often, data at only one or two time points are obtained, and the 
assumption is made that equilibrium has been reached. The distribution of drugs 
from the blood to the brain is of importance in pharmaceuticals and as well as 
toxicological sciences.
Unfortunately, the experimental determination of the blood/plasma/serum to 
brain distribution is time consuming, expensive, requiring animal experiments, 
synthesis of compounds (often in a radiolabeled form) and is a difficult technique to 
carry out. It would therefore be of very considerable value to devise a methodology 
whereby, log BB values could be predicted from other experimental results (such as 
other partition coefficients) that are easier to obtain than log BB values themselves, 
or even whereby log BB could be predicted from molecular structure.
Literature models for the correlation of blood to brain distribution for drugs 
have been reported by the following authors: Chadha et al.}5 Platts et al.,36'37
Norinder et al.,3S Lombardo et a l.39 Clark,40 Kaliszan and Markuszewski,41 Luco,42 
Keseru and Molnar,43 Hou and Xu,44'45 Ooms et al.,46 Liu et al.,47 Cabrera et al.,2] 
Kaznessis et al.,4% Feher et al.,49 Kelder et al 22 Ertl et al.,50 Salminen et al.}3 
Hutter,51 Rose et al.52 and Lobell et a lP
Chadha et al.35 modelled the passive distribution of drugs from the blood and 
into the brain by using the Abraham equation. Their data set of 57 compounds was
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used to correlate these distribution processes (equation 21.1). Here and elsewhere, N 
is the number of compounds, r is the square of the correlation coefficient, SD is the 
standard deviation and F is the Fisher statistics.
FULL SET
log BB = -0.038 + 0.198E - 0.687S - 0.715A - 0.698B + 0.995V Equation 21.1
n = 57 r2 = 0.92 SD = 0.20 F = 99 
NO TEST SETS
Although the model contained eight outliers (SKB3, SKB4, SKB6, SKB9, SKB13, 
SKB24, SKB25 and SKB45) the fits for the correlative equation were very good. It 
was very unfortunate to find that there were no test sets for this model, since it would 
have been very useful to see how good the predictions are for this blood to brain 
model.35
The method used to model the equilibrium distribution of drugs between blood
and brain was developed by Platts et al,36 They used the Abraham equation to
predict and correlate these passive distribution processes for 148 drug compounds. 
The five descriptors (E, S, A, B and V) plus an indicator variable (la) were used in a 
multiple linear regression analysis. Platts et al,36 also used a training set of 74 
compounds to predict the remaining log BB values in the test set with an SD value of
0.38 log units. They used an indicator variable, la, for carboxylic acids such that la 
= 1 for carboxylic acids, and la  = 0 for all other compounds. The equation for the 
total set of 148 compounds found by Platts et al. is given as equation 21.2.
FULL SET
log BB = 0.062 + 0.469E - 0.864S - 0.586A - 0.713B + 0.895V Equation 21.2
- 0.5641a
N = 148 r2 = 0.74 SD = 0.34 F = 83
TRAINING SET 
N = 74 r2= 0.76 SD = 0.34
TEST SET 
N = 74 SD = 0.38
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The indicator variable used by Platts et al., shows that carboxylic acids are less 
likely to distribute into the brain than expected from the usual descriptors. Nine 
outliers (SKB4, SKB9, SKB20, SKB21, YG-19, YG-20, thioridazine, org 12962 and 
fluphenazine) were removed from model, as they appeared to have large residuals. 
Platt suggested that the large residuals resulted from active transport, metabolism or 
error in the experimental measurements. The advantage of using this model, is that 
the descriptors for the unknown compounds can be calculated quickly, by using a 
commercially available program based on various fragment schemes.37
• 38Nonnder et al. used a quantitative structure-activity property analysis based 
on MolSurf parameterisation with the Partial Least Squares (PLS) method as a 
statistical engine. The computed properties of the solutes were calculated by using 
MolSurf (computer program) and this was used to create the training equation for 
blood to brain distribution for drugs. Hence all 14 descriptors can be calculated with 
available software. Norinder et al. divided the data set of Lombardo et al}9 into two 
parts: a training set (56 compounds) and a test set (6 compounds). The statistics for 
the PLS analysis, are shown below. The equations are not shown, as they absent 
from the author’s paper:
TRAINING SET
N = 56 r2 = 0.83 SD = 0.31 F = 87 
TEST SET
N = 6 RMSE = 0.51
The statistics were good, although the data set was not as large as that of Platts et 
al., and the test set is too small to afford a reliable predictive assessment. It would 
be useful to see if the training equation can be used to predict larger test sets for 
future work. This method is complicated and time consuming, as computational 
methods are required for the conformational analysis of the solutes, via the intensive 
semi-empirical and ab-intio calculations which can slow down the screening process. 
Norinder et al. also found that the most important factors that affected the models 
were associated with polarity and base strength. They also found that the properties 
associated with hydrogen bonding were important and should be kept to a minimum 
to facilitate high blood to brain distribution. High lipophilicity (log Poct) was also 
identified to be favourable for high partitioning. Furthermore, the presence of
272
polarisable electrons, e.g. conjugated and aromatic substructures as well as the larger 
halogens, is also beneficial for the compound to penetrate the brain effectively.38
Clark used a simple QSAR (quantitative structure-activity relationship) model 
for the prediction of log BB from a set of 55 diverse organic compounds.40 His data 
set was also obtained from Lombardo et al.39 Although, this data set is not as large 
as the Platts et al BB model,36 it can be used effectively to carry out rapid predictions 
of blood to brain distribution. The model contains two important variables: polar 
surface area (PSA) and calculated log Poct, both of which can be rapidly computed. 
The two descriptors (PSA and CLOG P) were used in a multiple linear regression 
analysis and the equations (21.3) are shown below. Note that two outliers were 
observed by Clark; they are: YG-19 and YG-20.
TRAINING SET
LogBB=-0.0148(±0.001)PSA + 0.152(±0.036)ClogP + 0.139(±0.073) Equation 21.3 
N = 55 r2 = 0.79 SD = 0.35 F = 96 
TEST SET 1 AND 2
1. N = 5 and MAE = 0.14 2. N = 5 and MAE = 0.24
The two test sets shows that there are good predictions, although, the compound 
numbers are still quite small. It would interesting to see again if larger test sets give 
more or less the same predictions.40
Kaliszan and Markuszewski41 initially used 20 compounds in their blood to 
brain data set. They used two parameters for the equation and this appeared to be 
one of the simplest forms of models to date, for blood to brain distribution for drugs. 
In the first correlative equation, they used square root of the molecular mass (Mm) 
and log Poet (octanol-water) as the main parameters, this is shown below as equation
21.4. The fits for the second equation (21.5) were improved by replacing log Poct 
with log Pcyciohexane (cyclohexane-water). The third equation (21.6) lead to better fits 
with the replacement of molecular mass (Mm), with the new volume parameter for 
the solute (V). This V parameter was used to represent the bulkiness of the solute. 
Again, the fits are found to be little better with this new parameter than found from 
equations 21.4 to 21.5. Finally, the parameter for equation 21.7 was reverted back to 
the parameters of equation 21.4. This was done to see if the fits of the equation 
would improve with larger data sets for the 33 blood to brain drug compounds. The
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fits for this equation improved with these larger data sets. It is very unfortunate that 
the data set for equation 21.4-21.7 is small, as it would be interesting to see how the 
correlations and predictions would be like with larger number of compounds (or data 
points), such as used in Platt’s model.
FULL SET [1]
LogBB= -0.476(±0.454) + 0.541(±0.106)logPoct - 0.008(±0.002)Mn 
N = 20 r2 = 0.64 SE = 0.49 F=15
FULL SET [2]
LogBB= 1.296(±0.313) + 0.309(±0.034)logPcyh - 0.006(±0.001)Mr 
N = 20 r2 = 0.84 SE = 0.32 F = 46
FULL SET [3]
LogBB= 1.979(±0.339) + 0.373(±0.032)logPcyh - 0.003(±0.001)V 
N = 20 r2 = 0.89 SE = 0.27 F = 68
FULL SET [4]
LogBB= -0.088(±0.051) + 0.272(±0.017)logPoct - 0.001(±0.000)Mr
Equation 21.4
Equation 21.5
Equation 21.6
Equation 21.7
N = 33 r = 0.90 SE = 0.13 F = 131
Luco used the partial least squares method to model the blood to brain 
distribution for 61 structurally diverse compounds.42 The PLS model was based on 
molecular descriptors that can be calculated for any compound simply from 
knowledge of its molecular structure. This provides information to polarity 
(hydrogen bond acceptors and donors), molecular size and the molecular shape. The 
statistics for the training equation were good, after removing three outliers form the 
model. The fits for the training set are shown below:
TRAINING SET
N = 58 r2 = 0.85 S = 0.32 F=102
TEST SET [1]
N = 12 RMSE = 0.24 
TEST SET [2]
N = 25 RMSE = 0.54
The test set (1) containing 12 other simple drug compounds, that were not 
used in the training set was predicted quite well. Whereas, the larger test set (2) of
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25 large drug compounds was rather poorly predicted. The reason is that these 
compounds are much larger and more complicated in structure, so that the training 
model may not predict compounds in descriptor space very well.
Lombardo and co-workers took a rather different approach in order to analyse 
the 57 drug compounds of the Abraham data set. The free energy of solvation was 
computed with the AMSOL 5.0 computer program using the AM1-SM2.1 solvation
'XQmodel. Lombardo et al. also identified two outliers and obtained the following 
model as shown by equation 21.8. The correlation established by this model for 
blood to brain distribution for drugs is not so impressive and the subsequent 
predictions of some additional six compounds as an external test set confirm this (SD 
=0.62).
TRAINING SET
LogBB = 0.054(±0.001)AGW° + 0.43(±0.070) Equation 21.8
N = 55 r2 = 0.67 SE = 0.41 F = 108 
TEST SET 
N = 6 SD = 0.62
They also computed the free energy of solvation in hexadecane (AGhex°) in the hope 
that this term might be more representative of the environment that the compounds 
would encounter while crossing the membrane of the brain. However, the inclusion 
of this term did not lead to a significant improvement in the correlation. Finally, 
although there is a correlation between the experimental and calculated values for the 
blood to brain distribution for drugs, the semi-empirical calculation required for each 
molecule made this approach very-time consuming.
Keseru and Molnar used the thermodynamic approach of the solvation of free 
energies.43 They used only one descriptor in their model -  the standard free energy 
of hydration of the gaseous compound, AGhyd, in kJ mol"1 Their training set involved 
a structurally diverse set of 55 compounds and the fits for the model can be found 
from equation 21.9.43 The prediction for the test sets appeared to be better than the 
equation produced by Lombardo.
TRAINING SET
LogBB = 0.035AGhydo + 0.2592 Equation 21.9
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N = 55 r2 = 0.72 SE = 0.37 
TEST SET
N = 5, 25 SD = 0.14, 0.37
Hou and Xu44'45 developed a blood to brain distribution model for drugs that is 
based on three descriptors, which are: octanol/water partition coefficient calculated 
using the SLOG approach; the high charged polar surface area (HCPSA) and a 
molecular weight term that takes the value (MW-360) for compounds with 
molecular weight greater than 360 and zero for other compounds. A combination of 
these properties gives rise to the following equation, 21.10, below:
TRAINING SET
Log BB = 0.00845 + 0.197SLOGP -  0.0135HCPSA -  0.0140 Equation 21.10
(MW -360)
N = 72 r2 = 0.77 SD = 0.36 F = 82
TEST SET 
N = 35 SD = 0.41
The prediction of the model was assessed through two external test sets of a total of 
35 drug compounds. Note the two test sets were predicted through equation 21.10 
as shown above.44'45
Following the success of equation 21.10, Hou and Xu44'45 re-parameterised the 
calculation of SLOGP, and replaced HCPSA with the more easily calculated high- 
charged topological polar surface area, HCTPSA, and derived the equation shown 
below, 21.11. The fits for this training and test set appeared little worse than that of 
equation 21.10., but equation, 21.10 can be used for high throughput screening, as 
the descriptors can be calculated quicker.
TRAINING SET
Log BB = 0.1256 + 0.160SLOGP -  0.0133HCTPSA -  0.0148(MW Equation 21.11 
-360)
N = 78 r2 = 0.74 SD = 0.38 F = 67
TEST SET 
N = 35 SD = 0.44
276
Ooms et al.46 developed a model to correlate blood to brain distribution for 79 
drug compounds. Their method involved the minimisation of the 3D structure of the 
drugs. Their descriptors were automatically calculated using a computer program 
called VolSurf. They obtained 31 useful descriptors and these refer to: molecular 
size, hydrogen bonding and the shape of hydrophilic and hydrophobic regions within 
the solute. The statistical analysis was performed with principle component analysis 
(PCA). Note that no test sets were used. The statistics for the model are shown 
below but no SD value was given.
FULL SET
N = 79 r2 = 0.76 SD = - F = - 
NO TEST SET
Liu et a l41 constructed equation (21.12) for blood to brain distribution for 
drugs using multiple linear regression. This was based on two important descriptors 
that are: lipoaffinity (LA) and molecular weight (MW). Their model was based on 
55 compounds (that included VOCs and drugs) and this was used to predict a test set 
of 11 solutes. They found that the lipoaffinity descriptor is the most significant 
descriptor for molecular transport of drugs across the blood to brain barrier. Finally, 
four outliers (comp-12, chlorambucil, trifluoropromazine and org-12962) were 
removed from model, as they appeared to have large residuals.
TRAINING SET
Log BB = 0.138(0.104) -  0.0112(0.0008)MW + 0.364(0.033)LA Equation 21.12
N = 55 r2 = 0.79 SD = 0.35 F = 98
TEST SET 
N = 11 SD = 0.30
Note that these statistical parameters are nearly identical to Clark’s model (equation 
21.3) based on polar surface area and CLOGP. Finally, four outliers were removed 
from Liu’s model and they are: nitrogen, compound 12, YG19 and YG20.
Cabrera et al.21 used only three descriptors in their equation for the correlation 
and the prediction of blood to brain distribution for drugs. Five outliers
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(chlorambucil, temelastine, tiotidine, YG-20 and indomethacin) were omitted from 
the model and large residuals possibly resulted from active transport or metabolism.
TRAINING SET
Log BB = -0.032 -  0.046(exp-3)PS * AM + 0.227H Equation 21.13
N = 114 r2 = 0.70 SD = 0.42 F=128
TEST SET
N = 28 MAE = 0.33
They use a simple notation for the descriptors: PS is related to the polar surface, AM
is the atomic mass (which appears to be the mass of atoms in a molecule excluding
hydrogen atoms), and H is related to hydrophobicity. The descriptors were
calculated by an in-house program, called TOPS-MODE (topological sub-structural
molecular design approach). They have found that hydrophobicity of the drug
compound has a positive effect with blood to brain distribution, whilst the polar
surface and atomic mass has a negative effect on this distribution. Although the
equation, 21.13, is very good and so is the predictive power, with MAE = 0.33 for a
test set, the method will not be very easy to carry out.
The results of Kaznessis et al. are also noteworthy. The best model, with SD
= 0.17 and r2 = 0.94 for a training set seems to be over fitted, because the SD value is
considerably smaller than the general error of the measurements. This is indicated
by a much larger SD value of 0.48 log units for a very small test set (4 compounds). 
48Kaznessis et al. also used another model with only three descriptors that yielded 
SD = 0.26 and r2 = 0.87; however, both of these models require very heavy 
computing time. Nine outliers (icotidine, temlastine, tiotidine, Org 12962, YG-19, 
YG-20 and compound 2, 4 and 13) were omitted from the model. The author 
suggested that these large residuals resulted from active transport, metabolism or 
error in the experimental measurements.
Of calculations mentioned earlier by other authors, the Feher et al.A9 method 
for predicting blood to brain distribution for drugs is very simple indeed. Only three 
descriptors are used in this model, which are: a calculated log Poct value, the polar 
surface area and the number of hydrogen bond acceptors in an aqueous medium, na. 
For a training set of 61 compounds, Feher et al 49 obtained the following equation 
(21.14) shown below:
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TRAINING SET
Log BB = 0.4275 -  0.3873na + 0.1092 log P0Ct(calc) -  0.0017PSA Equation 21.14 
N = 61 r2 = 0.73 RMSE = 0.42 F = 51 
TEST SET 
N = 14 SD = 0.76
N = 25 SD = 0.81
The results of the predictions through the test sets are disappointing, with SD values 
of 0.76 and 0.805 for test sets of 14 and 25 compounds. These SD values have been 
calculated in this work. Feher et al,49 give RMSE values of 0.63 and 0.79 but these 
seem to be calculated from plots of predicted vs. experimental values.
Of the models that had either no test set or a very limited test set, that of 
22Kelder et al. is the simplest; with the sole descriptor being the 3D dynamic polar 
surface area, as calculated by available software. The data set was restricted to only 
45 compounds and no validation of any sort was carried out. Nevertheless an r2 
value of 0.84 is impressive for a one-descriptor model. They also found that brain 
penetration decreases with increasing polar surface area.
Ertl et al.50 used polar surface as a descriptor in their model to correlate with 
the partition data of 45 drugs for blood to brain distribution. Although, there was no 
solid statistics on the fits of the correlation (i.e. standard deviation being absent), 
they did provide some information to the square of the correlation coefficients (r2) to 
be 0.84. Finally, no test sets have been provided for the model and this makes it 
difficult to determine whether or not the equation can be used to make any prediction 
for blood to brain distribution of drugs.50
• ITSalmmen et al examined two set of structurally dissimilar drugs compounds 
(dataset of 21 and 23 compounds) using retention factors (Kiam) measured by 
immobilised artificial membrane (packing material for HPLC column) using
1T •chromatography technique. From the two training sets, Salminen et al obtained 
the following equation shown below, 21.15 and 21.16. They concluded that the 
molecular size (Vm), the ionization of acidic (I3 = 1) or basic (I2 = -1) groups and the 
lipophilicity, reflected either by log Poct or log KIAM are the principle factors 
contributing to the brain uptake of the compounds examined. It is very unfortunate 
that they did not have a test set to verify their predictions, and, in any case, there are
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a very limited number of compounds used in their training set. Finally, six outliers 
were found in the Salminen model and they are: diphenhydramine, cimetidine, 
indomethacin, ranitidine, salicylic acid and thioridazine.
TRAINING SET
Log BB = 0.581og Kjam 0.89L — 0.01Vm + 1.28 
N = 21 r2 = 0.848 SD = 0.27 F = 32
TRAINING SET
Log BB = O.351og Koc + 0.99I3 -  0.01V„, + 1.25 
N = 23 r2 = 0.848 SD = 0.32 F = 35
NO TEST SET
Hutter has a model for the correlation of the blood to brain distribution (log 
BB) of drugs that is obtained by using multiple linear regression analysis of 
molecular descriptors, for a training set of 90 compounds. The descriptors for the 
drug compounds were computed using a computer program called VAMP. The
twelve descriptors are grouped into 5 categories, each representing specific
properties: polar surface area, hydrogen bond donor, hydrogen bond acceptor, the 
presence of chemical groups, physical quantities, shape of drug compound and 
entropy descriptors. This software can compute 1 compound per minute which 
includes time for structural optimization. Although this method is very slow, the 
statistics for the correlation (training set only) appear to be good.
TRAINING SET
N = 90 r2 = 0.87 SE = 0.31 F = 41 
NO TEST SETS
Rose and Hall 52 developed a QSAR model for correlation and the prediction 
of blood to the brain distribution at steady-steady for drugs. Their model is based on 
five structural properties which are: the hydrogen E-state index for hydrogen bond 
donors (HBD), the hydrogen E-state index for aromatic CHs (AROM), and the 
second order difference valence molecular connectivity index (VMC). The model 
indicates that molecules that penetrate the blood to brain barrier have large AROM 
values (presence of aromatic groups) but small values of HBD (fewer or weaker H-
Equation 21.15
Equation 21.16
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Bond donors) and smaller VMC values (less branched molecules with 
electronegative atoms). Finally, the presence of fluorine or chlorine atoms also leads 
to higher calculated log BB values. The correlation for this model is poor, compared 
to earlier models like that of Platts that have larger data sets.36 It is a shame again 
that no statistics for the predictions were provided for this large data set of 102 drug 
compounds.
TRAINING SET
Log BB = -0.202(HBD) + 0.006(AROM) -  0.105(VMC) -  0.425 Equation 21.17
N = 102 r2 = 0.66 SD = 0.45 F = 62 
NO TEST SETS
53Lobell et al. used 65 drug like structures with experimental log BB values 
from literature. Lobell et al, split the 65 compounds into 48 compounds in training 
set and 17 compounds in a test set, with equally homogenous log BB distributions. 
The 5 descriptors were calculated and obtained by using two computer programs that 
are: Cerius 2 and the ACD/log D suite. The stepwise linear regression analysis 
method was employed to obtain the training equation for the blood to brain 
distribution model for rats. Although, the training equation has very good 
correlation (n = 48, r2 = 0.84) and predictions (n = 17, predictive power, with MAE = 
0.33 for a test set), it would be interesting to see if this statistics can also be 
represented for larger data sets.
Ultimately, there are several models with good statistics for training sets that 
could be further tested using additional compounds for test sets. The general 
conclusion is that there are a number of models available with good statistics for 
both training sets and test sets. Some are very simple and can give rapid estimates of 
log BB. Others are more complicated but might provide better estimates. In 
addition, there are models that have good statistics for training sets. Most of these 
models have been constructed with much smaller data sets than are currently 
available and that is why the aim of this work is to construct a model with a larger 
data set than has been published before. Also, it is important to show if 
blood/plasma/serum to brain data for drugs in rats can combined or not and to 
ascertain if the in vivo data of the drugs can be combined with the in vitro data of the 
VOCs and see if a general equation can be made for this combined data set.
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Blood to brain/tissues distribution combined with plasma or 
serum to brain/tissues distribution data for drugs only
It was first necessary to examine the database of in vivo log BB (and log blood 
to tissue data for common compounds in serum, plasma or blood) values, Table 21.0 
(see appendix), and to distinguish those that were actually derived from blood to rat 
brain or tissues (skin, fat, heart, kidney, liver, lung and muscle), Pb-brain or tissues* 
plasma to rat brain or tissues (skin, fat, heart, kidney, liver, lung and muscle), Pp-brain 
or tissues* and serum to rat brain, Ps-brain, distribution coefficients. The values of log 
Pb-brain and log Pp-brain are known for 11 common compounds, and the following 
statistics were calculated: AE (the average error), AAE (the absolute average error), 
RMSE (the root mean square error) and SD (the standard deviation). The values of 
log Pb-tissues and log Pp-tissues are also found for 12 common compounds and the 
following statistics were also calculated (table 21.1). Results are found in table 21.1.
SAMPLE N SD(n-l) RMSE AAE AE
BLOOD-PLASMA3 11 0.449 0.428 0.301 0.104
BLOOD-SERUM3 8 0.221 0.207 0.110 -0.052
PLASMA-SERUM3 10 0.274 0.260 0.156 -0.058
BLOOD-PLASMAb 12 0.184 0.176 0.118 0.008
a Brain data only
bIncludes data from the following tissues: skin, fat, heart, kidney, liver, lung and 
muscle (brain data excluded)
Table 21.1. Correspondence between blood to brain, plasma to brain and serum to 
brain distribution coefficients, as log P values
The most useful statistic to assess whether there is any systematic difference 
between the two sets of brain data is the average error. For the 11 common 
compounds for blood-brain and plasma-brain, this is only 0.1 log units, statistically 
insignificant by comparison to the experimental error. The AAE and SD statistics 
indicate random differences; both of these are large, at 0.301 and 0.449 log units
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respectively. Since the AE is very small, these large values must either be due to 
experimental error or to some specific effects for certain compounds. There are two 
unusual observations in the blood/plasma set, due to codeine, and valproic acid, and 
some specific effect may be present in these cases.
For log Pb-brain and log Ps-brain there are only 8 common compounds for which 
AE is very small, at -0.05 log units. Values of AAE (0.11) and SD (0.22) are higher, 
as expected, but within the range of general experimental error. There is only one 
unusual observation in this set and that is promazine; again it is not possible to 
decide if this is the result of experimental error or specific effects. Since promazine 
is not unusual in comparisons of log Pb-brain and log Pp-brain there may be 
experimental error in the log Ps-brain value. For the plasma and serum data sets, there 
are 10 common compounds for which there is a very small value of AE, -0.06 log 
units, and reasonable values of AAE (0.16) and SD (0.27).
Finally, it was important to assess the systematic difference in statistics 
between the two sets of tissue data, blood to tissue and plasma to tissue. For the 12 
common compounds, this is only 0.01 log units, statistically insignificant by 
comparison to the experimental error. The AAE and SD statistics indicate random 
differences; both of these are not too large, at 0.118 and 0.184 log units respectively. 
Since the AE is very small, these values must either be due to experimental error or 
to some specific effects for certain compounds. There is one unusual observation in 
the blood/plasma set, due to toliprolol. This may be experimental error or may result 
from some specific effect.
The conclusion is straightforward; the systematic differences between log Pb-
brain or tisues, log Pp-brain or tissues, and log Ps-brain are so small that all three measures of 
distribution into brain or tissues (skin, fat, heart, kidney, liver, lung and muscle) can 
be combined into a global term, log BB or log BT. The random differences, as 
indicated by AAE and SD, are quite large and suggest that the experimental error in 
log BB (or log BT) must be around 0.2 log units (AAE) or 0.3 log units (SD).
The three in vivo distribution sets (log Pb-brain or tissues, lo§ Pp-brain or tissues, and 
log Ps-brain or tissues) can now be combined together for brain and all tissues mentioned 
in the thesis (skin, fat, heart, kidney, liver, lung and muscle), but these ratios will not
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be averaged; thus the data points will be greater than the number of compounds. The 
data set for brain tissue only is shown in table 21.0.
Discussion on blood/plasma/serum to brain distribution for 
drugs only
The 120 compounds (all of which are drugs) were used to construct the blood 
brain distribution model, see table 21.2. The structures for compounds with trivial 
names can be found in the appendix of this thesis.
Salminen also found in their dataset that some drugs have basic groups and it 
might be useful to investigate this further. They found that this indicator variable 
(lb) in the correlation for the BB model was not significant and tried to use an 
alternative new indicator variable for drug acids (la). They then found that this acid 
indicator variable for drugs was significant and it was found to be useful in their 
equation to describe the blood to brain transport process for various drugs.13 A first 
attempt to construct a model was to use the indicator variable for carboxylic acids
i / r  1
(la). Platts and Salminen found that acidic drugs bind more strongly to albumin 
then basic compounds, hence reducing their brain penetration. This descriptor has 
been used before by Platts and Salminen, and this is why it is important to use this 
for all drug blood to tissue distribution models. The independent variable la for a 
value of ‘ 1 ’ means the presence of carboxylic acid as a functional group to the drug 
compound. The independent variable la for a value of ‘0’ means that the carboxylic 
acid is absent drug compound. This descriptor was used in this model to correlate 
and predict blood to brain distribution for drugs and VOCs as shown in table 21.4 
(see later). Note no other descriptors have been in this model (or other models in the 
thesis) for neutral compounds that may have high plasma protein binding. This has 
not been investigated by anyone known in the literature for any blood to tissue 
distribution models for drug compounds.
1 3 2 1 3 5 3 6A number of compounds had previously been identified as outliers, ’ ’ ’ ’ 
39, 40, 47, 48 p 0S S i b i y  because of active transport or metabolism. There are also five 
additional compounds (AI-1, alfentanil, inaperisone, methylphenidate and 
tolbutamide) that were outliers, not only as regards blood to brain distribution, but 
also in distribution from blood to several other biological tissues. These were
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removed completely from subsequent models, as the residuals appeared to follow the 
same direction in terms of error. For the present model, aspirin, 2,4- 
dichlorophenoxyacetic acid, terbinafine, promazine and praxanthine were marked as 
new outliers. It is also not very surprising that from this model and other reported 
models that the remaining nine compounds (SKB3, SKB4, SKB9, SKB13, SKB19, 
Fluphenazine, Y-G 20, Orgl2962 and Temelastine) have found to be outliers.13’21,35’
36, 39,40,47,48
• ■ 54 55The original method ’ for the determination of in vivo log BB values
analysed material by a radioactive method. All radioactive species, including
35metabolites, were included in the count. As pointed out, this would lead to 
observed log BB values for compounds that were metabolized to be much more 
negative than the (true) log BB value for the parent compound. In addition, in silico 
methods for log BB all refer to passive transport. Active transport and efflux 
mechanisms will result in compounds appearing to be outliers to a passive transport 
algorithm.
EQUATIONS (rat model) N(dp) N(nc) r2 SD F OUTLIERS D
FULL SET ( I N  V I V O )
Log BB = 0.607 + 0.183E -  0.778S - 152 120 0.708 0.383 58.567 14(nc) 6
0.697A -  0.462B + 0.679V - 1 .1 991a
TRAINING SET
Log BB = 0.616 + 0.115E -  0.781S - 76 76 0.722 0.415 29.832 6
0.766A-0.357B +0.675V -  1.1951a
TEST SET
N(nc) = 65 N(dp) = 76
SD (n-1) = 0.359 RMSE = 0.356
AAE = 0.287 AE = -0.010
N (dp) = number of data points used in the training set 
N (nc) = number o f compounds used in the training set 
r2 = is the square of the overall correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number o f descriptors used in the model
Table 21.2. Summary of the in vivo equations for blood/serum/plasma to brain 
distributions for drugs only
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The statistics of the equation for the full set in table 21.2. are satisfactory and 
the predictive capability of the equation can be assessed by the usual method of 
constructing a training set and an independent test set. The selection of the training 
and test sets was carried out using the usual computing method called Kennard-Stone 
and that the two sets were made up of the same number of data points. These two 
criteria ensure that the chemical space covered by the training and test sets is the 
same. The training equation is shown table 21.2.
The statistics of the full set (table 21.2) and the training set (table 21.2), are 
similar and so are the coefficients. If the training set equation is used to predict the 
remainder of the data in the (unused) test set, it is found that AE = -0.01, AAE = 
0.29 RMSE = 0.36 and SD = 0.36, that is there is very little bias, and the predictive 
capability of the training equation (table 21.2) and by implication the full set 
equation (table 21.2) is therefore assessed. Thus the full (in vivo) equation and the 
training set can be used to predict further values of log BB close to the suggested 
experimental error of SD = 0.3 and AAE =0.2 log units.
The inter-correlations of descriptors used for drug blood/plasma/serum to 
brain distribution are shown in table 21.3. The largest r value for E versus S 
descriptor is 0.49. It appears that there is no strong inter-correlation between the set 
of descriptors used in this model.
r E S A B V la
E 1.00
S 0.70 1.00
A -0.11 -0.07 1.00
B 0.54 0.62 0.08 1.00
V 0.66 0.67 -0.13 0.67 1.00
la -0.23 -0.23 0.34 -0.28 -0.13 1.00
Table 21.3. The inter-correlation of descriptors for 120 compounds
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Combining the i n  v i v o  data of drugs with the i n  v i t r o  data of 
VOCs
Now that the data set of in vivo log BB values for passive transport from 
blood, plasma or serum to rat brain has been investigated, it would be interesting to 
see what happens if this data are combined with the previous set of in vitro values 
(chapter 12, table 12.3), for VOCs. Note that the in vitro data set is for transfer of 
VOCs from human blood and rat blood to human brain and rat brain. It was 
concluded in chapter 9 and 12, that there is very little difference in data from humans 
and rats, and that data from these two species can be combined for VOCs. Note that 
in the present work, the use of in vitro plasma to brain data for VOCs will not be 
used, mainly because of the small number of extra compounds involved. It appears 
that most authors have used some in vitro data in their drug models. Although, they 
have managed to combine these two different data sets of VOCs and drugs, it 
appears that there is no single indication with statistics to show how this is possible. 
The aim of this work is to show how this can be done and to see if these two data 
sets (in vivo and in vitro measurements) can be combined or not.
Discussion on blood/plasma/serum to brain distribution for 
drugs and VOCs combined
Before combining the two models together of in vivo (table 21.0 of this 
chapter) and in vitro (table 12.3 from chapter 12) data sets, it is first important to see 
if there are any differences in the two equations.
As described before in chapter 12, the in vitro equation for VOCs does not 
have the Ia-indicator variable, because there are no carboxylic acids in the data set. 
The two sets of coefficients appear to be different visibly and suggest that the in vivo 
and in vitro distributions may not be combined. In particular, the e-coefficients differ 
appreciably 0.607 (SD = 0.127) as against -  0.057 (SD = 0.070), which suggests that 
there is a systematic difference between the in vivo and in vitro distributions.
One way to check for systematic deviations is to use the coefficients in the in 
vivo equation to predict log BB values for the 78 VOCs used to construct the in vitro
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equation. It is found that for the predicted and observed in vitro log BB values, AE 
= 0.53, AAE = 0.53, RMSE = 0.58 and SD = 0.58 log units. The numerical values 
here show that the in vivo equation can only predict the in vitro dataset within 0.58 
log units (SD). The large value of AE, and the exact equivalent of AAE, suggests 
that there is a systematic difference in the two distribution models. It is possible that 
this could be due to the two series of compounds inhabiting different areas of 
chemical space and resulting in poor predictions.
However, especially in view of the marked difference in the c-coefficient for 
the in vivo and the in vitro equation, it might be possible to apply another indicator 
variable, Iv, defined as Iv = 1 for the in vitro data and Iv = 0 for the in vivo data. 
The resulting equation with this indicator variable is shown in blue in table 21.4 (in 
vivo + in vitro combined). The Iv term is statistically very significant (T-test = -
5.04, p-value = 9.78E-07), and the coefficient of the indicator variable, -0.487, is 
quite close to the difference in the c-coefficients of the in vivo and in vitro (-0.66) 
and to the AE for predictions of the VOC data from the drug data (0.53 log units). 
The coefficients of drug (in vivo) and the drug and VOC (in vivo + in vitro) 
combined equation are the same within experimental error (SD values of the 
coefficients are in the drug equation: c=0.127, e=0.071, s=0.078, a=0.113, b=0.108, 
v=0.082, ia=0.130 and in the combined equation (in vivo + in vitro): c=0.106, 
e=0.057, s=0.063, a=0.093, b=0.084, v=0.058, ia=0.109, iv=0.097). It is concluded 
that there is a systematic difference between the in vivo and in vitro distributions (as 
Iv is -0.5 log units), and that the two sets of distribution data can only be combined 
by taking into account this difference (see equation 21.4).
The full data set (in vivo and in vitro measurements) is given in table 12.3 and 
table 21.0, and consists of 206 compounds and 229 data points, the difference arising 
because blood/plasma/serum to brain distributions are counted separately. The 
correlation of this set of data points with the Abraham descriptors is shown in table
21.4. The fits for this very large data set appear to be good (S.D = 0.328 and r =
0.721). This represents a good model for a combined data set of VOCs and drugs for 
blood/plasma/serum to brain distribution, and is the largest general model yet 
reported for both types of data sets (in vivo rats + in vitro rats and humans 
combined).
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There was only one additional outlier observed from this training set and this 
is cimetidine (SKB1). The residual for this compound is 1 log unit and may result 
from experimental error.
EQUATIONS N(dp) N(nc) r2 SD F OUTLIERS D
FULL SET ( I N  V I V O )
Log BB = 0.607 + 0.183E -  0.778S - 152 120 0.708 0.383 58.567 14(nc) 6
0.697A -  0.462B + 0.679V -  1.1991a
FULL SET ( I N  V I T R O )
Log BB = - 0.057 + 0.017E -  0.536S - 78 78 0.725 0.203 37.908 2(nc) 5
0 .323A -0.335B  + 0.731V
FULL SET ( I N  V I V O  +  I N  V I T R O )
Log BB = 0.565 + 0.152E -  0.756S - 229 206 0.721 0.328 81.519 1 7
0.664A -  0.382B + 0.652V -  1.1961a -
0.487Iv
TRAINING SET
Log BB = 0.602 + 0.158E -  0.739S - 115 115 0.729 0.369 41.048 - 7
0.758A -  0.398B + 0.632V - 1 .1 791a -
0.477Iv
TEST SET
N(nc) = 104 N(dp) = 114 
SD (n-1) = 0.290 RMSE = 0.289
AAE = 0.221 AE = -0.001
N (dp) = number o f data points used in the training set 
N (nc) = number o f compounds used in the training set 
r2 = is the square of the overall correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number o f descriptors used in the model
Table 21.4. Summary of the equations for blood/serum/plasma to brain distributions 
for VOCs and drugs combined.
In order to assess the predictive capability of the combined equation (in vivo + 
in vitro) a training set and a test set was constructed. The equation for the training set 
was used to predict log BB values for the test set, as shown in table 21.4.
The coefficients and statistics of the full set of the combined equation (in vivo 
+ in vitro) and training equation (in vivo + in vitro) are reasonably consistent in 
terms of coefficients. The training equation of the combined set can then be used to
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predict log BB values for the (unused) test set. The statistic and predictions are for 
N(nc) = 104 and N(dp) = 114, that AE = 0.00, AAE = 0.22, RMSE = 0.29 and the 
SD = 0.29 log units. Thus the combined (in vivo + in vitro) training equation and the 
full combined equation (in blue) can be used to predict further values of log BB to 
close to our suggested experimental error of around 0.2 log units (AAE) or 0.3 log 
units (SD).
r E S A B V la Iv
E 1.00
S 0.89 1.00
A 0.31 0.33 1.00
B 0.84 0.87 0.42 1.00
V 0.85 0.84 0.26 0.85 1.00
la 0.02 0.01 0.37 0.00 0.06 1.00
Iv -0.82 -0.81 -0.44 -0.83 -0.76 -0.18 1.00
Table 21.5. The inter-correlation of descriptors for 120 compounds
The inter-correlations of descriptors are obtained for the combined in vivo and 
in vitro equation (from table 21.4) is shown by table 21.5. The largest r value for E 
versus S descriptor is 0.79. It appears that there is no other strong inter-correlation 
between the set of descriptors used in this model.
The descriptors used in the equation reflect solute/solvent interactions. One 
can, therefore, interpret the coefficients in terms of the effect that particular 
interactions have on the process under consideration. The positive e- and v- 
coefficients in the blood/plasma/serum to brain (in vivo + in vitro) equation from 
table 21.4, indicate that increasing molecular size and the presence of n- and II- 
electrons pairs can push drugs out of blood/plasma/serum and into brain. The 
coefficient of the ‘polar’ descriptor S is negative, indicating that polarity is stronger 
in the blood/plasma/serum phase than in the brain tissue phase. Therefore the drug 
compounds will move from the brain phase and into the blood/plasma/serum phase. 
The coefficients of the descriptors A and B are negative, indicating that the 
hydrogen-bond acidity and basicity act to keep drug compounds in
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blood/plasma/serum and out of the brain. In turn, this indicates that the brain has 
less hydrogen bond acidity and basicity than is blood/plasma/serum, but is more able 
to accommodate bulky solutes and interact with them via dispersive forces than 
blood/plasma/serum. The large negative coefficient of the indicator variable ( l a ) ,  in 
the combined equation from table 21.4., indicates a hitherto unknown factor 
affecting the transfer of solutes between blood/plasma/serum and the brain. It is 
apparent that the presence of -CO2H group acts to hinder brain penetration further. 
This could be simply due to intrinsic hydrogen bonding and the polarity properties of 
neutral acids. Finally, it is known that some carboxylic acids drugs may bind to 
albumin present in plasma/serum and blood, which may also account for the negative 
contribution of the coefficient l a .
Finally, this new model based on 206 compounds suggest that this can now be 
reliably and be used to correlate and predict blood (plasma or serum) to brain 
distribution for in vitro and in vivo drug compounds. Of course, any prediction using 
the full in vivo equation (drugs only) or the full combined equation (in vivo plus in 
vitro) can, or should, only be made within the chemical space of the test set used to 
assess the predictions. Note also that this model can also be used to predict a test set 
(104 compounds) within a standard deviation value 0.29 log units. This up to date 
model has now superseded current BB models like Platts et al.36 in terms of 
compound numbers and data points. This model for blood (plasma or serum) to brain 
distribution is very simple to calculate, and the method employed is robust and 
requires very little computing time. Whereas the Norinder et al method is 
complicated and time consuming, as computational methods are required for the 
conformational analysis of the solutes via the use of intensive computer calculations 
(which can slow down the screening process).
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Chapter
22
Blood/plasma to fat distribution for 
drugs and VOCs combined
The distribution drugs between blood (or plasma) and fat tissue has become a 
matter of interest for the pharmaceutical industry and toxicological sciences. Stored 
body fat is a kind of body tissue that serves as a source of energy and it also fulfils 
its purpose to cushion and insulate vital organs in human body. The fat tissue does 
not contain a rich supply of blood capillaries, unlike other tissues such as heart 
which has a huge supply of blood capillaries to the tissue.
There have been a small number of reports of data for drug blood (or plasma) 
to fat distribution in rats {in vivo)}'5 There have been no specific reviews reported 
yet that attempt to make models to predict blood to fat distribution either for rats or 
humans. The present work is restricted to a small data set of 17 drug compounds (18 
data points), which is all that has been published. The drug data {in vivo) for blood 
(or plasma) to fat distribution of rats, is at steady state concentration and the 
distribution from blood to fat, BF, is defined by the equation (22.0).
BF = (conc. of drug in fat)/(conc. of drug in blood or plasma) Equation 22.0
The aim is to attempt to construct a model based on the Abraham equations to 
predict the distribution process. Note that no attempts have been made in this work 
to construct a correlative equation to predict blood (or plasma) to fat distribution 
based on drugs only, as there are only a limited number of data points that can be 
used in this model. This small data set of drugs {in vivo data) can be combined with
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the VOC data (in vitro data), to construct an overall equation to predict blood (or 
plasma) to fat distribution for VOCs and drugs in general. The statistics will be 
obtained for the equations and it will be possible to see if VOC (in vitro) and the 
drugs (in vivo) can be combined. This equilibrium distribution for blood (or plasma) 
to fat distribution will be based on rats, and will be the first reported model in this 
area for blood (or plasma) to fat tissue transport. It should be possible to build 
bigger models in the near future providing further literature data are published based 
on drug blood to fat distribution.
Finally, the aim of this work is to construct an equation as part of a general 
method for ‘high-throughput’ prediction of equilibrium blood (or plasma)-fat 
distribution, based on structure using the Abraham descriptors (E, S, A, B, and V).6 
The drug data set used in this model to obtain model to predict blood (or plasma) to 
fat distributions in rats (see appendix) is found in table 22.0 (see appendix).
Discussion on blood/plasma to fat distribution for drugs
As discussed before (chapter 21), the distribution sets for the tissues that 
include fat, can be combined together for plasma, blood and serum. In this case, the 
two distribution sets (log Pp.fat and log Pb-fat) from table 22.0 (see appendix) can now 
be combined together for fat, but these ratios will not be averaged; thus the data 
points will be greater than the number of compounds.
Most of the data on blood to fat distribution is actually on VOCs, for which 
indirect (in vitro) values are available for 126 compounds (table 14.3, from chapter 
14). The total set of compounds (in vitro and in vivo) numbers were 141 and this 
combined set, resulted in the equation shown in table 22.1
The structures for compounds with trivial names can be found in the appendix 
of this thesis. A first attempt to construct a model, included the indicator variable for 
carboxylic acids (la). This descriptor has been used before for blood to brain 
distribution of drugs by Platt7 and Salminen.8 The independent variable la for a 
value of ‘ 1 * means the presence of carboxylic acid as a functional group to the drug 
compound. The independent variable la for a value of ‘0’ means that the carboxylic 
acid is absent. The second attempt is to see if there is any difference in the in vitro 
and in vivo data set for VOCs and drugs. In this case, one can apply another
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indicator variable, Iv, defined as Iv = 1 for the in vitro data and Iv = 0 for the in vivo 
data. This indicator descriptor was also used in this model to correlate and predict 
blood to fat distribution (drugs and VOCs combined) resulting in the equation as 
shown in table 22.1. The resulting equation is shown in blue in table 22.1 (in vivo + 
in vitro combined).
EQUATIONS N(dp) N(nc) r2 SD F OUTLIERS D
FULL SET (IN VIVO+IN VITRO)
Log BF = 0.432 + 0.117E -  0.099S - 142 141 0.873 0.312 154.982 2 6
1.543A -  2 .106B+ 1.596V -0.9461a
TRAINING SET
Log BF = 0.362 + 0.105E -  0.137S - 71 70 0.872 0.343 72.858 - 6
1.541A -2.113B + 1.688V - 1.0371a
TEST SET
N(nc) = 70 N(dp) = 71 SD (n-1) = 0.288
RMSE = 0.286 AAE = 0.234
AE = -0.023
FULL SET ( Iv not significant)
Log BF = 0.484 + 0.11 IE -  0.101S - 142 141 0.873 0.313 131.891 2 7
1.553A-2.117B + 1.589V -  0.9561a-
0.043Iv
N (dp) = number o f data points used in the training set 
N (nc) = number of compounds used in the training set 
r2 = is the square o f the overall correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number o f descriptors used in the model
Table 22.1. Summary of the two equations for blood/plasma to fat distributions for 
VOCs and drugs combined.
The full data set (in vitro and in vivo measurements) is given in table 14.3 
(chapter 14) and table 22.0, and consists of 141 compounds and 142 data points, the 
difference arising because blood/plasma to fat distributions was counted separately. 
The correlation of this set of data points with the Abraham descriptors is shown in 
table 22.1. The fits for this large data set appear to be very good (S.D = 0.312 and r2 
= 0.873). This represents the most up to date (and only) model for a combined data 
set of VOCs and drugs for blood to fat distribution.
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There were only two outliers observed from this training set: pyrene and p- 
phenylbenzoic acid. The residual for both of these compounds is 0.9 and 1.1 log 
units. This may of resulted from experimental error.
The Iv term is statistically not significant (T-test = -0.17, p-value = 0.86), and 
the coefficient of the indicator variable is 0.043. This suggests that there is a very 
small systematic difference between the in vivo and in vitro distributions, and that 
the distribution data can be combined, without taking into account the indicator 
variable (Iv). The in vivo and in vitro largely overlap in terms of their log BB 
values, see the graph on page 303, although the chemical space they occupy must be 
considerably different.
In order to assess the predictive capability of the combined equation (in vivo + 
in vitro) by the stratagem of constructing a training set and using the equation for the 
training set to predict log BF values for the test set, as shown in table 22.1.
The coefficients and statistics of the full set of the combined equation (in vivo 
+ in vitro) and training equation (in vivo + in vitro) are reasonably consistent in 
terms of coefficients. The training equation of the combined set can then be used to 
predict log BF values for the (unused) test set. The statistic and predictions are for 
N(nc) = 70 and N(dp) = 71, that AE = -0.02, AAE = 0.23, RMSE = 0.29 and the SD 
= 0.29 log units. Thus the combined (in vivo + in vitro) training equation and the full 
combined equation (in blue) can be used to predict further values of log BF within to 
close to the suggested experimental error (SD = 0.3 log units, chapter 21).
The inter-correlations of descriptors are obtained for the combined in vivo and 
in vitro equation is shown by table 22.2. The largest r value for E versus S 
descriptor is 0.74. It appears that there is no strong inter-correlation between the 
other set of descriptors used in this model.
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r E S A B V la
E 1.00
S 0.86 1.00
A 0.49 0.61 1.00
B 0.72 0.82 0.56 1.00
V 0.73 0.66 0.42 0.75 1.00
la 0.28 0.38 0.58 0.31 0.32 1.00
Table 22.2. The inter-correlation of descriptors for 141 (142 data points) 
compounds
The descriptors used in the equation reflect solute/solvent interactions. One 
can, therefore, interpret the coefficients in terms of the effect that particular 
interactions have on the process under consideration. The e-coefficient (P = 0.27) 
and s-coefficient (P = 0.46) is not significant. The positive v-coefficient in the 
blood/plasma to fat (in vivo + in vitro) equation from table 22.1, indicate that 
increasing molecular size can push drugs out of blood/plasma and into the fat phase. 
The coefficients of the descriptors A, and B are all negative, indicating that the 
hydrogen-bond acidity and basicity act to keep drug compounds in blood/plasma and 
out of the fat phase. In turn, this indicates that the fat is less acidic and basic than is 
blood/plasma, but is more able to accommodate bulky solutes and interact with them 
via dispersive forces than blood/plasma. The large negative coefficient of the 
indicator variable (la), in the combined equation from table 22.1., indicates a 
hitherto unknown factor affecting the transfer of solutes between blood/plasma and 
the fat. It is apparent that the presence of -CO2H group acts to hinder fat penetration 
further. This could be simply due to intrinsic hydrogen bonding and the polarity 
properties of neutral acids. Finally, it is known that some acidic drugs may bind to 
albumin present in plasma and blood, which may also account for this negative 
contribution of the coefficient la.
The statistics for this model is the best out of all the blood (plasma or serum) 
to tissue distribution models for VOCs and drugs combined. This is indicated by the 
large spread of data shown from the plot (page 303) giving rise to strong correlative 
fits.
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This new model based on 141 compounds suggest that this can now be reliably 
and be used to correlate and predict blood/plasma to fat distribution for in vitro and 
in vivo drug compounds. Of course, any prediction using the full combined equation 
(in vivo plus in vitro) can, or should, only be made within the chemical space of the 
test set used to assess the predictions.
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Chapter
23
Blood/plasma to heart distribution for drugs and 
VOCs combined
The distribution drugs between blood (or plasma) and heart tissue has become 
a matter of interest for the pharmaceutical industry, toxicological sciences and 
environmental health.
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(►LEFT 
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Scheme 23.0. Diagram showing the large muscular heart found in humans and rats.
The circulatory system is the body's main transport system, carrying food and 
oxygen to the cells and taking waste products away. Humans have a double 
circulatory system because it has two loops - one from the heart to the lungs and 
back, and another from the heart to the rest of the body and back. The heart is a
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four-chambered muscular pump which pumps blood round the circulatory system. 
The right side of the heart pumps de-oxygenated blood to the lungs to pick up 
oxygen. The left side of the heart pumps the oxygenated blood from the lungs around 
the rest of the body. More pumping force is required for this much longer journey, 
which is why the left side of the heart has more muscular walls. Note that the heart 
has huge supply of blood from capillaries, arteries and veins. The muscular wall of 
the heart is where solutes can distribute between the two different phases at steady 
state concentration.
There have been a number of reports of data for drug blood (or plasma) to 
heart distribution in rats (in vivo).1'15 Whereas, there have been no specific reviews 
reported yet that attempt to make models to predict blood (or plasma) to heart 
distribution either for rats or humans. The present work is restricted to a data set of 
51 different drug compounds (54 data points), which is all that has been published. 
The in vivo drug data for blood (or plasma) to heart distribution of rats is at steady 
state concentration and the distribution from blood (or plasma) to heart, BH, is 
defined by the equation (23.0).
BH = (conc. of drug in heart)/(conc. of drug in blood or plasma) Equation 23.0
The purpose of this work is to make an attempt to construct equations to 
predict blood/plasma to heart distribution. The complete list of drug log BH data is 
shown in table 23.0 (see appendix); where two or more results are reported for the 
same compound in the same system (blood/plasma) they have been averaged.
As discussed before (chapter 21), the distribution sets for the tissues that also 
include heart can be combined together for plasma, blood and serum. In this case, 
the two distribution sets blood (log P b - h e a r t )  and plasma (log P p - h e a r t )  into heart from 
table 23.0 (see appendix) can now be combined together, but these ratios will not be 
averaged; thus the data points will be greater than the number of compounds.
Discussion on blood/plasma to heart distribution for drugs 
only
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The 51 compounds (all of which are drugs) were used to construct the blood 
(or plasma) heart distribution model, see table 23.1. The structures for compounds 
with trivial names can be found in the appendix of this thesis. A first attempt to 
construct a model was to use the indicator variable for carboxylic acids (la). This 
descriptor has been used before for blood to brain distribution of drugs by Platt’s16
17and Salminen. The independent variable la for a value of ‘ 1 ’ means the presence of 
carboxylic acid as a functional group to the drug compound. The independent 
variable la for a value of ‘0’ means that the carboxylic acid is absent from the drug 
compound. This descriptor was used in this model to correlate and predict blood (or 
plasma) to heart distribution for drugs as shown in table 23.1.
EQUATIONS (rat model) N(dp) N(nc) r2 SD F OUTLIERS D
FULL SET (IN VIVO)
Log BH = 0.141 + 0.280E -  0.399S + 54 51 0.728 0.279 20.975 0 6
0.189A + 0.066B + 0.093V -  1,0031a 
TRAINING SET
Log BH = 0.258 + 0.235E -  0.454S + 40 40 0.769 0.287 18.334 6
0.154 A + 0.188B + 0.052V -  1.0181a 
TEST SET
N(nc) = 12 N(dp) = 14 
SD(n-l) = 0.297 RMSE = 0.287 
AAE = 0.235 AE = 0.026
N (dp) = number of data points used in the training set 
N (nc) = number o f compounds used in the training set 
r2 = is the square o f the overall correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model
Table 23.1. Summary of the two equations for blood/plasma to heart distributions 
for drugs only.
For the present model for blood/plasma to heart distribution, there were no 
marked outliers. The statistics of the equation for the full set in table 23.1. are 
satisfactory and the predictive capability of the equation can be assessed by the usual 
method of constructing a training set and an independent test set. The selection of 
the training (40 data points) and test sets (14 data points) was carried out using the 
usual computing method called Kennard-Stone. The training equation is also shown 
in table 23.1.
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The statistics of the full set (table 23.1) and the training set (table 23.1), are 
similar and so are some of the coefficients. If the training set equation is used to 
predict the remainder of the data in the (unused) test set, it is found that AE = 0.03, 
AAE = 0.24 RMSE = 0.29 and SD = 0.30, there is very little bias, and the predictive 
capability of the training equation (table 23.1) and by implication the full set 
equation (table 23.1) is therefore assessed. Thus the full (in vivo) equation and the 
training equation can be used to predict further values of log BH close to the 
suggested experimental error of SD = 0.3 and AAE = 0.2 log units (from chapter 21).
The inter-correlations of descriptors used for drug blood/plasma to heart 
distribution are shown in table 23.2. The largest r2 value for S versus B descriptor is 
0.71. It appears that there is no strong inter-correlation between the other set of 
descriptors used in this model.
r E S A B V I
E 1.00
S 0.83 1.00
A 0.41 0.59 1.00
B 0 .70 0.84 0.58 1.00
V 0 .73 0.80 0.51 0.83 1.00
1 0 .05 0.13 0.40 -0.06 0.03 1.00
Table 23.2. The inter-correlation of descriptors for 51 compounds
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Combining the i n  v i v o  data of drugs with the i n  v i t r o  data of 
VOCs
Now that the data set of in vivo log BH values for passive transport from blood 
or plasma to rat heart has been investigated, it would be interesting to see what 
happens if this is combined with the previous data set (in vitro) of Weathersby and 
Abraham and Nussbaum and Hursh,18'19 for VOCs. Note that the in vitro data set is 
for transfer of VOCs from human blood and rat blood to human heart and rat heart. 
It was concluded in chapter 9, that there is very little difference in the two species of 
humans and rats, and that data from these two species can be combined for VOCs. 
In the present work, the use of in vitro plasma to heart data for VOCs will not be 
used, mainly because of the small number of extra compounds involved. The aim of 
this work is to show whether it is possible (or not) to combine these two different 
data sets (in vitro + in vivo data set).
Discussion on blood/plasma to heart distribution for drugs 
and VOCs combined
Before combining the two models together of in vivo and in vitro data sets, it 
is first important to see if there are any differences in the two equations shown in 
table 23.1 and 23.3.
Note that the in vitro equation for VOCs does not have the Ia-indicator 
variable, because there are no carboxylic acids in the data set. The two sets of 
coefficients appear to be different visibly and suggest that the in vivo and in vitro 
distributions may possibly be different. In particular, the c-coefficients differ 0.141 
(SD = 0.110) as against -0.410 (SD = 0.101), which suggests that there might be a 
small systematic difference between the in vivo and in vitro distributions.
One way to check for systematic deviations is to use the coefficients in the in 
vivo equation to predict log BH values for the 24 VOCs used to construct the in vitro 
equation. It is found that the predicted and observed in vitro log BH values, AE = -
0.01, AAE = 0.18, RMSE = 0.23 and SD = 0.23 log units. The numerical values 
here show that the in vivo equation can predict the in vitro dataset within 0.23 log
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units (SD). This suggests that the in vivo model can successfully predict the in vitro 
dataset as covers a larger descriptor space than the in vitro model. Any systematic 
difference between the in vivo (drugs) in vitro (VOCs) distributions could be due to 
the two series of compounds inhabiting different areas of chemical space.
Another indicator variable was then used to test if there is any difference in 
the in vitro and in vivo data set for VOCs and drugs. In this case, one can apply the 
indicator variable, Iv, defined as Iv = 1 for the in vitro data and Iv = 0 for the in vivo 
data. An equation with the Iv term was constructed but is not shown because the Iv 
term was not statistically significant (T-test = 0.355, p-value = 0.724) and the value 
of the Iv coefficient was quite small (0.034). The coefficients of drug (in vivo) and 
the drug and VOC (in vivo + in vitro) combined equation are the same within 
experimental error (SD values of the coefficients are in the drug equation: c=0.110, 
e=0.084, s=0.114, a=0.149, b=0.119, v=0.089, ia=0.120 and in the combined 
equation (in vivo + in vitro): c=0.071, e=0.075, s=0.100, a=0.141, b=0.105, v=0.079, 
ia=0.109). It is concluded that there is no systematic difference between the in vivo 
and in vitro distributions (as Iv is 0.0 log units), and that the two sets of distribution 
data can be combined without taking into account this difference (see equation 23.3).
The full data set (in vivo and in vitro measurements) consists of 74 compounds 
and 77 data points, the difference arising because blood/plasma to heart distributions 
are counted separately. The correlation equation of this set of data points with the 
Abraham descriptors is shown in table 23.3. The fits for this full equation (in blue) 
appear to be reasonable (S.D = 0.258 and r = 0.689). This represents a good model 
for a combined data set of VOCs and drugs for blood/plasma to heart distribution, 
and is the only model yet reported for both types of data sets (in vivo rats + in vitro 
rats and humans combined).
There were one additional outlier observed from this full set and that is AI-6 
(structure can be found in the appendix of this thesis). The residual for this 
compound is 0.7 log unit and may result from experimental error.
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EQUATIONS N(dp) N(nc) r2 SD F OUTLIERS D
FULL SET (IN VIVO)
Log BH = 0.141 + 0.280E -  0.399S + 
0.189A + 0.066B + 0.093V -  1.0031a
54 51 0.728 0.279 20.975 0 6
FULL SET (IN VITRO)
Log BH = -0.410 + 0.033E + 0.177S -  
2.664A-0.749B +0.923V
24 24 0.822 0.145 16.619 2(nc) 5
FULL SET (IN VIVO + IN  VITRO) 
Log BH = 0.041 + 0.209E -  0.393S + 
0.076A -  0.046B + 0.279V -  0.9651a 
TRAINING SET
Log BH = 0.201 + 0.179E -  0.397S + 
0.080A + 0.138B + 0.115V -  0.9921a 
TEST SET
N(nc) = 36 N(dp) = 38 SD (n-1) = 0.273 
RMSE = 0.269 AAE = 0.219 
AE = 0.024
77
39
74
39
0.689
0.774
0.258
0.274
25.839
18.297
l(nc) 6
6
N (dp) = number o f data points used in the training set 
N (nc) = number of compounds used in the training set 
r2 = is the square o f the overall correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model
Table 23.3. Summary of the two equations for blood/plasma to heart distributions 
for VOCs and drugs combined.
In order to assess the predictive capability of the combined equation (in vivo + 
in vitro), a training set was constructed and the equation for the training set used to 
predict log BH values for the test set, as shown in table 23.3. The coefficients and 
statistics of the full set of the combined equation {in vivo + in vitro) and training
equation {in vivo + in vitro) are similar in terms of coefficients. The training
equation predicted log BH values for the (unused) test set as follows. N(nc) = 36 
and N(dp) = 38, that AE = 0.024, AAE = 0.219, RMSE = 0.269 and the SD = 0.273 
log units. Thus the combined (in vivo + in vitro) training equation and the full 
combined equation (in blue) can be used to predict further values of log BH to close 
to our suggested experimental error of around 0.2 log units (AAE) or 0.3 log units 
(SD).
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r E S A B V la
E 1.00
S 0.91 1.00
A 0.62 0.73 1.00
B 0.84 0.91 0.72 1.00
V 0.85 0.88 0.69 0.91 1.00
la 0.22 0.27 0.48 0.15 0.19 1.00
Table 23.4. The inter-correlation of descriptors for 74 compounds
The inter-correlations of descriptors for the combined in vivo and in vitro 
equation (from table 23.3) is shown by table 23.4. The largest r2 value for E versus 
S descriptor, S versus B and B versus V is 0.83. It appears that there is no strong 
inter-correlation between the other set of descriptors used in this model.
The descriptors used in the equation reflect solute/solvent interactions. One 
can, therefore, interpret the coefficients in terms of the effect that particular 
interactions have on the process under consideration. The positive e- and v- 
coefficients in the blood/plasma to heart (in vivo + in vitro) equation from table 23.3, 
indicate that increasing molecular size and the presence of n- and II-electrons pairs 
can push drugs out of blood/plasma and into the heart phase. The coefficient of the 
‘polar’ descriptors S is negative, indicating that polarity is stronger in the 
blood/plasma phase than in the heart tissue phase. Therefore the drug compounds 
will move from the heart phase and into the blood/plasma phase. The a-coefficients 
(P = 0.59) and b-coefficient (P = 0.66) is not significant. The large negative 
coefficient of the indicator variable (la), in the combined equation from table 23.3., 
indicates a hitherto unknown factor affecting the transfer of solutes between 
blood/plasma and the heart. It is apparent that the presence of -CO2H group acts to 
hinder heart penetration further. This could be simply due to intrinsic hydrogen 
bonding and the polarity properties of neutral acids. Finally, it is known that some 
acidic drugs may bind to albumin present in plasma and blood, which may also 
account for this negative contribution of the coefficient la.
This new model based on 74 compounds suggests that it can now be used to 
correlate and predict blood/plasma to heart distribution for in vitro and in vivo drug 
compounds. Of course, any prediction using the full combined equation (in vivo plus
313
in vitro) can, or should, only be made within the chemical space of the test set used 
to assess the predictions.
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Chapter
24
Blood/plasma/serum to lung distribution for 
drugs and VOCs combined
The distribution of drugs between blood (plasma or serum) and lung tissue has 
become a matter of interest for the pharmaceutical industry and environmental 
health.
Lungs are paired organs in the chest that carry on respiration. In the adult 
human, each lung is 25 to 30 cm (10 to 12 in) long and roughly conical. The two 
lungs are separated by a structure called the mediastinum, which contains the heart, 
trachea, oesophagus, and blood vessels. They are covered by a protective membrane 
called the pulmonary pleura, which is separated from the parietal pleura a similar 
membrane on the chest wall by a lubricating fluid. Inhaled air passes through the 
trachea, which divides into two tubes called bronchi; each bronchus leads to one 
lung. Within the lungs the bronchi subdivide into bronchioles, which give rise to 
alveolar ducts; these end in sacs called alveoli.
In this life-supporting process, oxygen from incoming air enters the blood and 
carbon dioxide, a waste gas from the metabolism of food, is exhaled into the 
atmosphere. The exchange of gases takes place when air reaches the alveoli. These 
small sacs are only one cell thick, and they are surrounded by a rich supply of blood 
capillaries that are also only one cell thick. Air diffuses through these cells into the 
capillary blood, which carries the oxygen-rich air or drugs to the heart to be 
distributed throughout the body. In the alveoli, at the same time, gaseous carbon 
dioxide diffuses from the blood into the lung and is expired. From the capillary
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network, there are also distribution of drugs or VOCS between blood and the lung 
tissue phase at steady-state.
Alveoli
Bronchioles
Bronchi
Bronchiolar
Muscle
Nasal Cavity
Oral Cavity 
Larynx
Scheme 24.0. Diagram showing the lung tissue present in humans
There have been a number of reports of data for drug blood (plasma or serum)
1
to lung distribution in rats (in vivo). ' There have been no specific reviews reported 
yet that attempt to make models to predict blood (plasma or serum) to lung 
distribution either for rats or humans. The present work is restricted to a data set of 
50 different drug compounds (53 data points), which is all that has been published. 
The drug data (in vivo) for blood (plasma or serum) to lung distribution of rats is at 
steady state concentration and the distribution from blood to lung, BL, is defined by 
the following equation (24.0).
BL = (conc. of drug in lung)/(conc. of drug in blood/plasma/serum) Equation 24.0
The purpose of this work is to collect as many existing literature data on 
distribution (as log BL values) and to make an attempt to construct equations to 
predict in vivo blood/plasma/serum to lung distribution. The complete list of in vivo
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drug log BL data is shown in table 24.0 (see appendix); where two or more results 
are reported for the same compound in the same system (blood/plasma/serum) they 
have been averaged.
As discussed before (chapter 21), the distribution sets for the tissues that also 
include lung can be combined together for plasma, blood and serum. In this case, the 
three distribution sets blood (log Pb-iung), plasma (log Pp.iUng) and serum (log Ps-iung) 
into lung from table 24.0 (see appendix) can now be combined together, but these 
ratios will not be averaged; thus the data points will be greater than the number of 
compounds.
Discussion on blood/plasm a/serum  to lung distribution for 
drugs only
The 50 compounds (all of which are drugs) were used to construct the blood 
(plasma or serum) lung distribution model are in table 24.1. The structures for 
compounds with trivial names can be found in the appendix of this thesis. A first 
attempt to construct a model was to use the indicator variable for carboxylic acids 
(la). This descriptor has been used before for blood to brain distribution of drugs by 
Platt’s22 and Salminen.23 The independent variable la for a value of ‘1’ means the 
presence of carboxylic acid as a functional group to the drug compound. The 
independent variable la for a value of ‘0’ means that the carboxylic acid is absent 
from the drug compound. This descriptor was used in a model to correlate and 
predict blood (plasma or serum) to lung distribution for drugs as shown in table 24.1.
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E Q U A T IO N S (rat model) N(dp) N(nc) r2 SD F O UTLIER S D
FULL SET
Log BL = -  0.012 + 0.03 IE -  0.174S -  
0.666A + 0.248B + 0.321V -  0.8331a 
TRAINING SET
53 50 0.749 0.351 22.846 3(nc) 6
Log BL = 0.093 + 0.026E -  0.217S -  
0.603A + 0.243B + 0.321V -  0.8821a 
TEST SET
N(nc) = 13 N(dp) = 13 
SD (n-l) = 0.291 RMSE = 0.280 
AAE = 0.238 AE = 0.145
40 40 0.770 0.381 18.439 6
N (dp) = number o f data points used in the training set 
N (nc) = number o f compounds used in the training set 
r2 = is the square o f the overall correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number o f descriptors used in the model
Table 24.1 Summary of the two equations for blood/plasma/serum to lung 
distributions for drugs only.
For the present model for blood (plasma or serum) to lung distribution, there 
were three compounds that were marked outliers: biperiden, pentazocine and 
propranolol. The residual for these compounds is 0.8, 0.8 and 1.0 log unit, and may 
result from experimental error. The statistics of the equation for the full set is shown 
in table 24.1., are good and the predictive capability of the equation can be assessed 
by the usual method of constructing a training set (40 data points) and an 
independent test set (13 data points). The selection of the training and test sets was 
carried out using the usual computing method called Kennard-Stone. The training 
equation constructed is also shown in table 24.1.
The statistics of the full set (table 24.1) and the training set (table 24.1), are 
similar and so are some of the coefficients. If the training set equation is used to 
predict the remainder of the data in the (unused) test set, it is found that AE = 0.15, 
AAE = 0.24 RMSE = 0.28 and SD = 0.29, there is very little bias, and the predictive 
capability of the training equation (table 24.1) and by implication of the full set 
equation (table 24.1) is therefore assessed. Thus the full {in vivo) equation and the 
training equation can be used to predict further values of log BL close to the 
suggested experimental error of SD = 0.3 and AAE = 0.2 log units (from chapter 21).
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The inter-correlations of descriptors used for drug blood (plasma or serum) to 
lung distribution are shown in table 24.2. The largest r value for B versus V 
descriptor is 0.76. It appears that there is no strong inter-correlation between the 
other set of descriptors used in this model.
r E S A B V I
E 1.00
S 0.82 1.00
A 0.13 0.44 1.00
B 0.50 0.76 0.51 1.00
V 0.53 0.73 0.37 0.87 1.00
I 0.06 0.12 0.28 -0.08 -0.02 1.00
Table 24.2. The inter-correlation of descriptors for 50 compounds
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Combining the i n  v i v o  data of drugs with the i n  v i t r o  data of 
VOCs
Now that the data set of in vivo log BL values for passive transport from blood 
/plasma/serum to rat lung has been investigated, it would be interesting to see what 
happens if this is combined with the previous data set (in vitro) of Abraham and 
Weathersby,24 Fiserova-Bergerova and Diaz,25 Sweeney et al,26 Filser et al,27 Knaak 
and Smith28 and Csandy et al?9 for VOCs. Note that the in vitro data set is for 
transfer of VOCs from human blood and rat blood to human lung and rat lung. It 
was concluded in chapter 9, that there is very little difference in data from the 
species of humans and rats, and that data from these two species can be combined for 
VOCs. In the present work, the use of in vitro plasma to lung data for VOCs will not 
be used, mainly because of the small number of extra compounds involved. The aim 
of this work is to show whether it is possible (or not) to combine these two different 
data sets (in vitro + in vivo).
Discussion on blood/plasma/serum to lung distribution for 
drugs and VOCs combined
Before combining the two models together of in vivo and in vitro data sets, it 
is first important to see if there are any differences in the two equations shown in 
table 24.1 and 24.3. Note that the in vitro equation for VOCs does not have the Ia- 
indicator variable, because there are no carboxylic acids in the data set. The two sets 
of coefficients appear to be different visibly and suggest that the in vivo and in vitro 
distributions may possibly be different. In particular, the c-coefficients differ -  
0.012 (SD = 0.143) as against -  0.114 (SD = 0.091), which suggests that there might 
be a small systematic difference between the in vivo and in vitro distributions.
One way to check for systematic deviations is to use the coefficients in the in 
vivo equation to predict log BL values for the 43 VOCs used to construct the in vitro 
equation. It is found that for the predicted and observed in vitro log BL values, AE = 
0.153, AAE = 0.190, RMSE = 0.249 and SD = 0.252 log units. The numerical 
values here show that the in vivo equation can predict the in vitro dataset within 0.26
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log units (SD). This suggests that the in vivo model can successfully predict the in 
vitro dataset as it covers a larger descriptor space than the in vitro model. Any 
systematic difference between the in vivo (drugs) and the in vitro (VOCs) 
distributions could be due to the two series of compounds inhabiting different areas 
of chemical space.
Another indicator variable was then used to test if there is any difference in the 
in vitro and in vivo data set for VOCs and drugs. In this case one can apply the 
indicator variable, Iv, defined as Iv = 1 for the in vitro data and Iv = 0 for the in vivo 
data. An equation with the Iv term was constructed but is not shown, because the Iv 
term was not statistically significant (T-test = -2.271, p-value = 0.026) and the value 
of the Iv coefficient was quite small (-0.23). The coefficients of drug (in vivo) and 
the drug and VOC (in vivo + in vitro) combined equation are the same within 
experimental error (SD values of the coefficients are in the drug equation: c=0.143, 
e=0.122, s=0.179, a=0.189 b=0.137, v=0.107, ia=0.145, and in the combined 
equation (in vivo + in vitro): c=0.058, e=0.078, s=0.119, a=0.141, b=0.097, v=0.072, 
ia=0.115). It is concluded that there is a very small systematic difference between 
the in vivo and in vitro distributions (as Iv is -0.2 log units), and that the two sets of 
distribution data can be combined without taking into account this small difference 
(see equation 24.3).
The full data set (in vivo and in vitro measurements) consists of 91 compounds 
and 94 data points, the difference arising because blood/plasma/serum to lung 
distributions are counted separately. The correlation of this set of data points with 
the Abraham descriptors is shown in table 24.3. The fits for this full equation (in 
blue) appear to be good (S.D = 0.272 and r2 = 0.760). This represents a good model 
for a combined data set of VOCs and drugs for blood/plasma/serum to lung 
distribution, and is the only model yet reported for both types of data sets (in vivo 
rats + in vitro rats and humans combined).
There were two additional outliers observed in the full set; cotinine and 
dicloxacillin. The residual for these compounds is 0.7 and 0.7 log unit and may 
result from experimental error.
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EQUATIONS N(dp) N(nc) r2 SD F OUTLIERS D
FULL SET (IN VIVO)
Log BL = -  0.012 + 0.03IE -  0.174S - 53 50 0.749 0.351 22.846 3(nc) 6
0.666A + 0.248B + 0.321V -  0.8331a
FULL SET (IN VITRO)
Log BL = -  0.114 -  0.193E + 0.004S - 43 43 0.275 0.194 2.802 0 5
0.279A-0.206B +0.256V
FULL SET (IN VIVO + IN  VITRO)
Log BL = -0.157 -  0.004E -  0.036S - 94 91 0.760 0.272 45.925 2(nc) 6
0.742A + 0.252B + 0.312 V -  0.7341a
TRAINING SET
Log BL = -0.067 -  0.010E -  0.033S -
0.683A + 0.279B + 0.253V -  0.7741a 47 47 0.801 0.314 26.812 - 6
TEST SET
N(nc) = 46 N(dp) = 47
SD (n-1) = 0.247 RMSE = 0.244
AAE = 0.201 AE = 0.080
N (dp) = number o f data points used in the training set 
N (nc) = number o f compounds used in the training set 
r2 = is the square of the overall correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model
Table 24.3. Summary of the two equations for blood/plasma/serum to lung 
distributions for VOCs and drugs combined.
In order to assess the predictive capability of the combined equation (in vivo + 
in vitro) a training set was constructed and the equation for the training set used to 
predict log BL values for the test set, as shown in table 24.3. The coefficients and 
statistics of the full set of the combined equation (in vivo + in vitro) and training 
equation (in vivo + in vitro) are similar in terms of coefficients. The training 
equation predicted log BL values for the (unused) test set as follows. N(nc) = 46 and 
N(dp) = 47, AE = 0.080, AAE = 0.201, RMSE = 0.244 and SD = 0.247 log units.
Thus the combined (in vivo + in vitro) training equation and the full combined
equation (in blue) can be used to predict further values of log BL to close to our 
suggested experimental error of around 0.2 log units (AAE) or 0.3 log units (SD).
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r E S A B V I
E 1.00
S 0.92 1.00
A 0.51 0.67 1.00
B 0.77 0.88 0.71 1.00
V 0.78 0.86 0.60 0.92 1.00
I 0.21 0.25 0.35 0.13 0.16 1.00
Table 24.4. The inter-correlation of descriptors for 91 compounds
The inter-correlations of descriptors obtained for the combined in vivo and in 
vitro equation (from table 24.3) as shown by table 24.4. The largest r value for E 
versus S and B versus V descriptor is 0.85. It appears that there is no strong inter­
correlation between the other set of descriptors used in this model.
The descriptors used in the equation reflect solute/solvent interactions. One 
can, therefore, interpret the coefficients in terms of the effect that particular 
interactions have on the process under consideration. The e-coefficients (P = 0.96) 
and s-coefficient (P = 0.76) is not significant. The positive v-coefficient in the 
blood/plasma/serum to lung (in vivo + in vitro) equation, indicate that increasing 
molecular size can push drugs out of blood/plasma/serum and into the lung phase. 
The coefficient of the A descriptors are negative, indicating that the hydrogen-bond 
acidity acts to keep drug compounds in the blood/plasma/serum phase and out of the 
lung tissue phase. In turn, this indicates that the lung tissue is less basic than is the 
blood/plasma/serum phase, so the solute will move from the lung tissue into the 
blood/plasma/serum phase. The coefficients of the descriptor B are positive, 
indicating that the hydrogen-bond basicity acts to keep drug compounds in the lung 
and out of the blood/plasma/serum phase. In turn, this indicates that the 
blood/plasma/serum is less acidic than is the lung phase, but is more able to 
accommodate bulky solutes and interact with them via dispersive forces than in the 
lung phase. The large negative coefficient of the indicator variable (la), in the 
combined equation from table 24.3., indicates a hitherto unknown factor affecting 
the transfer of solutes between blood/plasma/serum and the lung. It is apparent that 
the presence of -CO 2H group acts to hinder lung penetration further. This could be 
simply due to intrinsic hydrogen bonding and the polarity properties of neutral acids.
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Finally, it is known that some acidic drugs may bind to albumin present in plasma, 
blood and serum, which may also account for this negative contribution of the 
coefficient la.
This new model based on 91 compounds suggest that it can now be used to 
correlate and predict blood (plasma or serum) to lung distribution for in vitro and in 
vivo drug compounds. Of course, any prediction using the full combined equation 
(in vivo plus in vitro) can, or should, only be made within the chemical space of the 
test set used to assess the predictions.
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Chapter
Blood/plasma to muscle distribution for 
drugs and VOCs combined
The distribution of drugs between blood (or plasma) and muscle tissue has 
become a matter of interest for the pharmaceutical industry, toxicological sciences, 
environmental health, sports and forensic sciences.
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Scheme 25.0. Diagram showing the muscle tissue of the human body
The skeletal muscles of humans and rats are characterized by the ability to 
contract, usually in response to a stimulus from the nervous system. Muscles are 
made up of long cells called fibres that contract, or shorten, to move parts of the 
body. Most of the muscular system of up to half of the body weight of humans
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consists of skeletal muscle. More than 650 skeletal muscles cover the human 
skeleton in layers, give the body its shape, and are attached to, and pull on to the 
bones. By contracting they make the human body run, jump, or perform any one of 
the thousands of movements. Two other muscle types work unseen inside the body: 
cardiac muscle powers the heart beat, while the smooth muscle moves food and other 
materials around the body.
Skeletal muscle is supplied with nerves from the central nervous system and 
because it is partly under conscious control, it is also called voluntary muscle. Most 
skeletal muscle is attached to portions of the skeleton by connective-tissue 
attachments called tendons. Contractions of skeletal muscle serve to move the 
various bones and cartilages of the skeleton. Skeletal muscle forms most of the 
underlying flesh of humans and rats. The skeletal muscle is where solutes can 
distribute between the blood capillaries and muscle phase at steady state 
concentration.
There have been a number of reports of data for drug blood (or plasma) to
i i n
muscle distribution in rats (in vivo). ' However, there have been no specific 
reviews reported that attempt to obtain models to predict blood (or plasma) to muscle 
distribution either for rats or humans. The present work is restricted to a data set of 
59 different drug compounds (60 data points), which is all that has been published. 
The in vivo drug data for blood (or plasma) to muscle distribution of rats is at steady 
state concentration and the distribution from blood (or plasma) to muscle, BM, is 
defined by the equation (25.0).
BM = (conc. of drug in muscle)/(conc. of drug in blood or plasma) Equation 25.0
The purpose of this work is to collect as much existing literature data on 
distribution (as log BM values) and to make an attempt to construct equations to 
predict blood/plasma to muscle distribution. The complete list of in vivo drug log 
BM data is shown in table 25.0 (see appendix); where two or more results are 
reported for the same compound in the same system (blood/plasma) they have been 
averaged.
As discussed before (chapter 21), the distribution sets for the tissues that also 
include muscle can be combined together for blood, plasma and serum. In this case, 
the two distribution sets blood (log Pb-muscle) and plasma (log Pp.mUscie) into muscle
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from table 25.0 (see appendix) can now be combined together, but these ratios will 
not be averaged; thus the data points will be greater than the number of compounds.
Discussion on blood/plasma to muscle distribution for drugs 
only
The 59 compounds (all of which are drugs) were used to construct the blood to 
muscle distribution model, see table 25.1. The structures for compounds with trivial 
names can be found in the appendix of this thesis. A first attempt to construct a 
model was to use the indicator variable for carboxylic acids (la). This descriptor has 
been used before for blood to brain distribution of drugs by Platt’s18 and Salminen.19 
The independent variable la for a value of ‘ 1’ means the presence of carboxylic acid 
as a functional group to the drug compound. The independent variable la for a value 
of ‘0’ means that the carboxylic acid is absent from the drug compound. This 
descriptor was used in this model to correlate and predict blood (or plasma) to 
muscle distribution for drugs as shown in table 25.1.
EQUATIONS N(dp) N(nc) r2 SD F OUTLIERS D
FULL SET (IN VIVO)
Log BM = 0.082 -  0.059E + 0.01 OS - 60 59 0.745 0.253 25.850 0 6
0.248A + 0.028B + 0.110V -  1.0221a 
TRAINING SET
Log BM = 0.179 -  0.093E -  0.022S - 40 40 0.777 0.285 19.139 6
0.206A + 0.086B + 0.086V -  1.0541a 
TEST SET
N(nc) = 20 N(dp) = 20 
SD (n-l) = 0.213 RMSE = 0.208 
AAE = 0.169 AE = 0.051
N (dp) = number of data points used in the training set 
N (nc) = number o f compounds used in the training set 
r2 = is the square of the overall correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model
Table 25.1. Summary of the two equations for blood/plasma to muscle distributions 
for drugs only.
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For the present model for blood or plasma to muscle distribution, there were 
no marked outliers. The statistics of the equation for the full set in table 25.1. are 
good and the predictive capability of the equation can be assessed by the usual 
method of constructing a training set and an independent test set. The selection of 
the training (40 data points) and test sets (20 data points) was carried out using the 
usual computing method called Kennard-Stone. The training equation is also shown 
in table 25.1.
The statistics of the full set (table 25.1) and the training set (table 25.1), are 
similar and so are some of the coefficients. If the training set equation is used to 
predict the remainder of the data in the (unused) test set, it is found that AE = 0.05, 
AAE = 0.17, RMSE = 0.21 and SD = 0.21, that there is very little bias, and the 
predictive capability of the training equation (table 25.1) and by implication of the 
full set equation (table 25.1) is therefore assessed. Thus the full (in vivo) equation 
and the training equation can be used to predict further values of log BM, within the 
suggested experimental error of SD = 0.3 and AAE = 0.2 log units (from chapter 21).
The inter-correlations of descriptors used for drug blood (or plasma) to muscle 
distribution are shown in table 25.2. The largest r value for E versus S descriptor is 
0.76. It appears that there is no strong inter-correlation between the other set of 
descriptors used in this model.
r E S A B V I
E 1.00
S 0.87 1.00
A 0.29 0.51 1.00
B 0.63 0.80 0.64 1.00
V 0.68 0.78 0.43 0.77 1.00
I 0.08 0.16 0.42 0.12 0.09 1.00
Table 25.2. The inter-correlation of descriptors for 59 compounds
335
CA
LC
UL
AT
ED
 
LOG
 
P
Calculated log P versus oberved log P for the distribution of drugs
from blood and plasma to muscle
— — —" r-:.... ;....... .... -v-;., ■ ------------ -— ........................ . .. ..........^ 8 6 ”
y= 0 .7453x  + 0.0011..... ... ...__________  . .... a fin_ 2 * _ . _ * U.Ov
R = 0.7453
n An
<
4h
4
v  * ♦ > ♦  * ♦ ♦.«
t  ♦ *▼ A  A A
♦ ♦ * ♦
i—............... . ........ -..... .... ... 1'..... ...... .......... ..-...........
50 -1.00 -0.50
.......  A OA
♦ ♦
30 0.50 1.
u‘U.Z.v
n An-0.40
........... ..................... . ..... OtW-
n  o n^ 0 * * ' .................. ................. ~U:oU -
♦ ♦ ♦--------------------------x—__——........................  4 aa ^ I. \7\7 
♦
L ------- --------------------— --------— ------------------------------------------------— -----------------------1-20-
OBSERVED LOG P
336
Combining the i n  v i v o  data of drugs with the i n  v i t r o  data of 
VOCs
Now that the data set of in vivo log BM values for passive transport from blood 
(or plasma) to rat muscle has been investigated, it would be interesting to see what 
happens if this is combined with the previous data set (in vitro) from table 16.3 
(chapter 16) for VOCs. Note that the in vitro data set is for the transfer of VOCs 
from human blood and rat blood to human muscle and rat muscle. It was concluded 
in chapter 9, that there is very little difference data for the species of humans and 
rats, and that the data from these two species can be combined for VOCs. In the 
present work, the use of in vitro plasma to muscle data for VOCs will not be used, 
mainly because of the small number of extra compounds involved. The aim of this 
work is to show whether it is possible (or not) to combine these two different data 
sets (in vitro + in vivo data set).
Discussion on blood/plasma to muscle distribution for drugs 
and VOCs combined
Before combining the two models together of in vivo and in vitro data sets, it 
is first important to see if there are any differences in the two equations shown in 
table 25.1 and 25.3. Note that the in vitro equation for VOCs does not have the Ia- 
indicator variable, because there are no carboxylic acids in the data set. The two sets 
of coefficients appear to be different visibly and suggest that the in vivo and in vitro 
distributions may possibly be different. In particular, the c-coefficients differ 
somewhat 0.082 (SD = 0.100) as against -0.185 (SD = 0.067), which suggests that 
there might be a small systematic difference between the in vivo and in vitro 
distributions.
One way to check for systematic deviations is to use the coefficients in the in 
vivo equation to predict log BM values for the 110 VOCs used to construct the in 
vitro equation. It is found that the predicted and observed in vitro log BM values, 
AE = 0.13, AAE = 0.25, RMSE = 0.31 and SD = 0.31 log units. The numerical 
values here show that the in vivo equation can predict the in vitro dataset within 0.31
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log units (SD). This is probably because the in vivo data set covers a larger 
descriptor space than the in vitro model. Any systematic difference in the equations 
for in vivo (drugs) and in vitro (VOCs) distributions could be due to the two series of 
compounds inhabiting different areas of chemical space.
Another indicator variable was then used to test if there is any systematic 
difference in the in vitro and in vivo data set for VOCs and drugs. In this case one 
can apply the indicator variable, Iv, defined as Iv = 1 for the in vitro data and Iv = 0 
for the in vivo data. An equation with the Iv term was constructed shown in table 
25.3, because the Iv term was statistically significant (T-test = -2.124, p-value = 
0.035) and the value of the Iv coefficient was -0.140. The coefficients of drug (in 
vivo) and the drug and VOC (in vivo + in vitro) combined equation are the same 
within experimental error (SD values of the coefficients are in the drug equation: 
c=0.100, e=0.084, s=0.110, a=0.128, b=0.084, v=0.073, ia= 0.104 and in the 
combined equation (in vivo + in vitro): c=0.080, e=0.057, s=0.076, a=0.097, 
b=0.063, v=0.054, ia=0.088, iv=0.066). It is concluded that there is a systematic 
difference between the in vivo and in vitro distributions (as Iv is 0.1 log units), and 
that the two sets of distribution data can be combined by taking into account this 
difference (see equation 25.3).
The full data set (in vivo and in vitro measurements) consists of 163 
compounds and 164 data points, the difference arising because blood (or plasma) to 
muscle distributions are counted separately. The correlation equation of this set of 
data points with the Abraham descriptors is shown in table 25.3. The fits for this full 
equation (in blue) appear to be satisfactory (S.D = 0.220 and r2 = 0.595). This 
represents a relatively good model for a combined data set of VOCs and drugs for 
blood/plasma to muscle distribution, and is the only one yet reported for both types 
of data sets (in vivo rats + in vitro rats and humans combined).
There were six additional outliers observed in the full set: 1-nitropropane, 2- 
nitropropane, 2-methylpentane (isohexane), methylcyclopentane, 3-methylhexane 
and 3-methylpentane. The residual for these compounds is: -0.8, -0.7, 0.7, 0.7, 0.7 
and 0.7 log units and may result from experimental error.
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EQUATIONS N(dp) N(nc) r2 SD F OUTLIERS D
FULL SET (IN VIVO)
Log BM = 0.082 -  0.059E + 0.010S -  
0.248A+ 0.028B + 0.110V -  1.0221a
60 59 0.745 0.253 25.850 0 6
FULL SET (IN VITRO)
Log BM = -0.185 -  0.209E -  0.593S -  
0.081A -0.168B +0.741V
110 110 0.537 0.207 24.125 3 5
FULL SET (IN VIVO+IN VITRO)
Log BM = 0.039 -  0.100E -  0.080S -  
0.254A + 0.041B + 0 .233V - 1.0051a- 
0.140Iv
TRAINING SET
Log BM = 0.114 -  0.102E -  0.021S -
0.246A + 0.072B + 0.125 V -  1.0091a -
0.183Iv
TEST SET
N(nc) = 82 N(dp) = 82
SD (n-1) = 0.213 RMSE = 0.212
AAE = 0.166 AE = -0.023
164
82
163
82
0.595
0.697
0.220
0.235
32.699
24.365
6 7
7
N (dp) = number o f data points used in the training set 
N (nc) = number of compounds used in the training set 
r2 = is the square of the overall correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model
Table 25.3. Summary of the two equations for blood/plasma to muscle distributions 
for VOCs and drugs combined.
In order to assess the predictive capability of the combined equation {in vivo + 
in vitro) a training set was constructed and the equation for the training set used to 
predict log BM values for the test set, as shown in table 25.3. The coefficients and 
statistics of the full set of the combined equation {in vivo + in vitro) and training 
equation {in vivo + in vitro) are similar in terms of coefficients. The training 
equation predicted log BM values for the (unused) test set as follows. N(nc) = 82 
and N(dp) = 82, that AE = -0.023, AAE = 0.166, RMSE = 0.212 and SD = 0.213 log 
units. Thus the combined {in vivo + in vitro) training equation and the full combined 
equation (in blue) can be used to predict further values of log BM to close to our 
suggested experimental error of around 0.2 log units (AAE) or 0.3 log units (SD).
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r E S A B V la Iv
E 1.00
S 0.94 1.00
A 0.58 0.68 1.00
B 0.80 0.89 0.76 1.00
V 0.87 0.90 0.64 0.88 1.00
la 0.30 0.34 0.49 0.31 0.30 1.00
Iv -0.81 -0.77 -0.57 -0.73 -0.80 -0.32 1.00
Table 25.4. The inter-correlation of descriptors for 163 compounds
The inter-correlations of descriptors obtained for the combined in vivo and in 
vitro equation (from table 25.3) as shown by table 25.4. The largest r value for E 
versus S descriptor is 0.88. It appears that there is no strong inter-correlation 
between the other set of descriptors used in this model
The descriptors used in the equation reflect solute/solvent interactions. One 
can, therefore, interpret the coefficients in terms of the effect that particular 
interactions have on the process under consideration. The e-coefficients (P = 0.08), 
s-coefficient (P = 0.29) and b-coefficient (P = 0.52) is not significant. The positive 
v-coefficient in the blood (or plasma) to muscle (in vivo + in vitro) equation, indicate 
that increasing molecular size can push drugs out of blood (or plasma) and into the 
muscle phase. The coefficient of the A descriptors are negative, indicating that the 
hydrogen-bond basicity acts to keep drug compounds in the blood (or plasma) phase 
and out of the muscle tissue phase. The large negative coefficient of the indicator 
variable (la), in the combined equation from table 25.3, indicates a hitherto unknown 
factor affecting the transfer of solutes between blood (or plasma) and the muscle. It 
is apparent that the presence of -CO2H group acts to hinder muscle penetration. 
This could be simply due to intrinsic hydrogen bonding and the polarity properties of 
neutral acids. Finally, it is known that some acidic drugs may bind to albumin 
present in plasma and blood, which may also account for this negative contribution 
of the coefficient la.
This new model based on 163 compounds can now be used to correlate and 
predict blood (or plasma) to muscle distribution for in vitro and in vivo drug
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compounds. Of course, any prediction using the full combined equation (in vivo plus 
in vitro) can, or should, only be made within the chemical space of the test set used 
to assess the predictions.
The blood/plasma to muscle model is the poorest statistical model reported for 
blood to tissue distribution for VOCs and drugs combined The plots for this blood/ 
plasma to muscle distribution model also indicates that the data has not got an even 
spread data. The VOC and drug are too cluttered in specific regions of the graph 
(see page 342); this indicates that both datasets (in vitro and in vivo) inhabit different 
chemical space (see page 153). This model is poor when compared to other good 
models like blood/plasma to fat distribution (VOCs and drugs combined) that has an 
even spread of data as shown from the plots (see chapter 22) and give rise to good 
correlative equations
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Chapter
26
Blood/plasma/serum to liver distribution 
for drugs and VOCs combined
The distribution of drugs between blood (plasma or serum) and liver tissue has 
become a matter of interest for the pharmaceutical industry, toxicological sciences 
and environmental health.
Scheme 26.0. Diagram showing the liver, the largest internal organ of the body in 
humans and rats.
The liver is the largest internal organ of the human body. This organ, which is 
part of the digestive system, performs more than 500 different functions, all of which 
are essential to life. Its essential functions include helping the body to digest fats, 
storing reserves of nutrients, filtering poisons and wastes from the blood, 
synthesizing a variety of proteins, and regulating the levels of many chemicals found 
in the bloodstream. The liver is unique among the body’s vital organs in that it can
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regenerate, or grow back, cells that have been destroyed by some short-term injury 
or disease. But if the liver is damaged repeatedly over a long period of time, it may 
undergo irreversible changes that permanently interfere with function.
The human liver is a dark red-brown organ with a soft, spongy texture. It is 
located at the top of the abdomen, on the right side of the body just below the 
diaphragm (a sheet of muscle tissue that separates the lungs from the abdominal 
organs). The lower part of the rib cage covers the liver, protecting it from injury. In 
a healthy adult, the liver weighs about 1.5 kg (3 lb) and is about 15 cm (6 in) thick.
The liver has not one, but two blood supplies of oxygen rich blood, through 
the hepatic artery and nutrient rich blood from the portal vein. Inside the liver, fine 
branches of these blood vessels empty their blood into common vessels. Mixed 
blood flows past and is processed by liver cells. Cleaned blood leaves the liver 
through the hepatic veins. The liver is where solutes can distribute between the 
blood capillaries and liver phase at steady state concentration.
There have been a number of reports of data for drug blood (plasma or serum)
1 1 Tto liver distribution in rats (in vivo). " However, there have been no reviews 
reported yet that attempt to make models to predict blood (plasma or serum) to liver 
distribution either for rats or humans. The present work is restricted to a data set of 
52 different drug compounds (53 data points), which is all that has been published. 
The in vivo drug data for blood (plasma or serum) to liver distribution of rats is at 
steady state concentration and the distribution from blood (plasma or serum) to liver, 
BL, is defined by the equation (26.0).
BH = (conc. of drug in liver)/(conc. of drug in blood, plasma or serum) Equation 26.0
The purpose of this work is to collect as many existing literature data on 
distribution (as log BL values) and to make an attempt to construct equations to 
predict in vivo blood/plasma/serum to liver distribution. The complete list of drug 
log BL data is shown in table 26.0 (see appendix); where two or more results are 
reported for the same compound, in the same system (blood/plasma/serum) they 
have been averaged.
As discussed before (chapter 21), the distribution sets for the tissues that also 
include liver can be combined together for plasma, blood and serum. In this case, 
the three distribution sets blood (log P b - i i v e r )  plasma (log P p - i i Ve r )  and serum (log P s .
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liver) into liver from table 26.0 (see appendix) can now be combined together, but 
these ratios will not be averaged; thus the data points will be greater than the number 
of compounds.
Discussion on blood/plasm a/serum  to liver distribution for 
drugs only
The 52 compounds (all of which are drugs) were used to construct the blood 
(plasma or serum) liver distribution model, see table 26.1. The structures for 
compounds with trivial names can be found in the appendix of this thesis. A first 
attempt to construct a model was to use the indicator variable for carboxylic acids 
(la). This descriptor has been used before for blood to brain distribution of drugs by 
Platt’s24 and Salminen.25 The independent variable la  for a value of ‘1’ means the 
presence of carboxylic acid as a functional group to the drug compound. The 
independent variable la for a value of ‘0’ means that the carboxylic acid is absent 
from the drug compound. This descriptor was used in this model to correlate and 
predict blood to liver distribution for drugs as shown in table 26.1.
EQ U A T IO N S N(dp) N(nc) r2 SD F O UTLIERS D
FULL SET (IN VIVO)
Log BL = -0.008 + 0.119E -  0.077S - 53 52 0.708 0.320 18.574 2 6
0.276A + 0.149B + 0.194V -  0.8711a 
TRAINING SET
Log BL = 0.073 + 0 .1 1 3 E -0 .1 3 7 S - 40 39 0.733 0.342 15.126 6
0.351A + 0.293B + 0.121V -  0.8281a 
TEST SET
N(nc) = 13 N(dp) = 13 
SD (n-1) = 0.305 RMSE = 0.293 
AAE = 0.227 
AE = -0.128
N (dp) = number of data points used in the training set 
N (nc) = number of compounds used in the training set 
r2 = is the square o f the overall correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model
Table 26.1. Summary of the two equations for blood/plasma/serum to liver 
distributions for drugs only
347
For the present model for blood (plasma or serum) to liver distribution, there 
were two compounds that were marked outliers: p,p'-dichlorodiphenylsulfone and 
valproic acid. The residuals for these two compounds are both 0.8 units. These two 
outliers may have resulted from experimental errors. The statistics of the equation 
for the full set in table 26.1 are satisfactory and the predictive capability of the 
equation can be assessed by the usual method of constructing a training set and an 
independent test set. The selection of the training (40 data points) and test sets (13 
data points) was carried out using the usual computing method called Kennard- 
Stone. The training equation is also shown in table 26.1.
The statistics of the full set (table 26.1) and the training set (table 26.1) are 
similar and so are some of the coefficients. If the training set equation is used to 
predict the remainder of the data in the (unused) test set, it is found that AE = -0.13, 
AAE = 0.23 RMSE = 0.29 and SD = 0.31, that there is very little bias, and the 
predictive capability of the training equation (table 26.1) and by implication of the 
full set equation (table 26.1) is therefore assessed. Thus the full (in vivo) equation 
and the training equation can be used to predict further values of log BL, close to the 
suggested experimental error of SD = 0.3 and AAE = 0.2 log units (from chapter 21).
r E S A B V I
E 1.00
S 0.81 1.00
A 0.30 0.52 1.00
B 0.53 0.75 0.63 1.00
V 0.57 0.72 0.40 0.86 1.00
I 0.18 0.27 0.42 0.09 0.00 1.00
Table 26.2. The inter-correlation of descriptors for 52 compounds
The inter-correlations of descriptors used for drug blood (plasma or serum) to 
liver distribution are shown in table 26.2. The largest r value for B versus V 
descriptor is 0.74. It appears that there is no strong inter-correlation between the 
other set of descriptors used in this model.
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Combining the i n  v i v o  data of drugs with the i n  v i t r o  data of 
VOCs
Now that the data set of in vivo log BL values for passive transport from blood 
(plasma or serum) to rat liver has been investigated, it would be interesting to see 
what happens if this is combined with the previous data set (in vitro) from table 15.3 
(chapter 15) for VOCs. Note that the in vitro data set is transfer of VOCs from 
human blood and rat blood to human liver and rat liver. It was concluded in chapter 
9, that there is very little difference in the two species of humans and rats, and that 
data from these two species can be combined for VOCs. In the present work, the use 
of in vitro plasma to liver data for VOCs will not be used, mainly because of the 
small number of extra compounds involved. The aim of this work is to show 
whether it is possible (or not) to combine these two different data sets (in vitro + in 
vivo data set).
Discussion on blood/plasma/serum to liver distribution for 
drugs and VOCs combined
Before combining the two models together of in vivo and in vitro data sets, it 
is first important to see if there are any differences in the two equations shown in 
table 26.1 and 26.3.
Note that the in vitro equation for VOCs does not have the Ia-indicator 
variable, because there are no carboxylic acids in the data set. The two sets of 
coefficients appear to be different visibly and suggest that the in vivo and in vitro 
distributions may possibly be different. In particular, the c-coefficients differ -0.008 
(SD = 0.152) as against -0.202 (SD = 0.078), which suggests that there might be a 
small systematic difference between the in vivo and in vitro distributions.
One way to check for systematic deviations is to use the coefficients in the in 
vivo equation, to predict log BL values for the 120 VOCs used to construct the in 
vitro equation. It is found that for the predicted and observed in vitro log BL values, 
AE = -0.14, AAE = 0.25, RMSE = 0.34 and SD = 0.34 log units. The numerical 
values here show that the in vivo equation can predict the in vitro dataset within 0.34 
log units (SD). This suggests that the in vivo model can successfully predict the in
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vitro data set as it covers a larger descriptor space than the in vitro model. Any 
systematic difference between the in vivo (drugs) and the in vitro (VOCs) 
distributions could be due to the two series of compounds inhabiting different areas 
of chemical space.
Another indicator variable was then used to test if there is any difference in the 
in vitro and in vivo data set for VOCs and drugs. In this case one can apply the 
indicator variable, Iv, defined as Iv = 1 for the in vitro data and Iv = 0 for the in vivo 
data. An equation with the Iv term was constructed but is not shown, because the Iv 
term was not statistically significant (T-test = 1.612, p-value = 0.109) and the value 
of the Iv coefficient was quite small (0.137). The coefficients of drug (in vivo) and 
the drug and VOC (in vivo + in vitro) combined equation are the same within 
experimental error (SD values of the coefficients are in the drug equation: c= 0.152, 
e= 0.093, s= 0.137, a= 0.167, b= 0.118, v= 0.105, ia= 0.140 and in the combined 
equation (in vivo + in vitro): c= 0.048, e= 0.058, s= 0.082, a= 0.114, b= 0.073, v=
0.057, ia= 0.109). It is concluded that there is a very small systematic difference 
between the in vivo and in vitro distributions (as Iv is 0.1 log units), and that the two 
sets of distribution data can be combined without taking into account this difference 
(see equation 26.3).
The full data set (in vivo and in vitro measurements) consists of 169 
compounds and 170 data points, the difference arising because blood (plasma or 
serum) to liver distributions are counted separately. The correlation equation of this 
set of data points with the Abraham descriptors is shown in table 26.3. The fits for 
this full equation (in blue) appear to be reasonable (S.D = 0.254 and r2 = 0.660). 
This represents a satisfactory model for a combined data set of VOCs and drugs for 
blood/plasma/serum to liver distribution, and is the only model yet reported for both 
types of data sets (in vivo rats + in vitro rats and humans combined).
There were three additional outliers observed in the full set: terbinafine, l-(3- 
fluoropropyl)-2-nitroimidazole (FPN) and methotrexate. The residuals for these 
compounds are: -0.9, 0.8 and 0.8 log units and may result from experimental error.
351
EQUATIONS N(dp) N(nc) r2 SD F OUTLIERS D
FULL SET {IN VIVO)
Log BL = -0.008 + 0.119E -  0.077S - 53 52 0.708 0.320 18.574 2 6
0.276A + 0.149B + 0.194V -  0.8711a
FULL SET {IN VITRO)
Log BL = -0.202 -  0.048E -  0.295S - 120 120 0.648 0.211 42.012 4 5
0.213A-0.359B + 0.876V
FULL SET {IN VIVO + IN  VITRO)
Log BL = -  0.062 + 0.104E -  0.35IS - 170 169 0.660 0.254 52.762 3 6
0.202A -  0.127B + 0.617V -  0.8311a
TRAINING SET
Log BL = 0.022 + 0.148E -  0.377S -
0.220A -  0.007B + 0.491V -  0.8511 85 85 0.711 0.273 32.006 - 6
TEST SET
N(nc) = 85 N(dp) = 85
SD(n-l) = 0.245 RMSE = 0.243
AAE = 0.182 AE = 0.001
N (dp) = number of data points used in the training set 
N (nc) = number of compounds used in the training set 
r2 = is the square o f the overall correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number o f descriptors used in the model
Table 26.3. Summary of the two equations for blood/plasma/serum to liver 
distributions for VOCs and drugs combined.
In order to assess the predictive capability of the combined equation (in vivo + 
in vitro) a training set was constructed and the equation for the training set used to 
predict log BL values for the test set, as shown in table 26.3. The coefficients and 
statistics of the full set of the combined equation (in vivo + in vitro) and training 
equation (in vivo + in vitro) are similar in terms of coefficients. The training 
equation predicted log BL values for the (unused) test sets as follows. N(nc) = 85 
and N(dp) = 85, that AE = 0.001, AAE = 0.182, RMSE = 0.243 and the SD = 0.245 
log units. Thus the combined (in vivo + in vitro) training equation and the full 
combined equation (in blue) can be used to predict further values of log BL to close 
to our suggested experimental error of around 0.2 log units (AAE) or 0.3 log units 
(SD).
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r E S A B V la
E 1.00
S 0.91 1.00
A 0.61 0.72 1.00
B 0.74 0.85 0.76 1.00
V 0.80 0.83 0.65 0.89 1.00
la 0.32 0.37 0.45 0.24 0.23 1.00
Table 26.4. The inter-correlation of descriptors for 169 compounds
The inter-correlations of descriptors obtained for the combined in vivo and in 
vitro equations (from table 26.3) as shown by table 26.4. The largest r value for E 
versus S descriptor is 0.83. It appears that there is no strong inter-correlation 
between the other set of descriptors used in this model.
The descriptors used in the equation reflect solute/solvent interactions. One 
can, therefore, interpret the coefficients in terms of the effect that particular 
interactions have on the process under consideration. The e-coefficients (P = 0.08), 
a-coefficient (P = 0.08) and b-coefficient (P = 0.09) is not significant. The positive 
v-coefficient in the blood/plasma/serum to liver (in vivo + in vitro) equation from 
table 26.3, indicate that increasing molecular size can push drugs out of 
blood/plasma/serum and into liver. The coefficient of the ‘polar’ descriptor S is 
negative, indicating that polarity is stronger in the blood (plasma or serum) phase 
than in the liver tissue phase. Therefore the drug compounds will move from the 
liver phase and into the blood/plasma/serum phase. The negative coefficient of the 
indicator variable (la), in the combined equation from table 26.3., indicates a 
hitherto unknown factor affecting the transfer of solutes between 
blood/plasma/serum and the liver. It is apparent that the presence of-CC^H group 
acts to hinder liver penetration further. This could be simply due to intrinsic 
hydrogen bonding and the polarity properties of neutral acids. Finally, it is known 
that some acidic drugs may bind to albumin present in blood, plasma and serum, 
which may also account for this negative contribution of the coefficient la.
This new model based on 169 compounds can now be used to correlate and 
predict blood (plasma or serum) to liver distribution for in vitro and in vivo drug 
compounds. Of course, any prediction using the full combined equation (in vivo plus
353
in vitro) can, or should, only be made within the chemical 
to assess the predictions.
space o f the test set used
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Chapter
27
Blood/plasma to skin distribution (rat only)
Blood/plasma to skin distribution, or the ability of a molecule to enter the skin 
tissue, has become a subject of interest of interest to pharmaceutical industry. The 
skin acts as a physical barrier to the external environment and protects the body from 
environmental pollutants. The skin is made up of several layers also containing a 
rich supply of capillary blood network (see figure 27.0). Here the distribution of 
drugs can occur at steady state concentration between the blood and the skin (and 
vice versa).
Epidermis
Papillary Dermis
Reticular Dermis Swea* Gland
 Hair
Fat Tissue
Blood V essels  
Nerve
Oil Gland
Muscle
Figure 27.0. The structure of skin.
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There have been a number of reports of data for drug blood/plasma to skin
• • • • 112 distribution in rats. ' There have been no specific reviews reported yet that to
attempt to make models to predict blood/plasma to skin distribution either for rats or
humans. The present work is restricted to a small data set of 35 compounds, which
is all that has been published. The drug data for blood/plasma to skin distribution of
rats is at steady state concentration. The aim is to attempt to construct a model based
on the Abraham equations to predict the distribution process. This equilibrium
distribution for blood/plasma to skin distribution will be based on rats, and will be
the first reported model in this area for blood/plasma to skin transport. It should be
possible to build bigger models in the near future providing further literature data are
published. Blood/plasma to skin distribution, BS, is expressed by the equation
below.
BS = (conc. of drug in skin)/(conc. of drug in blood/plasma) Equation 27.0
The aim of this work is to construct an equation as part of a general method for 
‘high-throughput’ prediction of equilibrium blood/plasma-skin distribution based on 
structure using the Abraham descriptors (E, S, A, B, and V).13
Discussion on blood/plasma to skin distribution for drugs
The 35 compounds (most of which are drugs) were used to construct the 
blood/plasma skin distribution model, see table 27.0 (see appendix). The structures 
for compounds with trivial names can be found in the appendix of this thesis. The 
first attempt was to find out whether it is was necessary for this model to include the 
sixth descriptor (la) as an indicator variable for carboxylic acids. The correlations 
for this model have been carried out in order to test this indicator variable (see table 
27.1).
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EQUATIONS (IN VIVO DATA ONLY) N r2 SD F OUTLIERS D
Log BS = 0.557 + 0.246E -  0.155S 
-0.750A-0.453B + 0.144V
34 0.658 0.326 10.803 p-Phenylbenzoic
acid
Terbinafme
5
Log BS = 0.527 + 0.071E + 0.085S 
-  0.468A -  0.490B + 0.134V -  0.6741a
35 0.762 0.288 14.979 Terbinafme 6
N = number of compounds used in the training set 
r2 = is the square of the overall correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model
Table 27.1. Summary of the two equations for drug blood/plasma skin distributions
The first equation in Table 27.1 does not include the la  descriptor. The fit for 
this equation appears to be poorer than the second equation. However, several 
discrepancies were observed for carboxylic acid containing compounds, such as p- 
phenylbenzoic acid, glycyrrhetinic acid, nalidixic acid, salicylic acid, valproic acid 
and acrylic acid. From this set of carboxylic acid containing compounds p- 
phenylbenzoic acid appeared to be the biggest outlier (residual of 0.93 log units). An 
improvement over the first equation can be achieved by the inclusion of the indicator 
variable (la) that is set to 1 for a compound containing a carboxylic acid fragment 
and 0 otherwise. Carboxylic acid containing compounds are known to ionize in 
blood and therefore prevent passive distribution into tissues.14 From the above 
equations it seems to make sense to include this indicator variable to take into 
account the transport problems that are known to occur. The second equation has the 
best fit of the two equations (smaller standard deviation and the larger square of the 
correlation coefficient) and can be viewed graphically on page 363.
The molecule omitted from this model is terbinafme (residual of 0.88 log 
units). There could be several reasons why terbinafme appears as an outlier from 
this model. Possible reasons include experimental error (difficulties in determining 
log P values in vivo), metabolism of this compound (in skin, blood or plasma) and 
efflux that may affect the equilibrium processes. The inter-correlations of 
descriptors are obtained for the second equation and are shown by table 27.2. The 
largest r2 value for E versus S descriptor is 0.76. It appears that there is no strong 
inter-correlation between the other set of descriptors used in this model.
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r E S A B V la
E 1.00
S 0.87 1.00
A -0.21 0.14 1.00
B 0.42 0.57 0.35 1.00
V 0.55 0.57 0.06 0.58 1.00
la -0.05 0.15 0.54 0.06 -0.04 1.00
Table 27.2. The inter-correlation of descriptors for 35 compounds
The Abraham solvation equation has successfully been employed to correlate 
blood/plasma to skin distribution for drugs. The equation could be used to predict 
further values provided the solute is within the descriptor space of the training set. 
No test sets have been used for this model, as there are a limited number of 
compounds available. The descriptors used in the equation reflect solute/solvent 
interactions. Therefore, one can interpret the coefficients in terms of effect that 
particular interactions have on the process under consideration. The e-coefficients (P 
= 0.73), s-coefficient (P = 0.70), a-coefficient (P = 0.09) and v-coefficient (P = 0.24) 
is not significant. The coefficient of the ‘polar’ descriptors S is positive, indicating 
that polarity is stronger in the skin phase than in blood/plasma. Therefore the drug 
compounds will move from the blood/plasma phase and into the skin phase. The 
large negative coefficient of the indicator variable (la), in equation 27.1 and its low 
correlation with other descriptors (27.2), indicates a hitherto unknown factor 
affecting the transfer of solutes between blood/plasma and the skin. It is apparent 
that the presence of -CO2H group acts to hinder skin penetration further. This could 
be simply due to intrinsic hydrogen bonding and the polarity properties of neutral 
acids. Finally, it is known that some acidic drugs may bind to albumin present in 
plasma and blood, which may also account for this negative contribution of the 
coefficient la.
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Chapter
28
Blood/plasma/serum to kidney distribution 
for drugs and VOCs combined
The distribution of drugs between blood (plasma or serum) and kidney tissue 
has become a matter of interest for the pharmaceutical industry, toxicological 
sciences and environmental health.
A Kidney
Blood, w aste and w ater  
enter here through  the  
Renal A rtery
Blood w ith o u t w aste  
or excess w ater leave  
here through  the  
Renal Vein
Excess w ater and 
W aste in the form  
Urine leaves here  
the U reter
Toxic 4
o f /  via /
Scheme 28.0. Diagram showing the kidney found in humans and rats.
In humans, kidneys are situated one on each side of the spine and are 
embedded in fatty tissue. They have a bean-shaped structure, possessing a convex 
outer border and a concave inner border. The inner border presents an indentation,
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the hilum, at which the blood vessels enter and leave. In front is the renal vein 
carrying blood from the kidney; behind it lies the renal artery carrying blood to the 
kidney. The ureter is a tube that carries urine to the bladder from the kidney. The 
kidney also embodies glomeruli, aggregations or loops of capillaries enclosed within 
thin envelopes of endothelial lining called Bowman's capsules, located at the blind 
ends of the renal tubules.
The kidneys are important in maintaining a balance of fluid, salt and a normal 
degree of acidity. When disorders upset these delicate balances, the kidneys act to 
restore them by excreting more or less water, salt, and hydrogen ions. The kidneys 
help maintain normal blood pressure by secreting the hormone renin and elaborate a 
hormone that stimulates the production of red blood cells.
The kidney has a rich supply of blood from the renal artery and waste products 
are removed from the kidney via the renal vein. The distribution of drugs takes place 
between the blood capillaries and the kidney tissue at steady-state concentration.
There have been a number of reports of data for drug blood (plasma or serum) 
to kidney distribution in rats {in vz'vo).120 There have been no specific reviews 
reported yet that attempt to make models to predict blood (plasma or serum) to 
kidney distribution either for rats or humans. The present work is restricted to a data 
set of 50 different drug compounds (51 data points), which is all that has been 
published. The in vivo drug data for blood (plasma or serum) to kidney distribution 
of rats is at steady state concentration and the distribution from blood (plasma or 
serum) to kidney, BK, is defined by the equation (28.0).
BK = (conc. of drug in kidney)/(conc. of drug in blood, plasma or serum) Equation 28.0
The purpose of this work is to collect as many existing literature data on 
distribution (as log BK values) and to make attempt to construct equations to predict 
in vivo blood/plasma/serum to kidney distribution. The complete list of drug log BK 
data is shown in table 28.0 (see appendix); where two or more results are reported 
for the same compound in the same system (blood/plasma/serum) they have been 
averaged.
As discussed before (chapter 21), the distribution sets for the tissues that also 
include kidney can be combined together for plasma, blood and serum. In this case, 
the three distribution sets: blood (log P b - k i d n e y ) >  plasma (log P p - k i d n e y )  and serum (log
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P s - k i d n e y )  into kidney from table 28.0 (see appendix) can now be combined together, 
but these ratios will not be averaged; thus the data points will be greater than the 
number of compounds.
Discussion on blood/plasm a/serum  to kidney distribution  
for drugs only
The 50 compounds (all of which are drugs) were used to construct the blood 
(plasma or serum) to kidney distribution model, see table 28.1. The structures for 
compounds with trivial names can be found in the appendix of this thesis. A first 
attempt to construct a model was to use the indicator variable for carboxylic acids 
(la). This descriptor has been used before for blood to brain distribution of drugs by 
Platt’s21 and Salminen.22 The independent variable la for a value of ‘1’ means the 
presence of carboxylic acid as a functional group to the drug compound. The 
independent variable la for a value of ‘0’ means that the carboxylic acid is absent 
from the drug compound. This descriptor was used in a model to correlate and 
predict blood (plasma or serum) to kidney distribution for drugs as shown in table
28.1.
EQUATIONS (rat model) N(dp) N(nc) r2 SD F OUTLIERS D
FULL SET (IN VIVO)
Log BK = 0.048 -  0.022E -  0.118S - 51 50 0.726 0.299 19.465 1 6
0.486A + 0.215B + 0.317V -  0.4111a
TRAINING SET
Log BK = 0.073 -  0.026E -  0.122S - 40 40 0.726 0.327 14.550 6
0.520A + 0.236B + 0.304V -  0.3721a
TEST SET
N(nc) = 11 N(dp) = 11
SD(n-l) = 0.202 RMSE = 0.192
AAE = 0.180 AE = 0.004
N  (dp) =  num ber o f  data points used in the training set 
N  (nc) =  num ber o f  com pounds used in the training set 
r2 =  is the square o f  the overall correlation coeffic ien t 
SD  =  the standard deviation, F =  F-statistic 
D =  the num ber o f  descriptors used in the m odel
Table 28.1. Summary of the two equations for blood/plasma/serum to kidney 
distributions for drugs only
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For the present model for blood (plasma or serum) to kidney distribution, there 
was one outlier observed. This outlier known as AI-6, has a residual of 1.2 log units 
which may possibly result from experimental error. The statistics of the equation for 
the full set (table 28.1) are good and the predictive capability of the equation can be 
assessed by the usual method of constructing a training set and an independent test 
set. The selection of the training (40 data points) and test sets (11 data points) was 
carried out using the usual computing method called Kennard-Stone. The training 
equation is also shown in table 28.1.
The statistics of the full set (table 28.1) and the training set (table 28.1), are 
similar and so are some of the coefficients. If the training set equation is used to 
predict the remainder of the data in the (unused) test set, it is found that AE = 0.00, 
AAE = 0.18, RMSE = 0.19 and SD = 0.20, that there is very little bias, and the 
predictive capability of the training equation (table 28.1) and by implication the full 
set equation (table 28.1) is therefore assessed. Thus, the full (in vivo) equation and 
the training equation can be used to predict further values of log BK, close to the 
suggested experimental error of SD = 0.3 and AAE = 0.2 log units (from chapter 21).
The inter-correlations of descriptors used for drug blood (plasma or serum) to 
kidney distribution are shown in table 28.2. The largest r2 value for B versus V 
descriptor is 0.81. It appears that there is no strong inter-correlation between the 
other set of descriptors used in this model.
r E S A B V la
E 1.00
S 0.83 1.00
A 0.27 0.48 1.00
B 0.58 0.74 0.56 1.00
V 0.59 0.71 0.39 0.90 1.00
la 0.09 0.18 0.42 0.00 -0.06 1.00
Table 28.2. The inter-correlation of descriptors for 50 compounds
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Combining the i n  v i v o  data of drugs with the i n  v i t r o  data of 
VOCs
Now that the data set of in vivo log BK values for passive transport from blood 
(plasma or serum) to rat kidney has been investigated, it would be interesting to see 
what happens if this is combined with the previous data set (in vitro) from table 13.3 
(chapter 13) for VOCs. Note that the in vitro data set is transfer of VOCs from 
human blood and rat blood to human kidney and rat kidney. It was concluded in 
chapter 9, that there is very little difference in data for the species of humans and 
rats, and that data from these two species can be combined for VOCs. In the present 
work, the use of in vitro plasma to kidney data for VOCs will not be used, mainly 
because of the small number of extra compounds involved. The aim of this work is 
to show whether it is possible (or not) to combine these two different data sets (in 
vitro + in vivo data set).
Discussion on blood/plasma/serum to kidney distribution 
for drugs and VOCs combined
Before combining the two models together of in vivo and in vitro data sets, it 
is first important to see if there are any differences in the two equations.
Note that the in vitro equation for VOCs does not have the Ia-indicator 
variable, because there are no carboxylic acids in the data set. The two sets of 
coefficients appear to be different visibly and suggest that the in vivo and in vitro 
distributions may possibly be different. In particular, the c-coefficients differ 0.048 
(SD = 0.144) as against -0.361 (SD = 0.089), which suggests that there might be a 
small systematic difference between the in vivo and in vitro distributions.
One way to check for systematic deviations is to use the coefficients in the in 
vivo equation to predict log BK values for the 73 VOCs used to construct the in vitro 
equation. It is found that the predicted and observed in vitro log BK values, AE = - 
0.03, AAE = 0.28, RMSE = 0.33 and SD = 0.33 log units. The numerical values 
here show that the in vivo equation can predict the in vitro dataset within 0.33 log 
units (SD). This suggests that the in vivo model can successfully predict the in vitro
369
dataset as it covers a larger descriptor space than the in vitro model. Any systematic 
difference between the in vivo (drugs) and the in vitro (VOCs) distributions could be 
due to the two series of compounds inhabiting different areas of chemical space.
Another indicator variable was then used to test if there is any difference in the 
in vitro and in vivo data set for VOCs and drugs. In this case one can apply the 
indicator variable, Iv, defined as Iv = 1 for the in vitro data and Iv = 0 for the in vivo 
data. An equation with the Iv term was constructed but is not shown because the Iv 
term was not statistically significant (T-test = 0.709, p-value = 0.480) and the value 
of the Iv coefficient was quite small (0.065). The coefficients of drug (in vivo) and 
the drug and VOC (in vivo + in vitro) combined equation are the same within 
experimental error (SD values of the coefficients are in the drug equation: c= 0.144, 
e= 0.086, s= 0.120, a= 0.158, b= 0.127, v= 0.110, ia= 0.125, and in the combined 
equation (in vivo + in vitro): c= 0.055, e= 0.062, s= 0.086, a= 0.123, b= 0.086, v=
0.065, ia= 0.109). It is concluded that there is very small systematic difference 
between the in vivo and in vitro distributions (as Iv is 0.1 log units), and that the two 
sets of distribution data can be combined without taking into account this difference 
(see equation 28.3).
The full data set (in vivo and in vitro measurements) consists of 120 
compounds and 121 data points, the difference arising because blood (plasma or 
serum) to kidney distributions are counted separately. The correlation equation for 
this set of data points with the Abraham descriptors is shown in table 28.3. The fits 
for this full equation (in blue) appear to be reasonable (S.D = 0.259 and r = 0.711). 
This represents a good model for a combined data set of VOCs and drugs for 
blood/plasma/serum to kidney distribution, and is the only model yet reported for 
both types of data sets (in vivo rats + in vitro rats and humans combined).
There were three additional outliers observed in the full set: methotrexate, 
terbinafme and r-etodolac (structures can be found in the appendix of this thesis). 
The residual for these compounds are: 0.7, -0.7 and -0.8 log units and may result 
from experimental error.
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EQUATIONS N(dp) N(nc) r2 SD F OUTLIERS D
FULL SET (IN VIVO)
Log BK = 0.048 -  0.022E -  0.118S -  
0.486A + 0.215B + 0.317V -  0.4111a
51 50 0.726 0.299 19.465 1 6
FULL SET (IN VITRO)
Log BK = -0.361 + 0 .1 3 4 E -0 .5 1 5 S - 73 73 0.757 0.217 41.661 3 5
0.823A + 0.273B + 0.981V
FULL SET (IN VIVO+IN VITRO)
Log BK = -  0.148 -  0.025E -  0.243S - 121 120 0.711 0.259 46.815 3 6
0.493A -  0.109B + 0.722V -  0.3121a
TRAINING SET
Log BK = -  0.014 -  0.013E -  0.221S -
0.491 A + 0.014B + 0.559V -  0.3451a 61 61 0.763 0.263 28.948 - 6
TEST SET
N(nc) = 60 N(dp) = 60
SD (n-l) = 0.274 RMSE = 0.271
AAE = 0.235 AE = 0.046
N (dp) = number of data points used in the training set 
N (nc) = number of compounds used in the training set 
r2 = is the square of the overall correlation coefficient 
SD = the standard deviation 
F = F-statistic
D = the number of descriptors used in the model
Table 28.3. Summary of the two equations for blood/plasma/serum to kidney 
distributions for VOCs and drugs combined
In order to assess the predictive capability of the combined equation (in vivo + 
in vitro) a training set and was constructed and the equation for the training set used 
to predict log BK values for the test set, as shown in table 28.3. The coefficients and 
statistics of the full set of the combined equation (in vivo + in vitro) and training 
equation (in vivo + in vitro) are similar in terms of coefficients. The training 
equation predicted log BK values for the (unused) test sets as follows. N(nc) = 60 
and N(dp) = 60, that AE = 0.05, AAE = 0.24, RMSE = 0.27 and the SD = 0.27 log 
units. Thus the combined (in vivo + in vitro) training equation and the full combined 
equation (in blue) can be used to predict further values of log BK to close to our 
suggested experimental error of around 0.2 log units (AAE) or 0.3 log units (SD).
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r E S A B V la
E 1.00
S 0.92 1.00
A 0.60 0.70 1.00
B 0.78 0.87 0.74 1.00
V 0.80 0.83 0.64 0.91 1.00
la 0.26 0.31 0.41 0.18 0.17 1.00
Table 28.4. The inter-correlation of descriptors for 120 compounds
The inter-correlations of descriptors obtained for the combined in vivo and in
vitro equations (from table 28.3) are shown by table 28.4. The largest r2 value for E
2 2 versus S (r = 0.85) and B versus V (r = 0.83) descriptor. It appears that there is no
strong inter-correlation between the other set of descriptors used in this model.
The descriptors used in the equation reflect solute/solvent interactions. One 
can, therefore, interpret the coefficients in terms of the effect that particular 
interactions have on the process under consideration. The e-coefficient (P = 0.68) 
and b-coefficient (P = 0.21) is not significant. The positive v-coefficient in the 
blood/plasma/serum to kidney (in vivo + in vitro) equation, indicates that increasing 
molecular size can push drugs out of blood/plasma/serum and into the kidney phase. 
The coefficient of the ‘polar’ descriptors S is negative, indicating that polarity is 
stronger in the blood/plasma/serum phase than in the kidney tissue phase. Therefore 
the drug compounds will move from the kidney phase and into the 
blood/plasma/serum phase. The coefficient of the A descriptor is negative, 
indicating that the hydrogen-bond basicity ability act to keep drug compounds in the 
blood/plasma/serum phase and out of the kidney tissue. The negative coefficient of 
the indicator variable (Id), in the combined equation from table 28.3., indicates a 
hitherto unknown factor affecting the transfer of solutes between 
blood/plasma/serum and the kidney. It is apparent that the presence of-CC^H group 
acts to hinder kidney penetration further. This could be simply due to intrinsic 
hydrogen bonding and the polarity properties of neutral acids. Finally, it is known 
that some acidic drugs may bind to albumin present in blood, plasma and serum, 
which may also account for this negative contribution of the coefficient la.
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This new model based on 120 compounds suggests that it can now be used to 
correlate and predict blood (plasma or serum) to kidney distribution for in vitro and 
in vivo drug compounds. Of course, any prediction using the full combined equation 
(in vivo plus in vitro) can, or should, only be made within the chemical space of the 
test set used to assess the predictions.
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Chapter
29
Conclusion on blood to tissue distribution for 
VOCs and drugs combined
The equilibrium distribution models for blood to tissue for drugs (VOCs and 
drugs combined) were set up using the Abraham equations (note that blood also 
represents plasma and serum as shown in earlier chapters). The following blood to 
tissue phase distributions that were examined were for the following tissues: brain, 
heart, liver, kidney, muscle, lung, skin and fat. The coefficients for the equations are 
summarised in tables 29.0 and 29.1.
The partition coefficients, P b i o o d : t i s s u e s  for blood to tissues (VOCs and drugs 
combined) have been collected for a large number of compounds and measured in 
two different species, namely for humans and rats for VOCs, and rats for drugs. The 
general solvation equations from table 29.0 and 29.1 can be used to correlate the 
partition coefficients of these VOCs {in vitro) and drugs {in vivo) as log P  values. 
The equations from table 29.0 and 29.1 can be used for compound design. For 
example if one has a set of compounds with low partition into a particular tissue and 
it is required to synthesise related compounds with increased partition coefficients. 
Predictions can be made on compounds before they are synthesised and then it is 
only necessary to synthesise and test those most likely to have the right properties.
It has been found that human and rat partition data are the same within a given 
experimental error, as shown in chapter 9, for VOCs. This data set can also be 
combined with the dataset of drugs in rats to make new models to correlate and 
predict blood to tissue distribution as shown earlier in this thesis (chapter 21-28).
Table 29.0 is a summary of the equations constructed for blood to tissue 
distribution in rats for drugs only. These set of equations, were necessary in order to
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see if there were similarities to the VOC models. Finally, it was useful to examine 
how equations depend on tissue composition for the combined data sets (VOCs and 
drugs).
BLOOD:
TISSUE
e s a b V la TISSUE COMPOSITION
(WEIGHT FRACTIONS)
LIPID PROTEIN WATER
BRAIN 0.183 -0.778 -0.697 -0.462 0.679 -1.199 0.107 0.079 0.790
HEART 0.280 -0.399 0.189 0.066 0.093 -1.003 0.100 0.167 0.727
LIVER 0.119 -0.077 -0.276 0.149 0.194 -0.871 0.070 0.180 0.720
KIDNEY -0.022 -0.118 -0.486 0.215 0.317 -0.411 0.050 0.170 0.770
MUSCLE -0.059 0 .010 -0.248 0.028 0.110 - 1.022 0 .020 0.170 0.790
LUNG 0.031 -0.174 -0.666 0.248 0.321 -0.833 0.010 0.177 0.780
FAT - - - - - - 0.800 0.050 0.150
SKIN 0.071 0.085 -0.468 -0.490 0.134 -0.674 - - -
BLOOD 0.000 0.000 0.000 0.000 0.000 0.000 0.007 0.180 0.800
Table 29.0. Summary of equations for blood to tissue distribution (drugs only), and 
the tissue composition (lipid, protein and water) in humans.1
Coefficients e, s, a, b, v and la  versus the tissue composition 
for blood to tissue distribution of VOCs and drugs 
combined
It was found that plots of the coefficients e, s, a, b, v and Ia-coefficients 
versus weight fraction of proteins were so scattered that little could be deduced. An 
attempt was made to compare the coefficients (e, s, a, b, v and la) of the equations 
(table 29.1) with the composition of the tissues in terms of weight fractions of lipid 
and water. The compositions are given for humans (and not rats), as this is the only 
composition that is available from the literature.1 Visual comparisons are shown in 
schemes 29.0-29.11 using the program MINIITAB.2
The coefficients in the equations for blood to tissue distribution are harder to 
interpret than those for air to tissue distribution. The coefficients in the blood to 
tissue equations (VOCs and drugs combined) are much smaller than those in the air 
to tissue equations, because of partial cancellation of effects. This is because the
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coefficients in the blood to tissue equations reflect the difference in interactions 
between compounds and blood and compounds and tissue, whereas the coefficients 
in the air to tissue equations reflect only the interactions with the tissue. In addition, 
the percentage error in the blood to tissue coefficients will be much larger than the 
percentage error in the air to tissue coefficients. This is another factor that makes 
interpretation of the blood to tissue equation coefficients much more difficult, 
especially when the points in the plots are all clustered together, for example in 
schemes 29.2 to 29.4. From these plots one can establish that there is not great deal 
of connection between the equation coefficients and tissue composition.
In Table 29.1., are given the final equation coefficients for blood to tissue 
distribution of VOCs and drugs combined. Included in this table, is the blood to 
blood equation for which the coefficients are zero, by definition.
BLOOD:
TISSUE
e S a b V la Iv TISSUE COMPOSITION
(WEIGHT FRACTIONS)' S, ~ '• - ■ : LIPID PROTEIN WATER
FAT 0.117 -0.099 -1.543 -2.106 1.596 -0.946 0 0.800 0.050 0.150
BRAIN 0.152 -0.756 -0.664 -0.382 0.652 -1.196 -0.487 0.107 0.079 0.790
HEART 0.209 -0.393 0.076 -0.046 0.279 -0.965 0 0.100 0.167 0.727
LIVER 0.104 -0.351 -0.202 -0.127 0.617 -0.831 0 0.070 0.180 0.720
KIDNEY -0.025 -0.243 -0.493 -0.109 0.722 -0.312 0.050 0.170 0.770
MUSCLE -0.100 -0.080 -0.254 0.041 0.233 -1.005 -0.140 0.020 0.170 0.790
LUNG -0.004 -0.036 -0.742 0.252 0.312 -0.734 0 0.010 0.177 0.780
BLOOD 0.000 0.000 0.000 0.000 0.000 0.000 0 0.007 0.180 0.800
Table 29.1. Summary of equations for blood to tissue distribution (VOCs and drugs 
combined), and the tissue composition (lipid, protein and water) for humans.1
When the lipid fraction is increased in the blood to tissue equations, the e- 
coefficients for the equations appear to get larger and reach a plateau. This indicates 
that the London dispersion interaction is larger for partitions into lipids than into the 
polar water and protein constituents. This is shown in scheme 29.0. For blood to 
lung equation, the e-coefficient is very small at -0.004 units. These figures would 
suggest that the blood and lung have about the same London dispersion interactions, 
and this is why this point appears near the top left of the plot in scheme 29.1.
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If the lipid fraction is increased in the blood to tissue model, the s-coefficient 
for the equations gets smaller, see scheme 29.1. This is reasonable, because the 
tissue becomes less polar and less positive. Note that the coefficients for brain and 
heart do not follow this trend very well. This could be because the data set does not 
represent the true chemical space for that particular tissue. This problem is also 
observed later with fat tissue as shown in schemes 29.2-29.11, where the data point 
for fat is far away from the other data points.
The plot of the a-coefficients against the lipid fraction is shown in scheme
29.2. It is found that as the lipid fraction increases in the tissue (thus the latter 
becomes less polar), so the a-coefficient gets smaller. If the lipid fraction is 
increased in tissues, the b-coefficient for the equations also gets smaller, see scheme
29.3. This is reasonable, because as the tissue becomes less polar, so it becomes less 
basic and less acidic. As the lipid fraction is increased in tissues, the v-coefficient 
for the equations increases, as shown in scheme 29.4. This is also reasonable 
because the v-coefficient is an indication of the lipophilicity of a phase. In this case 
fat has the highest lipid fraction of all the tissues and this data point is observed at 
the top right of the plot. Finally, as the lipid fractions were increased in tissues, the 
la-coefficient for the equations decreases and reaches a plateau, see scheme 29.5. It 
is apparent that the presence of -CO2H group in drugs acts to hinder tissue 
penetration further, simply due to intrinsic hydrogen bonding and the polarity 
properties of neutral acids. This suggests that the fat tissue is least polar out of all 
tissues due high lipid content (as shown by graph) and is less likely to interact with 
drugs via hydrogen bonding than the blood or kidney phase (both of which are more 
polar and able to accommodate carboxylic acid containing drug compounds).
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Scheme 29.0. Scatter plot for e coefficient versus the fraction of lipid for blood to 
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Scheme 29.1. Scatter plot for s coefficient versus the fraction o f lipid for blood to
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Scheme 29.2. Scatter plot for a coefficient versus the fraction of lipid for blood to 
tissue distribution (VOCs and drugs combined)
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Scheme 29.3. Scatter plot for b coefficient versus the fraction o f lipid for blood to
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Scatterplot of v versus the fraction of lipid
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Scheme 29.4. Scatter plot for v coefficient versus the fraction of lipid for blood to 
tissue distribution (VOCs and drugs combined)
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tissue distribution (VOCs and drugs combined)
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The plots against the water fraction are almost the mirror images to the plots of 
the lipid fraction, except for the s-coefficient. If the water fraction is increased, the 
s-coefficient for the equations gets smaller, see scheme 29.7. This seems quite 
unreasonable. However, this graph is difficult to interpret as one can not tell if the 
fat and brain data point are reliable data points or if they are out of line again. This 
problem was also observed for the data points of fat and brain in some of the lipid 
fraction plots, as mentioned earlier. When the water fraction is increased in the 
tissue equations, the e -coefficients for the equations appear to get smaller. This 
indicates that the London dispersion interaction is larger for partitions into fats than 
into the polar phase like kidney and muscle that have high water fractions. This is 
also shown in scheme 29.6. The plot for the a-coefficient, scheme 29.8, is 
reasonable and shows that the a-coefficient increases as the tissue becomes more 
polar, and has more hydrogen bond basicity. Similarly, the plot for the b-coefficient, 
scheme 29.9, shows that the b-coefficient increases as the tissue becomes more 
polar, and has more hydrogen bond acidity. Also, as the water fraction is increased 
in tissues, the v-coefficient for the equations gradually decreases. This demonstrates 
that the tissues with larger water content are less lipophilic and less likely to 
accommodate larger solutes. This relationship is shown by scheme 29.10. Finally, 
as the water fractions were increased in tissues, the la-coefficient for the equations 
also increased (see scheme 29.11). This suggest that blood and kidney are able 
accommodate carboxylic acid containing compounds (via hydrogen bonding), as 
both of these tissue phases are more polar than the fat phase (which in turn has the 
least amount of water, hence less polar).
In conclusion, we show that for a large data set of blood to tissue partitions for 
drugs (VOCs and drugs combined), it is possible to construct statistically sound 
models and to assess the predictive capability of the models through selection of 
training and test sets of drugs (VOCs and drugs combined). A particular feature of 
the model is that the coefficients obtained are not just fitting parameters but encode 
chemical information about the nature of the process. This enables the blood to 
tissue distribution process to be compared, at least in part, in terms of the chemical 
interactions between the drugs (VOCs and drugs combined) and blood and tissues.
However, the comparisons of equation coefficients with tissue composition are 
not very good, and there seem to be many anomalies. It is unlikely that this is due to 
the compounds in the various equations occupying different areas of chemical space,
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because similar sets of compound are used in the various equations. Another 
possibility for the lack of connection between the equation coefficients and tissue 
composition is more fundamental. When a tissue is notionally divided up into 
separate components, water, protein and lipid, it is implied that, for example, the 
water in a tissue is somehow the same as water in bulk water, and that water in one 
tissue is somehow the same as water in another tissue. This cannot be completely 
correct. The properties of water in a tissue are unlikely to be the same as the 
properties of water in another tissue or as bulk water.
For example, Park et al.3 have measured the hydrogen bond acidity, a(m), of 
solvent mixtures. An interesting example is the water-tetrahydrofuran (THF) 
mixture, because the acidity is due only to the water component and not THF. A 
plot of am versus the solvent composition, as volume % is shown in Scheme 29.12. 
If the properties of water were the same at all compositions, the plot should be a 
straight line, but it is clear that the acidity of water in the mixed solvent is not the 
same as the acidity of bulk water. The conclusion would be the same no matter what 
composition scale was chosen. There have been several models for gas to tissue and 
blood or plasma to tissue partition that include tissue compositions,1’4'6 but these 
models are not satisfactory if they rely on properties of tissue components to be the 
same as properties of the bulk components.
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Scheme 29.7. Scatter plot for e coefficient versus the fraction o f water for blood to
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386
Scatterplot of a versus the fraction of water
HEART
OD
0.0 -
LIVER
- 0 .2 - m uszle
-0.4- KIDMEY
- 0 . 6 - BRAIN
LUNG*re
- 0 .8 -
- 1 . 0 -
- 1 .2 -
-1.4-
FAT
- 1.61
0.2 0.3 0.4 0.6 0.80.1 0.5 0.7
WATER
Average standard error for 7 biological samples
Scheme 29.8. Scatter plot for a coefficient versus the fraction of water for blood to 
tissue distribution (VOCs and drugs combined)
Scatterplot of b versus the fraction of w ater
LUNi
o.o-
[IDNEY
BRAIN
-0.5-
- 1.0 -
-1.5-
- 2 . 0 - FAT
0.80.6 0.70.3 0.4 0.50.1 0.2
WATER
Average standard error for 7 biological samples
Scheme 29.9. Scatter plot for b coefficient versus the fraction of water for blood to
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Conclusion and future work
Conclusion
This work contains the largest sets of literature values for in vitro and in vivo 
distribution of VOCs and drugs from air to blood (or air to tissue) and blood to tissue 
in rats and humans. Models based on the Abraham equations have been constructed 
to predict air to blood, air to tissue and blood to tissue distributions for VOCs in rats 
and humans, as shown in chapters 9-20. The Abraham equations have also been 
constructed for blood to tissue distribution for drugs in rats only (see chapters 21- 
29). This data on drugs was later combined with VOC data to enable the 
construction of new, extended equations, to correlate and predict drug and VOC 
blood to tissue distribution.
It was shown in this work that for a large data set of air to tissue and blood to 
tissue partitions for VOCs and drugs, it is possible to construct statistically sound 
models and to assess the predictive capability of the models, through selection of 
training and test sets. Although there have been previous attempts to model air to 
tissue and blood to tissue distributions, these have all used much smaller data sets 
and, except for blood to brain distributions, have not assessed at all the predictive 
capability of the obtained models.
The determination of blood to tissue distributions for drugs is difficult (due to 
compound instability and confounding impurities) and time-consuming, requiring 
animal experiments and synthesis (sometimes in radiolabelled form) of the 
compounds to be tested. That is why it is desirable that equations can be constructed
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to predict these distributions computationally with reasonable accuracy. This will 
therefore allow rejection of unsuitable candidates early on in drug discovery and will 
have a significant impact on drug research and development.
Future work
There are new data being published on blood to brain distribution for drugs, 
with respect to different compartments of the brain. These include: pituitary gland, 
hypothalamus, hippocampus, striatum, thalamus, cerebellum, amygdyla, caudate 
putamen, frontal cortex, globus pallidus, hippocampus, nucleus accumbens and 
septum. There are possibilities for future work to make models to predict 
distribution of drugs from blood to the different regions of the brain at steady-state 
concentrations.
The databases of compounds studied in the blood to tissue distribution model 
are mainly VOCs and drug compounds. Currently, there are new datasets being 
published for dioxin blood to tissue distribution in rats. It would be interesting to see 
how the various equations may look, if this new dataset is combined with the current 
model used in this thesis. Unfortunately, due to limited time, this was not possible 
during this project and would be a very suitable subject for future work.
Above a third of drugs are zwitterions, thus it would be useful to find a way in 
the future to obtain descriptors for these compounds, in order to predict blood to 
tissue distributions for zwitterionic drugs.1 Recently, there have been published a 
small amount of data for blood to tissue distribution, for the following tissues: 
adipose, bone, testes, ovary, stomach, pancreas, bile, adrenal gland, placenta, 
cerebrospinal fluid, trachea, ileum and spleen. It would be very interesting to find 
out if it is possible to obtain correlative and predictive models for these tissues. If 
so, how would the new equations compare in terms of coefficients, with the current 
models obtained in the present work?
In addition, small amounts of drug data (in vivo) have recently been published 
for blood to tissue distribution in the following species: humans, pregnant rats, 
mouse, rabbits, monkeys, guinea pigs, and dogs. It would be interesting to find out 
whether it is possible to make correlative and predictive models for blood to tissue 
distribution in these species too.
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Tables for distribution data
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Table 9.0. Air to blood distribution for VOCs
S O L U T E
N A M E
E s A B L H U M A N
R E F
H U M A N  
L O G  K
R A T
R E F
R A T  
L O G  K
C O M B I N E D
R E F
A V E R A G E  
L O G  K
1,1,1,2-T etrachloroethane 0.542 0.630 0.100 0.080 3.641 1 ,6 ,7 1.48 6 ,7 1.62 1 ,6 ,7 1.55
1,1,1 -Trichloroethane 
(Methyl chloroform) 0.369 0.410 0.000 0.090 2.733
1,4, 5, 6 , 
7 0.50 6 ,7 0.76 1,4, 5, 6 ,7 0.63
1,1,2,2-Tetrachloroethane 0.595 0.760 0.160 0.120 3.803 1,4, 6 , 7, 2.11 6 , 7, 2.15 1, 4, 6 , 7 2.13
1,1,2-Trichloroethane 0.499 0.680 0.130 0.130 3.290 1,4, 6 ,7 1.58 6 ,7 1.76 1,4, 6 ,7 1.67
1,1 -Dichloroethane 0.322 0.490 0.100 0.100 2.316 1,4, 6 ,7 0.70 6 ,7 1.05 1,4, 6 ,7 0.88
1,2,4-Trimethylbenzene 
(Pseudocumene) 0.677 0.560 0.000 0.190 4.441 7, 1.77 16, 17 1.16 7, 16, 17 1.47
1,2-Dichloroethane 0.416 0.640 0.100 0.110 2.573 1, 4, 6 , 7 1.30 6 ,7 1.48 1,4, 6 ,7 1.39
1,2-Dichloropropane 0.371 0.680 0.000 0.150 2.866 1,4, 6,7 1.01 6,7 1.27 1,4, 6,7 1.14
1 -Bromo-2-chloroethane
(1 -Chloro-2-Bromoethane) 0.572 0.700 0.100 0.090 2.982 6 ,7 1.47 6,7 1.72 6 ,7 1.60
1-Butanol 0.224 0.420 0.370 0.480 2.601 4, 7, 2.97 7, 3.19 4 ,7 3.08
1-Chloropropane (Propyl chloride) 0.216 0.400 0.000 0.100 2.202 1, 6 , 7, 0.46 6 , 7, 0.72 1,6,7 0.59
1-Nitropropane 0.240 0.950 0.000 0.310 2.894 6,7 2.27 6 ,7 2.35 6 ,7 2.31
1-Pentanol 0.219 0.420 0.370 0.480 3.106 7, 2.73 7, 2.92 7, 2.83
1-Propanol 0.236 0.420 0.370 0.480 2.031 1,5,7 2.99 7, 3.13 1,5,7 3.06
2,2,4-Trimethylpentane (Isooctane) 0.000 0.000 0.000 0.000 3.106 6,7 0.20 6,7 0.25 6,7 0.23
2-Chloropropane 0.177 0.350 0.000 0.120 1.970 6,7 0.14 6 , 7, 0.49 6,7 0.32
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2-Heptanone (Methyl pentyl ketone) 0.123 0.680 0.000 0.510 3.760 1,7 2.30 7, 2.35 1,7 2.33
2-Methyl-1,3-butadiene (Isoprene) 0.313 0.230 0.000 0.100 2.101 2 , -0.12 2, 6 ,7 0.32 2, 6 ,7 0.10
2-Methyl-1-propanol (Isobutanol) 0.217 0.390 0.370 0.480 2.413 1,4, 5,7 2.89 7, 2.94 1,4, 5,7 2.92
2-Nitropropane 0.216 0.920 0.000 0.330 2.550 6 ,7 2.19 6 ,7 2.26 6 ,7 2.23
2-Pentanone (Methyl propyl ketone) 0.143 0.680 0.000 0.510 2.755 1, 2.18 7, 2.10 1,7 2.14
2-Propanol (Isopropanol) 0.212 0.360 0.330 0.560 1.764 1,4, 5,7 2.92 7, 3.11 1,4, 5,7 3.02
3-Methyl-1-butanol (Isopentanol) 
(Isoamyl alcohol) 0.192 0.390 0.370 0.480 3.011 7, 2.58 7, 22 2.92 7, 22 2.75
4-Chlorobenzotrifluoride 0.530 0.580 0.000 0.010 3.730 10, 1.22 10, 1.64 10, 1.43
4-Methyl-2-pentanone (Methyl isobutyl 
ketone) 0.111 0.650 0.000 0.510 3.089 1,4, 7, 2.01 7, 1.90 1,4,7 1.96
Acetone (Propan-2-one) 0.179 0.700 0.040 0.490 1.696 1,4, 5,7 2.35 7, 22 2.37 1, 4, 5, 7, 22 2.36
Benzene 0.610 0.520 0.000 0.140 2.786 1,5, 6,7 0.87 6 , 7,17 1.22 1,5, 6 , 7, 17 1.05
Carbon tetrachloride 
(T etrachloromethane) 0.458 0.380 0.000 0.000 2.823 1,4, 6 , 7, 0.57 6 , 7, 0.66 1,4, 6,7 0.62
Bromochloromethane
(Chlorobromomethane) 0.541 0.800 0.010 0.060 2.445 4, 0.79 6 , 7, 1.62 4, 6 ,7 1.21
Bromodichloromethane 0.593 0.690 0.100 0.040 2.891 32, 1.42 31,33 1.56 31,32,  33 1.49
Butyl acetate 0.071 0.600 0.000 0.450 3.353 7, 1.92 7, 1.95 7, 1.94
Butan-2-one (Methyl ethyl ketone) 0.166 0.700 0.000 0.510 2.287 1,4, 5,7 2.19 7, 2.28 1,4, 5,7 2.24
CF3CBrClH (Halothane) 0.102 0.380 0.150 0.050 2.177 1,5,7 0.40 7, 12 0.73 1, 5, 7, 12 0.57
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CF3CH2C1 (2chlorol 1 ltrifluoroethane) 
(1 -Chloro-2,2,2-tTifluroethane) 0.010 0.400 0.150 0.000 1.168 1,5,7 0.18 6 , 7, 0.10 1, 5, 6 , 7 0.14
CHF20CF2CHFC1 (Enflmane) -0.230 0.400 0.120 0.130 1.750 1,5,7,  26 0.25 26, 0.45 1,5,7,  26 0.35
CHF20CHC1CF3 (Isoflurane) -0.240 0.500 0.100 0.100 1.576 1,5,7 0.15 6 , 7, 0.25 1,5, 6,7 0.20
Chlorobenzene 0.718 0.650 0.000 0.070 3.657 1,6,7 1.48 6 ,7 1.77 1,6,7 1.63
Chlorodibromomethane 0.775 0.710 0.070 0.080 3.304 6 , 7, 32 1.71 6 , 7,31 2.04 6 , 7,31,32 1.88
Chloroethane 0.227 0.400 0.000 0.100 1.678 1,6,7 0.36 6,7 0.61 1,6,7 0.49
Chloroform (Trichloromethane) 0.425 0.490 0.150 0.020 2.480
1,4,5,  6 , 
7, 32 0.98 7,31 1.32
1,4, 5, 6 , 7, 
31,32 1.15
cis-1,2-Dichloroethylene 0.436 0.610 0.110 0.050 2.4390 1,6, 7, 0.98 6 , 7, 1.33 1,6,7 1.16
Cyclohexane 0.305 0.100 0.000 0.000 2.964 1,4, 5,6 0.19 6 ,7 0.14 1,4, 5, 6,7 0.17
Cyclopropane 0.408 0.230 0.000 0.000 1.314 1,5,7,  26 -0.29 26, -0.12 1,5,7,  26 -0.21
Decane 0.000 0.000 0.000 0.000 4.686 4, 1.92 7, 17 1.02 4, 7, 17 1.47
Dichloromethane (Methylene chloride) 0.387 0.570 0.100 0.050 2.019
1,4,5,  6 , 
7 0.95 6 ,7 1.29 1,4,5,  6,7 1.12
Diethyl ether 0.041 0.250 0.000 0.450 2.015 1,5, 7, 26 1.09 7, 26 1.12 1, 5,7,  26 1.11
Ethane 0.000 0.000 0.000 0.000 0.492 1,26 -1.07 7, 26 -0.97 1,7, 26 - 1.02
Ethanol 0.246 0.420 0.370 0.480 1.485 1,4, 5,7 3.17 7, 3.37 1,4, 5, 7 3.27
Ethene 0.107 0.100 0.000 0.070 0.289 1,7, 29 -0.75 29, -0.31 1,7, 29 -0.53
Ethyl acetate 0.106 0.620 0.000 0.450 2.314 4 ,7 1.91 7, 22 1.89 4, 7, 22 1.90
Ethylbenzene 0.613 0.510 0.000 0.150 3.778 1,4,7 1.45 7, 1.48 1,4,7 1.47
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Ethylene Oxide 0.250 0.740 0.070 0.320 1.371 29, 1.79 23, 1.81 23,29 1.80
Heptane 0.000 0.000 0.000 0.000 3.173
1,4, 5, 6 , 
7 0.42 6 , 7,17 0.58 1,4, 5, 6 , 7,17 0.50
Hexachloroethane (Perchloroethane) 0.680 0.680 0.000 0.000 4.718 6 ,7 1.72 6 , 7, 1.80 6 ,7 1.76
Hexane 0.000 0.000 0.000 0.000 2.668 1,4, 5, 7 0.07 6 , 7, 17 0.35 1,4,5,  6 , 7,17 0.21
Isobutyl acetate 0.052 0.570 0.000 0.470 3.161 7, 1.65 7, 1.72 7, 1.69
Isopentylacetate (Aceticacidpentylester) 0.051 0.570 0.000 0.470 3.740 7, 1.77 7, 1.81 7, 1.79
Isopropyl acetate 0.055 0.570 0.000 0.470 2.546 4 ,7 1.54 7, 1.55 4 ,7 1.55
Isopropyl bromide (2-Brompropane) 0.332 0.350 0.000 0.140 2.390 6 , 7, 0.41 6 , 7 ,8 0.86 6 , 7 ,8 0.64
JP-10 0.590 0.450 0.000 0.060 4.840 6 , 1.72 6 , 1.79 6 , 1.76
MeOCF2CHC12 (Methoxyflurane) 0.109 0.670 0.070 0.140 2.864 1,5,7 1.16 7, 1.40 1,5,7 1.28
Methanol 0.278 0.440 0.430 0.470 0.970 1,4, 5, 7 3.29 7, 3.52 1,4,5,  7 3.41
Methyl acetate 0.142 0.640 0.000 0.450 1.911 7, 1.95 7, 2.00 7, 1.98
Methyl tertiary-butyl ether (MT BE) 0.024 0.210 0.000 0.590 2.380 7, 19 1.25 11, 19 1.11 7, 11, 19 1.18
Methylchloride (Chloromethane) 0.249 0.430 0.000 0.080 1.163 1,6,7 0.23 6 ,7 0.39 1,6,7 0.31
Methylcyclohexane 0.244 0.060 0.000 0.000 3.319 4, 0.61 17, 0.79 4,17 0.70
m-Xylene (1,3-Dimethylbenzene) 0.623 0.520 0.000 0.160 3.839 1,4, 6,7 1.51 6,7 1.66 1,4, 6,7 1.59
Nonane 0.000 0.000 0.000 0.000 4.182 4, 1.70 16, 17 0.63 4, 16, 17 1.17
Octane 0.000 0.000 0.000 0.000 3.677 4, 0.61 7, 17 0.74 4, 7, 17 0.68
o-Xylene 0.663 0.560 0.000 0.160 3.939 1,7 1.53 7, 17 1.30 1,7,17 1.42
Pentyl acetate 0.067 0.600 0.000 0.450 3.844 7, 1.97 7, 1.99 7, 1.98
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Propene (Propylene) 0.103 0.080 0.000 0.070 0.946 3, -0.36 3, -0.06 3, -0.21
Propyl acetate 0.092 0.600 0.000 0.450 2.819 7, 1.87 7, 1.88 7, 1.88
Propyl bromide (1-Bromopropane) 0.366 0.400 0.000 0.120 2.620 6,7 0.85 6 , 7 ,8 1.09 6 , 7 ,8 0.97
p-Xylene 0.613 0.520 0.000 0.160 3.839 1,4, 6,7 1.60 6 ,7 1.62 1, 4, 6 , 7 1.61
Styrene (Vinyl benzene) 0.849 0.650 0.000 0.160 3.856 1,4,7 1.73 6 ,7 1.60 1,4, 6,7 1.67
Sulphur Hexafluoride -0.600 -0.200 0.000 0.000 -0.120 1,26 -2.22 26, -2.12 1,26 -2.17
t-butanol (tert-butanol)(TBA) 
(2-Methyl-2-propanol) 0.180 0.300 0.310 0.600 1.963 7, 19 2.66 11, 19 2.70 7,11,19 2.68
tertiary-Amyl methyl ether (TAME) 0.050 0.210 0.000 0.600 2.916 19 1.25 19, 1.19 19, 1.22
Tetrachloroethene (Perchloroethylene) 0.639 0.440 0.000 0.000 3.584 1,4, 6,7 1.09 6 ,7 1.28 1,4, 6,7 1.19
Toluene 0.601 0.520 0.000 0.140 3.325 1,4,5 1.12 6 , 7, 17 1.16 1,4, 5, 6 , 7, 17 1.14
trans-1,2-Dichloroethylene 0.425 0.410 0.090 0.050 2.278 1,6,7 0.77 6 ,7 0.98 1,6,7 0.88
Tribromomethane (Bromoform) 0.974 0.680 0.150 0.060 3.784 4, 32 2.02 31, 2.27 4,31,32 2.15
Trichloroethene (Trichloroethylene) 0.524 0.370 0.080 0.030 2.997
1,4,5,  6 , 
7 0.94
6 , 7, 27, 
28 1.33
1,4, 5, 6 , 7, 
27, 28 1.14
Vinyl bromide (Bromoethene) 0.564 0.500 0.000 0.070 1.846 6 ,7 0.36 6,7 0.61 6 ,7 0.49
Vinyl chloride (Chloroethene) 0.258 0.380 0.000 0.050 1.404 6 , 7, 30 0.06
6 , 7, 27, 
30 0.27 6 , 7, 27, 30 0.17
Propylbenzene 0.604 0.500 0.000 0.150 4.230 1,7 1.67 1,7 1.67
(CF3)2CHOCH2F (Sevoflurane) -0.465 0.232 0.080 0.147 1.688 1,5,7 -0.20 1,5,7 -0.20
1,2,3-Trichloropropane 0.547 0.650 0.020 0.330 3.566 4, 2.01 4, 2.01
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1,2,3-Trimethylbenzene (Hemimellitene) 0.728 0.610 0.000 0.190 4.565 7, 1.82 7, 1.82
1,2-Dichlorobenzene 
(o-Dichlorobenzene) 0.872 0.780 0.000 0.040 4.518 1,7 2.63 1,7 2.63
1, 3,5 -T rime thy lbenzene (Mesitylene) 0.649 0.520 0.000 0.190 4.344 4 ,7 1.64 4 ,7 1.64
1,3-Butadiene 0.320 0.230 0.000 0.100 1.543 21 , 0.09 2 1 , 0.09
1,3-Dichlorobenzene 
(m-D ichlorobenzene) 0.847 0.730 0.000 0.020 4.410 1,7 2.30 1,7 2.30
1-Chlorobutane 0.210 0.400 0.000 0.100 2.722 1,7 0.63 1,7 0.63
1-Chloropentane 0.208 0.380 0.000 0.090 3.223 1,7 0.87 1,7 0.87
1-Fluropropane 0.034 0.350 0.000 0.130 1.103 1, 0.02 1, 0.02
1 -Methoxy-2-propanol 0.218 0.610 0.350 0.620 2.655 7, 20 4.09 7, 20 4.09
2,2-Dimethylbutane 0.000 0.000 0.000 0.000 2.352 1,5,7 -0.59 1,5,7 -0.59
2,3-Dimethylbutane 0.000 0.000 0.000 0.000 2.495 4 0.78 4 0.78
2-Butoxyethanol 0.201 0.500 0.300 0.830 3.806 7, 20 3.90 7, 20 3.90
2-Ethoxyethanol 0.237 0.520 0.310 0.810 2.792 7, 20 4.34 7, 20 4.34
2-Fluropropane 0.004 0.320 0.000 0.100 1.070 1, 0.06 1, 0.06
2-Hexanone 0.136 0.680 0.000 0.510 3.286 1, 2.10 1, 2.10
2 -Isopropoxyethanol 0.196 0.470 0.300 0.910 3.170 7, 20 4.16 7, 20 4.16
2-Methoxyethanol 0.269 0.500 0.300 0.840 2.490 7, 20 4.52 7, 20 4.52
2-Methylcyclohexanone
(o-Metbylcyclohexanone) 0.372 0.830 0.000 0.560 4.055 4, 2.87 4, 2.87
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2-Methylpentane (Isohexane) 0.000 0.000 0.000 0.000 2.503 1,5,7 -0.39 1,5,7 -0.39
3-Methylhexane 0.000 0.000 0.000 0.000 3.044 1,5,7 0.11 1,5,7 0.11
3-Methylpentane 0.000 0.000 0.000 0.000 2.581 1,5,7 -0.37 1,5,7 -0.37
3-Pentanone (Diethyl ketone) 0.154 0.660 0.000 0.510 2.811 1,7 2.21 1,7 2.21
Acetylene 0.190 0.600 0.060 0.040 0.140 1, -0.06 1, -0.06
Allylbenzene 0.717 0.600 0.000 0.220 4.136 1, 7 1.71 1, 7 1.71
Argon 0.000 0.000 0.000 0.000 -0.688 1, -1.52 1, -1.52
Carbon Disulfide 0.876 0.260 0.000 0.030 2.370 1, 0.30 1, 0.30
Carbon Monoxide 0.000 0.000 0.000 0.040 -0.836 1, -1.67 1, -1.67
CF2=CHC1 (1 -Chloro-2,2-difluroethylene) 
(1,1 -Difluro-2-chloroethene) -0.340 0.290 0.150 0.000 0.723 1,5 0.06 1,5 0.06
CF2C1CF2C1
(1,2-Dichlorotetrafluoroethane) -0.190 0.050 0.000 0.000 1.427 1, -0.82 1, -0.82
CF2HCF2CF2CF2H -0.710 0.040 0.090 0.000 0.590 7, -0.36 7, -0.36
CF2HCF2CFH2 -0.450 0.170 0.000 0.030 0.680 7, -0.48 7, -0.48
CF2HCF2H (1,1,2,2-Tetrafluoroethane) -0.280 -0.300 0.300 0.000 0.289 7, -0.12 7, -0.12
CF2HCFHCH2CF2H -0.500 1.250 0.120 0.130 2.324 7, 0.87 7, 0.87
CF2HCH3 (1,1 -Difluroethane) -0.250 0.490 0.040 0.050 0.517 7, 0.42 7, 0.42
CF3CBrFH (Teflurane) -0.070 0.210 0.200 0.020 1.370 1,7 -0.22 1,7 -0.22
CF3CF2CF2CF2H -0.780 -0.300 0.100 0.100 0.420 7, -1.52 7, -1.52
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CF3CFH2 (Norflurane) 
(1,1,1,2-T etrafluoroethane) -0.640 0.200 0.240 0.000 0.226 7, -0.25 7, -0.25
CF3CFHCFHCF3 -0.710 -0.090 0.090 0.040 0.590 7, -0.59 7, -0.59
CF3CH20CH=CH2 
(Fluomar/ Fluroxene) 0.183 0.300 0.000 0.270 1.600 1,5,7 0.15 1,5,7 0.15
CF4 (Perfluoromethane) 
(Carbon Tetrafluoride) -0.550 -0.200 0.000 0.000 -0.819 7, - 1.10 7, - 1.10
CHF2CF2CH2Br (Halopropane) -0.070 0.280 0.200 0.000 2.030 1, 0.75 1, 0.75
CHF20CHFCF3 (Desflurane) -0.540 0.270 0.070 0.170 0.740 1, -0.37 1, -0.37
Cyclohexanone 0.403 0.860 0.000 0.560 3.792 4, 3.33 4, 3.33
Diflurodichloromethane 0.037 0.130 0.000 0.000 1.124 1, -0.82 1, -0.82
Dimethyl ether 0.000 0.270 0.000 0.410 1.285 1, 1.16 1, 1.16
Divinyl ether 0.259 0.390 0.000 0.130 1.760 1,5,7 0.41 1,5,7 0.41
Ethyl formate 0.146 0.660 0.000 0.380 1.845 1, 1.65 1, 1.65
Ethyl t-butyl ether (ETBE) -0.020 0.160 0.000 0.600 2.720 7, 19 1.07 7, 19 1.07
Ethyl t-pentyl ether 0.030 0.230 0.000 0.370 3.200 7, 1.25 7, 1.25
Fluoroethane 0.052 0.350 0.000 0.100 0.576 1, 0.09 1, 0.09
Fluorotrichloromethane
(Trichlorofluromethane) 0.207 0.240 0.000 0.070 1.950 1, -0.06 1, -0.06
Helium 0.000 0.000 0.000 0.000 -1.741 1, -2.00 1, -2.00
Hydrogen 0.000 0.000 0.000 0.000 - 1.200 1, -1.77 1, -1.77
402
Iodoethane 0.640 0.400 0.000 0.150 2.573 1, 0.83 1, 0.83
Isophorone
(3,5,5-trimethylcyclohex-2-en-1 -one) 0.511 1.120 0.000 0.530 4.740 4, 3.37 4, 3.37
Isopropylbenzene (Cumene) 0.602 0.490 0.000 0.160 4.084 1,7 1.57 1,7 1.57
Krypton 0.000 0.000 0.000 0.000 -0.211 1, - 1.22 1, - 1.22
Methane 0.000 0.000 0.000 0.000 -0.323 1, -1.42 1, -1.42
Methyl butyl ketone 
(3-Methylpentan-2-one) 0.110 0.650 0.000 0.510 3.163 7, 2.23 7, 2.23
Methylcyclopentane 0.225 0.100 0.000 0.000 2.907 1,5,7 -0.07 1,5,7 -0.07
Neon 0.000 0.000 0.000 0.000 -1.575 1, -2.01 1, -2.01
Nitrogen 0.000 0.000 0.000 0.000 -0.978 1, -1.83 1> -1.83
Nitrous Oxide 0.068 0.350 0.000 0.100 0.164 1,5 -0.34 1,5 -0.34
Oxygen 0.000 0.000 0.000 0.000 -0.723 1, -1.58 1, -1.58
Pentane 0.000 0.000 0.000 0.000 2.162 1,4, 5,7 -0.29 1,4, 5, 7 -0.29
Xenon 0.000 0.000 0.000 0.000 0.378 1,5 -0.85 1,5 -0.85
1,1 -Dichloro-1 -Fluoroethane 
(HCFC-141b) 0.084 0.430 0.010 0.050 1.920 13, 0.32 13, 0.32
1,1 -Dichloroethylene 0.362 0.340 0.000 0.050 2.110 6 ,7 0.70 6 ,7 0.70
1,2,4-Trifluorobenzene 0.410 0.650 0.000 0.020 2.850 7, 0.76 7, 0.76
1,2,4-Trimethylcyclohexane 0.360 0.210 0.000 0.000 4.100 16, 17 0.87 16, 17 0.87
1,2-Dibromoethane 0.747 0.760 0.100 0.170 3.382 6 , 7, 2.08 6 , 7, 2.08
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1,2-Diflurobenzene (o-Diflurobenzene) 0.390 0.630 0.000 0.060 2.843 7, 0.96 7, 0.96
1,2-Dimethylcyclohexane 0.320 0.230 0.000 0.000 3.800 17, 0.91 17, 0.91
l,2-Epoxy-3-butene (BMO) 0.370 0.470 0.000 0.360 2.257 24, 1.97 24, 1.97
1,3,5-Triflurobenzene 0.390 0.490 0.000 0.000 2.660 7, 0.49 7, 0.49
1,4-Diflurobenzene (p-Diflurobenzene) 0.384 0.600 0.000 0.060 2.766 7, 0.87 7, 0.87
1-Decene 0.093 0.080 0.000 0.070 4.533 18, 1.21 18, 1.21
1-Hexanol 0.210 0.420 0.370 0.480 3.610 7, 3.21 7, 3.21
1-Nonene 0.900 0.080 0.000 0.070 4.073 18, 1.18 18, 1.18
1-Octene 0.094 0.080 0.000 0.070 3.568 18, 1.07 18, 1.07
2,2-Dichloro-l, 1,1-Trifluroethane
(HCFC-123) -0.160 0.400 0.220 0.000 1.746 12, 0.61 12, 0.61
2,3,4-Trimethylpentane 0.000 0.000 0.000 0.000 3.481 6,7 0.57 6 ,7 0.57
2-Methyl heptane 0.000 0.000 0.000 0.000 3.480 18, 0.49 18, 0.49
2-Methyl nonane 0.000 0.000 0.000 0.000 4.453 18, 0.76 18, 0.76
2-Methyl octane 0.000 0.000 0.000 0.000 3.966 18, 0.52 18, 0.52
Allyl chloride (3-Chloro-l-propylene) 0.327 0.560 0.000 0.050 2.109 6,7 1.24 6,7 1.24
Bromobenzene 0.882 0.730 0.000 0.090 4.041 22 , 1.72 22 , 1.72
Butane 0.000 0.000 0.000 0.000 1.615 7, -0.53 7, -0.53
Cyanoethylene Oxide 0.390 1.000 0.000 0.520 2.543 25, 3.22 25, 3.22
Cycloheptane 0.350 0.100 0.000 0.000 3.704 7, 0.72 7, 0.72
Cyclopentane 0.263 0.100 0.000 0.000 2.477 7, 0.24 7, 0.24
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Dibromomethane 0.714 0.690 0.110 0.070 2.886 6,7 1.87 6 ,7 1.87
Difluromethane (CF2H2) -0.320 0.490 0.060 0.050 0.040 6,7 0.20 6,7 0.20
Fluorobenzene 0.477 0.570 0.000 0.100 2.788 7, 1.06 7, 1.06
Flurochloromethane -0.080 0.270 0.090 0.030 1.030 6,7 0.71 6 ,7 0.71
Furan 0.369 0.510 0.000 0.130 1.913 9, 0.82 9, 0.82
Hexaflurobenzene 0.088 0.560 0.000 0.010 2.345 7, 0.39 7, 0.39
Methylpentaflurobenzene
(2,3,4,5,6-Pentyllluorotoluene) 0.240 0.450 0.040 0.000 0.946 7, 0.73 7, 0.73
m-Methylstyrene
(1 -vinyl-3-me thy lbenzene) 0.866 0.650 0.000 0.180 4.375 6 ,7 2.28 6 ,7 2.28
Pentachloroethane 0.648 0.660 0.170 0.060 4.267 6,7 2.02 6 ,7 2.02
Pentaflurobenzene 0.154 0.680 0.000 0.020 2.578 7, 0.51 7, 0.51
p-Methylstyrene 
(1 -vinyl-4-methylbenzene) 0.871 0.650 0.000 0.180 4.399 6,7 2.37 6 ,7 2.37
Radon 0.000 0.000 0.000 0.000 0.877 15, -0.39 15, -0.39
t-Butylbenzene 0.619 0.490 0.000 0.180 4.413 17, 1.24 17, 1.24
t-Butylcyclohexane 0.300 0.100 0.000 0.100 4.603 17, 1.16 17, 1.16
tertiary-amyl alcohol (TAA) 0.194 0.300 0.310 0.600 2.630 19, 2.59 19, 2.59
405
Vinylidene fluoride
(1,1-Difluoroediylene) -0.100 0.000 0.000 0.050 0.240 14, -0.74 14, -0.74
Table 9.1. Air to tissue (brain, fat, kidney, liver, lung, muscle and plasma) distribution for VOCs
TISSUE SOLUTE NAME E S A B L TISSUE
REF
HUMAN 
LOG K
TISSUE
REF
RAT 
LOG K
LUNG (CF3)2CHOCH2F (Sevoflurane) -0.465 0.232 0.080 0.147 1.688 1,5 0.11 1,5, 0.11
LUNG Propene (Propylene) 0.103 0.080 0.000 0.070 0.946 3, -0.21 3, -0.27
PLASMA Acetone (Propan-2-one) 0.179 0.700 0.040 0.490 1.696 1, 2.54 26, 2.20
PLASMA Cyclopropane 0.408 0.230 0.000 0.000 1.314 1, -0.62 26, -0.63
PLASMA Diethyl ether 0.041 0.250 0.000 0.450 2.015 1, 1.08 26, 1.16
PLASMA Ethane 0.000 0.000 0.000 0.000 0.492 1, -1.34 26, -1.44
PLASMA Sulphur Hexafluoride -0.600 -0.200 0.000 0.000 -0.120 1, -2.28 26, -2.41
FAT 1,1,1-Trichloroethane (Methyl chloroform) 0.369 0.410 0.000 0.090 2.733 1, 5 2.40 6,7 2.42
FAT 1-Propanol 0.236 0.420 0.370 0.480 2.031 1,5,7 2.47 7, 2.60
FAT 2-Methyl-1 -propanol (Isobuta nol) 0.217 0.390 0.370 0.480 2.413 1,5,7 2.59 7, 2.86
FAT 2-Propanol (Isopropanol) 0.212 0.360 0.330 0.560 1.764 1,5,7 2.26 7, 2.44
FAT Acetone (Propan-2-one) 0.179 0.700 0.040 0.490 1.696 1,5,7 1.93 7, 1.89
406
FAT Benzene 0.610 0.520 0.000 0.140 2.786 1,5,7 2.62 6 , 7, 17 2.65
FAT Butan-2-one (Methyl ethyl ketone) 0.166 0.700 0.000 0.510 2.287 1,5,7 2.21 7, 2.30
FAT CF3CBrClH (Halothane) 0.102 0.380 0.150 0.050 2.177 1,5,7 2.31 6 , 7, 12 2.23
FAT
CF3CH2C1 (2chlorol 1 Itrifluoroethane) 
(1 -Chloro-2,2,2-trifluroethane) 0.010 0.400 0.150 0.000 1.168
1,5,7
1.53 6 ,7 1.33
FAT CHF20CHC1CF3 (Isoflurane) -0.240 0.500 0.100 0.100 1.576 1,5,7 1.84 6 ,7 1.99
FAT Chloroform (Trichloromethane) 0.425 0.490 0.150 0.020 2.480 1,5,7 2.45 6 ,7 2.31
FAT Cyclohexane 0.305 0.100 0.000 0.000 2.964 1,5,7 2.41 6 , 7,17 2.47
FAT Dichloromethane (Methylene chloride) 0.387 0.570 0.100 0.050 2.019 1,5,7 1.93 6 ,7 2.08
FAT Diethyl ether 0.041 0.250 0.000 0.450 2.015 1,5,7 1.80 6 ,7 1.68
FAT Ethanol 0.246 0.420 0.370 0.480 1.485 1,5,7 2.33 7 2.35
FAT Ethylbenzene 0.613 0.510 0.000 0.150 3.778 7, 3.25 7 3.19
FAT Ethylene Oxide 0.250 0.740 0.070 0.320 1.371 29 1.63 23 1.64
FAT Ethylene (Ethene) 0.107 0.100 0.000 0.070 0.289 1, 7, 29 0.08 29 0.31
FAT Heptane 0.000 0.000 0.000 0.000 3.173 1,5,7 2.59 6 , 7, 17 2.42
FAT Hexane 0.000 0.000 0.000 0.000 2.668 1,5,7 2.02 6, 7,17 2.22
FAT Methanol 0.278 0.440 0.430 0.470 0.970 5,7 2.36 7, 2.29
FAT m-Xylene (1,3-Dimethylbenzene) 0.623 0.520 0.000 0.160 3.839 7, 3.28 6 ,7 3.30
FAT Octane 0.000 0.000 0.000 0.000 3.677 1,7 2.71 17, 2.73
FAT o-Xylene (1,2-dimethylbenzene) 0.663 0.560 0.000 0.160 3.939 7, 3.39 6 , 7,17 3.00
FAT Propene (Propylene) 0.103 0.080 0.000 0.070 0.946 3, 0.71 3, 0.80
FAT p-Xylene (1,4-dimethylbenzene) 0.613 0.520 0.000 0.160 3.839 7, 3.31 6,7 3.24
407
FAT Styrene (Vinyl benzene) 0.849 0.650 0.000 0.160 3.856 7, 3.50 6 ,7 3.54
FAT Toluene (methylbenzene) 0.601 0.520 0.000 0.140 3.325 1,5,7 2.95 6 , 7, 17 2.89
FAT Trichloroethene (Trichloroethylene) 0.524 0.370 0.080 0.030 2.997 1,5,7 2.77 6 , 7, 28 2.72
FAT Vinyl chloride (Chloroethene) 0.258 0.380 0.000 0.050 1.404 30, 1.30 6 , 7, 30 1.30
LIVER 1,1,1-Trichloroethane (Methyl chloroform) 0.369 0.410 0.000 0.090 2.733 1,5,7 1.21 6,7 0.93
LIVER Benzene 0.610 0.520 0.000 0.140 2.786 1,5,7 1.36 6 , 7, 17 1.15
LIVER CF3CBrClH (Halothane) 0.102 0.380 0.150 0.050 2.177 1,5,7 0.86 6 , 7, 12 0.86
LIVER
CF3CH2C1 (2chlorol 1 Itrifluoroethane) 
(1 -Chloro-2,2,2-trifluroethane) 0.010 0.400 0.150 0.000 1.168 1,5,7 0.36 6 ,7 0.26
LIVER CHF20CHC1CF3 (Isoflurane) -0.240 0.500 0.100 0.100 1.576 1,5,7 0.55 6,7 0.57
LIVER Chloroform (Trichloromethane) 0.425 0.490 0.150 0.020 2.480 1,5,7 1.23 6 ,7 1.32
LIVER Cyclohexane 0.305 0.100 0.000 0.000 2.964 1,5,7 1.03 6 , 7, 17 1.06
LIVER Dichloromethane (Methylene chloride) 0.387 0.570 0.100 0.050 2.019 1,5,7 0.86 6,7 1.15
LIVER Diethyl ether 0.041 0.250 0.000 0.450 2.015 1,5,7 1.05 6 ,7 0.83
LIVER Ethylene (Ethene) 0.107 0.100 0.000 0.070 0.289 29, -0.35 29, -0.24
LIVER Heptane 0.000 0.000 0.000 0.000 3.173 1,5,7 1.04 6 , 7, 17 0.87
LIVER Hexane 0.000 0.000 0.000 0.000 2.668 1,5,7 0.72 6 , 7,17 0.65
LIVER MeOCF2CHC12 (Methoxyflurane) 0.109 0.670 0.070 0.140 2.864 1,5,7 1.46 7, 1.47
LIVER Octane 0.000 0.000 0.000 0.000 3.677 1,7 1.41 17, 0.99
LIVER Propene (Propylene) 0.103 0.080 0.000 0.070 0.946 3, -0.27 3, -0.29
• LIVER Toluene (Methylbenzene) 0.601 0.520 0.000 0.140 3.325 1,5,7 1.68 6 , 7, 17 1.60
LIVER Trichloroethene (Trichloroethylene) 0.524 0.370 0.080 0.030 2.997 1,5,7 1.41 6 , 7, 28 1.40
LIVER Vinyl chloride (Chloroethene) 0.258 0.380 0.000 0.050 1.404 30, 0.20 6 , 7, 30 0.20
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MUSCLE
1,1,1 -Trichloroethane 
(Methyl chloroform) 0.369 0.410 0.000 0.090 2.733 1,5,7 0.83 6 ,7 0.50
MUSCLE 1-Propanol 0.236 0.420 0.370 0.480 2.031 1,5,7 2.83 7, 3.06
MUSCLE 2-Methyl-1 -propanol (Isobutanol) 0.217 0.390 0.370 0.480 2.413 1,5,7 2.54 7, 2.93
MUSCLE 2-Propanol (Isopropanol) 0.212 0.360 0.330 0.560 1.764 1,5,7 2.70 7, 3.04
MUSCLE Acetone (Propan-2-one) 0.179 0.700 0.040 0.490 1.696 1,5,7 2.18 7, 2.23
MUSCLE Benzene 0.610 0.520 0.000 0.140 2.786 1,5,7 1.21 6,7 1.01
MUSCLE Butan-2-one (Methyl ethyl ketone) 0.166 0.700 0.000 0.510 2.287 1,5,7 2.01 7, 2.26
MUSCLE CF3CBrClH (Halothane) 0.102 0.380 0.150 0.050 2.177 1,5,7 0.83 6 ,7 0.65
MUSCLE
CF3CH2C1 (2chlorol I Itrifluoroethane) 
(1 -Chloro-2,2,2-trifluroethane) 0.010 0.400 0.150 0.000 1.168 1,5,7 0.34 6 ,7 0.09
MUSCLE CHF20CHC1CF3 (Isoflurane) -0.240 0.500 0.100 0.100 1.576 1,5,7 0.41 6 ,7 0.20
MUSCLE Chloroform (Trichloromethane) 0.425 0.490 0.150 0.020 2.480 1,5,7 1.09 6 ,7 1.14
MUSCLE Cyclohexane 0.305 0.100 0.000 0.000 2.964 1,5,7 1.02 6,7 0.01
MUSCLE Dichloromethane (Methylene chloride) 0.387 0.570 0.100 0.050 2.019 1,5,7 0.68 6,7 0.90
MUSCLE Diethyl ether 0.041 0.250 0.000 0.450 2.015 1,5,7 1.01 6,7 0.72
MUSCLE Ethanol 0.246 0.420 0.370 0.480 1.485 1,5,7 2.93 7, 3.23
MUSCLE Ethylene Oxide 0.250 0.740 0.070 0.320 1.371 29, 1.82 23, 1.68
MUSCLE Ethylene (Ethene) 0.107 0.100 0.000 0.070 0.289 29, -0.19 29, -0.20
MUSCLE Heptane 0.000 0.000 0.000 0.000 3.173 1,5,7 1.08 6 ,7 0.62
MUSCLE Hexane 0.000 0.000 0.000 0.000 2.668 1,5,7 0.70 6,7 0.46
MUSCLE Methanol 0.278 0.440 0.430 0.470 0.970 1,5,7 3.12 7, 3.60
MUSCLE Propene (Propylene) 0.103 0.080 0.000 0.070 0.946 3, -0.19 3, -0.34
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MUSCLE Toluene (methylbenzene) 0.601 0.520 0.000 0.140 3.325 1,5,7 1.54 6 ,7 1.44
MUSCLE Trichloroethene (Trichloroethylene) 0.524 0.370 0.080 0.030 2.997 1,5,7 1.25 6 ,7 1.00
KIDNEY 1-Propanol 0.236 0.420 0.370 0.480 2.031 1,5,7 2.84 7, 3.09
KIDNEY 2-Methyl-1-propanol (Isobutanol) 0.217 0.390 0.370 0.480 2.413 1,5,7 2.57 7, 2.94
KIDNEY 2-Propanol (Isopropanol) 0.212 0.360 0.330 0.560 1.764 1,5,7 2.70 7, 3.03
KIDNEY Benzene 0.610 0.520 0.000 0.140 2.786 1,5,7 1.08 17 1.51
KIDNEY Ethanol 0.246 0.420 0.370 0.480 1.485 1,5,7 2.97 7, 3.31
KIDNEY Ethylene (Ethene) 0.107 0.100 0.000 0.070 0.289 29, -0.44 29, -0.55
KIDNEY Heptane 0.000 0.000 0.000 0.000 3.173 1,5,7 0.95 17, 1.20
KIDNEY Hexane 0.000 0.000 0.000 0.000 2.668 1,5,7 0.48 17 1.41
KIDNEY Methanol 0.278 0.440 0.430 0.470 0.970 1,5,7 3.13 7, 3.50
KIDNEY Octane 0.000 0.000 0.000 0.000 3.677 1,7 0.91 17, 1.76
KIDNEY Propene (Propylene) 0.103 0.080 0.000 0.070 0.946 3, -0.35 3, -0.28
KIDNEY Toluene (methylbenzene) 0.601 0.520 0.000 0.140 3.325 1,5,7 1.26 17, 1.79
BRAIN 1-Propanol 0.236 0.420 0.370 0.480 2.031 1, 5, 7 2.87 7, 3.09
BRAIN 2-Methyl-1 -propanol (Isobutanol) 0.217 0.390 0.370 0.480 2.413 1,5,7 2.61 7, 2.94
BRAIN 2-Propanol (Isopropanol) 0.212 0.360 0.330 0.560 1.764 1,5,7 2.76 7, 3.05
BRAIN Benzene 0.610 0.520 0.000 0.140 2.786 1,5,7 1.26 17, 1.24
BRAIN CF3CBrClH (Halothane) 0.102 0.380 0.150 0.050 2.177 1,5,7 0.77 7, 0.65
BRAIN CHF20CHC1CF3 (Isoflurane) -0.240 0.500 0.100 0.100 1.576 1,5,7 0.46 7, 0.31
BRAIN Cyclohexane 0.305 0.100 0.000 0.000 2.964 1,5,7 1.04 17 1.52
BRAIN Ethanol 0.246 0.420 0.370 0.480 1.485 1,5,7 3.02 7, 3.27
BRAIN Ethylene Oxide 0.250 0.740 0.070 0.320 1.371 29, 1.84 23, 1.77
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BRAIN Ethylene (Ethene) 0.107 0.100 0.000 0.070 0.289 29, -0.26 29, -0.19
BRAIN Heptane 0.000 0.000 0.000 0.000 3.173 1,5,7 1.09 17, 0.79
BRAIN Hexane 0.000 0.000 0.000 0.000 2.668 1,5,7 0.70 17, 1.07
BRAIN MeOCF2CHC12 (Methoxyflurane) 0.109 0.670 0.070 0.140 2.864 1,5,7 1.41 7, 1.39
BRAIN Methanol 0.278 0.440 0.430 0.470 0.970 5,7 3.18 7, 3.54
BRAIN Octane 0.000 0.000 0.000 0.000 3.677 1,7 1.22 17, 1.52
BRAIN Propene (Propylene) 0.103 0.080 0.000 0.070 0.946 3, -0.22 3, -0.32
BRAIN Toluene (Methylbenzene) 0.601 0.520 0.000 0.140 3.325 1,5,7 1.56 17 1.26
BRAIN Trichloroethene (Trichloroethylene) 0.524 0.370 0.080 0.030 2.997 1,5,7 1.33 28, 1.16
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Table 10.0. Air to blood distribution for VOCs
SOLUTE NAME AVERAGE LOG K CALC LOG K
(CF3)2CHOCH2F (Sevoflurane) -0.20 0.28
1,1,1,2-T etrachloroethane 1.55 1.81
1,1,1-Trichloroethane (Methyl chloroform) 0.63 0.80
1,1,2 ,2 -Tetrachloroethane 2.13 2.36
1,1,2-Trichloroethane 1.67 1.95
1,1 -Dichloro-1 -Fluoroethane (HCFC- 141b) 0.32 0.32
1,1 -Dichloroethane 0.88 1.11
1,1 -Dichloroethylene 0.70 0.39
1,2,3-Trichloropropane 2.01 2.15
1,2,3-Trimethylbenzene (Hemimellitene) 1.82 2.13
1,2,4-Trifluorobenzene 0.76 0.94
1,2,4-Trimethylbenzene (Pseudocumene) 1.47 2.01
1,2,4-Trimethylcyclohexane 0.87 0.86
1,2-Dibromoethane 2.08 2.18
1,2-Dichlorobenzene (o-Dichlorobenzene) 2.63 1.97
1,2-Dichloroethane 1.39 1.44
1,2-Dichloropropane 1.14 1.30
1,2-Diflurobenzene (o-Diflurobenzene) 0.96 1.01
1,2-Dimethylcyclohexane 0.91 0.75
l,2-Epoxy-3-butene (BMO) 1.97 1.39
1,3,5-Triflurobenzene 0.49 0.64
1,3,5-Trimethylbenzene (Mesitylene) 1.64 1.91
1,3-Butadiene 0.09 0.16
1,3-Dichlorobenzene (m-Dichlorobenzene) 2.30 1.82
1,4-Diflurobenzene (p-Diflurobenzetie) 0.87 0.95
1 -Bromo-2-chloroethane 
(1 -Chloro-2-Bromoethane) 1.60 1.68
1-Butanol 3.08 3.09
1-Chlorobutane 0.63 0.74
1-Chloropentane 0.87 0.88
1-Chloropropane (Propyl chloride) 0.59 0.55
1-Decene 1.21 0.94
1-Fluropropane 0.02 0.08
1-Hexanol 3.21 3.46
1 -Methoxy-2-propanol 4.09 3.60
1-Nitropropane 2.31 1.96
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1-Nonene 1.18 1.14
1-Octene 1.07 0.58
1-Pentanol 2.83 3.27
1-Propanol 3.06 2.88
2,2,4-Trimethylpentane (Isooctane) 0.23 0.10
2,2-Dichloro-1,1,1 -Trifluroethane 
(HCFC-123) 0.61 0.77
2,2-Dimethylbutane -0.59 -0.18
2,3,4-Trimethylpentane 0.57 0.24
2,3 -Dimethylbutane 0.78 -0.13
2-Butoxyethanol 3.90 4.26
2-Chloropropane 0.32 0.44
2-Ethoxyethanol 4.34 3.90
2-Fluropropane 0.06 -0.06
2-Heptanone (Methyl pentyl ketone) 2.33 2.45
2-Hexanone 2.10 2.28
2-Isopropoxyethanol 4.16 4.19
2-Methoxyethanol 4.52 3.82
2-Methyl heptane 0.49 0.24
2-Methyl nonane 0.76 0.60
2-Methyl octane 0.52 0.42
2-Methyl-1,3-butadiene (Isoprene) 0.10 0.37
2-Methyl-1 -propanol (Isobutanol) 2.92 2.98
2-Methylcyclohexanone
(o-Methylcyclohexanone) 2.87 2.97
2-Methylpentane (Isohexane) -0.39 -0.13
2-Nitropropane 2.23 1.84
2-Pentanone (Methyl propyl ketone) 2.14 2.08
2-Propanol (Isopropanol) 3.02 2.76
3-Methyl-1-butanol (Isopentanol) 
(Isoamyl alcohol) 2.75 3.19
3-Methylhexane 0.11 0.08
3 -Methylpentane -0.37 -0.10
3-Pentanone (Diethyl ketone) 2.21 2.09
4-Chlorobenzotrifluoride 1.43 1.23
4-Methyl-2-pentanone (Methyl isobutyl ketone) 1.96 2.16
Acetone (Propan-2-one) 2.36 1.82
Acetylene -0.06 0.05
Allyl chloride (3-Chloro-l-propylene) 1.24 0.61
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Allylbenzene 1.71 2.03
Argon -1.52 -1.33
Benzene 1.05 1.18
Bromobenzene 1.72 1.87
Bromochloromethane (Chlorobromomethane) 1.21 1.16
Bromodichloromethane 1.49 1.51
Butan-2-one (Methyl ethyl ketone) 2.24 1.94
Butane -0.53 -0.46
Butyl acetate 1.94 2.03
Carbon Disulfide 0.30 0.58
Carbon Monoxide -1.67 -1.28
Carbon tetrachloride (Tetrachloromethane) 0.62 0.61
CF2=CHC1 (1 -Chloro-2,2-difluroethylene) 
(1,1 -Difluro-2-chloroethene) 0.06 -0.08
CF2C1CF2C1 (1,2-Dichlorotetrafluoroethane) -0.82 -0.56
CF2HCF2CF2CF2H -0.36 -0.79
CF2HCF2CFH2 -0.48 -0.76
CF2HCF2H (1,1,2,2-Tetrafluoroethane) -0.12 -0.29
CF2HCFHCH2CF2H 0.87 1.71
CF2HCH3 (1,1 -Difluroethane) 0.42 -0.18
CF3CBrClH (Halothane) 0.57 0.90
CF3CBrFH (Teflurane) -0.22 0.44
CF3CF2CF2CF2H -1.52 -0.96
CF3CFH2 (Norfiurane) 
(1,1,1,2-Tetrafluoroethane) -0.25 -0.16
CF3CFHCFHCF3 -0.59 -0.83
CF3CH2C1 (2chlorol 1 Itrifluoroethane) 
(1 -Chloro-2,2,2-trifluroethane) 0.14 0.37
CF3CH20CH=CH2 (Fluomar/ Fluroxene) 0.15 0.64
CF4 (Perfluoromethane)(Carbon Tetrafluoride) - 1.10 -1.84
CHF2CF2CH2Br (Halopropane) 0.75 0.71
CHF20CF2CHFC1 (Enflurane) 0.35 0.70
CHF20CHC1CF3 (Isoflurane) 0.20 0.59
CHF20CHFCF3 (Desflurane) -0.37 -0.04
Chlorobenzene 1.63 1.52
Chlorodibromomethane 1.88 1.76
Chloroethane 0.49 0.36
Chloroform (Trichloromethane) 1.15 1.20
cis-1,2-Dichloroethylene 1.16 1.25
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Cyanoethylene Oxide 3.22 2.49
Cycloheptane 0.72 0.59
Cyclohexane 0.17 0.29
Cyclohexanone 3.33 2.92
Cyclopentane 0.24 0.09
Cyclopropane -0.21 -0.14
Decane 1.47 0.69
Dibromomethane 1.87 1.68
Dichloromethane (Methylene chloride) 1.12 0.99
Diethyl ether 1.11 1.14
Diflurodichloromethane -0.82 -0.49
Difluromethane (CF2H2) 0.20 -0.32
Dimethyl ether 1.16 0.76
Divinyl ether 0.41 0.47
Ethane - 1.02 -0.88
Ethanol 3.27 2.68
Ethene -0.53 -0.62
Ethyl acetate 1.90 1.68
Ethyl formate 1.65 1.39
Ethyl t-butyl ether (ETBE) 1.07 1.67
Ethyl t-pentyl ether 1.25 1.35
Ethylbenzene 1.47 1.57
Ethylene Oxide 1.80 1.45
Fluorobenzene 1.06 1.07
Fluoroethane 0.09 -0.19
Fluorotrichloromethane (Trichlorofluromethane) -0.06 0.20
Flurochloromethane 0.71 -0.01
Furan 0.82 0.71
Helium -2.00 -1.72
Heptane 0.50 0.12
Hexachloroethane (Perchloroethane) 1.76 1.75
Hexaflurobenzene 0.39 0.48
Hexane 0.21 -0.07
Hydrogen -1.77 -1.52
Iodoethane 0.83 1.01
Isobutyl acetate 1.69 1.97
Isopentylacetate (Aceticacidpentylester) 1.79 2.19
Isophorone (3,5,5-trimethylcyclohex-2-en-l-one) 3.37 3.53
Isopropyl acetate 1.55 1.74
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Isopropyl bromide (2-Brompropane) 0.64 0.72
Isopropylbenzene (Cumene) 1.57 1.68
JP-10 1.76 1.66
Krypton - 1.22 -1.15
MeOCF2CHC12 (Methoxyflurane) 1.28 1.41
Methane -1.42 -1.19
Methanol 3.41 2.72
Methyl acetate 1.98 1.57
Methyl butyl ketone (3-Methylpentan-2-one) 2.23 2.19
Methyl tertiary-butyl ether (MTBE) 1.18 1.59
Methylchloride (Chloromethane) 0.31 0.15
Methylcyclohexane 0.70 0.35
Methylcyclopentane -0.07 0.23
Methylpentaflurobenzene
(2,3.4,5,6-Pentylfluorotoluene) 0.73 0.03
m-Methylstyrene (1 -vinyl-3-rnethylbenzene) 2.28 2.14
m-Xylene (1,3-Dimethylbenzene) 1.59 1.63
Neon -2.01 -1.66
Nitrogen -1.83 -1.44
Nitrous Oxide -0.34 -0.34
Nonane 1.17 0.50
Octane 0.68 0.31
Oxygen -1.58 -1.34
o-Xylene 1.42 1.73
Pentachloroethane 2.02 2.34
Pentaflurobenzene 0.51 0.76
Pentane -0.29 -0.26
Pentyl acetate 1.98 2.22
p-Methylstyrene (1 -viny 1-4-methylbenzene) 2.37 2.15
Propene (Propylene) -0.21 -0.40
Propyl acetate 1.88 1.84
Propyl bromide (1-Bromopropane) 0.97 0.83
Propylbenzene 1.67 1.72
p-Xylene 1.61 1.63
Radon -0.39 -0.74
Styrene (Vinyl benzene) 1.67 1.88
Sulphur Hexafluoride -2.17 -1.60
t-butanol (tert-butanol)(TBA) 
(2-Methyl-2-propanol) 2.68 2.78
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t-Butylbenzene 1.24 1.87
t-Butylcyclohexane 1.16 1.16
tertiary-amyl alcohol (TAA) 2.59 3.04
tertiary-Amyl methyl ether (TAME) 1.22 1.83
Tetrachloroethene (Perchloroethylene) 1.19 1.05
Toluene 1.14 1.38
trans-1,2-Dichloroethylene 0.88 0.89
Tribromomethane (Bromoform) 2.15 2.25
Trichloroethene (Trichloroethylene) 1.14 1.07
Vinyl bromide (Bromoethene) 0.49 0.60
Vinyl chloride (Chloroethene) 0.17 0.12
Vinylidene fluoride (1,1-Difluoroethylene) -0.74 -0.90
Xenon -0.85 -0.93
OUTLIERS
CFH2CH2CFH2 0.97 -0.05
Cyclopentadiene 1.61 0.65
Descriptors E, S, A, B and L are found from chapter 9, table 9.0.
Ref = Literature reference, Comp No = Abraham’s compound number
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Table 11.0. Data set used to obtain a model to correlate air to plasma distributions
for VOCs in humans and rats combined
SOLUTE NAME
HUM
REFb
HUM 
PLASMA 
LOG K
RAT
REFb
RAT 
PLASMA 
LOG K REFb
AVERAGE 
OF H&R 
LOG K
CALC3 
LOG K
Helium 1, -2.07 1, -2.07 -1.77
Argon 1, -1.58 1, -1.58 -1.57
Krypton 1, -1.29 1, -1.29 -1.48
Xenon 1, -1.04 1, -1.04 -1.36
Hydrogen 1, -1.76 1, -1.76 -1.67
Oxygen 1, -1.61 1, -1.61 -1.57
Nitrogen 1, -1.87 1, -1.87 -1.62
Nitrous Oxide 1, -0.34 1, -0.34 -0.38
Methane 1, -1.59 1, -1.59 -1.50
Ethane 1, -1.34 2 , -1.44 1 ,2 -1.39 -1.34
Cyclopropane 1, -0.62 2 , -0.63 1 ,2 -0.63 -0.58
Acetylene 1, -0.11 1, -0.11 0.07
Fluoroethane 1, 0.07 1, 0.07 -0.31
Fluoromethane 1, 0.01 1, 0.01 -0.40
1-Fluropropane 1, -0.01 1, -0.01 -0.10
2-Fluropropane 1, 0.00 1, 0.00 -0.29
Iodoethane 1, 0.69 1, 0.69 0.68
Fluorotrichloromethane
(Trichlorofluromethane) 1, -0.12 1, -0.12 -0.27
Diflurodichloromethane 1, -1.07 1, -1.07 -0.98
CF3CBrClH (Halothane) 1, 0.40 1, 0.40 0.40
CF2C1CF2C1 (1,2- 
Dichlorotetrafluoroethane) 1, -0.66 1, -0.66 -1.18
Dimethyl ether 1, 1.12 1, 1.12 0.90
Diethyl ether 1, 1.08 2 , 1.16 1 ,2 1.12 1.19
MeOCF2CHC12
(Methoxyflurane) 1, 1.00 1, 1.00 1.10
CHF20CHC1CF3
(Isoflurane) 1, 0.20 1, 0.20 0.33
CF3CH20CH=CH2 
(Fluomar/ Fluroxene) 1, 0.05 1, 0.05 0.55
Acetone (Propan-2-one) 1, 2.54 2 , 2.20 1 ,2 2.37 2.25
Butan-2-one 1, 2.12 1, 2.12 2.30
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(Methyl ethyl ketone)
Methanol 1, 3.27 1, 3.27 3.02
Ethanol 1, 3.16 1, 3.16 2.90
1-Propanol 1, 2.99 1, 2.99 3.00
2-Propanol (Isopropanol) 1, 2.91 1, 2.91 3.01
2-Methyl-1 -propanol 
(Isobutanol) 1, 2.77 1, 2.77 3.01
Sulphur hexafluride 1, -2.28 2 , -2.41 1 ,2 -2.35 -2.12
Carbon Disulfide 1, -0.10 1, -0.10 0.05
CHF20CF2CHFC1
(Enflurane) 2 , 0.00 2 , 0.00 0.39
Calculated values for log K, obtained when correlating with the Abraham descriptors (E, S, A, B and
L)
Descriptors E, S, A, B and L for all solutes are found in table 9.0 from chapter 9 and table 18.0 from 
chapter 18.
bREF= Literature reference
419
Table 11.5. Data set used in this model to obtain model to predict blood to plasma
distributions for VOCs
SOLUTE NAME V
LOG K 
PLASMAb 
(H&R)
LOG K 
BLOODb 
(H&R)
LOG P 
(B to P)
CALCULATED 
LOG Ka
Helium 0.0680 -2.07 -2.00 -0.07 -0.07
Argon 0.1900 -1.58 -1.52 -0.06 -0.09
Krypton 0.2460 -1.29 - 1.22 -0.07 -0.11
Xenon 0.3290 -1.04 -0.85 -0.19 -0.12
Hydrogen 0.1086 -1.76 -1.77 0.01 -0.08
Oxygen 0.1830 -1.61 -1.58 -0.03 -0.09
Nitrogen 0.2222 -1.87 -1.83 -0.04 -0.10
Nitrous Oxide 0.2810 -0.34 -0.34 0.00 -0.06
Methane 0.2495 -1.59 -1.42 -0.17 -0.11
Ethane 0.3904 -1.39 - 1.02 -0.37 -0.13
Cyclopropane 0.4227 -0.63 -0.21 -0.42 -0.21
Acetylene 0.3044 -0.11 -0.06 -0.05 -0.10
Fluoroethane 0.4081 0.07 0.09 -0.02 -0.08
1 -Fluropropane 0.5490 -0.01 0.02 -0.03 -0.10
2-Fluropropane 0.5490 0.00 0.06 -0.06 -0.10
Iodoethane 0.6486 0.69 0.83 -0.14 -0.24
Fluorotrichloromethane 
(T richlorofluromethane) 0.6344 -0.12 -0.06 -0.06 -0.18
Diflurodichloromethane 0.5297 -1.07 -0.82 -0.25 -0.16
CF3CBrClH
(Halothane) 0.7410 0.40 0.57 -0.17 -0.21
CF2C1CF2C1 (1,2- 
Dichlorotetrafluoroethane) 0.7060 -0.66 -0.82 0.16 -0.15
Dimethyl ether 0.4491 1.12 1.16 -0.04 0.01
Diethyl ether 0.7309 1.12 1.11 0.01 -0.05
MeOCF2CHC12 (Methoxyflurane) 0.8700 1.00 1.28 -0.28 -0.16
CHF20CHC1CF3 (Isoflurane) 0.8010 0.20 0.20 0.00 -0.11
CF3CH20CH=CH2 (Fluomar/ 
Fluroxene) 0.7410 0.05 0.15 -0.10 -0.13
Acetone (Propan-2-one) 0.5470 2.37 2.36 0.01 0.00
Butan-2-one
(Methyl ethyl ketone) 0.6879 2.12 2.24 -0.12 -0.01
Methanol 0.3082 3.27 3.41 -0.14 -0.11
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Ethanol 0.4491 3.16 3.27 -0.11 -0.11
1-Propanol 0.5900 2.99 3.06 -0.07 -0.14
2-Propanol (Isopropanol) 0.5900 2.91 3.02 -0.11 -0.10
2-Methyl-1-propanol (Isobutanol) 0.7309 2.77 2.92 -0.15 -0.17
Sulphur hexafluoride 0.4643 -2.35 -2.17 -0.18 -0.03
Carbon Disulfide 0.4905 -0.10 0.30 -0.40 -0.32
CHF20CF2CHFC1 (Enflurane) 0.8009 0.00 0.35 -0.35 -0.12
Calculated values for log K, obtained when correlating with the Abraham descriptors (E, S, A, B and 
V)
Descriptors E, S, A and B can be found in table 9.0 from chapter 9.
bliterature reference for air to blood is found in chapter 10 (table 10.0). The reference for air to 
plasma data is found in table 11.0 of this chapter
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Table 12.0. Air to brain distribution for VOCs
SOLUTE NAME BRAIN
REF
BRAIN 
HUM 
LOG K
BRAIN
REF
BRAIN 
RAT 
LOG K
BRAIN
REF
(H&R)
BRAIN 
AVERAGE 
LOG K (H&R)
CALC 
LOG K
(CF3)2CHOCH2F (Sevoflurane) 1,2,3 0.10 1,2,3 0.10 0.55
1,1,1 -T richloroethane
(Methyl chloroform) 1,2,3 0.92 1,2,3 0.92 1.08
1,2,4-Trimethylbenzene 
(Pseudocumene) 5, 12 1.63 5, 12 1.63 2.43
1,2,4-Trimethylcyclohexane 5, 12 1.89 5, 12 1.89 1.62
1,2-Dimethylcyclohexane 5, 1.98 5, 1.98 1.44
1,3-Butadiene 7, -0.08 7, -0.08 0.31
1 -Butanol 1, 3.06 1, 3.06 3.00
1-Pentanol 1, 3.03 1, 3.03 3.29
1-Propanol 1,2,3 2.87 1, 3.09 1,2,3, 2.98 2 .6 6
1-Octene 4, 1.81 4, 1.81 1.32
1-Nonene 4, 2.04 4, 2.04 1.83
1-Decene 4, 2.17 4, 2.17 1.89
2,2-Dimethylbutane 1,2,3 0.45 1,2,3 0.45 0.40
2-Methyl-1-propanol (Isobutanol) 1,2,3 2.61 1, 2.94 1,2,3 2.78 2.87
2-Methylpentane (Isohexane) 1,2,3 0.58 1,2,3 0.58 0.49
2-Methyl heptane 4, 1.35 4, 1.35 1.07
2-Methyl octane 4, 1.50 4, 1.50 1.36
2-Methyl nonane 4, 1.81 4, 1.81 1.65
2-Propanol (Isopropanol) 1,2,3 2.76 1, 3.05 1,2,3 2.91 2.50
3-Methyl-1-butanol (Isopentanol) 1, 2.79 1, 2.79 3.22
3-Methylhexane 1,2,3 1.01 1,2,3 1.01 0.81
3-Methylpentane 1,2,3 0.64 1, 2, 3 0.64 0.54
4-Chlorobenzotrifluoride 11, 1.60 11, 1.60 1.62
Acetone (Propan-2-one) 1,2,3 2.19 1,2,3 2.19 1.48
Argon 3, -1.49 3, -1.49 -1.39
Benzene 1,2,3 1.26 5, 1.24
1,2, 3, 
5 1.25 1.32
Butan-2-one (Methyl ethyl ketone) 1,2,3 2.07 1,2,3 2.07 1.73
Butyl acetate 1, 2.22 1, 2.22 2.17
Carbon Disulfide 3 0.90 3 0.90 0.81
CF2=CHC1
(1 -Chloro-2,2-difluroethylene) 2 ,3 0.04 2,3 0.04 -0.03
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(1,1 -Difluro-2-chloroethene)
CF3CBrClH (Halothane) 1,2,3 0.77 1, 0.65 1,2,3 0.71 1.09
CF3CBrFH (Tellurane) 1,3 0.05 1,3 0.05 0.60
CF3CH2C1
(2chlorol 1 ltrifluoroethane)
(1 -Chloro-2,2,2-trifluroethane) 1,2,3 0.26 1,2,3 0.26 0.37
CF3CH20CH=CH2 
(Fluomar/ Fluroxene) 1,2,3 0.29 1,2,3 0.29 0 .6 8
CHF20CF2CHFC1 (Enflurane) 1,2,3 0.49 1,2,3 0.49 0.82
CHF20CHC1CF3 (Isoflurane) 1,2,3 0.46 1, 0.31 1,2,3 0.39 0.63
Chloroform (Trichloroinethane) 1,2,3 1.30 1,2,3 1.30 1.34
Cyclohexane 1,2,3 1.04 5, 1.52
1,2,3,
5 1.28 0.89
Cyclopropane 1 ,2 -0.10 1 ,2 -0.10 -0.01
Decane 5, 1.84 5, 1.84 1.78
Dichloromethane (Methylene 
chloride) 1,2,3 0.78 1,2,3 0.78 0.98
Diethyl ether 1,2,3 1.10 1,2,3 1.10 1.23
Divinyl ether 1,2,3 0.54 1, 2, 3 0.54 0.55
Ethanol 1,2,3 3.02 1, 3.27 1,2,3 3.15 2.34
Ethyl acetate 1, 1.90 1, 1.90 1.58
Ethyl t-butyl ether (ETBE) 8 , 1.29 8 , 1.29 1.90
t-butanol (tert-butanol)(TBA) 
(2-Methyl-2-propanol) 8 , 2.79 8 , 2.79 2.60
Methyl tertiary-butyl ether
(MTBE) 8 , 1.54 8 , 1.54 1.71
tertiary-Amyl methyl ether
(TAME) 8 , 1.39 8 , 1.39 2.05
tertiary-amyl alcohol (TAA) 8 , 2.66 8 , 2.66 3.00
Ethylene Oxide 15, 1.84 14, 1.77 14, 15 1.81 1.08
Ethylene (Ethene) 15, -0.26 15, -0.19 15, -0.23 -0.60
Heptane 1,2,3 1.09 5, 0.79
1 2 31 5 ?
5 0.94 0.89
Hexane 1,2,3 0.70 5, 1.07
1,2,3,
5 0.89 0.59
Isobutyl acetate 1, 2.14 1, 2.14 2.08
Isopentylacetate
(Aceticacidpentylester) 1, 2.34 1, 2.34 2.42
Isopropyl acetate 1, 1.95 1, 1.95 1.72
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Krypton 3, -1.38 3, -1.38 -1.11
MeOCF2CHC12 (Methoxyflurane) 1,2,3 1.41 1, 1.39 1,2,3 1.40 1.53
Methane 3, -1.39 3, -1.39 -1.18
Methyl acetate 1, 1.85 1, 1.85 1.36
Methylcyclopentane 1,2,3 0.86 1,2,3 0.86 0.83
Methylcyclohexane 5, 1.66 5, 1.66 1.06
Neon 3, -1.81 3, -1.81 -1.92
Nitrogen 3, -1.80 3, -1.80 -1.56
Nitrous Oxide 2 ,3 -0.31 2 ,3 -0.31 -0.53
Nonane 5, 12 1.69 5, 12 1.69 1.49
Octane 1,3 1.22 5, 1.52 1,3,5 1.37 1.19
o-Xylene (1,2-dimethylbenzene) 5, 1.39 5, 1.39 2.07
Pentane 1,2,3 0.34 1,2,3 0.34 0.29
Pentyl acetate 1, 2.38 1, 2.38 2.46
Propyl acetate 1, 2.00 1, 2.00 1.86
Propene (Propylene) 9, -0.22 9, -0.32 9, -0.27 -0.23
Radon 10, -0.51 10, -0.51 -0.47
Sulphur Hexafluoride 3, -1.78 3, -1.78 -1.30
t-Butylcyclohexane 5, 1.77 5, 1.77 2.06
t-Butylbenzene 5, 1.67 5, 1.67 2.35
Toluene (Methyl benzene) 1,2,3 1.56 5, 1.26
1,2, 3, 
5 1.41 1.64
Trichloroethene 
(T richloroethylene) 1,2,3 1.33 13, 1.16
1,2,3,
13 1.25 1.41
Xenon 2 , -0.70 2 , -0.70 -0.76
Carbon Dioxide 3, -0.25 3, -0.25 -0.47
OUTLIERS
Cyanoethylene Oxide 6 , 3.37 6 , 3.37 2.25
Methanol 1 ,2 3.18 1, 3.54 1 ,2 3.36 2.39
Ref = Literature reference, H&R = humans and rats
Descriptors E, S, A, B and L for all solutes are found in table 9.0 from chapter 9 and table 18.0 from 
chapter 18.
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Table 12.3. Blood to brain distribution for VOCs
SOLUTE NAME V
BRAIN 
AVERAGE 
LOG K 
(H&R)
BLOOD 
AVERAGE 
LOG K 
(H&R)
BLOOD 
TO BRAIN 
LOG P 
(H&R)
CALC 
LOG P
(CF3)2CHOCH2F (Sevoflurane) 0.8548 0.10 -0.20 0.30 0.36
1,1,1-Trichloroethane (Methyl chloroform) 0.7576 0.92 0.63 0.29 0.25
1,2,4-Trimethylbenzene (Pseudocumene) 1.1391 1.63 1.47 0.16 0.42
1,2,4-Trimethylcyclohexane 1.2681 1.89 0.87 1.02 0.76
1,2-Dimethylcyclohexane 1.1270 1.98 0.91 1.07 0.65
1,3-Butadiene 0.5862 -0.08 0.09 -0.17 0.22
1-Butanol 0.7309 3.06 3.08 -0.02 -0.02
1-Pentanol 0.8718 3.03 2.83 0.20 0.08
1-Propanol 0.5900 2.98 3.06 -0.08 -0.13
1-Octene 1.1928 1.81 1.07 0.74 0.75
1-Nonene 1.3337 2.04 1.18 0.86 0.87
1-Decene 1.4746 2.17 1.21 0.96 0.96
2,2-Dimethylbutane 0.9540 0.45 -0.59 1.04 0.64
2-Methyl-1-propanol (Isobutanol) 0.7309 2.78 2.92 -0.14 -0.01
2-Methylpentane (Isohexane) 0.9540 0.58 -0.39 0.97 0.64
2-Methyl heptane 1.2358 1.35 0.49 0.86 0.85
2-Methyl octane 1.3767 1.50 0.52 0.98 0.95
2-Methyl nonane 1.5176 1.81 0.76 1.05 1.05
2-Propanol (Isopropanol) 0.5900 2.91 3.02 -0.11 -0.11
3-Methyl-1-butanol (Isopentanol) 0.8718 2.79 2.75 0.04 0.09
3-Methylhexane 1.0949 1.01 0.11 0.90 0.74
3-Methylpentane 0.9540 0.64 -0.37 1.01 0.64
4-Chlorobenzotrifluoride 1.0328 1.60 1.43 0.17 0.39
Acetone (Propan-2-one) 0.5470 2.19 2.36 -0.17 -0.21
Argon 0.1900 -1.49 -1.52 0.03 0.08
Benzene 0.7164 1.25 1.05 0.20 0.15
Butan-2-one (Methyl ethyl ketone) 0.6879 2.07 2.24 -0.17 -0.10
Butyl acetate 1.0284 2.22 1.94 0.28 0.22
Carbon Disulfide 0.4905 0.90 0.30 0.60 0.17
CF2=CHC1 (1 -Chloro-2,2-difluroethylene) 
(1,1 -Difluro-2-chloroethene) 0.5052 0.04 0.06 -0.02 0.10
CF3CBrClH (Halothane) 0.7410 0.71 0.57 0.14 0.22
CF3CBrFH (Teflurane) 0.6360 0.05 -0.22 0.27 0.22
CF3CH2C1 (2chloro 111 trifluoroethane) 0.5659 0.26 0.14 0.12 0.09
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CF3CH20CHCH2 (Fluomar/ Fluroxene) 0.7410 0.29 0.15 0.14 0.24
CHF20CF2CHFC1 (Enflurane) 0.8009 0.49 0.35 0.14 0.23
CHF20CHC1CF3 (Isoflurane) 0.8010 0.39 0.20 0.19 0.19
Chloroform (Trichlorome thane) 0.6167 1.30 1.15 0.15 0.08
Cyclopropane 0.4227 -0.10 -0.21 0.11 0.14
Dichloromethane (Methylene chloride) 0.4943 0.78 1.12 -0.34 -0.04
Diethyl ether 0.7309 1.10 1.11 -0.01 0.19
Divinyl ether 0.6449 0.54 0.41 0.13 0.17
Ethanol 0.4491 3.15 3.27 -0.12 -0.23
Ethyl acetate 0.7466 1.90 1.90 0.00 0.01
Ethyl t-butyl ether (ETBE) 1.0127 1.29 1.07 0.22 0.40
t-butanol (tert-butanol)(TBA) 
(2-Methyl-2-propanol) 0.7309 2.79 2.68 0.11 0.02
Methyl tertiary-butyl ether (MTBE) 0.8718 1.54 1.18 0.36 0.27
tertiary-Amyl methyl ether (T AME) 1.0127 1.39 1.22 0.17 0.37
tertiary-amyl alcohol (TAA) 0.8718 2.66 2.59 0.07 0.12
Ethylene Oxide 0.3405 1.81 1.80 0.01 -0.33
Ethylene (Ethene) 0.3474 -0.23 -0.53 0.31 0.12
Heptane 1.0949 0.94 0.50 0.44 0.74
Hexane 0.9540 0.89 0.21 0.68 0.64
Isobutyl acetate 1.0284 2.14 1.69 0.45 0.23
Isopentylacetate (Aceticacidpentylester) 1.1693 2.34 1.79 0.55 0.34
Isopropyl acetate 0.8875 1.95 1.55 0.40 0.13
Krypton 0.2460 -1.38 - 1.22 -0.16 0.12
MeOCF2CHC12 (Methoxyflurane) 0.8700 1.40 1.28 0.12 0.15
Methane 0.2495 -1.39 -1.42 0.03 0.13
Methyl acetate 0.6057 1.85 1.98 -0.13 -0.10
Methylcyclopentane 0.8454 0.86 -0.07 0.93 0.51
Methylcyclohexane 0.9863 1.66 0.70 0.96 0.64
Neon 0.0850 -1.81 -2.01 0.20 0.01
Nitrogen 0.2222 -1.80 -1.83 0.03 0.11
Nitrous Oxide 0.2810 -0.31 -0.34 0.03 -0.07
Nonane 1.3767 1.69 1.17 0.52 0.95
Octane 1.2358 1.37 0.68 0.69 0.85
o-Xylene (1,2-dimethylbenzene) 0.9982 1.39 1.42 -0.03 0.33
Pentane 0.8131 0.34 -0.29 0.63 0.54
Pentyl acetate 1.1693 2.38 1.98 0.40 0.33
Propyl acetate 0.8875 2.00 1.88 0.12 0.12
Propene (Propylene) 0.4883 -0.27 -0.21 -0.06 0.24
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Radon 0.3840 -0.51 -0.39 -0.12 0.22
Sulphur Hexafluoride 0.4643 -1.78 -2.17 0.39 0.38
t-Butylcyclohexane 1.4090 1.77 1.16 0.61 0.89
t-Butylbenzene 1.2800 1.67 1.24 0.43 0.57
Toluene (methylbenzene) 0.8573 1.41 1.14 0.27 0.25
Trichloroethene (Trichloroethylene) 0.7146 1.25 1.14 0.11 0.24
Xenon 0.3290 -0.70 -0.85 0.15 0.18
OUTLIERS
Decane 1.5176 1.84 1.47 0.37 1.01
Cyclohexane 0.8454 1.28 0.17 1.11 0.53
Descriptors E, S, A and B for all solutes are found in table 9.0 from chapter 9 and table 18.0 from 
chapter 18.
Note no blood values carbon dioxide 
H&R = human and rat 
Ref = Literature reference
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Table 12.6. Plasma to brain distribution for VOCs
SOLUTE NAME V
LOG K 
BRAIN 
(H&R)
LOG K 
PLASMA3 
(H&R)
LOG P 
(PLASMA TO 
BRAIN)
CALC 
LOG P
Argon 0.1900 -1.49 -1.58 0.09 0.16
Krypton 0.2460 -1.38 -1.29 -0.09 0.19
Xenon 0.3290 -0.70 -1.04 0.34 0.24
Nitrogen 0.2222 -1.80 -1.87 0.07 0.18
Nitrous Oxide 0.2810 -0.31 -0.34 0.03 0.06
Methane 0.2495 -1.39 -1.59 0.20 0.20
Cyclopropane 0.4227 -0.10 -0.63 0.53 0.27
CF3CBrClH (Halothane) 0.7410 0.71 0.40 0.31 0.42
Diethyl ether 0.7309 1.10 1.12 -0.02 0.06
MeOCF2CHC12 (Methoxyflurane) 0.8700 1.40 1.00 0.40 0.34
CHF20CHC1CF3 (Isoflurane) 0.8010 0.39 0.20 0.19 0.36
CF3CH20CH=CH2 
(Fluomar/ Fluroxene) 0.7410 0.29 0.05 0.24
0.21
Acetone (Propan-2-one) 0.5470 2.19 2.37 -0.18 -0.16
Butan-2-one (Methyl ethyl ketone) 0.6879 2.07 2.12 -0.05 -0.11
Methanol 0.3082 3.36 3.27 0.09 -0.09
Ethanol 0.4491 3.15 3.16 -0.01 -0.03
1 -Propanol 0.5900 2.98 2.99 -0.01 0.05
2-Propanol (Isopropanol) 0.5900 2.91 2.91 0.00 -0.02
2-Methyl-1-propanol (Isobutanol) 0.7309 2.78 2.77 0.01 0.14
Sulphur hexafluride 0.4643 -1.78 -2.35 0.57 0.34
CHF20CF2CHFC1 (Enflurane) 0.8009 0.49 0.00 0.49 0.37
aThe literature data for air to plasma VOC distribution was obtained from chapter 11 (table 11.0) 
Note references for plasma data can be found in the plasma chapter of the thesis 
H&R = human and rat
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Table 12.9. Plasma to brain and blood to brain distribution combined for VOCs
SOLUTE NAME BLOOD OR 
PLASMA
BLOOD OR PLASMA TO BRAIN 
LOG P (H&R)
CALC 
LOG P
(CF3)2CHOCH2F (Sevoflurane) BLOOD 0.30 0.39
1,1,1 -T richloroethane 
(Methyl chloroform) BLOOD 0.29 0.27
1,2,4-Trimethylbenzene 
(Pseudocumene) BLOOD 0.16 0.42
1,2,4-Trimethylcyclohexane BLOOD 1.02 0.76
1,2-Dimethylcyclohexane BLOOD 1.07 0.65
1,3-Butadiene BLOOD -0.17 0.23
1-Butanol BLOOD -0.02 0.04
1-Pentanol BLOOD 0.20 0.14
1-Propanol BLOOD -0.08 -0.06
1-Octene BLOOD 0.74 0.74
1-Nonene BLOOD 0.86 0.84
1-Decene BLOOD 0.96 0.94
2,2-Dimethylbutane BLOOD 1.04 0.64
2-Methyl-1 -propanol
(Isobutanol) BLOOD -0.14 0.06
2-Methylpentane (Isohexane) BLOOD 0.97 0.64
2-Methyl heptane BLOOD 0.86 0.84
2-Methyl octane BLOOD 0.98 0.94
2-Methyl nonane BLOOD 1.05 1.04
2-Propanol (Isopropanol) BLOOD -0.11 -0.05
3-Methyl-1 -butanol 
(Isopentanol) BLOOD 0.04 0.16
3-Methylhexane BLOOD 0.90 0.74
3-Methylpentane BLOOD 1.01 0.64
4-Chlorobenzotrifluoride BLOOD 0.17 0.41
Acetone (Propan-2-one) BLOOD -0.17 -0.19
Argon BLOOD 0.03 0.11
Benzene BLOOD 0.20 0.17
Butan-2-one
(Methyl ethyl ketone) BLOOD -0.17 -0.09
Butyl acetate BLOOD 0.28 0.22
Carbon Disulfide BLOOD 0.60 0.18
CF2=CHC1 BLOOD -0.02 0.17
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CF3CBrClH (Halothane) BLOOD 0.14 0.27
CF3CBrFH (Teflurane) BLOOD 0.27 0.29
CF3CH2C1
(2chlorol 11 trifluoroethane)
(1 -Chloro-2,2,2-trifluroethane) BLOOD 0.12 0.16
CF3CH20CH=CH2 
(Fluomar/ Fluroxene) BLOOD 0.14 0.24
CHF20CF2CHFC1 (Enflurane) BLOOD 0.14 0.27
CHF20CHC1CF3 (Isoflurane) BLOOD 0.19 0.24
Chloroform (Trichloromethane) BLOOD 0.15 0.14
Cyclopropane BLOOD 0.11 0.16
Dichloromethane
(Methylene chloride) BLOOD -0.34 0.01
Diethyl ether BLOOD -0.01 0.18
Divinyl ether BLOOD 0.13 0.18
Ethanol BLOOD -0.12 -0.15
Ethyl acetate BLOOD 0.00 0.01
Ethyl t-butyl ether (ETBE) BLOOD 0.22 0.36
t-butanol (tert-butanol)(TBA) 
(2-Methyl-2-propanol) BLOOD 0.11 0.06
Methyl tertiary-butyl ether 
(MTBE) BLOOD 0.36 0.24
tertiary-Amyl methyl ether 
(TAME) BLOOD 0.17 0.34
tertiary-amyl alcohol (TAA) BLOOD 0.07 0.16
Ethylene Oxide BLOOD 0.01 -0.29
Ethylene (Ethene) BLOOD 0.31 0.14
Heptane BLOOD 0.44 0.74
Hexane BLOOD 0.68 0.64
Isobutyl acetate BLOOD 0.45 0.23
Isopentylacetate
(Aceticacidpentylester) BLOOD 0.55 0.33
Isopropyl acetate BLOOD 0.40 0.13
Krypton BLOOD -0.16 0.15
MeOCF2CHC12
(Methoxyflurane) BLOOD 0.12 0.19
Methane BLOOD 0.03 0.15
Methyl acetate BLOOD -0.13 -0.10
Methylcyclopentane BLOOD 0.93 0.52
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Methylcyclohexane BLOOD 0.96 0.64
Neon BLOOD 0.20 0.03
Nitrogen BLOOD 0.03 0.13
Nitrous Oxide BLOOD 0.03 -0.04
Nonane BLOOD 0.52 0.94
Octane BLOOD 0.69 0.84
o-Xylene (1,2-dimethylbenzene) BLOOD -0.03 0.34
Pentane BLOOD 0.63 0.54
Pentyl acetate BLOOD 0.40 0.32
Propyl acetate BLOOD 0.12 0.12
Propene (Propylene) BLOOD -0.06 0.25
Radon BLOOD -0.12 0.24
Sulphur Hexafluoride BLOOD 0.39 0.40
t-Butylcyclohexane BLOOD 0.61 0.87
t-Butylbenzene BLOOD 0.43 0.56
Toluene (methylbenzene) BLOOD 0.27 0.27
Trichloroethene
(Trichloroethylene) BLOOD 0.11 0.27
Xenon BLOOD 0.15 0.20
Argon PLASMA 0.09 0.11
Krypton PLASMA -0.09 0.15
Xenon PLASMA 0.34 0.20
Nitrogen PLASMA 0.07 0.13
Nitrous Oxide PLASMA 0.03 -0.04
Methane PLASMA 0.20 0.15
Cyclopropane PLASMA 0.53 0.16
CF3CBrClH (Halothane) PLASMA 0.31 0.27
Diethyl ether PLASMA -0.02 0.18
MeOCF2CHC12
(Methoxyflurane) PLASMA 0.40 0.19
CHF20CHC1CF3 (Isoflurane) PLASMA 0.19 0.24
CF3CH20CH=CH2 
(Fluomar/ Fluroxene) PLASMA 0.23 0.24
Acetone (Propan-2-one) PLASMA -0.18 -0.19
Butan-2-one 
(Methyl ethyl ketone) PLASMA -0.05 -0.09
Methanol PLASMA 0.09 -0.27
Ethanol PLASMA -0.01 -0.15
1-Propanol PLASMA -0.01 -0.06
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2-Propanol (Isopropanol) PLASMA 0.00 -0.05
2-Methyl-1 -propanol 
(Isobutanol) PLASMA 0.01 0.06
Sulphur hexafluride PLASMA 0.57 0.40
CHF20CF2CHFC1 (Enflurane) PLASMA 0.49 0.27
H&R = human and rat
Descriptor V, are found from tables 12.3 and 12.6.
Descriptors E, S, A and B for all solutes are found in table 9.0 from chapter 9 and table 18.0 from 
chapter 18.
432
Table 13.0. Air to kidney distribution for VOCs
SOLUTE NAME KID
REF
KIDNEY
HUM
LOG K
KID
REF
KIDNEY
RAT
LOG K
KID
REF
(H&R)
KIDNEY
AVERAGE
LOG K (H&R)
CALC 
LOG K
(CF3)2CHOCH2F (Sevoflurane) 1,2,4 0.25 1,2,4 0.25 0.54
1,1,1 -Trichloroethane 
(Methyl chloroform) 1,2,4 0.83 1,2,4 0.83 1.09
1,2,4-Trimethylbenzene 
(Pseudocumene) 6, 13 2.19 6, 13 2.19 2.57
1,2,4-Trimethylcyclohexane 6, 13 2.33 6, 13 2.33 1.67
1,2-Dimethylcyclohexane 6, 2.30 6, 2.30 1.47
1,3-Butadiene 7, -0.08 7, -0.08 0.26
1 -Butanol 1 3.06 1 3.06 3.04
1 -Pentanol 1 3.04 1 3.04 3.37
1 -Propanol 1,2,4 2.84 1 3.09 1,2,4 2.97 2.67
1 -Octene 5, 2.15 5, 2.15 1.39
1 -Nonene 5, 2.15 5, 2.15 1.89
1-Decene 5, 2.21 5, 2.21 2.02
2,2-Dimethylbutane 1,2,4 0.15 1,2,4 0.15 0.38
2-Methyl-1,3-butadiene (Isoprene) 12, 0.03 12, 0.03 0.62
2-Methyl-1 -propanol (Isobutanol) 1,2,4 2.57 1 2.94 1,2,4 2.76 2.91
2-Methylpentane (Isohexane) 1,2,4 0.30 1,2,4 0.30 0.47
2-Methyl heptane 5, 1.60 5, 1.60 1.11
2-Methyl octane 5, 1.59 5, 1.59 1.43
2-Methyl nonane 5, 1.65 5, 1.65 1.74
2-Propanol (Isopropanol) 1,2,4 2.70 1 3.03 1,2,4 2.87 2.56
3-Methyl-1-butanol (Isopentanol) 1 2.86 1 2.86 3.29
3-Methylhexane 1,2,4 0.86 1,2,4 0.86 0.83
3 -Methylpentane 1,2,4 0.40 1,2,4 0.40 0.53
4-Chlorobenzotri fluoride 11, 1.58 11, 1.58 1.63
Acetone (Propan-2-one) 1,2,4 2.16 1,2,4 2.16 1.61
Benzene 1,2,4 1.08 6, 1.51 1,2, 4,6 1.30 1.34
Bromodichloromethane 15, 1.52 15, 1.52 1.51
Butan-2-one 
(Methyl ethyl ketone) 1,2,4 2.03 1,2,4 2.03 1.93
Butyl acetate 1 2.39 1 2.39 2.41
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Carbon Disulfide 4, 0.90 4, 0.90 0.74
CF2CHC1
(1 -Ch1oro-2,2-difluroethylene) 
(1,1 -Difl uro-2 -chi oroeth en e) 2 ,4 0.00 2,4 0.00 -0.21
CF3CBrClH (Halothane) 1,2,4 0.69 1,2,4 0.69 0.99
CF3CH2C1
(2chlorol 1 ltrifluoroethane)
(1 -Chloro-2,2,2-trifluroethane) 1,2,4 0.32 1,2,4 0.32 0.20
CF3CH20CH=CH2 
(Fluomar/ Fluroxene) 1,2,4 0.12 1,2,4 0.12 0.72
CHF20CF2CHFC1 (Enflurane) 1,2,4 0.53 1,2,4 0.53 0.77
CHF20CHC1CF3 (Isoflurane) 1,2,4 0.29 1,2,4 0.29 0.56
Chloroform (Trichloromethane) 1,2,4 1.04 1,2,4 1.04 1.22
Cyclohexane 1,2,4 0.86 1,2,4 0.86 0.88
Cyclopropane 1,2,4 -0.38 1,2,4 -0.38 -0.13
Decane 6, 1.75 6, 1.75 1.90
Dichloromethane
(Methylene chloride) 1,2,4 0.76 1,2,4 0.76 0.88
Diethyl ether 1,2,4 1.02 1,2,4 1.02 1.40
Divinyl ether 1,2,4 0.30 1,2,4 0.30 0.52
Ethanol 1,2,4 2.97 1 3.31 1,2,4 3.14 2.32
Ethyl acetate 1 1.94 1 1.94 1.75
Ethyl t-butyl ether (ETBE) 8, 2.10 8, 2.10 2.19
t-butanol (tert-butanol) 
(TBA)
(2-Methyl-2-propanol) 3,8 2.78 3, 8 2.78 2.70
Methyl tertiary-butyl ether (MTBE) 3, 8 1.84 3, 8 1.84 1.97
tertiary-Amyl methyl ether (TAME) 8, 2.21 8, 2.21 2.35
tertiary-amyl alcohol (TAA) 8, 2.68 8, 2.68 3.14
Ethylene Oxide 14, 1.83 14, 1.83 1.09
Ethylene (Ethene) 14, -0.44 14, -0.55 14, -0.50 -0.73
Heptane 1,2,4 0.95 6, 1.20 1,2, 4, 6 1.08 0.91
Hexane 1,2,4 0.48 6, 1.41 1,2, 4, 6 0.95 0.58
Isobutyl acetate 1 2.33 1 2.33 2.32
Isopentylacetate
(Aceticacidpentylester) 1 2.48 1 2.48 2.70
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Isopropyl acetate 1 2.15 1 2.15 1.92
Krypton 4 -1.37 4 -1.37 -1.29
MeOCF2CHC12 (Methoxyflurane) 1,2,4 1.32 1,2,4 1.32 1.55
Methyl acetate 1 1.92 1 1.92 1.50
Methylcyclopentane 1,2,4 0.67 1,2,4 0.67 0.82
Nitrous Oxide 2 ,4 -0.40 2 ,4 -0.40 -0.65
Nonane 6, 13 1.65 6, 13 1.65 1.57
Octane 1,4 0.91 6, 1.76 1,4,6 1.34 1.24
Oxygen 4 -1.52 4 -1.52 -1.62
o-Xylene (1,2-dimethylbenzene) 6, 1.89 6, 1.89 2.17
Pentane 1,2,4 -0.22 1,2,4 -0.22 0.25
Pentyl acetate 1 2.51 1 2.51 2.73
Propyl acetate 1 2.29 1 2.29 2.07
Propene (Propylene) 9, -0.35 9, -0.28 9, -0.32 -0.31
Radon 10, -0.55 10, -0.55 -0.58
t-Butylcyclohexane 6, 2.33 6, 2.33 2.19
t-Butylbenzene 6, 2.34 6, 2.34 2.49
Toluene (Methylbenzene) 1,2,4 1.26 6, 1.79 1,2, 4, 6 1.53 1.69
Trichloroethene (Trichloroethylene) 1,2,4 1.12 1,2,4 1.12 1.36
Xenon 2 -1.00 2 -1.00 -0.91
OUTLIER
Methanol 1,2,4 3.13 1 3.50 1,2,4 3.32 2.31
Methylcyclohexane 6, 2.05 6, 2.05 1.10
Ref = Literature reference
Descriptors E, S, A, B and L for all solutes are found in table 9.0 from chapter 9 and table 18.0 from 
chapter 18.
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Table 13.3. Blood to kidney distribution for VOCs
SOLUTE NAME V
KIDNEY  
AVERAGE 
LOG K 
(H&R)
BLOOD 
LOG K
KIDNEY 
LOG P 
(H & R )
CALC 
LOG P
(CF3)2CHOCH2F (Sevoflurane) 0.8548 0.25 -0.20 0.45 0.27
1,1,1 -Trichloroethane 
(Methyl chloroform) 0.7576 0.83 0.63 0.20 0.25
1,2,4-Trimethylbenzene 
(Pseudocumene) 1.1391 2.19 1.47 0.72 0.61
1,3-Butadiene 0.5862 -0.08 0.09 -0.17 0.17
1 -Butanol 0.7309 3.06 3.08 -0.02 0.00
1 -Pentanol 0.8718 3.04 2.83 0.21 0.13
1 -Propanol 0.5900 2.97 3.06 -0.09 -0.14
1-Octene 1.1928 2.15 1.07 1.08 0.80
1-Nonene 1.3337 2.15 1.18 0.97 1.05
1 -Decene 1.4746 2.21 1.21 1.00 1.08
2,2-Dimethylbutane 0.9540 0.15 -0.59 0.74 0.57
2-Methyl-1,3-butadiene (Isoprene) 0.7271 0.03 0.10 -0.07 0.30
2-Methyl-1 -propanol (Isobutanol) 0.7309 2.76 2.92 -0.16 0.01
2-Methylpentane
(Isohexane) 0.9540 0.30 -0.39 0.69 0.57
2-Methyl heptane 1.2358 1.60 0.49 1.11 0.85
2-Methyl octane 1.3767 1.59 0.52 1.07 0.99
2-Methyl nonane 1.5176 1.65 0.76 0.89 1.13
2-Propanol (Isopropanol) 0.5900 2.87 3.02 -0.15 -0.06
3-Methyl-1 -butanol (Isopentanol) 0.8718 2.86 2.75 0.11 0.15
3-Methylhexane 1.0949 0.86 0.11 0.75 0.71
3-Methylpentane 0.9540 0.40 -0.37 0.77 0.57
4-Chlorobenzotri fluoride 1.0328 1.58 1.43 0.15 0.43
Acetone (Propan-2-one) 0.5470 2.16 2.36 -0.20 -0.06
Benzene 0.7164 1.30 1.05 0.25 0.19
Bromodichloromethane 0.6693 1.52 1.49 0.03 -0.05
Butan-2-one
(Methyl ethyl ketone) 0.6879 2.03 2.24 -0.21 0.11
Butyl acetate 1.0284 2.39 1.94 0.45 0.47
Carbon Disulfide 0.4905 0.90 0.30 0.60 0.11
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CF2=CHC1
(] -Chloro-2,2-difIuroethylene) 
(1 ,l-Difluro-2-chloroethene) 0.5052 0.00 0.06 -0.06 -0.18
CF3CBrClH (Halothane) 0.7410 0.69 0.57 0.12 0.07
CF3CH2C1
(2chlorol 1 ltrifluoroethane)
(1-Ch loro-2,2,2-trifluroethane) 0.5659 0.32 0.14 0.18 -0.13
CF3CH20CH=CH2 (Fluomar/ 
Fluroxene) 0.7410 0.12 0.15 -0.03 0.31
CHF20CF2CHFC1 (Enflurane) 0.8009 0.53 0.35 0.18 0.12
CHF20CHC1CF3 (Isoflurane) 0.8010 0.29 0.20 0.09 0.08
Chloroform (Trichloromethane) 0.6167 1.04 1.15 -0.11 -0.07
Cyclohexane 0.8454 0.86 0.17 0.69 0.46
Cyclopropane 0.4227 -0.38 -0.21 -0.17 -0.01
Dichloromethane (Methylene 
chloride) 0.4943 0.76 1.12 -0.36 -0.19
Diethyl ether 0.7309 1.02 1.11 -0.09 0.36
Divinyl ether 0.6449 0.30 0.41 -0.11 0.14
Ethanol 0.4491 3.14 3.27 -0.13 -0.28
Ethyl acetate 0.7466 1.94 1.90 0.04 0.19
Ethyl t-butyl ether (ETBE) 1.0127 2.10 1.07 1.03 0.71
t-butanol
(tert-butanol)(TBA)
(2-Methyl-2-propanol) 0.7309 2.78 2.68 0.10 0.13
Methyl tertiary-butyl ether (MTBE) 0.8718 1.84 1.18 0.66 0.55
tertiary-Amyl methyl ether (TAME) 1.0127 2.21 1.22 0.99 0.69
tertiary-amyl alcohol (TAA) 0.8718 2.68 2.59 0.09 0.27
Ethylene Oxide 0.3405 1.83 1.80 0.03 -0.34
Ethylene (Eihene) 0.3474 -0.50 -0.53 0.04 -0.04
Heptane 1.0949 1.08 0.50 0.58 0.71
Hexane 0.9540 0.95 0.21 0.74 0.57
Isobutyl acetate 1.0284 2.33 1.69 0.64 0.49
Isopentylacetate
(Aceticacidpentylester) 1.1693 2.48 1.79 0.69 0.63
Isopropyl acetate 0.8875 2.15 1.55 0.60 0.35
Krypton 0.2460 -1.37 -1.22 -0.15 -0.12
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MeOCF2CHC12 (Methoxyflurane) 0.8700 1.32 1.28 0.04 0.14
Methyl acetate 0.6057 1.92 1.98 -0.06 0.05
Methylcyclopentane 0.8454 0.67 -0.07 0.74 0.45
Nitrous Oxide 0.2810 -0.40 -0.34 -0.06 -0.23
Nonane 1.3767 1.65 1.17 0.48 0.99
Octane 1.2358 1.34 0.68 0.66 0.85
Oxygen 0.1830 -1.52 -1.58 0.06 -0.18
o-Xylene
(1,2-dimethylbenzene) 0.9982 1.89 1.42 0.47 0.46
Pentane 0.8131 -0.22 -0.29 0.07 0.44
Pentyl acetate 1.1693 2.51 1.98 0.53 0.61
Propyl acetate 0.8875 2.29 1.88 0.41 0.34
Propene (Propylene) 0.4883 -0.32 -0.21 -0.11 0.11
Radon 0.3840 -0.55 -0.39 -0.16 0.02
t-Butylcyclohexane 1.4090 2.33 1.16 1.17 1.04
t-Butylbenzene 1.2800 2.34 1.24 1.10 0.77
Toluene (Methylbenzene) 0.8573 1.53 1.14 0.39 0.33
Tri chloroethene (Tri ch loroethy 1 ene) 0.7146 1.12 1.14 -0.02 0.16
Xenon 0.3290 -1.00 -0.85 -0.15 -0.04
OUTLIER
1,2-Dimethylcyclohexane 1.1270 2.30 0.91 1.39 0.69
Decane 1.5176 1.75 1.47 0.28 1.05
1,2,4-Trimethylcyclohexane 1.2681 2.33 0.87 1.46 0.86
Ref = Literature reference
Descriptors E, S, A and B for all solutes are found in table 9.0 from chapter 9 and table 18.0 from chapter 
18.
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Table 14.0. Air to fat distribution for VOCs
SOLUTE NAME FAT
REF
FAT
HUM
LOG K
FAT
REF
FAT
RAT
LOG K
FAT
REF
FAT 
AVERAGE 
LOG K 
(H&R)
CALC  
LOG K
(CF3)2CHOCH2F
(Sevoflurane) 1,2,4 1.62 1,2,4 1.62 1.54
1,1,1,2-Tetrachloroethane 1,3 3.33 1,3 3.33 3.35
1,1,1 -Trichloroethane 
(Methyl chloroform) 2,4 2.40 1,3 2.42 1,2, 3, 4 2.41 2.33
1,1,2,2-Tetrachloroethane 1,3 3.58 1,3 3.58 3.68
1,1,2-Trichloroethane 1,3 3.16 1,3 3.16 3.19
1,1 -Dichloroethane 1,3 2.21 1,3 2.21 2.25
1,1 -Dichloroethylene 1,3 1.84 1,3 1.84 1.80
1,1 -Dichloro-1 -Fluoroethane 
(!ICFC-141b) 15, 1.56 15, 1.56 1.73
1,2,4-Trimethylbenzene 
(Pseudocumene) 6, 18 3.25 6, 18 3.25 3.75
1,2,4-Trimethylcyclohexane 6, 18 3.19 6, 18 3.19 3.17
1,2-Dibromoethane 1,3 3.09 1,3 3.09 3.29
1,2-Dichloroethane 1,3 2.54 1,3 2.54 2.56
1,2-Dichloropropane 1,3 2.70 1,3 2.70 2.64
1,2-Dimethylcyclohexane 6, 3.24 6, 3.24 2.96
1,3-Butadiene 8, 1.35 8, 1.35 1.31
l,2-Epoxy-3-butene (BMO) 24, 2.23 24, 2.23 2.11
1 -Bromo-2-chloroethane 
(1 -Chloro-2-Bromoethane) 1,3 2.98 1,3 2.98 2.91
1-Butanol 1 2.95 1 2.95 3.02
1 -Chloropropane 
(Propyl chloride) 1,3 2.07 1,3 2.07 1.92
1 -Nitropropane 1,3 2.70 1,3 2.70 2.91
1-Pentanol 1 3.41 1 3.41 3.39
I-Propanol 1,2,4 2.47 1 2.60 1,2,4 2.54 2.59
1-Octene 5, 2.89 5, 2.89 2.69
1 -Nonene 5, 3.24 5, 3.24 3.10
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1 -Decene 5, 3.36 5, 3.36 3.40
2,2,4-Trimethylpentane
(Isooctane) 1,3 2.47 1,3 2.47 2.26
2,2-Dimethylbutane 1,2,4 1.82 1,2,4 1.82 1.70
2,2-Dichloro-l,l,l- 
Trifluroethane (HCFC-123) 16, 1.80 16, 1.80 1.92
2,3,4-Trimethylpentane 1,3 2.65 1,3 2.65 2.54
2-Chloropropane 1,3 1.84 1,3 1.84 1.72
2-Heptanone 
(Methyl pentyl ketone) 1 3.66 1 3.66 3.41
2-Methyl-1,3-butadiene 
(Isoprene) 1,3, 17 1.84 1,3, 17 1.84 1.73
2-Methyl-1 -propanol 
(Isobutanol) 1,2,4 2.59 1 2.86 1,2,4 2.73 2.86
2-Methylpentane
(Isohexane) 1,2,4 1.94 1,2,4 1.94 1.81
2-Methyl heptane 5, 2.30 5, 2.30 2.53
2-Methyl octane 5, 2.56 5, 2.56 2.90
2-Methyl nonane 5, 2.84 5, 2.84 3.26
2-Nitropropane 1,3 2.19 1,3 2.19 2.63
2-Pentanone 
(Methyl propyl ketone) 1 2.57 1 2.57 2.67
2-Propanol (Isopropanol) 1,2,4 2.26 1 2.44 1,2,4 2.35 2.31
3-Methyl-1 -butanol 
(Isopentanol) 1 3.18 1 3.18 3.30
3-Methylhexane 1,2,4 2.44 1,2,4 2.44 2.21
3-Methylpentane 1,2,4 2.01 1,2,4 2.01 1.87
4-Methyl-2-pentanone
(Methyl isobutyl ketone) 1 2.72 1 2.72 2.89
4-Chlorobenzotri fluoride 13 2.99 13 2.99 3.17
Acetone (Propan-2-one) 1,2,4 1.93 1 1.89 1,2,4 1.91 1.96
Allyl chloride 
(3-Chloro-l -propylene) 1,3 2.00 1,3 2.00 1.96
Benzene 1,2,4 2.62 1,3,6 2.65 1,2, 3,4,  6 2.64 2.47
Bromochloromethane
(Chlorobromomethane) 1,3 2.51 1,3 2.51 2.41
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Bromodichloromethane 23, 2.72 23, 2.72 2.82
Butan-2-one 
(Methyl ethyl ketone) 1,2,4 2.21 1 2.30 1,2,4 2.26 2.34
Butyl acetate 1 3.18 1 3.18 3.03
Carbon tetrachloride
(Tetrachloromethane) 1,3 2.56 1,3 2.56 2.35
CF2=CHC1
(1 -Chloro-2,2-difluroethylene) 
(1,1 -Difluro-2-ch loroethene) 2 ,4 1.30 2,4 1.30 0.95
CF3CBrClH (Halothane) 1,2,4 2.31 1,3, 16 2.23 1,2, 3,4,  16 2.27 2.13
CF3CBrFH (Teflurane) 1,4 1.30 1,4 1.30 1.48
CF3CH2C1
(2chlorol 1 ltrifluoroethane) 
(l-Chloro-2,2,2-trifluroethane) 1,2,4 1.53 1,3 1.33 1,2, 3, 4 1.43 1.38
CF3CH20CH=CH2 
(Fluomar/ Fluroxene) 1,2,4 1.53 1,2,4 1.53 1.45
CHF2CF2CH2Br
(Halopropane) 4 2.35 4 2.35 2.01
CHF20CF2CHFC1
(Enflurane) 1,4 1.97 1,4 1.97 1.79
CHF20CHC1CF3
(Isoflurane) 1,2,4 1.84 1,3 1.99 1,2, 3, 4 1.92 1.68
Chlorobenzene 1,3 3.11 1,3 3.11 3.20
Chlorodibromomethane 1,3 3.28 1,3 3.28 3.11
Chloroethane 1,3 1.59 1,3 1.59 1.53
Chloroform
(T richloromethane) 1,2,4 2.45 1,3 2.31 1,2, 3, 4 2.38 2.44
cis-1,2-Dichloroethylene 1,3 2.36 1,3 2.36 2.40
Cyclohexane 1,2,4 2.41 1,3,6 2.47 1,2, 3,4,  6, 2.44 2.24
Cyclopropane 1,2,4 0.99 1,2,4 0.99 1.11
Cyanoethylene Oxide 7, 3.11 7, 3.11 2.76
Decane 6, 3.05 6, 3.05 3.43
Dibromomethane 1,3 2.90 1,3 2.90 2.85
Dichloromethane
(Methylene chloride) 1,2,4 1.93 1,3 2.08 1,2, 3, 4 2.01 2.08
Diethyl ether 1,2,4 1.80 1,3 1.68 1,2, 3, 4 1.74 1.78
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Difluromethane (CF2H2) 1,3 0.16 1,3 0.16 0.44
Divinyl ether 1,2,4 1.60 1,2,4 1.60 1.60
Ethanol 1,2,4 2.33 1 2.35 1,2,4 2.34 2.19
Ethyl acetate 1 2.18 1 2.18 2.27
Ethyl t-butyl ether (ETBE) 9, 2.13 9, 2.13 2.28
t-butanol (tert-butanol)(TBA) 
(2-Methyl-2-propanol) 9,25 2.20 9, 25 2.20 2.39
Methyl tertiary-butyl ether 
(MTBE) 9,25 1.97 9, 25 1.97 2.07
tertiary-Amyl methyl ether 
(TAME) 9, 2.52 9, 2.52 2.47
tertiary-amyl alcohol (T A A) 9, 2.66 9, 2.66 2.88
Ethylbenzene 1 3.25 1 3.19 1, 3.22 3.21
Ethylene Oxide 21, 1.63 20, 1.64 20,21 1.64 1.75
Ethylene (Ethene) 1,4,21 0.08 21, 0.31 1,4,21, 0.20 0.26
Flurochloromethane 1,3 1.19 1,3 1.19 1.08
Furan 11, 1.81 11, 1.81 1.80
Heptane 1,2,4 2.59 1,3,6 2.42 1,2, 3, 4, 6 2.51 2.31
Hexachloroethane
(Perchloroethane) 1,3 3.52 1,3 3.52 3.98
Hexane 1,2,4 2.02 1,3,6 2.22 1,2, 3 , 4 , 6 2.12 1.93
Isobutyl acetate 1 3.05 1 3.05 2.87
Isopentylacetate
(Aceticacidpentylester) 1 3.44 1 3.44 3.30
Isopropyl acetate 1 2.48 1 2.48 2.41
Isopropyl bromide (2- 
Brompropane) 1,3 2.20 1,3 2.20 2.04
JP-10 3, 4.01 3, 4.01 3.92
Krypton 4 -0.48 4 -0.48 -0.21
MeOCF2CHC12
(Methoxyflurane) 1,2,4 2.90 1,2,4 2.90 2.74
Methanol 1,2 2.36 1 2.29 1,2 2.33 1.93
Methyl acetate 1 2.00 1 2.00 1.99
Methylchloride
(Chloromethane) 1,3 1.13 1,3 1.13 1.16
Methylcyclopentane 1,2,4 2.25 1,2,4 2.25 2.19
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Methylcyclohexane 6, 2.65 6, 2.65 2.47
m-Methylstyrene
(1 -vinyl-3-methylbenzene) 1,3 4.08 1,3 4.08 3.78
m-Xylene
(1,3-Dimethylbenzene) 1 3.28 1,3 3.30 1,3 3.29 3.26
Nitrogen 4 -1.27 4 -1.27 -0.78
Nitrous Oxide 2,4 0.04 2 ,4 0.04 0.36
Nonane 6, 18 2.92 6, 18 2.92 3.06
Octane 1,4 2.71 6, 2.73 1,4,6 2.72 2.68
o-Xylene (1,2- 
di m eth yl benzen e) 1 3.39 1,3,6 3.00 1,3,6 3.20 3.37
Pentachloroethane 1,3 3.61 1,3 3.61 3.96
Pentane 1,2,4 1.60 1,2,4 1.60 1.55
Pentyl acetate 1 3.57 1 3.57 3.39
p-Methylstyrene 
(1 -vinyl-4-methylbenzene) 1,3 4.05 1,3 4.05 3.79
Propyl acetate 1 2.71 1 2.71 2.63
Propyl bromide 
(1 -Bromopropane) 1,3 2.37 1,3 2.37 2.24
Propene (Propylene) 10, 0.71 10, 0.80 10, 0.76 0.74
p-Xylene (1,4- 
dimethylbenzene) 1 3.31 1,3 3.24 1,3 3.28 3.26
Radon 12, 0.68 12, 0.68 0.60
Styrene (Vinyl benzene) 1 3.50 1,3 3.54 1,3 3.52 3.38
t-Butylcyclohexane 6, 3.17 6, 3.17 3.49
t-Butylbenzene 6, 3.26 6, 3.26 3.68
Tetrachloroethene
(Perchloroethylene) 1,3 3.21 1,3 3.21 2.96
Toluene (methylbenzene) 1,2,4 2.95 1,3,6 2.89 1,2, 3,4,  6 2.92 2.87
trans-1,2-Dichloroethylene 1,3 2.17 1,3 2.17 2.14
Trichloroethene
(Trichloroethylene) 1,2,4 2.77 1,3,19 2.72 1,2, 3,4,  19 2.75 2.62
Vinyl bromide (Bromoethene) 1,3 1.69 1,3 1.69 1.74
Vinyl chloride (Chloroethene) 22, 1.30 1,3,22 1.30 1,3,22 1.30 1.30
Vinylidene fluoride 
(hl-Difluoroethylene ) 14, -0.10 14, -0.10 0.33
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Xenon 2 0.26 2 0.26 0.23
R ef =  Literature reference
Descriptors E, S, A , B  and L for all solutes are found in table 9 .0  from chapter 9 and table 18.0 from  
chapter 18.
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Table 14.3. Blood to fat distribution for VOCs
S O L U T E  N A M E V
F A T  
A V E R A G E  
L O G  K  
(H & R )
B L O O D  
A V E R A G E  
L O G  K  
(H & R )
L O G  P 
(B L O O D  TO  
F A T )
C A L C  
L O G  P
(CF3)2CH OCH2F (Sevoflurane) 0 .8548 1.62 -0 .20 1.82 1.29
1,1,1,2-Tetrachloroethane 0 .8800 3.33 1.55 1.78 1.50
1,1,1-Trichloroethane (M ethyl chloroform ) 0.7576 2.41 0.63 1.78 1.45
1,1,2,2-Tetrachloroethane 0 .8800 3.58 2.13 1.45 1.31
1,1,2-Trichloroethane 0.7576 3.16 1.67 1.49 1.15
1,1 -Dichloroethane 0.6352 2.21 0 .88 1.33 1.08
1,1 -D ichloroethylene 0.5922 1.84 0 .70 1.14 1.29
1,1 -D ich loro-1 -Fluoroethane (H C F C -141 b) 0 .6529 1.56 0.32 1.24 1.34
1,2,4-Trim ethylbenzene (Pseudocum ene) 1.1391 3.25 1.47 1.78 1.82
1,2,4-Trim ethylcyclohexane 1.2681 3.19 0 .87 2.32 2.43
1,2-Dibrom oethane 0.7404 3.09 2.08 1.01 1.10
1,2-Dichloroethane 0.6352 2.54 1.39 1.15 1.05
1,2-Dichloropropane 0.7761 2.70 1.14 1.56 1.32
1,2-D im ethylcyclohexane 1.1270 3.24 0.91 2.33 2.21
1,3-Butadiene 0.5862 1.35 0 .09 1.26 1.18
l,2-E poxy-3-butene (B M O ) 0.5793 2.23 1.97 0.26 0.58
1 -Brom o-2-chloroethane
(1 -Chloro-2-Brom oethane) 0 .6878 2.98 1.60 1.38 1.18
1-Butanol 0 .7309 2.95 3.08 -0.13 -0.03
1-Chloropropane (Propyl chloride) 0 .6537 2.07 0 .59 1.48 1.26
1-Nitropropane 0.7055 2.70 2.31 0.39 0.83
1 -Pentanol 0 .8718 3.41 2.83 0.58 0.18
1 -Propanol 0 .5900 2.54 3.06 -0.52 -0.25
1 -Octene 1.1928 2.89 1.07 1.82 2.15
1 -N onene 1.3337 3.24 1.18 2.06 2.43
1 -D ecene 1.4746 3.36 1.21 2.15 2.57
2,2,4-Trim ethylpentane (Isooctane) 1.2358 2.47 0.23 2.24 2.37
2,2-D im ethylbutane 0 .9540 1.82 -0 .59 2.41 1.94
2 ,2-D ich loro-1,1,1 -Trifluroethane 
(H CFC -123) 0.6883 1.80 0.61 1.19 1.16
2,3,4-Trim ethylpentane 1.2358 2.65 0 .57 2.08 2 .37
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2-Chloropropane 0.6537 1.84 0.32 1.52 1.21
2-Heptanone (M ethyl pentyl ketone) 1.1106 3.66 2.33 1.33 1.01
2-M ethyl-1,3-butadiene (Isoprene) 0.7271 1.84 0 .10 1.74 1.39
2-M ethyl-1 -propanol (1 sobutanol) 0.7309 2.73 2.92 -0 .19 -0.03
2-M ethylpentane (Isohexane) 0 .9540 1.94 -0 .39 2.33 1.94
2-M ethyl heptane 1.2358 2.30 0.49 1.81 2.37
2-M ethyl octane 1.3767 2.56 0 .52 2.04 2.58
2-M ethyl nonane 1.5176 2.84 0.76 2.08 2.79
2-Pentanone (M ethyl propyl ketone) 0 .8288 2.57 2.14 0.43 0.59
2-Propanol (Isopropanol) 0.5900 2.35 3.02 -0 .67 -0 .36
3-M ethyl-1 -butanol (Isopentanol) 0 .8718 3.18 2.75 0.43 0.18
3-M ethylhexane 1.0949 2.44 0.11 2.33 2.16
3-M ethylpentane 0.9540 2.01 -0 .37 2.38 1.94
4-M ethyl-2-pentanone 
(M ethyl isobutyl ketone) 0.9697 2.72 1.96 0.76 0.80
4-Chlorobenzotrifluoride 1.0328 2.99 1.43 1.56 2.04
A cetone (Propan-2-one) 0 .5470 1.91 2.36 -0.45 0.15
A lly l chloride (3-C hloro-l -propylene) 0 .6106 2.00 1.24 0.76 1.30
B enzene 0 .7164 2.64 1.05 1.59 1.29
Brom ochlorom ethane 
(Ch 1 orobromomethan e) 0 .5469 2.51 1.21 1.30 1.17
Brom odichlorom ethane 0.6693 2.72 1.49 1.23 1.27
Butan-2-one (M ethyl ethyl ketone) 0 .6879 2.26 2.24 0.02 0.37
Butyl acetate 1.0284 3.18 1.94 1.24 1.02
Carbon tetrachloride (Tetrachlorom ethane) 0.7391 2.56 0.62 1.94 1.63
CF2=CHC1 (1 -C hloro-2,2-difluroethylene) 
(1,1 -D ifluro-2-chloroethene) 0 .5052 1.30 0 .06 1.24 0.98
CF3CBrClH (H alothane) 0 .7410 2.27 0.57 1.70 1.26
CF3CBrFH (Teflurane) 0 .6360 1.30 -0 .22 1.52 1.09
CF3CH2C1 (2ch lorol 1 ltrifluoroethane) 
(1 -Chloro-2,2,2-tri fluroethane) 0.5659 1.43 0.14 1.29 1.10
C F3C H 20C H =C H 2 (Fluom ar/ Fluroxene) 0.7410 1.53 0.15 1.38 1.02
CHF2CF2CH2Br (H alopropane) 0.7771 2.35 0.75 1.60 1.34
CHF20CF2CHFC1 (Enflurane) 0.8009 1.97 0.35 1.62 1.19
CHF20CHC1CF3 (Isoflurane) 0 .8010 1.92 0 .20 1.72 1.28
Chlorobenzene 0.8388 3.11 1.63 1.48 1.63
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Chlorodibrom omethane 0.7219 3.28 1.88 1.40 1.32
Chloroethane 0.5128 1.59 0.49 1.10 1.05
Chloroform (Trichlorom ethane) 0 .6167 2.38 1.15 1.23 1.16
cis-1,2-D ichloroethylene 0.5922 2.36 1.16 1.20 1.11
C yclohexane 0 .8454 2 .44 0.17 2.27 1.80
Cyclopropane 0.4227 0.99 -0.21 1.20 1.16
C yanoethylene O xide 0.4952 3.11 3.22 -0.11 0.06
Dibromom ethane 0.5995 2.90 1.87 1.03 1.09
Dichlorom ethane (M ethylene chloride) 0.4943 2.01 1.12 0.89 0.98
D iethyl ether 0.7309 1.74 1.11 0.63 0.60
Difluromethane (C F2H 2) 0 .2849 0.16 0 .20 -0.04 0.67
D ivinyl ether 0.6449 1.60 0.41 1.19 1.18
Ethanol 0.4491 2.34 3.27 -0.93 -0 .46
Ethyl acetate 0 .7466 2.18 1.90 0.28 0.60
Ethyl t-butyl ether (ETBE) 1.0127 2.13 1.07 1.06 0.69
t-butanol (tert-butanol)(TBA) 
(2-M ethyl-2-propanol) 0 .7309 2.20 2.68 -0.48 -0 .20
M ethyl tertiary-butyl ether (M TBE) 0.8718 1.97 1.18 0.79 0.50
tertiary-Amyl m ethyl ether (T A M E) 1.0127 2.52 1.22 1.30 0.69
tertiary-amyl alcohol (T A A ) 0.8718 2.66 2 .59 0.07 0.01
Ethylbenzene 0 .9982 3.22 1.47 1.75 1.69
Ethylene O xide 0 .3405 1.64 1.80 -0.17 0.17
Ethylene (Ethene) 0 .3474 0.20 -0.53 0.73 0.88
Flurochloromethane 0 .5300 1.19 0.71 0.48 1.07
Furan 0.5363 1.81 0.82 0.99 1.02
Heptane 1.0949 2.51 0 .50 2.01 2.16
Hexachloroethane (Perchloroethane) 1.1248 3.52 1.76 1.76 2.20
Hexane 0 .9540 2.12 0.21 1.91 1.94
Isobutyl acetate 1.0284 3.05 1.69 1.36 0.98
Isopentylacetate (A ceticacidpentylester) 1.1693 3.44 1.79 1.65 1.19
Isopropyl acetate 0.8875 2.48 1.55 0.93 0.76
Isopropyl bromide (2-Brom propane) 0 .7063 2.20 0 .64 1.56 1.26
JP-10 1.1918 4.01 1.76 2.25 2.18
Krypton 0.2460 -0.48 -1 .22 0.74 0.88
MeOCF2CHC12 (M ethoxyflurane) 0 .8700 2 .90 1.28 1.62 1.35
Methanol 0 .3082 2.33 3.41 -1.08 -0 .74
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M ethyl acetate 0.6057 2.00 1.98 0.02 0.39
M ethylchloride (Chlorom ethane) 0.3719 1.13 0.31 0.82 0.88
M ethylcyclopentane 0.8454 2.25 -0 .07 2.32 1.79
M ethylcyclohexane 0.9863 2.65 0 .70 1.95 2.01
m -M ethylstyrene (1 -vinyl-3-m ethylbenzene) 1.0961 4.08 2.28 1.80 1.78
m -X ylene (1,3-D im ethyIbenzene) 0 .9982 3.29 1.59 1.70 1.67
Nitrogen 0.2222 -1 .27 -1.83 0.56 0.84
Nitrous Oxide 0 .2810 0.04 -0 .34 0.38 0.69
Octane 1.2358 2.72 0 .68 2.04 2.37
o-X ylene (1,2-d im ethylbenzene) 0 .9982 3.20 1.42 1.78 1.67
Pentachloroethane 1.0024 3.61 2 .02 1.59 1.62
Pentane 0.8131 1.60 -0 .29 1.89 1.73
Pentyl acetate 1.1693 3.57 1.98 1.59 1.23
p-M ethylstyrene (1 - vinyl-4-m ethylbenzene) 1.0961 4.05 2 .37 1.68 1.78
Propyl acetate 0 .8875 2.71 1.88 0.83 0.81
Propyl bromide (1-Brom opropane) 0.7063 2.37 0.97 1.40 1.31
Propene (Propylene) 0.4883 0.76 -0.21 0.97 1.09
p-X ylene (1,4-d im ethylbenzene) 0 .9982 3.28 1.61 1.67 1.67
Radon 0 .3840 0 .68 -0 .39 1.07 1.09
Styrene (V inyl benzene) 0 .9552 3.52 1.67 1.85 1.61
t-Butylcyclohexane 1.4090 3.17 1.16 2.01 2.42
t-Butylbenzene 1.2800 3 .26 1.24 2.02 2.05
Tetrachloroethene (Perchloroethylene) 0 .8370 3.21 1.19 2.02 1.79
Toluene (m ethylbenzene) 0 .8573 2.92 1.14 1.78 1.50
trans-1,2-D ichloroethylene 0.5922 2 .17 0.88 1.29 1.15
Trichloroethene (Trichloroethylene) 0 .7146 2.75 1.14 1.61 1.41
V inyl bromide (B rom oethene) 0 .5224 1.69 0 .49 1.20 1.15
V inyl chloride (C hloroethene) 0 .4698 1.30 0 .17 1.13 1.10
V inylidene fluoride (1 ,1 -D iflu oroeth y len e) 0 .3828 -0 .10 -0 .74 0 .64 0.96
Xenon 0 .3290 0.26 -0.85 1.11 1.00
O U T L IE R S
Decane 1.5176 3.05 1.47 1.58 2.70
2-Nitropropane 0 .7055 2.19 2 .23 -0.04 0.78
N onane 1.3767 2.92 1.17 1.75 2.58
R ef = Literature reference
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Descriptors E, S, A  and B  for all solutes are found in table 9 .0  from chapter 9 and table 18.0 from chapter 
18.
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Table 15.0. Data set used to obtain a model to correlate air to liver distributions for VOCs in humans and rats combined
SOLUTE NAME LIVER
REF
LIVER HUM 
LOG K
LIVER
REF
LIVER RAT 
LOG K
LIVER REF 
(H&R)
LIVER AVERAGE 
LOG K (H&R)
CALC 
LOG K
(CF3)2CH OCH2F (Sevoflurane) 1 ,2 ,4 0.43 1 ,2 ,4 0.43 0.71
1,1,1,2-Tetrachloroethane 1 ,3 1.95 1 ,3 1.95 2.08
1,1,1 -Trichloroethane 
(M ethyl chloroform) 1 ,2 ,4 1.21 1 ,3 0.93 1 ,2 , 3 ,4 1.07 1.14
1,1,2,2-Tetrachloroethane 1 ,3 2.29 1 ,3 2 .29 2.53
1,1,2-Trichloroethane 1 ,3 1.86 1 ,3 1.86 2.11
1,1-Dichloroethane 1 ,3 1.03 1 ,3 1.03 1.27
1,1 -D ichloroethylene 1 ,3 0.65 1 ,3 0.65 0.65
1,1 -D ich loro-1 -Fluoroethane 
(HCFC- 141b) 15, 0.52 15, 0.52 0.63
1,2,4-Trim ethylcyclohexane 6, 18 1.72 6, 18 1.72 1.55
1,2-Dibrom oethane 1 ,3 2.08 1 ,3 2.08 2.24
1,2-Dichloroethane 1 ,3 1.55 1 ,3 1.55 1.55
1,2-Dichloropropane 1 ,3 1.39 1 ,3 1.39 1.54
1,2-D im ethylcyclohexane 6, 2.08 6, 2.08 1.40
1,3-Butadiene 8, -0.17 8, -0.17 0.36
l,2-E poxy-3-butene (BM O ) 23, 1.74 23, 1.74 1.48
1 -Brom o-2-chloroethane 
(1 -Chloro-2-Brom oethane) 1 ,3 1.63 1 ,3 1.63 1.79
1 -Butanol 1 3.10 1 3.10 2.92
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1-Chloropropane (Propyl chloride) 1 ,3 0.71 1 ,3 0.71 0.85
1 -Nitropropane 1 ,3 2.18 1 ,3 2.18 2 .09
1 -Pentanol 1 3.24 1 3.24 3.20
1 -Propanol 1 3.11 1 3.11 2 .60
1-Octene 5, 1.87 5, 1.87 1.29
1-Nonene 5, 2.11 5, 2.11 1.62
1-D ecene 5, 2.27 5, 2.27 1.82
2,2,4-Trim ethylpentane (Isooctane) 1 ,3 1.03 1 ,3 1.03 0.82
2,2-Dim ethylbutane 1 ,2 ,4 0.54 1 ,2 ,4 0.54 0 .40
2 ,2-D ich loro-1,1,1 -Trifluroethane 
(H CFC -123) 16, 0.67 16, 0.67 0.98
2,3,4-Trim ethylpentane 1 ,3 1.27 1 ,3 1.27 1.03
2-Chloropropane 1 ,3 0.50 1 ,3 0.50 0.72
2-H eptanone (M ethyl pentyl ketone) 1 2.63 1 2.63 2 .77
2-M ethyl-1,3-butadiene (Isoprene) 1 ,3 , 17 0.42 1 ,3 , 17 0.42 0.67
2-M ethyl-1 -propanol (Isobutanol) 1 2.94 1 2.94 2.79
2-M ethylpentane (Isohexane) 1 ,2 ,4 0.65 1 ,2 ,4 0.65 0.48
2-M ethyl heptane 5, 1.01 5, 1.01 1.03
2-M ethyl octane 5, 1.26 5, 1.26 1.29
2-M ethyl nonane 5, 1.52 5, 1.52 1.56
2-Nitropropane 1 ,3 1.80 1 ,3 1.80 1.92
2-Pentanone (M ethyl propyl ketone) 1 2.27 1 2.27 2.22
2-Propanol (Isopropanol) 1 2.99 1 2.99 2.46
3-M ethyl-1 -butanol (Isopentanol) 1 2.97 1 2.97 3.12
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3-M ethylhexane 1 ,2 ,4 1.04 1 ,2 ,4 1.04 0.78
3 -M ethylpentane 1 ,2 ,4 0.69 1 ,2 ,4 0.69 0.53
4-M ethyl-2-pentanone
(M ethyl isobutyl ketone) 1 2.19 1 2 .19 2.38
4-Chlorobenzotri fluoride 13, 1.71 13, 1.71 1.66
A cetone (Propan-2-one) 1 2.38 1 2.38 1.72
B enzene 1 ,2 ,4 1.36 1 ,3 ,6 1.15 1 ,2 , 3, 4 ,6 1.26 1.37
Bromochlorom ethane (Chlorobromomethane) 1 ,3 1.47 1 ,3 1.47 1.25
Bromodichloromethane 22, 1.49 22, 1.49 1.63
Butan-2-one (M ethyl ethyl ketone) 1 2.36 1 2.36 1.97
Butyl acetate 1 2.45 1 2.45 2.36
Carbon D isulfide 4 0.78 4 0.78 0.73
Carbon tetrachloride 
(T etrachloromethane) 1 ,3 1.15 1 ,3 1.15 0.98
CF2=CHC1
(1 -Chloro-2,2-difluroethylene) 
(1,1 -D ifiuro-2-chloroethene) 2 ,4 0.04 2 ,4 0.04 0.12
CF3CBrClH (Halothane) 1 ,2 ,4 0.86 1 ,3 , 16 0.86 1 ,2 , 3, 4 , 16 0.86 1.13
CF3CBrFH (Teflurane) 1 ,4 0.01 1 ,4 0.01 0.62
CF3CH2C1 (2chlorol 1 ltrifluoroethane) 
(1 -Chloro-2,2,2-trifluroethane) 1 ,2 ,4 0.36 1 ,3 0.26 1 ,2 , 3, 4 0.31 0.48
C F3C H 20C H =C H 2  
(Fluomar/ Fluroxene) 1 ,2 ,4 0.33 1 ,2 ,4 0.33 0.79
CHF20CF2CHFC1 (Enfiurane) 1 ,2 ,4 0.62 1 ,2 ,4 0.62 0.97
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CHF20CHC1CF3 (Isoflurane) 1 ,2 ,4 0.55 1 ,3 0.57 1 ,2 , 3, 4 0.56 0.83
Chlorobenzene 1 ,3 1.94 1 ,3 1.94 1.81
Chlorodibromomethane 1 ,3 2.10 1 ,3 2.10 1.88
Chloroethane 1 ,3 0.56 1 ,3 0.56 0.56
Chloroform (Trichloromethane) 1 ,2 ,4 1.23 1 ,3 1.32 1 ,2 , 3, 4 1.28 1.34
cis-1,2-D ichloroethylene 1 ,3 1.18 1 ,3 1.18 1.31
Cyclohexane 1 ,2 ,4 1.03 1 ,3 ,6 1.06 1 ,2 , 3, 4 , 6 1.05 0.84
Cyclopropane 1 ,2 ,4 -0 .19 1 ,2 ,4 -0 .19 0.03
C yanoethylene O xide 7, 2.66 7, 2.66 2.38
D ecane 6, 1.64 6, 1.64 1.69
Dibromom ethane 1 ,3 1.83 1 ,3 1.83 1.73
Dichlorom ethane
(M ethylene chloride) 1 ,2 ,4 0.86 1 ,3 1.15 1 ,2 , 3 ,4 1.01 1.06
D iethyl ether 1 ,2 ,4 1.05 1 ,3 0.83 1 ,2 , 3 ,4 0.94 1.34
Difluromethane (CF2H2) 1 ,3 0.44 1 ,3 0.44 -0.25
D ivinyl ether 1 ,2 ,4 0.48 1 ,2 ,4 0.48 0.66
Ethyl acetate 1 2.03 1 2.03 1.80
Ethyl t-butyl ether (ETBE) 9, 1.52 9, 1.52 1.97
t-butanol (tert-butanol)(TBA) 
(2-M ethyl-2-propanol) 9, 24 2.69 9, 24 2.69 2.55
M ethyl tertiary-butyl ether (M TBE) 9, 24 1.35 9, 24 1.35 1.81
tertiary-Amyl m ethyl ether (TAM E) 9, 1.50 9, 1.50 2.12
tertiary-amyl alcohol (T A A ) 9, 2.68 9, 2.68 2.92
Ethylbenzene 1 1.78 1 1.78 1.93
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Ethylene O xide 20, 1.73 20, 1.73 1.30
Ethylene (Ethene) 20, -0.35 20, -0 .24 20, -0 .30 -0.51
Flurochloromethane 1 ,3 0.54 1 ,3 0.54 0.19
Furan 11, 0 .77 11, 0.77 0.84
Heptane 1 ,2 ,4 1.04 1 ,3 ,6 0 .87 1 ,2 , 3, 4 , 6 0.96 0.86
Hexachloroethane
(Perchloroethane) 1 ,3 2.57 1 ,3 2.57 2.28
Hexane 1 ,2 ,4 0.72 1 ,3 ,6 0.65 1 ,2 , 3, 4 , 6 0 .69 0.58
Isobutyl acetate 1 2.42 1 2.42 2.27
Isopentylacetate
(Aceticacidpentylester) 1 2.55 1 2.55 2.59
Isopropyl acetate 1 2.17 1 2.17 1.93
Isopropyl bromide 
(2-Brompropan e) 1 ,3 0.64 1 ,3 0.64 1.00
JP-10 3, 2.74 3, 2.74 2.29
Krypton 4 -1.14 4 -1.14 -1.02
MeOCF2CHC12 (M ethoxyflurane) 1 ,2 ,4 1.46 1 1.47 1 ,2 ,4 1.47 1.69
M ethyl acetate 1 1.95 1 1.95 1.59
M ethylchloride (Chloromethane) 1 ,3 0.54 1 ,3 0.54 0.25
M ethylcyclopentane 1 ,2 ,4 0.89 1 ,2 ,4 0.89 0.80
M ethylcyclohexane 6, 1.50 6, 1.50 1.00
m -M ethylstyrene
(l-v inyl-3-m ethylbenzene) 1 ,3 2.51 1 ,3 2.51 2.45
m -X ylene (1 ,3-Dim ethyl benzene) 1 ,3 1.96 1 ,3 1.96 1.99
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Nitrous O xide 2 ,4 -0.38 2 ,4 -0 .38 -0.33
Nonane 6, 18 1.14 6, 18 1.14 1.41
Octane 1 ,4 1.41 6, 0 .99 1 ,4 ,6 1.20 1.13
o-X ylene (1 ,2-dimethyl.benzene) 1 ,3 ,6 1.76 1 ,3 ,6 1.76 2.08
Pentachloroethane 1 ,3 2.41 1 ,3 2.41 2.61
Pentane 1 ,2 ,4 0.32 1 ,2 ,4 0.32 0.30
Pentyl acetate 1 2.64 1 2 .64 2.63
p-M ethylstyrene
(1 -vinyl-4-m ethylbenzene) 1 ,3 2.51 1 ,3 2.51 2.46
Propyl acetate 1 2.36 1 2.36 2.06
Propyl bromide (1-Brom opropane) 1 ,3 0.91 1 ,3 0.91 1.13
Propene (Propylene) 10, -0.27 10, -0 .29 10, -0 .28 -0.17
p-X ylene (1 ,4-dim ethylbenzene) 1 ,3 1.95 1 ,3 1.95 1.99
Radon 12, -0.51 12, -0.51 -0.42
Styrene (V inyl benzene) 1 ,3 2.14 1 ,3 2.14 2.12
t-Butylcyclohexane 6, 1.46 6, 1.46 1.95
t-Butylbenzene 6, 1.73 6, 1.73 2.33
Tetrachloroethene 
(Perch loroethylene) 1 ,3 1.85 1 ,3 1.85 1.46
Toluene (m ethylbenzene) 1 ,2 ,4 1.68 1 ,3 ,6 1.60 1 ,2 , 3, 4, 6 1.64 1.67
trans-1,2-Dichloroethylene 1 ,3 0.95 1 ,3 0.95 1.06
Trichloroethene (Trichloroethylene) 1 ,2 ,4 1.41 1 ,3 ,1 9 1.40 1 ,2 ,3 ,4 ,1 9 1.41 1.36
Vinyl bromide (Brom oethene) 1 ,3 0.52 1 ,3 0.52 0.68
V inyl chloride (Chioroethene) 21, 0.20 1 ,3 ,2 1 0.20 1 ,3 ,2 1 0.20 0.29
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V inylidene fluoride 
(1,1 -D ifluoroethylene ) 14, 0 .00 14, 0.00 -0.51
Xenon 2 -1.00 2 -1 .00 -0.69
O U T L IE R S
Methanol 1 3.49 1 3.49 2.45
Ethanol 1 3.24 1 3.24 2 .39
A lly l chloride 
(3-C hloro-1 -propylene) 1 ,3 1.59 1 ,3 1.59 0.82
1,2,4-Trim ethylbenzene (Pseudocum ene) 6, 18 1.67 6, 18 1.67 2.42
“Calculated values for log K, obtained when correlating with the Abraham descriptors (E , S, A , B and L) 
bREF= Literature reference
Descriptors E, S, A , B and L for all solutes are found in table 9 .0  from chapter 9 and table 18.0 from chapter 18.
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Table 15.3. Data set used to obtain a model to correlate blood to liver distributions for
VOCs in humans and rats combined
SO L U T E  N A M E V L IV E R  (A V E ) 
L O G  K  (H & R )
B L O O D  
L O G  K
L IV E R  L O G  P 
(H & R )
C A L C  
L O G  P
(CF3)2CH OCH2F (Sevoflurane) 0 .8548 0.43 -0 .20 0.63 0.43
1,1,1,2-Tetrachloroethane 0 .8800 1.95 1.55 0.40 0.31
1,1,1 -Trichloroethane 
(M ethyl chloroform )
0 .7576
1.07 0.63 0.44 0.29
1,1,2,2-Tetrachloroethane 0 .8800 2.29 2.13 0.16 0.24
1,1,2-Trichloroethane 0 .7576 1.86 1.67 0.19 0 .16
1,1 -D ichloroethane 0.6352 1.03 0.88 0.15 0.14
1,1 -D ichloroethylene 0 .5922 0.65 0 .70 -0 .05 0.18
1,1 -D ich loro-1 -Fluoroethane 
(HCFC-141b)
0 .6529
0.52 0.32 0 .20 0.22
1,2,4-T rim ethylcyclohexane 1.2681 1.72 0 .87 0.85 0.83
1,2-Dibrom oethane 0 .7404 2.08 2.08 0 .00 0.10
1,2-D ichloroethane 0 .6352 1.55 1.39 0 .16 0.09
1,2-Dichloropropane 0.7761 1.39 1.14 0.25 0.21
1,2-D im ethylcyclohexane 1.1270 2.08 0.91 1.17 0.70
1,3-Butadiene 0 .5862 -0.17 0.09 -0 .26 0.19
l,2-E poxy-3-butene (B M O ) 0.5793 1.74 1.97 -0.23 0.02
1 -Brom o-2-chloroethane
(1 -C hloro-2-Brom oethane)
0 .6878
1.63 1.60 0.03 0.11
1-Butanol 0 .7309 3.10 3.08 0.02 0.05
1 -Chloropropane
(Propyl chloride)
0 .6537
0.71 0.59 0.12 0.21
1 -Nitropropane 0.7055 2 .18 2.31 -0.13 0.01
1 -Pentanol 0 .8718 3 .24 2.83 0.41 0.18
1 -Propanol 0 .5900 3.11 3.06 0.05 -0.07
1 -Octene 1.1928 1.87 1.07 0 .80 0.79
1 -N onene 1.3337 2.11 1.18 0.93 0 .87
1-D ecene 1.4746 2.27 1.21 1.06 1.04
2 ,2 ,4-T rim ethylpentane 
(Isooctane)
1.2358
1.03 0.23 0.80 0.88
2,2-D im ethylbutane 0 .9540 0.54 -0 .59 1.13 0.63
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2 ,2 -D ic h lo r o - l,l ,l-  
Trifluroethane (H C FC -123)
0.6883
0.67 0.61 0.06 0.24
2,3,4-T  rim ethylpentane 1.2358 1.27 0.57 0.70 0.88
2-Chloropropane 0 .6537 0.50 0 .32 0.18 0.22
2-Heptanone
(M ethyl pentyl ketone)
1.1106
2.63 2.33 0 .30 0 .38
2-M ethyl-1,3-butadiene 
(Isoprene)
0.7271
0.42 0 .10 0.32 0.32
2-M ethyl-1 -propanol 
(Isobutanol)
0 .7309
2 .94 2 .92 0.02 0.06
2-M ethylpentane (Isohexane) 0 .9540 0.65 -0 .39 1.04 0.63
2-M ethyl heptane 1.2358 1.01 0 .49 0.52 0.88
2-M ethyl octane 1.3767 1.26 0 .52 0.74 1.00
2-M ethyl nonane 1.5176 1.52 0 .76 0.76 1.13
2-Nitropropane 0.7055 1.80 2.23 -0.43 0.02
2-Pentanone (M ethyl propyl 
ketone)
0 .8288
2.27 2 .14 0.13 0.13
2-Propanol (Isopropanol) 0 .5900 2.99 3.02 -0.03 -0.07
3-M ethyl-1 -butanol 
(Isopentanol)
0.8718
2.97 2.75 0.22 0.19
3-M ethylhexane 1.0949 1.04 0.11 0.93 0.76
3-M ethylpentane 0 .9540 0.69 -0 .37 1.06 0.63
4-M ethyl-2-pentanone
(M ethyl isobutyl ketone)
0 .9697
2.19 1.96 0.23 0.27
4-Chlorobenzotri fluoride 1.0328 1.71 1.43 0.28 0 .50
A cetone (Propan-2-one) 0 .5470 2.38 2 .36 0.02 -0.12
B enzene 0 .7164 1.26 1.05 0.21 0.19
Brom ochlorom ethane 
(Chi orobromomethane)
0.5469
1.47 1.21 0.26 -0.01
Brom odichlorom ethane 0.6693 1.49 1.49 0.00 0.12
Butan-2-one
(M ethyl ethyl ketone)
0 .6879
2.36 2.24 0.12 0.00
Butyl acetate 1.0284 2.45 1.94 0.51 0.36
Carbon D isulfide 0.4905 0.78 0.30 0.48 0.10
Carbon tetrachloride
(Tetrachloromethane)
0.7391
1.15 0.62 0.53 0.31
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CF2=CHC1
(1 -C hloro-2,2-dif1uroethylene) 
(1,1 -D ifluro-2-chloroethene)
0 .5052
0.04 0.06 -0 .02 0.14
CF3CBrClH (H alothane) 0 .7410 0.86 0.57 0.29 0.28
CF3CBrFH (Teflurane) 0 .6360 0.01 -0 .22 0.23 0.25
CF3CH2C1
(2chlorol 1 ltrifluoroethane)
(] -C hloro-2,2,2-trifluroethane)
0 .5659
0.31 0 .14 0.17 0.14
C F3C H 20C H =C H 2  
(Fluoniar/ Fluroxene)
0 .7410
0.33 0.15 0.18 0.25
CHF20CF2CHFC1 (Enflurane) 0 .8009 0.62 0.35 0.27 0.32
CHF20CHC1CF3 (Isoflurane) 0 .8010 0.56 0 .2 0 0.36 0.31
Chlorobenzene 0.8388 1.94 1.63 0.31 0.28
Chlorodibromomethane 0 .7219 2.10 1.88 0.22 0.14
Chloroethane 0.5128 0.56 0 .49 0.07 0.08
Chloroform (Trichlorom ethane) 0 .6167 1.28 1.15 0.13 0.13
c is -1,2-D ichloroethylene 0 .5922 1.18 1.16 0.02 0.09
Cyclohexane 0 .8454 1.05 0.17 0.88 0.49
Cyclopropane 0 .4227 -0.19 -0.21 0.02 0.08
Cyanoethylene O xide 0 .4952 2.66 3.22 -0 .56 -0.27
Dibromom ethane 0 .5995 1.83 1.87 -0 .04 0.04
D ichlorom ethane
(M ethylene chloride)
0.4943
1.01 1.12 -0.11 0.01
D iethyl ether 0 .7309 0.94 1.11 -0.17 0.20
Difluromethane (CF2I I2) 0 .2849 0.44 0 .20 0.24 -0.11
D ivinyl ether 0 .6449 0.48 0.41 0.07 0.19
Ethyl acetate 0 .7466 2.03 1.90 0.13 0.10
Ethyl t-butyl ether (ETBE) 1.0127 1.52 1.07 0.45 0.42
t-butanol (tert-butanol)(TBA) 
(2-M ethyl-2-propanol)
0 .7309
2.69 2.68 0.01 0.06
M ethyl tertiary-butyl ether 
(M TBE)
0.8718
1.35 1.18 0.17 0.29
tertiary-Amyl m ethyl ether 
(TAM E)
1.0127
1.50 1.22 0.28 0.41
tertiary-amyl a lcohol 
(TA A)
0.8718
2.68 2 .59 0 .09 0.18
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Ethylbenzene 0.9982 1.78 1.47 0.31 0.44
Ethylene O xide 0.3405 1.73 1.80 -0 .07 -0 .26
Ethylene (Ethene) 0.3474 -0 .30 -0.53 0.24 0.04
Flurochloromethane 0 .5300 0.54 0.71 -0 .17 0.16
Furan 0.5363 0.77 0.82 -0 .05 0.05
Heptane 1.0949 0.96 0 .50 0.46 0.76
Hexachloroethane
(Perchloroethane)
1.1248
2.57 1.76 0.81 0.55
Hexane 0.9540 0.69 0.21 0.48 0.63
Isobutyl acetate 1.0284 2.42 1.69 0.73 0.36
Isopentylacetate
(A ceticacidpentylester)
1.1693
2.55 1.79 0 .76 0.48
Isopropyl acetate 0.8875 2.17 1.55 0.62 0.24
Isopropyl bromide 
(2-Brom propane)
0 .7063
0.64 0.64 0 .00 0.25
JP-10 1.1918 2.74 1.76 0.98 0.66
Krypton 0.2460 -1 .14 -1 .22 0.08 0.01
MeOCF2CHC12
(M ethoxyflurane)
0 .8700
1.47 1.28 0.19 0.29
M ethyl acetate 0.6057 1.95 1.98 -0.03 -0.03
M ethylchloride (Chlorom ethane) 0 .3719 0.54 0.31 0.23 -0.04
M ethylcyclopentane 0.8454 0.89 -0 .07 0.96 0.50
M ethylcyclohexane 0.9863 1.50 0 .70 0 .80 0.63
m -M ethylstyrene
(1 -vinyl-3-m ethylbenzene)
1.0961
2.51 2.28 0.23 0.46
m -X ylene (1 ,3- 
D im ethylbenzene)
0 .9982
1.96 1.59 0.37 0.43
Nitrous O xide 0 .2810 -0.38 -0 .34 -0 .04 -0.10
Octane 1.2358 1.20 0.68 0.52 0.88
o-X ylene (1 ,2-dim ethylbenzene) 0 .9982 1.76 1.42 0.34 0.42
Pentachloroethane 1.0024 2.41 2.02 0.39 0.39
Pentane 0.8131 0.32 -0 .29 0.61 0.51
Pentyl acetate 1.1693 2.64 1.98 0.66 0.48
p-M ethylstyrene 
(1 -vinyl-4-m ethylbenzene)
1.0961
2.51 2.37 0.14 0.46
Propyl acetate 0.8875 2.36 1.88 0.48 0.23
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Propyl bromide 
(1 -Bromopropane)
0 .7063
0.91 0 .97 -0 .06 0.24
Propene (Propylene) 0.4883 -0.28 -0.21 -0 .07 0.17
p-X ylene (1 .4-dim ethylbenzene) 0 .9982 1.95 1.61 0.34 0.43
Radon 0.3840 -0.51 -0 .39 -0 .12 0.13
Styrene (V inyl benzene) 0 .9552 2.14 1.67 0.47 0.35
t-Butylbenzene 1.2800 1.73 1.24 0.49 0.68
T etrachloroethene 
(Perchloroethylene)
0 .8370
1.85 1.19 0.66 0.37
Toluene (m ethylbenzene) 0 .8573 1.64 1.14 0.50 0.32
trans-1,2-D ichloroethylene 0.5922 0.95 0.88 0.07 0.14
Trichloroethene
(Trichloroethylene)
0 .7146
1.41 1.14 0.27 0.26
V inyl bromide (B rom oethene) 0 .5224 0.52 0 .49 0.03 0.06
V inyl chloride (C hloroethene) 0 .4698 0.20 0.17 0.03 0.07
Xenon 0 .3290 -1 .00 -0 .85 -0.15 0.09
O U T L IE R S
Nonane 1.3767 1.14 1.17 -0.03 0.86
Decane 1.5176 1.64 1.47 0.17 0.95
t-Butylcyclohexane 1.4090 1.46 1.16 0 .30 0.91
V inylidene fluoride 
(1,1 -D iflu oroeth y len e)
0 .3828 0 .00 -0 .74 0.74 0.14
“Calculated values for log  P, obtained when correlating with the Abraham descriptors (E , S, A , B and V )
Descriptors E, S, A  and B  for all solutes are found in table 9 .0  from chapter 9 and table 18.0 from chapter 
18.
bREF= Literature reference
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Table 16.0. Data set used to obtain a model to correlate air to muscle distributions for VOCs in humans and rats combined.
SO L U T E  N A M E M U S
R E F
M U SC L E
H U M
L O G  K
M U S
R E F
M U SC L E
R A T
L O G  K
M U S
R E F
(H & R )
M U SC L E
A V E R A G E
L O G  K  (H & R )
C A L C 8 
L O G  K
(CF3)2CH OCH2F (Sevoflurane) 1 ,2 ,4 0.22 1 ,2 ,4 0.22 0.44
1,1,1,2-T  etrachloroethane 1 ,3 1.60 1 ,3 1.60 1.74
1,1,1-Trichloroethane (M ethyl chloroform) 1 ,2 ,4 0.83 1 ,3 0.50 1 ,2 , 3, 4 0.67 0.82
1,1,2,2-T  etrachloroethane 1 ,3 2.00 1 ,3 2.00 2.21
1,1,2-Trichloroethane 1 ,3 1.36 1 ,3 1.36 1.82
1,1 -D ichloroethane 1 ,3 0.71 1 ,3 0.71 1.03
1,1 -D ichloroethylene 1 ,3 0.31 1 ,3 0.31 0.38
1,1 -D ich loro-1 -Fluoroethane (IICFC- 141b) 11, 0.02 11, 0.02 0.33
1,2-Dibrom oethane 1 ,3 1.66 1 ,3 1.66 1.97
1,2-Dichloroethane 1 ,3 1.37 1 ,3 1.37 1.30
1,2-Dichloropropane 1 ,3 1.08 1 ,3 1.08 1.23
1,3-Butadiene 5, -0.06 5, -0.06 0.16
l,2-E poxy-3-butene (BM O) 16, 1.66 16, 1.66 1.31
1 -Brom o-2-chloroethane
(1 -Chloro-2-Brom oethane) 1 ,3 1.40 1 ,3 1.40 1.51
1 -Butanol 1 2.95 1 2.95 2.90
1-Chloropropane (Propyl chloride) 1 ,3 0.32 1 ,3 0.32 0.56
1 -Nitropropane 1 ,3 1.46 1 ,3 1.46 1.80
1 -Pentanol 1 2.91 1 2.91 3.13
1 -Propanol 1 ,2 ,4 2.83 1 3.06 1 ,2 ,4 2.95 2.64
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2,2,4-Trim ethylpentane (Isooctane) 1 ,3 0.52 1 ,3 0.52 0.40
2,2-Dim ethylbutane 1 ,2 ,4 0.00 1 ,2 ,4 0.00 0.05
2,2-D ich loro-1,1,1 -Trifluroethane
(H C FC -123) 12, 0.39 12, 0.39 0.74
2,3,4-Trim ethylpentane 1 ,3 0.64 1 ,3 0.64 0.57
2-Chloropropane 1 ,3 0.31 1 ,3 0.31 0.46
2-H eptanone (M ethyl pentyl ketone) 1 2.33 1 2.33 2.48
2-M ethyl-1,3-butadiene (Isoprene) 1 ,3 ,1 3 0.26 1 ,3 ,1 3 0.26 0.41
2-M ethyl-1-propanol (Isobutanol) 1 ,2 ,4 2.54 1 2.93 1 ,2 ,4 2.74 2.79
2-M ethylpentane (isohexane) 1 ,2 ,4 0.46 1 ,2 ,4 0.46 0.12
2-Nitropropane 1 ,3 1.46 1 ,3 1.46 1.67
2-Pentanone (M ethyl propyl ketone) 1 2.00 1 2.00 2.02
2-Propanol (Isopropanol) 1 ,2 ,4 2.70 1 3.04 1 ,2 ,4 2.87 2.53
3-M ethyl-1 -butanol (Isopentanol) 1 2.90 1 2.90 3.06
3-M ethylhexane 1 ,2 ,4 1.04 1 ,2 ,4 1.04 0.37
3-M ethylpentane 1 ,2 ,4 0.58 1 ,2 ,4 0.58 0.16
4-M ethyl-2-pentanone
(M ethyl isobutyl ketone) 1 1.81 1 1.81 2.14
Acetone (Propan-2-one) 1 ,2 ,4 2.18 1 2.23 1 ,2 ,4 2.21 1.63
A cetylene 4 0.03 4 0.03 -0.21
A llyl chloride (3-Chloro-l -propylene) 1 ,3 1.04 1 ,3 1.04 0.53
Argon 4 -1.64 4 -1.64 -1.36
Benzene 1 ,2 ,4 1.21 1 ,3 1.01 1 ,2 , 3, 4 1.11 1.10
Bromochloromethane (Ch lorobromomethane) 1 ,3 1.05 1 ,3 1.05 0.96
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Butan-2-one (M ethyl ethyl ketone) 1 ,2 ,4 2.01 1 2.26 1 ,2 ,4 2.14 1.82
Butyl acetate 1 2 .20 1 2.20 2.07
Carbon tetrachloride (Tetrachloromethane) 1 ,3 0.66 1 ,3 0.66 0.64
C F 2C H C 1
(1 -Chloro-2,2-di fluroethylene) 
(1,1 -D ifluro-2-chloroethene) 2 ,4 0.00 2 ,4 0.00 -0.08
CF3CBrClH (Halothane) 1 ,2 ,4 0.83 1 ,3 0.65 1 ,2 , 3, 4 0.74 0.87
CF3CBrFH (Teflurane) 2 ,4 0.34 2 ,4 0.34 0.43
CF3CH2C1 (2chlorol 1 ltrifluoroethane) 
(1-Chloro-2,2,2-trifluroethane) 1 ,2 ,4 0.34 1 ,3 0 .09 1 ,2 , 3, 4 0.22 0.28
C F3C H 20C H =C H 2 (Fluornar/ Fluroxene) 1 ,2 ,4 0.35 1 ,2 ,4 0.35 0.62
CHF20CF2CHFC1 (Enflurane) 1 ,2 ,4 0.64 1 ,2 ,4 0.64 0.72
CHF20CHC1CF3 (Isoflurane) 1 ,2 ,4 0.41 1 ,3 0.20 1 ,2 , 3 ,4 0.31 0.57
Chlorobenzene 1 ,3 1.53 1 ,3 1.53 1.45
Chlorodibromomethane 1 ,3 1.75 1 ,3 1.75 1.59
Chloroethane 1 ,3 0.51 1 ,3 0.51 0.32
Chloroform (Trichloromethane) 1 ,2 ,4 1.09 1 ,3 1.14 1 ,2 , 3, 4 1.12 1.09
c is -1,2-D ichloroethylene 1 ,3 0.78 1 ,3 0.78 1.06
Cyclohexane 1 ,2 ,4 1.02 1 ,3 0.01 1 ,2 , 3, 4 0.52 0.47
Cyclopropane 1 ,2 ,4 -0.31 1 ,2 ,4 -0.31 -0.18
Dibromomethane 1 ,3 1.61 1 ,3 1.61 1.47
Dichlorom ethane (M ethylene chloride) 1 ,2 ,4 0.68 1 ,3 0.90 1 ,2 ,3 ,4 0.79 0.84
Diethyl ether 1 ,2 ,4 1.01 1 ,3 0.72 1 ,2 , 3, 4 0.87 1.19
Difluromethane (CF2H2) 1 ,3 0.16 1 ,3 0.16 -0.41
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D ivinyl ether 1 ,2 ,4 0.34 1 ,2 ,4 0.34 0.43
Ethanol 1 ,2 ,4 2.93 1 3.23 1 ,2 ,4 3.08 2.39
Ethyl acetate 1 1.84 1 1.84 1.61
Ethyl t-butyl ether (ETBE) 6, 1.35 6, 1.35 1.81
t-butanol (tert-butanol)(TBA) 
(2- M ethy 1-2-propanol) 6, 17 2.80 6, 17 2.80 2.61
M ethyl tertiary-butyl ether (M TBE) 6, 1.57 6, 1.57 1.68
tertiary-Amyl m ethyl ether (TAM E) 6, 1.38 6, 1.38 1.95
tertiary-amyl alcohol (T A A ) 6, 2.59 6, 2.59 2.92
Ethylbenzene 1 1.41 1 1.41 1.58
Ethylene O xide 15, 1.82 14, 1.68 14, 15 1.75 1.20
Ethylene (Ethene) 15, -0 .19 15, -0.20 15, -0.20 -0.64
Flurochloromethane 1 ,3 0.39 1 ,3 0.39 -0.02
H elium 4 -1.93 4 -1.93 -1.84
Heptane 1 ,2 ,4 1.08 1 ,3 0.62 1 ,2 , 3, 4 0.85 0.43
Hexachloroethane (Perchloroethane) 1 ,3 1.88 1 ,3 1.88 1.78
Hexane 1 ,2 ,4 0.70 1 ,3 0.46 1 ,2 , 3 ,4 0.58 0.20
Hydrogen 4 -1.76 4 -1.76 -1.59
Isobutyl acetate 1 2.04 1 2.04 2.01
Isopentylacetate (Aceticacidpentylester) 1 2.32 1 2.32 2.28
Isopropyl acetate 1 1.85 1 1.85 1.72
Isopropyl bromide (2-Brompropane) 1 ,3 0.61 1 ,3 0.61 0.74
Krypton 4 -1.38 4 -1.38 -1.14
MeOCF2CHC12 (M ethoxyflurane) 1 ,2 ,4 1.35 1 ,2 ,4 1.35 1.37
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Methane 4 -1.41 4 -1.41 -1.19
M ethyl acetate 1 1.81 1 1.81 1.45
M ethylchloride (Chloromethane) 1 ,3 -0.01 1 ,3 -0.01 0.06
M ethylcyclopentane 1 ,2 ,4 0.70 1 ,2 ,4 0.70 0.43
m -M ethylstyrene
( I - vinyl-3 -m ethylbenzene) 1 ,3 2.26 1 ,3 2.26 2.08
m -X ylene (1 ,3-D im ethylbenzene) 1 ,3 1.62 1 ,3 1.62 1.64
Nitrous O xide 2 ,4 -0.43 2 ,4 -0.43 -0.45
Octane 1 ,4 0.93 1 ,4 0.93 0.66
o-X ylene (1 ,2-dim ethylbenzene) 1 ,3 1.71 1 ,3 1.71 1.72
Pentachloroethane 1 ,3 1.86 1 ,3 1.86 2.25
Pentane 1 ,2 ,4 -0.15 1 ,2 ,4 -0.15 -0.04
Pentyl acetate 1 2.36 1 2.36 2.30
p-M ethyl styrene 
(1 -vinyl-4-m ethylbenzene) 1 ,3 2.26 1 ,3 2.26 2.09
Propyl acetate 1 1.93 1 1.93 1.83
Propyl bromide (1 -Brornopropane) 1 ,3 0.62 1 ,3 0.62 0.84
Propene (Propylene) 7, -0.19 7, -0.34 7, -0.27 -0.35
p-X ylene (1 ,4-dim ethylbenzene) 1 ,3 1.58 1 ,3 1.58 1.64
Radon 8, -0.81 8, -0.81 -0.63
Styrene (V inyl benzene) 1 ,3 1.67 1 ,3 1.67 1.79
Sulphur Hexafluoride 4 -1.85 4 -1.85 -1.36
Tetrachloroethene (Pere h 1 oroeth y 1 ene) 1 ,3 1.30 1 ,3 1.30 1.07
Toluene (M ethylbenzene) 1 ,2 ,4 1.54 1 ,3 1.44 1 ,2 , 3, 4 1.49 1.35
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trans-1,2-Dichloroethylene 1 ,3 0.55 1 ,3 0.55 0.82
Tri chloroethene (Tri ch loroethy 1 en e) 1 ,2 ,4 1.25 1 ,3 1.00 1 ,2 , 3, 4 1.13 1.06
V inyl bromide (Brom oethene) 1 ,3 0.35 1 ,3 0.35 0.47
V inyl chloride (Chloroethene) 1 ,3 0.32 1 ,3 0.32 0.06
V inylidene fluoride (1,1 -D ifluoroethylene ) 10, -0.54 10, -0.54 -0.67
Xenon 2 -1.00 2 -1 .00 -0 .86
Difluorochlorom ethane (CHF2CI) 4 0.03 4 0.03 0.11
O U T L IE R S
T ricyclo[5.2.1.0]-decane (JP10) 3, 2.83 3, 2.83 1.86
Methanol 1 ,2 ,4 3.12 1 3.60 1 ,2 ,4 3.36 2.46
4-Chlorobenzotri fl uori de 9, 2.03 9, 2.03 1.25
C alcu lated  values for log K, obtained when correlating with the Abraham descriptors (E , S, A , B  and L ) using equation from table 16.0 
REF= Literature reference
Descriptors E, S, A , B and L for all solutes are found in table 9 .0  from chapter 9 and table 18.0 from chapter 1
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Table 16.3. Data set used to obtain a model to correlate air to liver distributions for
VOCs in humans and rats combined.
SO L U T E  N A M E
V M U SC L E
A V E R A G E
L O G
B L O O D  
L O G  K
B L O O D  T O
M U SC L E
L O G  P
C A L C  
L O G  P
(C F3)2CH O C H 2F (Sevoflurane) 0 .8548 0.22 -0 .20 0.42 0.38
1 ,1,1,2-T etrachloroethane 0 .8800 1.60 1.55 0.05 -0 .04
1,1,1 -Trichloroethane 
(Methyl chloroform )
0.7576
0.67 0.63 0.04 0.04
1,1,2,2-Tetrachloroethane 0 .8800 2.00 2.13 -0.13 -0 .14
1,1,2-Trichloroethane 0 .7576 1.36 1.67 -0.31 -0 .16
1,1 -D ichloroethane 0.6352 0.71 0.88 -0 .17 -0 .10
1,1 -D ichloroethylene 0.5922 0.31 0 .70 -0 .39 -0.03
1,1 -D ich loro-1 -Fluoroethane 
(H CFC -141b)
0 .6529
0.02 0.32 -0 .30 0.02
1,2-Dibrom oethane 0 .7404 1.66 2.08 -0 .42 -0.28
1,2-D ichloroethane 0.6352 1.37 1.39 -0 .02 -0.21
1,2-D ichloropropane 0.7761 1.08 1.14 -0 .06 -0.12
1,3-Butadiene 0 .5862 -0 .06 0.09 -0.15 0.03
l,2-E poxy-3-butene (B M O ) 0.5793 1.66 1.97 -0.31 -0.17
1 -Brom o-2-chloroethane  
(1 -C hloro-2-Brom oethane)
0 .6878
1.40 1.60 -0 .20 -0.23
1-Butanol 0 .7309 2.95 3.08 -0.13 -0.05
1-Chloropropane (Propyl chloride) 0 .6537 0.32 0 .59 -0 .27 0.00
1 -Nitropropane 0.7055 1.46 2.31 -0.85 -0.33
2-Nitropropane 0.7055 1.46 2.23 -0 .77 -0.31
3-M ethylpentane 0 .9540 0.58 -0 .37 0.95 0.52
1 -Pentanol 0 .8718 2.91 2.83 0.08 0.06
1 -Propanol 0 .5900 2.95 3.06 -0.11 -0.16
2,2-D im ethylbutane 0 .9540 0.00 -0 .59 0.59 0.52
2 ,2 -D ich loro-1,1,1 -Trifluroethane
(H CFC -123)
0.6883
0.39 0.61 -0.22 0.10
2-Chloropropane 0.6537 0.31 0.32 -0.01 0.04
2-H eptanone (M ethyl pentyl ketone) 1.1106 2.33 2.33 0.00 0.12
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2-M ethyl-1,3-butadiene (Isoprene) 0.7271 0.26 0 .10 0.16 0.14
2-M ethyl-1 -propanol (Isobutanol) 0 .7309 2.74 2 .92 -0 .18 -0.03
2-M ethylpentane (Isohexane) 0 .9540 0.46 -0 .39 0.85 0.52
2-Pentanone (M ethyl propyl ketone) 0.8288 2.00 2.14 -0 .14 -0 .09
2-Propanol (Isopropanol) 0 .5900 2.87 3.02 -0.15 -0.13
3-M ethyl-1-butanol (Isopentanol) 0 .8718 2.90 2.75 0.15 0.08
3-M ethylhexane 1.0949 1.04 0.11 0.93 0.63
4-M ethyl-2-pentanone 
(M ethyl isobutyl ketone)
0 .9697
1.81 1.96 -0.15 0 .04
A cetone (Propan-2 -one) 0 .5470 2.21 2 .36 -0.15 -0.32
A cetylene 0 .3044 0.03 -0 .06 0.09 -0.37
A llyl chloride (3 -C h loro-l-  
propylene)
0 .6106
1.04 1.24 -0 .20 -0.14
Argon 0.1900 -1 .64 -1 .52 -0.12 -0 .04
Benzene 0 .7164 1.11 1.05 0.06 -0.11
Brom ochlorom ethane
(Chlorobrom om ethane)
0 .5469
1.05 1.21 -0 .16 -0.38
Butan-2-one (M ethyl etliyl ketone) 0 .6879 2 .14 2 .24 -0 .10 -0.21
Butyl acetate 1.0284 2 .20 1.94 0.26 0.13
Carbon tetrachloride 
(T etrachloromethane)
0.7391
0 .66 0 .62 0.04 0.04
CF2=CHC1 (l-C h lo ro -2 ,2 -  
difluroethylene)
(1,1 -D ifluro-2-chloroethene)
0 .5052
0 .00 0 .06 -0 .06 0.08
CF3CBrClH (H alothane) 0 .7410 0 .74 0 .57 0.17 0 .10
CF3CBrFH (T eflurane) 0 .6360 0.34 -0 .22 0.56 0.16
CF3CH2C1
(2chlorol 1 ltrifluoroethane)
(1 -C hloro-2.2,2-trifluroethane)
0 .5659
0.22 0.14 0.08 -0.02
C F 3C H 20C H =C H 2 (Fluom ar/ 
Fluroxene)
0 .7410
0.35 0 .15 0.20 0.10
C HF20CF2C H FC1 (Enflurane) 0 .8009 0.64 0.35 0.29 0.19
CHF20CH C1CF3 (Isoflurane) 0 .8010 0.31 0 .20 0.11 0.14
Chlorobenzene 0.8388 1.53 1.63 -0 .10 -0.11
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Chlorodibrom om ethane 0.7219 1.75 1.88 -0.13 -0 .25
Chloroethane 0.5128 0.51 0 .49 0.02 -0.11
Chloroform (Trich loro methane) 0 .6167 1.12 1.15 -0.03 -0 .12
c is -1,2-D ichloroethylene 0.5922 0.78 1.16 -0 .38 -0.18
C yclohexane 0.8454 0.52 0.17 0.35 0.32
Cyclopropane 0.4227 -0.31 -0.21 -0 .10 -0 .09
Dibrom om ethane 0.5995 1.61 1.87 -0 .26 -0.32
Dichlorom ethane 
(M ethylene chloride)
0.4943
0.79 1.12 -0 .33 -0 .25
D iethyl ether 0.7309 0.87 1.11 -0 .24 0.12
Diflurom ethane (C F2H 2) 0 .2849 0.16 0 .2 0 -0 .04 -0.21
D ivinyl ether 0 .6449 0.34 0.41 -0 .07 -0.01
Ethanol 0.4491 3.08 3.27 -0 .19 -0 .26
Ethyl acetate 0 .7466 1.84 1.90 -0 .06 -0 .10
Ethyl t-butyl ether (ETBE) 1.0127 1.35 1.07 0.28 0.37
t-butanol (tert~butanol)(TBA  
(2-M ethyl-2-propanol)
0 .7309
2.80 2.68 0.12 0.02
M ethyl tertiary-butyl ether (M TBE) 0.8718 1.57 1.18 0.39 0.23
tertiary-Amyl m ethyl ether (TA M E) 1.0127 1.38 1.22 0.16 0.33
tertiary-amyl a lcohol (T A A ) 0.8718 2.59 2 .59 0 .00 0.12
Ethylbenzene 0.9982 1.41 1.47 -0 .06 0.10
Ethylene O xide 0.3405 1.75 1.80 -0.05 -0.48
Ethylene (E thene) 0 .3474 -0 .20 -0 .53 0.34 -0.02
Flurochloromethane 0 .5300 0.39 0.71 -0 .32 0.05
Helium 0.0680 -1.93 -2 .00 0.07 -0.13
Heptane 1.0949 0.85 0 .50 0.35 0.63
Hexachloroethane (Perchloroethane) 1.1248 1.88 1.76 0.12 0.10
Hexane 0 .9540 0.58 0.21 0.37 0.52
Hydrogen 0.1086 -1 .76 -1 .77 0.01 -0 .10
Isobutyl acetate 1.0284 2.04 1.69 0.35 0.15
Isopentylacetate
(A ceticacidpentylester)
1.1693
2.32 1.79 0.53 0.25
Isopropyl acetate 0.8875 1.85 1.55 0.30 0.04
Isopropyl brom ide (2-Brom propane) 0.7063 0.61 0 .64 -0.03 0.04
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Krypton 0 .2460 -1 .38 -1 .22 -0 .16 0.00
MeOCF2CHC12 (M ethoxyflurane) 0.8700 1.35 1.28 0.07 0.01
M ethane 0.2495 -1.41 -1 .42 0.01 0.00
M ethyl acetate 0.6057 1.81 1.98 -0 .17 -0.22
M ethylchloride (Chlorom ethane) 0 .3719 -0.01 0.31 -0 .32 -0.23
M ethylcyclopentane 0.8454 0.70 -0 .07 0.77 0.34
m -M ethylstyrene
(1 -vinyl-3-m ethylbenzene)
1.0961
2 .26 2.28 -0 .02 0.03
m -X ylene (1 ,3-D im ethylbenzene) 0 .9982 1.62 1.59 0.03 0.09
Nitrous O xide 0.2810 -0.43 -0 .34 -0 .09 -0.21
o-X ylene (1.2-d im ethylbenzene) 0 .9982 1.71 1.42 0.29 0.06
Pentachloroethane 1.0024 1.86 2.02 -0 .16 0.01
Pentane 0.8131 -0.15 -0 .29 0 .14 0.42
Pentyl acetate 1.1693 2.36 1.98 0.38 0.24
p-M ethylstyrene 
(1 -vinyl-4-m ethylbenzene)
1.0961
2.26 2.37 -0.11 0.03
Propyl acetate 0.8875 1.93 1.88 0.05 0.02
Propyl brom ide 
(1 -Bromopropane)
0 .7063
0.62 0.97 -0.35 0.00
Propene (Propylene) 0.4883 -0.27 -0.21 -0 .06 0.10
p-X ylene (1 ,4-dim ethylbenzene) 0 .9982 1.58 1.61 -0.03 0.09
Radon 0 .3840 -0.81 -0 .39 -0 .42 0.10
Styrene (V inyl benzene) 0 .9552 1.67 1.67 0.00 -0.07
Sulphur H exafluoride 0.4643 -1.85 -2 .17 0.32 0.40
T etrachloroethene 
(Perchloroethylene)
0 .8370
1.30 1.19 0.11 0.04
Toluene (m ethylbenzene) 0 .8573 1.49 1.14 0.35 -0.01
trans-1,2-D ichloroethylene 0.5922 0.55 0.88 -0.33 -0.09
Trichloroethene (Trichloroethylene) 0 .7146 1.13 1.14 -0.01 0.00
V inyl brom ide (B rom oethene) 0 .5224 0.35 0 .49 -0 .14 -0.22
V inyl chloride (C hloroethene) 0 .4698 0.32 0.17 0.15 -0.12
V inylidene fluoride 
(1 ,1 -D iflu oroeth y len e)
0 .3828
-0 .54 -0 .74 0.20 0.07
Xenon 0.3290 -1 .00 -0 .85 -0.15 0.06
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O U T L IE R S
2 ,3 ,4-Trim ethylpentane 1.2358 0.64 0.57 0.07 0.63
Octane 1.2358 0.93 0.68 0.25 0.63
2,2,4-Trim ethylpentane (Isooctane) 1.2358 0.52 0.23 0.29 0.63
“Calculated values for log  P, obtained when correlating with the Abraham descriptors (E , S, A , B and V ) 
Descriptors E, S, A  and B for all solutes are found in table 9 .0  from chapter 9 and table 18.0 from chapter 
18.
bREF= Literature reference
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Table 17.0. Data set used in this model to obtain model to correlate air to urine
distributions in humans for VOCs
S O L U T E  N A M E V R E F b S P E C IE S
U R IN E  
L O G  K
C A L C  
L O G  K a
1,1,1 -Trichloroethane  
(M ethyl chloroform ) 0 .7576 * 5 H U M A N 0.18 0 .42
1 ,1 ,2,2-T etrachloroethane 0 .8 8 0 0 1, H U M A N 1.63 1.84
1,1,2-T richloroethane 0 .7576 1, H U M A N 1.31 1.55
1,1 -D ichloroethane 0 .6352 1, H U M A N 0.89 0 .9 0
1,2-D ichloroethane 0 .6352 1, H U M A N 1.53 1.14
1,2-D ichloropropane 0.7761 1, H U M A N 0.82 1.00
1,3 ,5-T rim ethylbenzene (M esity len e) 1.1391 1, H U M A N 1.27 1.18
1,2,3-T richloropropane 0 .8985 1, H U M A N 1.74 1.73
2-m ethylcyclohexanon e
(o-M eth y lcycloh exan on e) 1.0020 1, H U M A N 3.18 2 .9 0
2-M ethylpropan-l -o l (isobutanol) 0 .7309 1, H U M A N 3.39 3.33
M ethylcycloh exan e 0 .9863 1, H U M A N 0.67 -0 .07
4-M ethylpentan-2-one 0 .9697 1, H U M A N 1.86 2 .39
B u ta n -l-o l 0 .7 3 0 9 1, H U M A N 3.10 3.42
Butanone (M eth yl ethyl ketone) 0 .6 8 7 9 1, H U M A N 2.52 2 .18
B rom odichlorom ethane 0 .6693 H U M A N 0.81 0.95
C hlorobrom om ethane (B rom ochlorom ethane) 0 .5 4 6 9 1, H U M A N 1.10 0 .66
C hlorodibrom om ethane 0 .7 2 1 9 5^ H U M A N 1.05 0 .97
C yclohexane 0 .8 4 5 4 1, H U M A N -0.05 -0 .17
C yclohexanone 0.8611 1, H U M A N 3.09 2.83
C yclopropane 0 .4227 H U M A N -0 .76 -0 .56
D ichlorom enthane  
(M ethylene C hloride) 0 .4943 1, H U M A N 0.86 0.71
D iethyl ether 0 .7 3 0 9 H U M A N 1.11 1.40
Ethanol 0 .4491 1, H U M A N 3.28 3 .07
Ethane 0 .3904 H U M A N -1.55 -0 .83
Ethyl acetate 0 .7 4 6 6 1, H U M A N 2.29 1.92
E thylbenzene 0 .9982 1, H U M A N 1.21 0 .89
Isopropyl acetate 0 .8875 1, H U M A N 1.60 2.03
M ethanol 0 .3082 1, H U M A N 3.30 3.15
m -X ylen e (1 ,3 -D im eth y lb en zen e) 0 .9982 1, H U M A N 0.83 0 .94
Heptane 1.0949 1, H U M A N 0.11 -0 .02
H exane 0 .9 5 4 0 1, H U M A N 0.04 -0 .17
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Octane 1.2358 1, HUMAN -0.05 0.13
Pentane 0.8131 1, HUMAN 0.02 -0.32
Propan-2-ol 0.5900 1, HUMAN 3.11 3.18
Propan-2-one (Acetone) 0.5470 1, HUMAN 2.63 2.10
p-Xylene
(1,4-Dimethylbenzene) 0.9982 1, HUMAN 0.77 0.95
Styrene (Vinyl benzene) 0.9552 1, HUMAN 0.83 0.96
Tetrachloroethene (Perchloroethylene) 0.8370 1, HUMAN 0.23 0.23
T etrachloromethane 
(Carbon tetrachloride) 0.7391 1, HUMAN 0.05 0.05
Toluene 0.8573 1, HUMAN 0.38 0.74
Tribromomethane (Bromoform) 0.7745 1,3 HUMAN 1.39 1.23
Trichloroethene (Trichloroethylene) 0.7146 1, HUMAN 0.35 0.50
Trichloromethane (Chloroform) 0.6167 1,3 HUMAN 0.57 0.84
Isophorone
(3,5,5-trimethylcyclohex-2-en-1 -one) 1.2408 1, HUMAN 2.85 3.28
OUTLIERS
Sulphur hexafluride 0.4643 2 , HUMAN -2.59 -1.52
Cyclopentadiene 0.6185 1, HUMAN 1.22 0.23
CHF20CF2CHFC1 (Enflurane) 0.8009 2 , HUMAN -0.24 0.63
2,3-Dimethylbutane 0.9540 1, HUMAN 0.72 -0.11
Decane 1.5176 1, HUMAN 1.53 0.71
Nonane 1.3767 1, HUMAN 1.53 0.73
Descriptors E, S, A, B and L for all solutes are found in table 9.0 from chapter 9 and table 18.0 from 
chapter 18. This was used to correlate with the observed values for VOC air to urine distribution (log 
K).
“Calculated values for log K, obtained when correlating with the Abraham descriptors (E, S, A, B and
L ).
bREF= Literature reference
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Table 18.0. Data set used to obtain a model to correlate air to olive oil distributions for VOCs
SOLUTE NAME E S A B L REF <
(CF3)2CHOCH2F (Sevoflurane) -0.465 0.232 0.080 0.147 1.688 1 ,2
1,1,1,2-Tetrachloroethane 0.542 0.630 0.100 0.080 3.641 1,2, 3, 4, 9, 10
1,1,1-Trichloroethane (Methyl chloroform) 0.369 0.410 0.000 0.090 2.733 1,2, 3, 4, 5 ,9 , 10, 11
1,1,2,2-Tetrachloroethane 0.595 0.760 0.160 0.120 3.803 1,2, 4, 5 ,9 , 10,11
1,1,2-Trichloroethane 0.499 0.680 0.130 0.130 3.290 1,2, 3, 4, 9, 10, 11
1,1 -Dichloro-1 -Fluoroethane (HCFC- 141b) 0.084 0.430 0.010 0.050 1.920 7,
1,1 -Dichloroethane 0.322 0.490 0.100 0.100 2.316 1,2, 3, 4, 5, 9, 10, 11
1,1 -Dichloroethylene 0.362 0.340 0.000 0.050 2.110 2 , 10
1,2,3-Trimethylbenzene (Hemimellitene) 0.728 0.610 0.000 0.190 4.565 2,9
1,2,4-Trifluorobenzene 0.410 0.650 0.000 0.020 2.850 2 ,
1,2,4-Trimethylbenzene (Pseudocumene) 0.677 0.560 0.000 0.190 4.441 2 ,9
1,2-Dibromoethane 0.747 0.760 0.100 0.170 3.382 2 ,3 ,4 , 5, 10
1,2-Dichlorobenzene (o-Dichlorobetizene) 0.872 0.780 0.000 0.040 4.518 1,2, 3 ,4
1,2-Dichloroethane 0.416 0.640 0.100 0.110 2.573 1,2, 3, 4, 5, 9, 10, 11
1,2-Dichloropropane 0.371 0.680 0.000 0.150 2.866 1 ,2 ,3 ,4 ,1 0
1,2-Diflurobenzene (o-Diflurobenzene) 0.390 0.630 0.000 0.060 2.843 2 ,
1,2-Dimethoxyethane 0.116 0.670 0.000 0.680 2.654 3,4
1,3,5 -T riflurobenzene 0.390 0.490 0.000 0.000 2.660 2 ,
1,3,5-Trimethylbenzene (Mesitylene) 0.649 0.520 0.000 0.190 4.344 2,9
1,3-Dichlorobenzene (m-Dichlorobenzene) 0.847 0.730 0.000 0.020 4.410 1,2, 3 ,4
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1,4-Diflurobenzene (p-Diflurobenzene) 0.384 0.600 0.000 0.060 2.766 2 2.82 2.69
1,4-Dioxane 0.329 0.750 0.000 0.640 2.892 3 4,5 2.83 2.90
1 -Bromo-2-chloroethane
(1 -Chloro-2-Bromoethane) 0.572 0.700 0.100 0.090 2.982 2 10 2.76 3.09
1-Butanol 0.224 0.420 0.370 0.480 2.601 2 3,4 2.99 3.02
1-Chlorobutane 0.210 0.400 0.000 0.100 2.722 1 2, 3, 4, 5 2.48 2.52
1-Chloropentane 0.208 0.380 0.000 0.090 3.223 1 2, 3, 4, 5 2.99 2.94
1-Chloropropane (Propyl chloride) 0.216 0.400 0.000 0.100 2.202 1 2 ,3 ,4 , 5, 10 2.06 2.06
1-Fluropropane 0.034 0.350 0.000 0.130 1.103 1 3,4 0.92 1.10
1-Heptanol 0.211 0.420 0.370 0.480 4.115 3 4 4.26 4.35
1-Hexanol 0.210 0.420 0.370 0.480 3.610 2 3,4 3.90 3.91
1 -Methoxy-2-propanol 0.218 0.610 0.350 0.620 2.655 2 2.84 3.19
1-Nitropropane 0.240 0.950 0.000 0.310 2.894 2 10 3.03 3.14
1-Pentanol 0.219 0.420 0.370 0.480 3.106 2 3,4 3.30 3.46
1-Propanol 0.236 0.420 0.370 0.480 2.031 1 2, 3 ,4 2.49 2.52
2,2,4-Trimethylpentane (Isooctane) 0.000 0.000 0.000 0.000 3.106 2 10, 11 2.58 2.56
2,2-Dichloro-1,1,1 -Trifluroethane 
(IICFC-123) -0.160 0.400 0.220 0.000 1.746 6 1.81 2.15
2,2-Dimethylbutane 0.000 0.000 0.000 0.000 2.352 1 2 1.85 1.90
2,3,4-Trimethylpentane 0.000 0.000 0.000 0.000 3.481 2 10 2.82 2.89
2-Butoxyethanol 0.201 0.500 0.300 0.830 3.806 2 3.74 4.00
2-Chloropropane 0.177 0.350 0.000 0.120 1.970 2 10 1.84 1.82
2-Ethoxyethanol 0.237 0.520 0.310 0.810 2.792 2 2.98 3.14
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2-Fluropropane 0.004 0.320 0.000 0.100 1.070 1 ,3 ,4 1.09 1.06
2-Heptanone (Methyl pentyl ketone) 0.123 0.680 0.000 0.510 3.760 2 ,3 ,4 3.85 3.67
2-Hexanone (Methyl butyl ketone) 0.136 0.680 0.000 0.510 3.286 1,2, 3, 4, 5 ,9 3.08 3.25
2-Isopropoxyethanol 0.196 0.470 0.300 0.910 3.170 2 , 3.21 3.41
2-Methoxyethanol 0.269 0.500 0.300 0.840 2.490 2 , 2.72 2.83
2-Methyl-1 -propanol (I sobutanol) 0.217 0.390 0.370 0.480 2.413 1 ,2 2.71 2.83
2-Methyl-2-propanol (t-butanol) 0.180 0.300 0.310 0.600 1.963 2 ,3 ,4 2.25 2.25
2-Methylpentane (Isohexane) 0.000 0.000 0.000 0.000 2.503 1 ,2 2.01 2.03
2-Methylpyridine 0.598 0.750 0.000 0.580 3.422 3,4 3.54 3.30
2-Nitropropane 0.216 0.920 0.000 0.330 2.550 2 , 10 2.81 2.81
2-Pentanone (Methyl propyl ketone) 0.143 0.680 0.000 0.510 2.755 1,2 ,4 , 5, 9 2.65 2.78
2-Propanol (Isopropanol) 0.212 0.360 0.330 0.560 1.764 1,2, 3, 4 2.17 2.16
3-Carene 0.511 0.220 0.000 0.100 4.649 8 , 3.70 3.96
3-Methyl-1 -butanol (Isopentanol) 0.192 0.390 0.370 0.480 3.011 2 , 3.00 3.36
3-Methylhexane 0.000 0.000 0.000 0.000 3.044 1 ,2 2.49 2.51
3 -Methy lpentane 0.000 0.000 0.000 0.000 2.581 1 ,2 2.07 2.10
3-Methylpyridine 0.631 0.810 0.000 0.540 3.631 3,4 3.74 3.53
3-Pentanone (Diethyl ketone) 0.154 0.660 0.000 0.510 2.811 1,2, 3, 4, 5 ,9 2.68 2.81
4-Methyl-2-pentanone 
(Methyl isobutyl ketone) 0.111 0.650 0.000 0.510 3.089 1 ,2 3.03 3.06
4-Methylpyridine 0.630 0.820 0.000 0.540 3.640 3,4 3.75 3.55
Acetic acid 0.265 0.640 0.620 0.440 1.816 3, 3.64 2.95
Acetone (Propan-2-one) 0.179 0.700 0.040 0.490 1.696 1,2, 3, 4, 5 ,9 1.85 1.93
All
Acetylene (Ethyne) 0.190 0.600 0.060 0.040 0.140 1 ,3 ,4 0.24 0.55
Allyl chloride (3-Chloro-l -propylene) 0.327 0.560 0.000 0.050 2.109 2 , 10 2.04 2.10
Allylbenzene 0.717 0.600 0.000 0.220 4.136 1,2, 3, 4 ,9 3.85 3.79
Argon 0.000 0.000 0.000 0.000 -0.688 1,3 -0.82 -0.76
Benzene 0.610 0.520 0.000 0.140 2.786 1,2, 3, 4, 5, 9, 10, 11 2.65 2.57
Benzyl alcohol 0.803 0.870 0.390 0.560 4.221 3,4 4.73 4.71
Bromobenzene 0.882 0.730 0.000 0.090 4.041 3 ,4 ,5 4.14 3.79
Bromochloromethane
(Chlorobroniomethane) 0.541 0.800 0.010 0.060 2.445 2 , 10 2.56 2.57
Butan-2-one (Methyl ethyl ketone) 0.166 0.700 0.000 0.510 2.287 1,2, 3, 4, 5 ,9 2.30 2.38
Butane 0.000 0.000 0.000 0.000 1.615 2, 3, 4, 5 1.27 1.26
Butyl acetate 0.071 0.600 0.000 0.450 3.353 2, 3, 4, 5 3.20 3.26
Butyl formate 0.121 0.630 0.000 0.380 2.958 3,4 2.87 2.93
Butyl propanoate 0.058 0.560 0.000 0.470 3.833 3,4 3.67 3.64
Butylbenzene 0.600 0.510 0.000 0.150 4.730 3,4 4.46 4.26
Carbon Dioxide 0.000 0.280 0.050 0.100 0.058 1,3 0.13 0.22
Carbon Disulfide 0.876 0.260 0.000 0.030 2.370 1,3 2.18 1.91
Carbon Monoxide 0.000 0.000 0.000 0.040 -0.836 1,3 -1.01 -0.89
Carbon tetrachloride 
(Tetrachloromethane) 0.458 0.380 0.000 0.000 2.823 1,2, 3 ,4 , 5, 10, 11 2.56 2.53
CF2=CHC1 (1 -Chloro-2,2-difluroethy lene) 
(1,1 -Difluro-2-chloroethene) -0.340 0.290 0.150 0.000 0.723 1 ,3 ,4 1.15 1.08
CF2C1CF2C1 -0.190 0.050 0.000 0.000 1.427 1, 1.25 1.19
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CF2HCF2CF2CF2H -0.710 0.040 0.090 0.000 0.590 2 , 1.48 0.74
CF2HCF2CFH2 -0.450 0.170 0.000 0.030 0.680 2 , 1.01 0.71
CF2HCF2H (1,1,2,2-Tetrafluoroethane) -0.280 -0.300 0.300 0.000 0.289 2 , 0.67 0.41
CF2HCH3 (1,1 -Difluroethane) -0.250 0.490 0.040 0.050 0.517 2 , 0.93 0.87
CF3CBrClH (Halothane) 0.102 0.380 0.150 0.050 2.177 1,2, 3, 4, 6 , 10 2.30 2.31
CF3CBrFH (Teflurane) -0.070 0.210 0.200 0.020 1.370 1,2, 3 ,4 1.46 1.59
CF3CF2CF2CF2H -0.780 -0.300 0.100 0.100 0.420 2 , 0.61 0.31
CF3CFH2 (Norflurane) 
( 1,1, 1,2 -Tetrafluoroethane) -0.640 0.200 0.240 0.000 0.226 2 , 0.48 0.80
CF3CFHCFHCF3 -0.710 -0.090 0.090 0.040 0.590 2 , 1.34 0.62
CF3CH2C1 (2chloro 111 trifluoroethane) 
( l-Chloro-2,2,2-trifluroethane) 0.010 0.400 0.150 0.000 1.168 1,2, 3, 4, 10 1.38 1.48
CF3CH20CH=CH2 (Fluomar/ Fluroxene) 0.183 0.300 0.000 0.270 1.600 1,2, 3, 4 1.68 1.44
CF3CH20CH2CF3 -0.510 0.030 0.080 0.360 1.419 1, 1.67 1.35
CF4 (Perfluoromethane) 
(Carbon Tetrafluoride) -0.550 -0.200 0.000 0.000 -0.819 2 , -1.28 -0.90
CFH2CH2CFH2 (1,3-Difluoropropane) -0.190 0.270 0.050 0.050 1.280 2 , 1.67 1.34
CHF2CF2CH2Br (Halopropane) -0.070 0.280 0.200 0.000 2.030 1 ,3 ,4 2.51 2.23
CHF20CF2CHFC1 (Enflurane) -0.230 0.400 0.120 0.130 1.750 1 ,2 ,4 2.01 1.99
CHF20CHC1CF3 (Isoflurane) -0.240 0.500 0.100 0.100 1.576 1,2, 3, 4, 10 1.96 1.90
CHF20CHFCF3 (Desflurane) -0.300 0.112 0.067 0.000 1.404 1, 1.27 1.37
Chlorobenzene 0.718 0.650 0.000 0.070 3.657 1,2, 3, 4, 5, 10 3.44 3.43
Chlorodibromomethane 0.775 0.710 0.070 0.080 3.304 2 , 10 3.43 3.27
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Chloroethane 0.227 0.400 0.000 0.100 1.678 1 ,2 ,3 , 5, 10 1.57 1.60
Chloroform (Trichloromethane) 0.425 0.490 0.150 0.020 2.480 1 ,2 ,3 , 5, 10, 11 2.60 2.59
cis-1,2-Dichloroethylene 0.436 0.610 0.110 0.050 2.439 1,2, 3, 9, 10 2.36 2.59
Cycloheptane 0.350 0.100 0.000 0.000 3.704 2 , 3.44 3.08
Cyclohexane 0.305 0.100 0.000 0.000 2.964 1,2, 3, 4, 5, 10, 11 2.47 2.44
Cyclohexene 0.395 0.280 0.000 0.090 2.952 11, 2.66 2.56
Cyclopentane 0.263 0.100 0.000 0.000 2.477 2 ,4 ,5 2.05 2.03
Cyclopentanone 0.373 0.860 0.000 0.520 3.221 3,4 3.21 3.29
Cyclopropane 0.408 0.230 0.000 0.000 1.314 1 ,2 ,4 1.07 1.09
Decane 0.000 0.000 0.000 0.000 4.686 2, 3, 4, 5 3.98 3.94
Dibromomethane 0.714 0.690 0.110 0.070 2.886 2 , 2.98 2.97
Dichloromethane (Methylene chloride) 0.387 0.570 0.100 0.050 2.019 1,2, 3, 4, 5, 10, 11 2.15 2.18
Diethyl ether 0.041 0.250 0.000 0.450 2.015 1,2, 3, 4, 5, 10 1.80 1.78
Difluorochloromethane 0.000 0.250 0.200 0.000 0.690 1 ,3 ,4 0.64 1.01
Difluromethane (CF2H2) -0.320 0.490 0.060 0.050 0.040 2 , 10 0.68 0.50
Di-isopropyl ether -0.060 0.160 0.000 0.580 2.530 3,4 2.15 2.16
Dimethoxymethane (Methylal) 0.099 0.460 0.000 0.520 1.894 3,4 1.96 1.84
Dimethyl ether 0.000 0.270 0.000 0.410 1.285 1, 0.97 1.17
Dimethylacetamide (DMA) 0.363 1.350 0.000 0.770 3.638 3,5 3.90 4.08
Dimethylformamide (DMF) 0.367 1.310 0.000 0.740 3.173 3,5 3.46 3.63
Dimethylsulfoxide (DMSO) 0.522 1.720 0.000 0.970 3.459 3, 4.38 4.19
Di-n-butyl ether 0.000 0.250 0.000 0.450 3.924 3 ,4 ,5 3.42 3.46
Divinyl ether 0.259 0.390 0.000 0.130 1.760 1 ,2 ,3 1.78 1.65
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Dodecane 0.000 0.000 0.000 0.000 5.696 4, 5 4.80 4.83
Ethane 0.000 0.000 0.000 0.000 0.492 1 ,2 ,4 0.26 0.27
Ethanol 0.246 0.420 0.370 0.480 1.485 1,2, 3 ,4 1.98 2.04
Ethene 0.107 0.100 0.000 0.070 0.289 1,2, 3 ,4 0.10 0.15
Ethyl acetate 0.106 0.620 0.000 0.450 2.314 2, 3 ,4 , 5 2.33 2.36
Ethyl formate 0.146 0.660 0.000 0.380 1.845 1 ,4 ,3 1.96 1.98
Ethyl propanoate 0.087 0.580 0.000 0.450 2.807 3 ,4 2.71 2.76
Ethyl t-butyl ether (tert-Butylether) -0.020 0.160 0.000 0.600 2.720 2 , 2.28 2.32
Ethyl t-pentyl ether 0.030 0.230 0.000 0.370 3.200 2 , 2.53 2.81
Ethylbenzene 0.613 0.510 0.000 0.150 3.778 1,2, 3, 4, 5, 9 3.54 3.43
Ethyl-iodide (C2H5I) 0.640 0.400 0.000 0.140 2.573 3, 2.16 2.27
Fluorobenzene 0.477 0.570 0.000 0.100 2.788 2 , 2.82 2.66
Fluoroethane 0.052 0.350 0.000 0.100 0.576 1 ,3 ,4 0.58 0.64
Fluoromethane 0.066 0.350 0.000 0.090 0.057 1 ,3 ,4 0.06 0.18
Fluorotrichloromethane (Trichlorofluromethane) 0.207 0.240 0.000 0.070 1.950 1, 1.60 1.70
Fluorochloromethane -0.080 0.270 0.090 0.030 1.030 2 , 10 1.35 1.16
Formic acid 0.343 0.750 0.760 0.330 1.545 3, 3.23 3.04
Helium 0.000 0.000 0.000 0.000 -1.741 1,3 -1.76 - 1.68
Heptane 0.000 0.000 0.000 0.000 3.173 1,2, 3, 4, 5, 10, 11 2.61 2.62
Hexachloroethane (Perchloroethane) 0.680 0.680 0.000 0.000 4.718 2 , 10 3.70 4.40
Hexadecane 0.000 0.000 0.000 0.000 7.714 4, 5 6.57 6.60
Hexaflurobenzene 0.088 0.560 0.000 0.010 2.345 2 , 2.40 2.37
Hexane 0.000 0.000 0.000 0.000 2.668 1,2, 3, 4, 5, 10, 11 2.16 2.18
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Hydrogen 0.000 0.000 0.000 0.000 - 1.200 1,3 -1.31 - 1.21
Isobutyl acetate 0.052 0.570 0.000 0.470 3.161 2 , 3.11 3.07
Isopentylacetate (Aceticacidipentylester) 0.051 0.570 0.000 0.470 3.740 2 , 3.47 3.57
Isopropyl acetate 0.055 0.570 0.000 0.470 2.546 2 ,3 ,4 2.69 2.53
Isopropyl bromide (2-Brompropane) 0.332 0.350 0.000 0.140 2.390 2 , 10 2.21 2.15
Isopropylbenzene (Curnene) 0.602 0.490 0.000 0.160 4.084 1,2, 3, 4, 9 3.75 3.68
Tricyclo[5.2.1.0]-decane (JP10) 0.590 0.450 0.000 0.060 4.840 10, 4.11 4.32
Krypton 0.000 0.000 0.000 0.000 -0.211 1,3 -0.35 -0.34
Limonene 0.488 0.280 0.000 0.210 4.725 8 , 3.76 4.08
MeOCF2CHC12 (Methoxyflurane) 0.109 0.670 0.070 0.140 2.864 1,2, 3, 4 2.94 3.03
Methanal (Formaldehyde) 0.220 0.620 0.000 0.330 0.730 3,4 1.41 0.95
Methane 0.000 0.000 0.000 0.000 -0.323 1,3 -0.51 -0.44
Methanol 0.278 0.440 0.430 0.470 0.970 1,2, 3, 4 1.56 1.70
Methyl acetate 0.142 0.640 0.000 0.450 1.911 2, 3, 4, 5 2.00 2.01
Methyl formate 0.192 0.680 0.000 0.380 1.285 3 ,4 ,5 1.56 1.49
Methyl tert-butyl ether (MTBE) 0.024 0.210 0.000 0.590 2.380 2 , 2.08 2.05
Methylchloride (Chloromethane) 0.249 0.430 0.000 0.080 1.163 2 , 10 0.93 1.17
Methylcyclopentane 0.225 0.100 0.000 0.000 2.907 1 ,2 2.31 2.41
Methylcyclohexane 0.244 0.060 0.000 0.000 3.319 11, 2.82 2.73
Methylpentaflurobenzene
(2,3,4,5,6-Pentylfluorotoluene) 0.240 0.450 0.040 0.000 2.900 2 , 3.17 2.79
m-Methylstyrene 
(1 - vinyl-3-methylbenzene) 0.866 0.650 0.000 0.180 4.375 2 , 10 4.17 4.00
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m-Xylene (1,3-Dimethylbenzene) 0.623 0.520 0.000 0.160 3.839 1,2, 3, 4, 9 ,10,11 3.56 3.49
Neon 0.000 0.000 0.000 0.000 -1.575 1,3 -1.66 -1.54
Nitroethane 0.270 0.950 0.020 0.330 2.414 3, 4 ,5 2.75 2.74
Nitrogen 0.000 0.000 0.000 0.000 -0.978 1, -1.13 - 1.02
Nitromethane 0.313 0.950 0.060 0.310 1.892 1 ,3 ,4 , 5 2.44 2.34
Nitrous Oxide 0.068 0.350 0.000 0.100 0.164 1,5 0.15 0.27
N,N-Dimethylaniline 0.957 0.810 0.000 0.410 4.701 3 ,4 4.66 4.39
Nonane 0.000 0.000 0.000 0.000 4.182 3 ,4 ,5 3.48 3.50
Octane 0.000 0.000 0.000 0.000 3.677 1,2, 3, 4, 5,11 3.07 3.06
Oxygen 0.000 0.000 0.000 0.000 -0.723 1,3 -0.94 -0.79
o-Xylene 0.663 0.560 0.000 0.160 3.939 1,2, 3, 4, 9, 10,11 3.64 3.60
p-Xylene 0.613 0.520 0.000 0.160 3.839 1,2, 3, 4, 5, 9, 10, 11 3.55 3.49
Pentachloroethane 0.648 0.660 0.170 0.060 4.267 2 , 10 3.83 4.28
Pentadecane 0.000 0.000 0.000 0.000 7.209 4, 6.13 6.15
Pentaflurobenzene 0.154 0.680 0.000 0.020 2.578 2 , 2.59 2.67
Pentane 0.000 0.000 0.000 0.000 2.162 1,2, 3, 4, 5, 11 1.71 1.73
Pentyl acetate 0.067 0.600 0.000 0.450 3.844 2 ,3 ,4 3.52 3.69
Phenol 0.805 0.890 0.600 0.300 3.766 3,4 4.29 4.71
Piperidine 0.422 0.460 0.130 0.680 3.304 3, 3.91 3.19
p-Methylstyrene (1 -vinyl-4-methylbenzene) 0.871 0.650 0.000 0.180 4.399 2 , 10 4.14 4.02
Propane 0.000 0.000 0.000 0.000 1.050 5, 0.74 0.76
Propanoic acid 0.233 0.650 0.610 0.440 2.276 3, 3.94 3.35
Propyl acetate 0.092 0.600 0.000 0.450 2.819 2 ,3 ,4 2.75 2.78
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Propyl bromide (1 -Bromopropane) 0.366 0.400 0.000 0.120 2.620 2 , 10 2.43 2.38
Propyl formate 0.132 0.630 0.000 0.380 2.433 4, 2.42 2.47
Propylbenzene 0.604 0.500 0.000 0.150 4.230 1,2, 3, 4, 9 3.95 3.82
Pyridine 0.631 0.840 0.000 0.520 3.022 3 ,4 ,5 3.20 3.02
Styrene (Vinyl benzene) 0.849 0.650 0.000 0.160 3.856 1,2, 3, 4, 9, 10, 11 3.65 3.56
Sulphur Hexafluoride -0.600 -0.200 0.000 0.000 -0.120 1,3 -0.58 -0.28
Tetrachloroethene (Perchloroethyleue) 0.639 0.440 0.000 0.000 3.584 1,2, 3, 5, 9, 10, 11 3.25 3.20
Tetradecane 0.000 0.000 0.000 0.000 6.705 4, 5.69 5.71
Tetrahydrofuran (THF) 0.289 0.520 0.000 0.480 2.636 3 ,4 ,5 2.39 2.50
Toluene 0.601 0.520 0.000 0.140 3.325 1,2, 3, 4, 5,9, 10, 11 3.10 3.04
trans-1,2-Dichloroethylene 0.425 0.410 0.090 0.050 2.278 1,2, 3, 4, 9,10 2.22 2.24
Trichloroethene (Trichloroethylene) 0.524 0.370 0.080 0.030 2.997 1,2, 3, 9, 10, 11 2.79 2.79
Tridecane 0.000 0.000 0.000 0.000 6.200 4, 5.24 5.27
Triethylamine 0.101 0.150 0.000 0.790 3.040 3, 4 ,5 2.83 2.54
Undecane 0.000 0.000 0.000 0.000 5.191 4, 5 4.36 4.39
Vinyl bromide (Bromoethene) 0.564 0.500 0.000 0.070 1.846 2 , 10 1.75 1.75
Vinyl chloride (Chloroethene) 0.258 0.380 0.000 0.050 1.404 2 , 10 1.39 1.34
Xenon 0.000 0.000 0.000 0.000 0.378 1,4 0.24 0.17
a-Pinene 0.446 0.140 0.000 0.120 4.308 8, 3.46 3.61
P-Pinene 0.530 0.240 0.000 0.190 4.394 8, 3.63 3.74
OUTLIERS
CF2HCFHCH2CF2H -0.500 1.250 0.120 0.130 2.324 2 , 0.12 2.74
N-Methylimidazole 0.589 0.950 0.000 0.800 3.805 3, 4.84 3.84
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2-Methyl-1,3-butadiene (Isoprene) 0.313 0.230 0.000 0.100 2.101 2 , 10 0.95 1.78
Calculated values for log K, obtained when correlating with the Abraham descriptors (E, S, A, B and L) 
bREF= Literature reference
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Table 19.0. Data set used to obtain a model to correlate air to saline distributions for
VOCs.
SOLUTE NAME CONC % REFb SALINE LOG K CALC LOG Ka
(CF3)2CHOCH2F (Sevoflurane) 1, -0.43 -0.39
1,1,1,2-T etrachloroethane 0.90% 1,2 ,3 0.62 0.63
1,1,1-Trichloroethane (Methyl chloroform) 0.90% 1,2 ,3 -0.09 -0.20
1,1,2,2-T etrachloroethane 0.90% 1,2 ,3 1.46 1.36
1,1,2-Trichloroethane 0.90% 1,2 ,3 1.14 1.13
1,1 -Dichloro-1 -Fluoroethane (HCFC-141 b) 0.90% 5, -0.29 -0.30
1,1 -Dichloroethane 0.90% 1 ,2 ,3 0.34 0.51
1,1 -Dichloroethylene 0.90% 1 ,2 -0.46 -0.42
1,2,3-Trimethylbenzene (Hemimellitene) 1,3 0.31 0.56
1,2,4-Trifluorobenzene 1, 0.26 0.09
1,2,4-Trimethylbenzene (Pseudocumene) 1,3 0.26 0.43
1,2-Dibromoethane 0.90% 1, 2 1.24 1.52
1,2-Dichlorobenzene (o-Dichlorobenzene) 1, 0.95 0.44
1,2-Dichloroethane 0.90% 1,2 ,3 1.03 0.92
1,2-Dichloropropane 0.90% 1 ,2 0.53 0.68
1,2-Diflurobenzene (o-Diflurobenzene) 1, 0.49 0.20
1,3,5 -T riflurobenzene 1, -0.14 -0.36
1,3,5 -T rime thy lbenzene (Mesitylene) 1,3 0.15 0.33
1,3-Dichlorobenzene 
(m-Dichlorobenzene) 1, 0.74 0.24
1,4-Diflurobenzene (p-Diflurobenzene) 1, 0.38 0.14
1 -Bromo-2-chloroethane
(1 -Chloro-2-Bromoethane) 0.90% 1 ,2 0.95 1.00
1-Butanol 1, 3.13 2.94
1-Chlorobutane 0.90% 1, -0.07 -0.29
1-Chloropentane 0.90% 1, -0.15 -0.49
1-Chloropropane (Propyl chloride) 0.90% 1 ,2 0.02 -0.17
1-Hexanol 1, 2.96 2.72
1 -Methoxy-2-propanol 1, 4.09 3.90
1-Nitropropane 0.90% 1 ,2 2.10 1.93
1-Pentanol 1, 3.03 2.83
1-Propanol 1, 3.32 3.07
2,2-Dichloro-1,1,1 -Trifluroethane 
(HCFC-123) 0.90% 4, -0.68 0.16
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2,2-Dimethylbutane 1, -2.02 -1.75
2,3,4-Trimethylpentane 0.90% 1, -2.62 -1.99
2-Butoxyethanol 1, 3.85 4.07
2-Chloropropane 0.90% 1 ,2 -0.09 -0.19
2-Ethoxyethanol 1, 4.36 4.31
2-Heptanone (Methyl pentyl ketone) 1, 2.16 1.86
2-Hexanone (Methyl butyl ketone) 1,3 2.04 1.97
2-Isopropoxyethanol 1, 4.09 4.46
2-Methoxyethanol 1, 4.55 4.43
2-Methyl-1,3-butadiene (Isoprene) 0.90% 1, 2 -0.68 -0.51
2-Methyl-1 -propanol (Isobutanol) 1, 3.01 2.90
2-Methyl-2-propanol (t-butanol) 1, 2.78 3.02
2-Methylpentane (Isohexane) 1, -2.03 -1.78
2-Nitropropane 0.90% 1 ,2 1.99 2.00
2-Pentanone (Methyl propyl ketone) 1,3 1.88 2.09
2-Propanol (Isopropanol) 1, 3.08 3.14
3-Methyl-1 -butanol (Isopentanol) 1, 2.93 2.76
3-Methylhexane 1, -2.21 -1.90
3-Pentanone (Diethyl ketone) 1,3 2.06 2.03
4-Methyl-2-pentanone
(Methyl isobutyl ketone) 1, 1.94 1.92
Acetone (Propan-2-one) 1,3 2.41 2.46
Allyl chloride (3-Chloro-1-propylene) 0.90% 1 ,2 0.31 0.10
Allylbenzene 1,3 0.42 0.74
Benzene 0.90% 1,2 ,3 0.45 0.42
Bromochloromethane (Chlorobromomethane) 0.90% 1 ,2 0.94 0.84
Butan-2-one (Methyl ethyl ketone) 1,3 2.24 2.25
Butane 1, -1.74 -1.59
Butyl acetate 1, 1.51 1.46
Carbon tetrachloride (Tetrachloromethane) 0.90% 1 ,2 -0.45 -0.62
CF2HCF2CF2CF2H 1, -0.80 -1.37
CF2HCF2CFH2 1, -0.49 -1.15
CF2HCF2H (1,1,2,2-Tetrafluoroethane) 1, -0.18 -0.99
CF2HCH3 (1,1 -Difluroethane) 1, 0.40 0.05
CF3CBrClH (Halothane) 0.90% 1 ,2 ,4 -0.30 0.12
CF3CBrFH (Teflurane) 1, -0.49 -0.16
CF3CF2CF2CF2H 1, -2.28 -1.75
CF3CFH2 (Norflurane) 
(1,1,1,2-T etrafluoroe thane) 1, -0.64 -0.24
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CF3CFHCFHCF3 1, -0.89 -1.52
CF3CH2C1 (2chlorol 1 ltrifluoroethane) 
(1 -Chloro-2,2,2-trifluroethane) 0.90% 1 ,2 -0.38 0.11
CF3CH20CH=CH2 (Fluomar/ Fluroxene) 1, -0.08 0.41
CF4 (Perfluoromethane) 
(Carbon Tetrafluoride) 1, -2.39 -1.93
CHF20CF2CHFC1 (Enflurane) 1, -0.13 0.25
CHF20CHC1CF3 (Isoflurane) 0.90% 1 ,2 -0.25 0.32
Chlorobenzene 0.90% 1 ,2 0.49 0.33
Chlorodibromomethane 0.90% 1 ,2 0.87 0.92
Chloroethane 0.90% 1 ,2 0.05 -0.06
Chloroform (Trichloromethane) 0.90% 1 ,2 0.55 0.41
cis-1,2-Dichloroethylene 0.90% 1,2 ,3 0.38 0.68
Cycloheptane 1, - 1.12 -1.56
Cyclohexane 1, -0.82 -1.44
Cyclopentane 1, -1.06 -1.36
Cyclopropane 1, -0.68 -0.70
Decane 1, -2.39 -2.24
Dibromomethane 1, 1.16 1.04
Dichloromethane (Methylene chloride) 0.90% 1 ,2 0.80 0.59
Diethyl ether 0.90% 1 ,2 1.08 0.87
Difluromethane (CF2II2) 0.90% 1, 2 0.12 0.19
Divinyl ether 1, 0.15 0.05
Ethane 1, -1.60 -1.36
Ethanol 1, 3.31 3.19
Ethene 1, -1.05 -0.70
Ethyl acetate 1, 1.85 1.75
Ethyl t-butyl ether (tert-Butylether) 1, 0.92 1.10
Ethyl t-pentyl ether 1, 1.08 0.22
Ethylbenzene 1,3 0.24 0.23
Fluorobenzene 1, 0.36 0.29
Fluorochloromethane 0.90% 1 ,2 0.49 -0.36
Hexachloroethane (Perchloroethane) 0.90% 1 ,2 -0.18 -0.14
Hexaflurobenzene 1, -0.40 -0.28
Hexane 0.90% 1 ,2 -1.71 -1.82
Isobutyl acetate 1, 1.41 1.50
Isopentylacetate (Aceticacidipentylester) 1, 1.35 1.38
Isopropyl acetate 1, 1.53 1.63
Isopropyl bromide (2-Brompropane) 0.90% 1 ,2 0.03 -0.09
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Isopropylbenzene (Cumene) 1,3 0.03 0.16
Tricyclo[5.2.1.0]-decane (JP10) 0.90% 2 , -0.68 -0.53
MeOCF2CHC12 (Methoxyflurane) 1, 0.62 0.74
Methanol 1, 3.49 3.58
Methyl acetate 1, 2.03 1.91
Methyl tert-butyl ether (MTBE) 1, 1.18 1.28
Methylchloride (Chloromethane) 0.90% 1 ,2 -0.06 0.05
Methylcyclopentane 1, -1.37 -1.48
Methylpentaflurobenzene
(2,3,4,5,6-Pentylfluorotoluene) 1, -0.37 -0.44
m-Methylstyrene (1 -vinyl-3-methylbenzene) 0.90% 1 ,2 0.29 0.74
m-Xylene (1,3-Dimethylbenzene) 0.90% 1 ,2 ,3 0.26 0.29
Octane 1, -2.29 -2.03
o-Xylene 0.90% 1,2 ,3 0.52 0.40
p-Xylene 0.90% 1,2 ,3 0.26 0.29
Pentachloroethane 0.90% 1 ,2 0.37 0.84
Pentaflurobenzene 1, -0.13 0.05
Pentane 1, -1.85 -1.71
Pentyl acetate 1, 1.38 1.36
p-Methylstyrene (1 -vinyl-4-methylbenzene) 0.90% 1 ,2 0.32 0.74
Propyl acetate 1, 1.72 1.59
Propyl bromide (1 -Bromopropane) 0.90% 1 ,2 0.16 -0.08
Propylbenzene 1,3 0.20 0.11
Styrene (Vinyl benzene) 0.90% 1,2 ,3 0.44 0.76
Tetrachloroethene (Perchloroethylene) 0.90% 1,2 ,3 -0.12 -0.52
Toluene 0.90% 1 ,2 ,3 0.31 0.30
trans-1,2-Dichloroethylene 0.90% 1,2 ,3 0.16 0.13
Trichloroethene (Trichloroethylene) 0.90% 1,2 ,3 0.01 -0.18
Vinyl bromide (Bromoethene) 0.90% 1 ,2 -0.36 0.25
Vinyl chloride (Chloroethene) 0.90% 1 ,2 -0.37 -0.24
OUTLIERS
CFH2CH2CFH2 (1 ,3-Difluoropropane) 1, 0.96 -0.59
Heptane 0.90% 1 ,2 -0.96 -1.94
2,2,4-Trimethylpentane (Isooctane) 0.90% 1, -2.85 -1.92
3 -Methy lpentane 1, -2.72 -1.80
CF2HCFHCH2CF2H 1, 0.77 1.68
Calculated values for log K, obtained when correlating with the Abraham descriptors (E, S, A, B and 
L)
bREF= Literature reference for the observed values for log K
Descriptors E, S, A, B and L for all solutes are found in table 9.0 from chapter 9 and table 18.0 from 
chapter 18.
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Table 19.3. Data set used to obtain a model to correlate saline to olive oil
distributions for VOCs.
SOLUTE NAME V SAL:OIL LOG P CALC LOG P
(CF3)2CHOCH2F (Sevoflurane) 0.8548 2.13 2.16
1,1,1,2-T etrachloroethane 0.8800 2.94 2.84
1,1,1-Trichloroethane (Methyl chloroform) 0.7576 2.58 2.61
1,1,2,2-T etrachloroethane 0.8800 2.57 2.45
1,1,2-Trichloroethane 0.7576 2.17 1.98
1,1 -Dichloro-1 -Fluoroethane (HCFC-141 b) 0.6529 2.03 2.12
1,1 -Dichloroethane 0.6352 1.93 1.74
1,1 -Dichloroethylene 0.5922 2.27 2.18
1,2,3-Trimethylbenzene (Hemimellitene) 1.1391 3.70 3.77
1,2,4-T rifluorobenzene 0.7695 2.53 2.77
1,2,4-Trimethylbenzene (Pseudocumene) 1.1391 3.70 3.78
1,2-Dibromoethane 0.7404 2.14 1.89
1,2-Dichlorobenzene (o-Dichlorobenzene) 0.9612 3.65 3.66
1,2-Dichloroethane 0.6352 1.59 1.62
1,2-Dichloropropane 0.7761 2.27 2.15
1,2-Diflurobenzene (o-Diflurobenzene) 0.7518 2.44 2.52
1,3,5 -T riflurobenzene 0.7690 2.67 3.00
1,3,5-Trimethylbenzene (Mesitylene) 1.1391 3.76 3.80
1,3-Dichlorobenzene (m-Dichlorobenzene) 0.9612 3.73 3.78
1,4-Diflurobenzene (p-Diflurobenzene) 0.7518 2.44 2.55
1 -Bromo-2-chloroethane
(1 -Chloro-2-Bromoelhane) 0.6878 1.81 1.97
1-Butanol 0.7309 -0.14 -0.17
1-Chlorobutane 0.7946 2.55 2.61
1-Chloropentane 0.9355 3.14 3.25
1-Chloropropane (Propyl chloride) 0.6537 2.04 2.04
1-Hexanol 1.0127 0.94 0.97
1 -Methoxy-2-propanol 0.7896 -1.25 -0.70
1-Nitropropane 0.7055 0.93 0.80
1-Pentanol 0.8718 0.27 0.40
1-Propanol 0.5900 -0.83 -0.73
2,2-Dichloro-1,1,1 -Trifluroethane 
(HCFC-123) 0.6883 2.49 1.90
2,2-Dimethylbutane 0.9540 3.87 3.95
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2,3,4-Trimethylpentane 1.2358 5.44 5.09
2-Butoxyethanol 1.0714 -0.11 -0.30
2-Chloropropane 0.6537 1.93 1.97
2-Ethoxyethanol 0.7896 -1.38 -1.37
2-Heptanone (Methyl pentyl ketone) 1.1106 1.69 1.72
2-Hexanone (Methyl butyl ketone) 0.9697 1.04 1.16
2-Isopropoxyethanol 0.9305 -0.88 - 1.21
2-Methoxyethanol 0.6487 -1.83 -2.02
2-Methyl-1 -propanol (Isobutanol) 0.7309 -0.30 -0.14
2-Methyl-2-propanol (t-butanol) 0.7309 -0.53 -0.49
2-Methylpentane (Isohexane) 0.9540 4.04 3.95
2-Nitropropane 0.7055 0.82 0.72
2-Pentanone (Methyl propyl ketone) 0.8288 0.77 0.59
2-Propanol (Isopropanol) 0.5900 -0.91 -0.96
3-Methyl-1 -butanol (Isopentanol) 0.8718 0.07 0.41
3-Methylhexane 1.0949 4.70 4.52
3-Pentanone (Diethyl ketone) 0.8288 0.62 0.61
4-Methyl-2-pentanone
(Methyl isobutyl ketone) 0.9697 1.09 1.17
Acetone (Propan-2-one) 0.5470 -0.56 -0.55
Allyl chloride (3-Chloro-l-propylene) 0.6106 1.73 2.02
Allylbenzene 1.0960 3.43 3.46
Benzene 0.7164 2.20 2.28
Bromochloromethane (Chlorobromomethane) 0.5469 1.62 1.61
Butan-2-one (Methyl ethyl ketone) 0.6879 0.06 0.01
Butane 0.6722 3.01 2.80
Butyl acetate 1.0284 1.69 1.70
Carbon tetrachloride (Tetrachloromethane) 0.7391 3.01 3.03
CF2HCF2CF2CF2H 0.8130 2.28 2.64
CF2HCF2CFH2 0.6190 1.50 1.97
CF2HCF2H (1,1,2,2-Tetrafluoroeihane) 0.4610 0.85 1.39
CF2HCH3 (1,1 -Difluroethane) 0.4258 0.53 0.84
CF3CBrClH (Flalothane) 0.7410 2.60 2.24
CF3CBrFH (Teflurane) 0.6360 1.95 1.88
CF3CF2CF2CF2H 0.8310 2.89 2.52
CF3CFH2 (Norflurane) 
(1,1,1,2-T etrafluoroethane) 0.4612 1.12 0.79
CF3CFHCFHCF3 0.8310 2.23 2.66
CF3CH2C1 (2chlorol 11 trifluoroethane) 0.5659 1.76 1.67
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CF3CH20CH=CH2 (Fluomar/ Fluroxene) 0.7410 1.76 1.70
CF4 (Perfluoromethane) 
(Carbon Tetrafluoride) 0.3203 1.11 1.18
CHF20CF2CHFC1 (Enflurane) 0.8009 2.14 1.94
CHF20CHC1CF3 (Isoflurane) 0.8010 2.21 2.01
Chlorobenzene 0.8388 2.95 3.04
Chlorodibromomethane 0.7219 2.56 2.35
Chloroethane 0.5128 1.52 1.48
Chloroform (Trichloromethane) 0.6167 2.05 1.99
cis-1,2-Dichloroethylene 0.5922 1.98 1.73
Cycloheptane 0.9863 4.56 4.23
Cyclohexane 0.8454 3.29 3.62
Cyclopentane 0.7045 3.11 3.02
Cyclopropane 0.4227 1.75 1.85
Decane 1.5176 6.37 6.24
Dibromomethane 0.5995 1.82 1.79
Dichloromethane (Methylene chloride) 0.4943 1.35 1.36
Diethyl ether 0.7309 0.72 0.80
Difluromethane (CF2II2) 0.2849 0.56 0.18
Divinyl ether 0.6449 1.63 1.91
Ethane 0.3904 1.86 1.65
Ethanol 0.4491 -1.33 -1.30
Ethene 0.3474 1.15 1.14
Ethyl acetate 0.7466 0.48 0.56
Ethyl t-butyl ether (tert-Bntylether) 1.0127 1.36 1.32
Ethylbenzene 0.9982 3.30 3.39
Fluorobenzene 0.7341 2.46 2.39
Fluorochloromethane 0.5300 0.86 1.58
Hexachloroethane (Perchloroethane) 1.1248 3.88 4.46
Hexane 0.9540 3.87 3.95
Isobutyl acetate 1.0284 1.70 1.62
Isopentylacetate (Aceticacidipentylester) 1.1693 2.12 2.19
Isopropyl acetate 0.8875 1.16 1.05
Isopropyl bromide (2-Brompropane) 0.7063 2.18 2.21
Isopropylbenzene (Cumene) 1.1391 3.72 3.93
Tricyclo[5.2.1.0]-decane (JP10) 1.1918 4.79 4.63
MeOCF2CHC12 (Methoxyflurane) 0.8700 2.32 2.26
Methanol 0.3082 -1.93 -1.95
Methyl acetate 0.6057 -0.03 -0.01
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Methyl tert-butyl ether (MTBE) 0.8718 0.90 0.77
Methylchloride (Chloromethane) 0.3719 0.99 0.98
Methylcyclopentane 0.8454 3.68 3.57
Methylpentaflurobenzene 
(2,3,4,5,6-Pentyl fluorotoluene) 0.9458 3.54 3.56
m-Methylstyrene (1 -vinyl-3-methylbenzene) 1.0961 3.88 3.70
m-Xylene (1,3-Dimethylbenzene) 0.9982 3.30 3.34
Octane 1.2358 5.36 5.09
o-Xylene 0.9982 3.12 3.33
p-Xylene 0.9982 3.29 3.34
Pentachloroethane 1.0024 3.46 3.33
Pentaflurobenzene 0.8049 2.72 2.71
Pentane 0.8131 3.56 3.37
Pentyl acetate 1.1693 2.14 2.27
p-Methylstyrene (l-vinyl-4-methylbenzene) 1.0961 3.82 3.70
Propyl acetate 0.8875 1.03 1.14
Propyl bromide (1 -Bromopropane) 0.7063 2.27 2.27
Propylbenzene 1.1391 3.75 3.97
Styrene (Vinyl benzene) 0.9552 3.21 3.20
Tetrachloroethene (Perchloroethylene) 0.8370 3.37 3.50
Toluene 0.8573 2.79 2.84
trans-1,2-Dichloroethylene 0.5922 2.06 1.96
Trichloroethene (Trichloroethylene) 0.7146 2.78 2.68
Vinyl bromide (Bromoethene) 0.5224 2.11 1.79
Vinyl chloride (Chloroethene) 0.4698 1.76 1.57
OUTLIERS
Ethyl t-pentyl ether 1.1530 1.45 2.81
Hexaflurobenzene 1.1248 2.80 4.02
Descriptors E, S, A and B for all solutes are found in table 9.0 from chapter 9 and table 18.0 from 
chapter 18.
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Table 21.0. Blood/plasma/serum to brain distribution for drugs only.
SOLUTE NAME SAMPLE E S A B V I
BRAIN
REF
LOG P 
(B:B) CALC
1 -(3-Fluoropropyl)-2-nitroimidazole (FPN) Blood 0.760 1.64 0.00 0.76 1.1519 0 24, -0.24 -0.10
1 -(8-fluorooctyl)-2-nitroimidazole (FON) Blood 0.750 1.62 0.00 0.76 1.8555 0 24, -0.17 0.39
4-Fluoroantipyrine Blood 1.380 1.60 0.00 1.25 1.5023 0 25, -0.05 0.06
4-Iodoantipyrine Blood 2.100 2.05 0.00 1.31 1.7428 0 25, -0.10 -0.03
5-Butyl-5-ethyl barbituric acid (Butethal) Plasma 1.030 1.14 0.47 1.18 1.6557 0 7, 0.19 0.16
5-Heptyl-5-ethyl barbituric acid Plasma 1.030 1.14 0.47 1.18 2.0784 0 7, 0.02 0.45
5-Hexyl-5-ethyl barbituric acid Plasma 1.030 1.14 0.47 1.18 1.9375 0 7, 0.36 0.35
5-Methyl-5-ethyl barbituric acid Plasma 1.030 1.17 0.46 1.18 1.2330 0 7, -0.22 -0.14
5-Octyl-5-ethyl barbituric acid Plasma 1.030 1.14 0.47 1.18 2.2193 0 7, 0.24 0.54
5-Pentyl-5-ethyl barbituric acid Plasma 1.030 1.14 0.47 1.18 1.7966 0 7, 0.09 0.25
5-Propyl-5-ethyl barbituric acid Plasma 1.030 1.14 0.47 1.18 1.5148 0 7, 0.09 0.06
9-OH Risperidone Blood 3.050 2.75 0.32 2.02 3.0982 0 22 , -0.67 -0.03
AI-9 (YH 1.885) Plasma 2.498 2.20 0.28 1.21 2.8039 0 5, 0.67 0.50
Alprazolam Blood 2.896 2.50 0.00 1.55 2.2041 0 13, 0.04 -0.03
Alprazolam Serum 2.896 2.50 0.00 1.55 2.2041 0 14, -0.04 -0.03
Aminopyrine Serum 1.680 1.74 0.00 1.60 1.8662 0 20 , 0.00 0.09
Amobarbital (5-Ethyl-5-(3-methylbutyl)barbital) Serum 1.030 1.11 0.47 1.23 1.7966 0 16, 0.04 0.25
Antipyrene (Phenazone) Blood 1.300 1.83 0.00 1.37 1.4846 0 13, 18 -0.10 -0.21
Barbital (5-Ethyl-5-ethyl barbituric acid) Plasma 1.030 1.14 0.47 1.18 1.3739 0 7, -0.14 -0.03
BESP Blood 2.550 3.41 0.00 2.00 3.4622 0 29, -0.43 -0.16
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Biperiden Plasma 1.850 1.25 0.31 1.57 2.6196 0 6 , 33 0.85 0.81
BMSP Blood 2.520 3.41 0.00 2.00 3.3213 0 29, -0.55 -0.26
BPSP Blood 2.550 3.41 0.00 2.00 3.6031 0 29, -0.01 -0.06
Bromperidol Plasma 2.070 1.50 0.40 1.80 2.8506 0 33, 1.38 0.64
Bromperidol Serum 2.070 1.50 0.40 1.80 2.8506 0 23, 1.38 0.64
BSP Blood 2.660 2.95 0.24 1.89 3.3213 0 29, 0.07 0.01
C5H8N4S (SKB2) Blood 1.305 1.00 0.75 0.80 1.1382 0 11, -0.04 -0.05
Caffeine (] ,3,7-Trimethylxanthine) Blood 1.500 1.72 0.05 1.28 1.3632 0 13, -0.06 -0.16
Caffeine (1,3,7-Trimethylxanthine) Plasma 1.500 1.72 0.05 1.28 1.3632 0 17, 0.12 -0.16
Chlorpromazine Blood 2.200 1.57 0.00 1.01 2.4056 0 13, 1.06 0.95
Chlorpromazine Serum 2.200 1.57 0.00 1.01 2.4056 0 23, 1.06 0.95
Chlorpromazine Plasma 2.200 1.57 0.00 1.01 2.4056 0 33, 1.06 0.95
Cimetidine (SK B1) Blood 1.700 1.73 0.67 1.93 1.9563 0 11, 13 -1.42 -0.46
Clobazam Serum 2.200 2.71 0.00 1.29 2.1326 0 14, 0.35 -0.25
Clonidine (SKB6) Blood 1.600 1.34 0.55 1.16 1.5317 0 11, 13 0.11 -0.02
Clozapine Plasma 2.560 1.52 0.25 1.70 2.4310 0 33, 1.30 0.58
Cocaine Plasma 1.355 1.92 0.00 1.50 2.2977 0 32, 34 0.73 0.23
Codeine Plasma 1.960 1.95 0.22 1.79 2.2057 0 8 , -0.22 -0.04
Codeine Blood 1.960 1.95 0.22 1.79 2.2057 0 3, 13 0.57 -0.04
Cotinine Plasma 1.049 1.49 0.00 1.38 1.3867 0 33, -0.38 -0.06
Daidzein Blood 2.170 2.05 0.92 1.13 1.7871 0 28, -0.15 -0.54
Desipramine Blood 1.620 1.82 0.09 0.91 2.2606 0 13, 1.20 0.54
Desmethylclobazam Serum 2.240 2.25 0.25 1.24 1.9900 0 14, 0.36 -0.13
Desmethyldiazepam Serum 2.210 1.68 0.26 1.16 1.9330 0 14, 0.50 0.30
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Diazepam Plasma 2.078 1.55 0.00 1.28 2.0739 0 1, 0.03 0.60
Diazepam Serum 2.078 1.55 0.00 1.28 2.0739 0 14, 0.52 0.60
Didanosine Plasma 1.810 1.78 0.58 1.90 1.5951 0 15, -1.30 -0.65
Fentanyl Plasma 1.830 1.75 0.00 1.81 2.8399 0 6 , 0.56 0.67
Flunitrazepam Serum 2.097 2.15 0.00 1.48 2.1433 0 14, 0.06 0.09
Fluoromisonidazole ( I -(3-Fluoro-2-hydroxyproyl-2- 
nitroimidazole)(FMISO) Blood 1.020 1.88 0.32 1.29 1.4092 0 24, -0.01 -0.53
Fluoxetine Plasma 1.000 1.30 0.10 0.93 2.2403 0 31, 0.36 0.80
Glycyrrhetinic acid Plasma 1.560 2.17 0.93 1.60 3.8984 1 33, -1.40 -0.74
Haloperidol Plasma 1.900 1.39 0.40 1.76 2.7980 0 33, 1.34 0.68
Haloperidol Serum 1.900 1.39 0.40 1.76 2.7980 0 23, 1.34 0.68
Hexobarbital Serum 1.500 1.37 0.17 1.37 1.7859 0 16, 0.05 0.28
Hydroxyzine Blood 2.000 2.21 0.10 1.89 2.9231 0 13, 0.39 0.29
Ibuprofen Blood 0.730 0.59 0.59 0.81 1.7771 1 13, -0.18 -0.50
Imipramine (SKB8) Blood 1.150 1.60 0.00 1.15 2.4015 0 11,13, 18 1.21 0.67
Indinavir Plasma 3.500 3.83 1.12 4.00 4.8988 0 15, 27 -0.74 -1.04
Indomethacin Blood 2.236 1.35 0.57 1.57 2.5299 1 13, -1.26 -0.64
Indomethacin Serum 2.236 1.35 0.57 1.57 2.5299 1 20 , -1.26 -0.64
Lorazepam Plasma 2.510 1.28 0.45 1.63 2.1141 0 9, 0.47 0.44
Lorazepam Serum 2.510 1.28 0.45 1.63 2.1141 0 14, 0.41 0.44
Lupitidine (SKB5) Blood 2.960 3.39 0.40 2.20 3.1776 0 11, -1.06 -0.63
Mannitol Plasma 0.836 2.26 0.86 1.79 1.3062 0 8, -1.60 -1.54
Mefloquine (+ve) (A 1-8) Plasma 0.999 1.34 0.43 1.30 2.3276 0 2 , 0.63 0.43
Mepyramine (SKB7) (Pyrilamine) Blood 1.819 1.92 0.00 1.59 2.3870 0 11, 13 0.50 0.33
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Mesori dazine Serum 2.790 2.90 0.00 1.51 2.9604 0 23, -0.74 0.17
Methohexital Serum 1.367 1.55 0.21 1.48 2.0903 0 16, -0.06 0.24
Mianserin Blood 2.070 1.67 0.00 1.09 2.1520 0 22 , 0.99 0.64
Midazolam Plasma 2.570 2.01 0.00 1.38 2.2629 0 6 , 0.52 0.41
Midazolam Blood 2.570 2.01 0.00 1.38 2.2629 0 13, 0.36 0.41
Midazolam Serum 2.570 2.01 0.00 1.38 2.2629 0 14, 0.40 0.41
Miloxacin Plasma 2.000 1.81 0.36 1.38 1.6675 1 33, -0.92 -1.39
Mirtazapine Blood 2.090 1.73 0.00 1.37 2.1109 0 22 , 0.53 0.44
Morphine Plasma 2.120 1.88 0.49 1.83 2.0648 0 3, 8 -0.65 -0.25
MSP Blood 2.300 3.14 0.00 1.98 3.1462 0 29, 0.46 -0.20
Nalidixic acid Plasma 1.558 1.80 0.59 1.25 1.6999 1 6 , -0.66 -1.54
Nevirapine Plasma 2.780 2.22 0.30 1.44 1.9946 0 15,27 0.00 -0.13
Nicotine Plasma 0.865 0.88 0.00 1.09 1.3710 0 33, 0.32 0.51
Northioridazine Serum 2.820 1.94 0.21 1.19 2.7608 0 23, 0.75 0.79
o-Ethoxybenzamide (A 1-5) Plasma 0.914 1.51 0.49 0.80 1.3133 0 1, -0.05 -0.22
Olanzapine Plasma 2.450 1.40 0.23 1.75 2.3742 0 4, 0.78 0.61
Orgl3011 Blood 1.070 1.98 0.00 1.96 2.6577 0 22 , 0.16 0.16
Org30526 Blood 2.000 1.52 0.13 0.83 1.9515 0 22 , 0.39 0.64
Org32104 Blood 2.130 2.00 0.30 1.20 2.1696 0 22 , 0.52 0.15
Org34167 Blood 1.801 1.87 0.25 1.12 2.0924 0 22 , 0.00 0.21
Org4428 (Beloxepin) Blood 2.080 1.50 0.25 1.12 2.3105 0 22 , 0.82 0.70
Org5222 Blood 1.960 1.80 0.00 0.86 2.0924 0 22 , 1.03 0.59
Oxazepam Blood 2.350 1.10 0.45 1.60 1.9917 0 13, 0.61 0.48
Oxazepam Serum 2.350 1.10 0.45 1.60 1.9917 0 14, 0.55 0.48
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Paracetamol (Acetaminophen) Blood 1.060 1.63 1.04 0.86 1.1724 0 13, -0.31 -0.79
Pentazocine Plasma 1.400 1.15 0.60 1.25 2.4464 0 6 , 33 0.64 0.63
Pentobarbital (5-Ethyl-5-( 1 -methylbutyl)barbital) Blood 1.030 1.11 0.47 1.23 1.7966 0 13, 0.12 0.25
Pentobarbital (5-Ethyl-5-( 1 -metbylbutyl)barbital) Serum 1.030 1.11 0.47 1.23 1.7966 0 16, 0.16 0.25
Phenylbutazone Blood 1.846 2.62 0.00 1.28 2.4329 0 18, -0.52 -0.04
Phenytoin Plasma 1.713 2.19 0.85 1.00 1.8693 0 6 , 33 -0.16 -0.57
Pindolol Blood 1.700 1.65 0.30 1.48 2.0090 0 30, -0.15 0.10
Pindolol Plasma 1.700 1.65 0.30 1.48 2.0090 0 30, -0.12 0.10
p-Phenylbenzoic acid Plasma 1.480 1.30 0.59 0.50 1.5395 1 6 , -1.26 -0.93
Promazine Blood 2.050 1.70 0.00 1.01 2.2832 0 13, 1.23 0.74
Promazine Plasma 2.050 1.70 0.00 1.01 2.2832 0 19, 0.67 0.74
Propofol Plasma 0.815 0.88 0.32 0.51 1.6205 0 33, 0.91 0.71
Propranolol (Propanolol) Plasma 1.840 1.43 0.44 1.31 2.1480 0 1, 0.96 0.38
Pyrene Plasma 2.808 1.71 0.00 0.28 1.5846 0 26, 0.23 0.74
R-Etodolac Plasma 1.803 2.17 1.05 1.15 2.2390 1 6 , -1.51 -1.70
Risperidone Blood 2.830 2.45 0.00 2.34 3.0395 0 22 , -0.02 0.20
Salicylic acid Plasma 0.890 0.84 0.71 0.38 0.9904 1 6 , -1.22 -1.08
Salicylic acid (2-Hydroxybenzoic acid) Blood 0.890 0.84 0.71 0.38 0.9904 1 13, -1.10 -1.08
S-Etodolac Plasma 1.803 2.17 1.05 1.15 2.2390 1 6 , -1.34 -1.70
SKB15 (C12H I3BrN402S) Blood 2.360 2.36 0.40 1.60 2.1793 0 11, -0.67 -0.34
SKB16 (C12H14N402S) Blood 2.070 2.30 0.70 1.70 2.0043 0 11, -0.66 -0.72
SKB17 (C19H20N4O2S) Blood 2.671 2.68 0.40 1.83 2.7530 0 11, -0.12 -0.25
SKB 19 (C10H10N4S) Blood 1.906 1.52 0.75 0.94 1.6051 0 11, -0.18 -0.10
SKB20 (C10H11N5S) Blood 2.245 1.95 0.98 1.24 1.7050 0 11, -1.15 -0.60
499
SKB22 (C12H13N50S) Blood 2.776 2.92 1.25 1.61 2.0024 0 11, -1.57 -1.41
SKB23 (C13H14N8S) Blood 2.845 2.55 1.46 1.80 2.2980 0 11, -1.54 -1.15
SKB24 (C14H20N4O3S) Blood 1.960 3.28 0.26 1.55 2.3870 0 11, - 1.12 -0.87
SKB25 (C21H26N403S) Blood 2.561 2.63 0.40 2.08 3.1365 0 11, -0.73 -0.08
SKB26 (C17H I8N403) Blood 2.321 2.25 0.46 1.67 2.4094 0 11, -0.27 -0.18
SKB29 (C18H19N502) Blood 2.591 2.51 0.46 2.05 2.5484 0 11, -0.28 -0.41
SKB30 (C17H26N202) Blood 1.409 2.40 0.40 1.65 2.4317 0 11, -0.46 -0.39
SKB31 (C22H28N202) Blood 2.009 2.54 0.35 1.66 2.8986 0 11, -0.24 -0.05
SKB34 (C15H23N02) Blood 1.255 1.52 0.37 1.41 2.0931 0 11, -0.02 0.16
SKB36 (C20H27N3O) Blood 1.989 2.30 0.20 1.35 2.7009 0 11, 0.69 0.25
SKB37 (C18H25N30S) Blood 2.159 2.34 0.28 1.53 2.6256 0 11, 0.44 0.06
SKB42 (C22H27N302) Blood 2.694 2.69 0.40 1.40 2.8898 0 11, 0.22 0.04
SKF 101468 Blood 1.340 1.35 0.55 1.32 2.2321 0 12, 0.25 0.32
SKF 89124 Blood 1.530 1.86 0.87 1.60 2.2908 0 12, -0.43 -0.35
Spiperone Blood 2.240 2.80 0.24 1.96 3.0053 0 29, 0.26 -0.20
Stavudine Plasma 1.257 1.76 0.75 1.61 1.5628 0 27, -0.48 -0.74
Sulforidazine Serum 2.720 2.86 0.00 1.63 3.0191 0 23, 0.18 0.17
Theobromine (3,7-Dimethylxanthine) Plasma 1.500 1.60 0.50 1.38 1.2223 0 17, -0.30 -0.52
Theophylline (1,3-Dimethylxanthine) Blood 1.500 1.60 0.54 1.34 1.2223 0 13, -0.29 -0.53
Theophylline ( 1,3-Dimethylxanthine) Plasma 1.500 1.60 0.54 1.34 1.2223 0 17, 0.21 -0.53
Thiopental (Thiopentone) Plasma 1.480 1.36 0.55 1.04 1.9014 0 6 , -0.15 0.25
Thiopental (Thiopentone) Serum 1.480 1.36 0.55 1.04 1.9014 0 16, -0.14 0.25
Thioridazine Blood 2.700 2.10 0.00 1.30 2.9017 0 13, 0.24 0.83
Thioridazine Serum 2.700 2.10 0.00 1.30 2.9017 0 23, 0.15 0.83
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Thioridazine Plasma 2.700 2.10 0.00 1.30 2.9017 0 31,33 0.46 0.83
Tiotidine (SKB 10) Blood 2.305 1.98 1.18 2.23 2.2760 0 11, -0.82 -0.82
Toliprolol Blood 1.050 1.16 0.15 1.40 1.9199 0 30, 0.47 0.45
Toliprolol Plasma 1.050 1.16 0.15 1.40 1.9199 0 30, 0.09 0.45
Triazolam Serum 2.640 2.20 0.00 1.65 2.3265 0 14, 0.74 0.19
Trifluroperazine Blood 2.000 1.80 0.00 1.50 2.8911 0 13, 1.44 0.84
Valproic acid Plasma 0.140 0.57 0.60 0.50 1.3102 1 6 , -1.15 -0.77
Valproic acid Blood 0.140 0.57 0.60 0.50 1.3102 1 13, -0.22 -0.77
Y-G 14 Blood 0.750 1.00 0.08 1.08 1.1978 0 12, -0.30 0.22
Y-G 15 Blood 0.750 0.80 0.00 1.25 1.3387 0 12, -0.06 0.45
Y-G 16 Blood 0.970 1.20 0.16 0.89 0.9816 0 12, -0.42 -0.01
Zidovudine (AZT) Plasma 1.830 1.70 0.47 1.83 1.8192 0 15,27 -0.70 -0.32
Zolantidine (SKB41) Blood 2.689 2.64 0.40 1.38 2.9946 0 11, 0.14 0.16
OUTLIERS
SKB 13 (C12H16BrN5S) Blood 1.900 1.88 0.43 1.81 2.2703 0 11, -2.15 -0.20
Y-G 19 Blood 1.571 1.70 0.16 0.95 1.5894 0 12, -1.30 0.15
SKB4 Blood 3.170 2.52 0.35 2.50 3.4468 0 11, -1.30 -0.04
Fluphenazine Serum 2.160 2.30 0.26 1.80 3.0907 0 23, 1.49 0.24
Fluphenazine Plasma 2.160 2.30 0.26 1.80 3.0907 0 33, 1.49 0.24
Y-G 20 Blood 1.390 1.65 0.16 1.24 1.2869 0 12, -1.40 -0.21
Org12962 Blood 1.100 1.15 0.26 0.93 1.6463 0 22 , 1.64 0.47
Temelastine Blood 2.960 3.24 0.60 2.00 3.0660 0 21 , - 1.88 -0.72
Icotidine (SKB3) Blood 2.740 3.30 0.50 2.27 2.9711 0 11, -2.00 -0.89
Ranitidine (SKB9) Blood 1.600 1.63 0.25 2.33 2.3985 0 11, 13 -1.23 -0.13
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2,4-Diclorophenoxyacetic acid (AI-4) Plasma 1.206 1.20 0.72 0.56 1.3761 1 33, 0.15 -0.94
Acetylsalicylic acid (Asprin) Blood 0.781 1.69 0.71 0.67 1.2879 1 13, -0.50 -1.57
Terbinafine Plasma 1.891 1.38 0.00 1.03 2.6061 0 10, 0.08 1.13
Promazine Serum 2.050 1.70 0.00 1.01 2.2832 0 23, 1.80 0.75
Paraxan thine Plasma 1.930 1.84 0.37 1.38 1.2223 0 17, 0.57 -0.48
Ref = Literature reference
Note the log BB data is for rats only
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Table 22.0. Drug data set used in this model to obtain model to predict blood (or
plasma) to fat distributions in rats.
SOLUTE NAME SAMPLE FAT REF LOG P (B:F)
Biperiden Plasma 2 , 1.76
Cocaine Plasma 5, 0.83
Daidzein Blood 4, -0.54
Fentanyl Plasma 2 , 1.43
Hexobarbital Plasma 2 , 0.20
Midazolam Plasma 1 ,2 0.95
Midazolam Blood 1, 0.93
Nalidixic acid Plasma 2 , - 1.00
Pentazocine Plasma 2 , 0.40
Phenobarbital Plasma 2 , -0.52
Phenytoin Plasma 2 , 0.26
p-Phenylbenzoic acid Plasma 2 , -1.23
Procainamide Plasma 2 , -0.89
Pyrene Plasma 3, 1.07
R-Etodolac Plasma 2 , -1.17
S-Etodolac Plasma 2 , -0.77
Thiopental (Thiopentone) Plasma 2 , 0.89
Valproic acid Plasma 2 , -0.82
Descriptors E, S, A, B, V and la for the rest of the solutes are found in table 21.0 (from chapter 21) 
and table 25.0 (from chapter 25).
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Table 23.0. Drug data set used in this model to obtain model to predict blood (or
plasma) to heart distributions in rats.
SOLUTE NAME SAMPLE REF
HEART 
LOG P (B/P:H) CALC
1 -(3-Fluoropropyl)-2-nitroimidazole (FPN) Blood 11, -0.02 -0.14
1 -(8-fluorooctyl)-2-nitroimidazole (FON) Blood 11, -0.05 -0.07
5-Methyl-5-ethyl barbituric acid Plasma 6 , -0.26 0.24
5-Ethyl-5-ethyl barbituric acid (Barbital) Plasma 6 , -0.16 0.27
5-Propyl-5-ethyl barbituric acid Plasma 6 , 0.03 0.28
5-Butyl-5-ethyl barbituric acid (Butethal) Plasma 6 , 0.27 0.29
5-Pentyl-5-ethyl barbituric acid Plasma 6 , 0.37 0.31
5-Hexyl-5-ethyl barbituric acid Plasma 6 , 0.36 0.32
5-Heptyl-5-ethyl barbituric acid Plasma 6 , 0.21 0.33
5-Octyl-5-ethyl barbituric acid Plasma 6 , 0.21 0.35
5-Nonyl-5-ethyl barbituric acid Plasma 6 , 0.59 0.36
AI-6 Plasma 9, 0.98 0.45
AI-9 (YH1885) Plasma 10, 0.20 0.36
Biperiden Plasma 1,5 0.85 0.57
Cocaine Plasma 8 , 0.60 0.07
Cefazolin Plasma 1,5 -0.96 -0.86
Cotinine Plasma 1, -0.32 0.06
Diazepam Plasma 1 ,2 0.36 0.38
Digoxin Plasma 1, 0.13 0.32
Dicloxacillin Plasma 1,5 -1.14 -0.72
Doxorubicin Plasma 15, 0.76 0.59
Fentanyl Plasma 1, 5 0.66 0.34
Fluoromisonidazole (1 -(3-Fluoro-2- 
hydroxyproyl-2-ni troimidazol e)(FM ISO) Blood 11, 0.04 -0.05
Fluoxetine Plasma 14, 0.09 0.19
Glycyrrhetinic acid Plasma 1, -0.92 -0.65
Hexobarbital Plasma 1,5 0.11 0.30
Lorazepam Plasma 7, 0.60 0.72
Midazolam Plasma 3 ,4 ,5 0.62 0.36
Midazolam Blood 4, 0.59 0.36
Nalidixic acid Plasma 5, -0.31 -0.79
Nicotine Plasma 1, 0.10 0.23
N-Acetylprocainamide (Acecainamide) Plasma 1, 0.34 0.25
o-Ethoxybenzamide (AI-5) Plasma 1, 0.01 0.06
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Pentazocine Plasma 1,5 0.73 0.50
PenicillinV Plasma 1,5 - 1.01 -0.50
Phenobarbital Plasma 1,5 0.06 0.25
Phenytoin Plasma 1,5 -0.15 0.15
Pindolol Blood 13, 0.22 0.30
Pindolol Plasma 13, 0.26 0.30
p-Phenylbenzoic acid Plasma 1,5 -0.64 -0.68
Propranolol (Propanolol) Plasma 2 , 0.70 0.45
Procainamide Plasma 1,5 0.40 0.03
Pyrene Plasma 12, 0.27 0.41
R-Etodolac Plasma 5, -0.74 -0.74
R-Carvedilol Plasma 5, 0.54 0.47
Salicylic acid (2-Hydroxybenzoic acid) Plasma 5, -0.72 -0.70
S-Carvedilol Plasma 5, 0.87 0.47
S-Etodolac Plasma 5, -0.35 -0.74
Terbinafine Plasma 16, 0.26 0.43
Thiopental (Thiopentone) Plasma 1,5 0.07 0.36
Thioridazine Plasma 14, 0.26 0.41
Toliprolol Blood 13, 0.40 0.27
Toliprolol Plasma 13, 0.03 0.27
Valproic acid Plasma 5, -0.37 -0.78
REF -- reference
LOG P (rat data for blood or plasma to heart distribution)
Doxorubicin: E = 3.630, S = 3.50, A = 1.30, B = 3.64, V= 3.7284 and la = 0 
N-Acetylprocainamide: E = 1.389, S = 1.75, A = 0.42, B = 1.95, V= 2.3153 and la = 0 
Descriptors E, S, A, B, V and la for the rest of the solutes are found in table 21.0 (from chapter 21) 
and table 25.0 (from chapter 25).
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Table 24.0. Drug data set used in this model to obtain a model to predict blood
(plasma or serum) to lung distributions in rats.
SOLUTE NAME SAMPLE LUNG REF LOG P (B:L) CALC
5-Methyl-5-ethyl barbituric acid Plasma 14, -0.21 0.20
5-Ethyl-5-ethyl barbituric acid (Barbital) Plasma 14, 0.00 0.24
5-Propyl-5-ethyl barbituric acid Plasma 14, 0.16 0.29
5-Butyl-5-ethyl barbituric acid (Butethal) Plasma 14, 0.18 0.33
5-Pentyl-5-ethyl barbituric acid Plasma 14, 0.22 0.38
5-Hexyl-5-ethyl barbituric acid Plasma 14, 0.08 0.42
5-Heptyl-5-ethyl barbituric acid Plasma 14, 0.12 0.47
5-Octyl-5-ethyl barbituric acid Plasma 14, 0.49 0.51
5-Nonyl-5-ethyl barbituric acid Plasma 14, 0.35 0.56
Acebutalol (Acebutolol) Blood 7, 0.73 0.42
AI-2 (SCH442416) Blood 2 , 0.62 0.69
AI-6 Plasma 5, 0.60 0.11
AI-9 (YH1885) Plasma 18, 1.34 0.69
Antenolol Blood 7, 0.28 0.44
Azithromycin Serum 4, 2.08 1.85
Cocaine Plasma 6 , 20 1.06 0.80
Cefazolin Plasma 3, 13 -0.11 -0.36
Cotinine Plasma 3, -0.18 0.55
Diazepam Plasma 3, 10 0.53 0.76
Dicloxacillin Plasma 3, 13 -0.92 -0.28
Doxorubicin Plasma 9, 0.53 0.72
Erythromycin Serum 4, 1.62 1.68
Fentanyl Plasma 3, 13 1.14 1.10
Fluoxetine Plasma 1, 1.24 0.67
Glycyrrhetinic acid Plasma 3, -0.66 -0.15
Hexobarbital Plasma 3, 13 0.45 0.59
Hydroquinone
(1,4-Dihydroxybenzene) Blood 15, -0.16 -0.50
Lorazepam Plasma 16, 0.44 0.63
Metoprolol Blood 7, 1.06 0.84
Midazolam Plasma 11, 12, 13 0.65 0.79
Midazolam Blood 12, 0.62 0.79
Miloxacin Plasma 3, -0.29 -0.46
Nalidixic acid Plasma 13, -0.48 -0.65
Nicotine Plasma 3, 0.18 0.57
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o-Ethoxybenzamide (AI-5) Plasma 3, -0.01 0.05
Olanzapine Plasma 17, 1.43 0.86
Oxeprenolol Blood 7, 1.27 0.77
PenicillinV Plasma 3,13 -0.80 -0.39
Phenobarbital Plasma 3, 13 -0.06 0.07
Phenytoin Plasma 3, 13 -0.14 -0.06
Pindolol Blood 21 , 0.99 0.56
Pindolol Plasma 21 , 1.03 0.56
p-Phenylbenzoic acid Plasma 3, 13 -0.55 -0.80
Practolol Blood 7, 0.48 0.46
Pyrene Plasma 19, 0.35 0.35
Salicylic acid 
(2-Hydroxybenzoic acid) Plasma 13, -0.72 -1.02
Terbinafine Plasma 8, 0.41 0.90
Theophylline (1,3-Dimethylxanthine) Plasma 3, -0.15 0.12
Thiopental (Thiopentone) Plasma 3, 13 0.12 0.30
Thioridazine Plasma 1, 1.13 0.96
Toliprolol Blood 2 1 , 1.08 0.68
Toliprolol Plasma 21 , 0.70 0.68
Valproic acid Plasma 13, -0.38 -0.80
OUTLIERS
Propranolol (Propanolol) Plasma 10, 1.74 0.70
Propranolol (Propanolol) Blood 7, 1.53 0.65
Pentazocine Plasma 3, 13 1.43 0.61
Biperiden Plasma 3, 13, 1.79 0.99
REF = reference
LOG P (rat data for blood, plasma or serum to lung distribution)
Acebutalol: E = 1.600, S = 2.42, A = 0.90, B = 2.10, V= 2.7556 and la = 0 
Azithromycin: E = 2.242, S — 3.20, A = 1.19, B = 4.90, V= 5.9980 and la = 0 
Doxorubicin: E = 3.630, S = 3.50, A = 1.30, B = 3.64, V= 3.7284 and la = 0 
Erythromycin: E = 2.900, S = 3.73, A = 1.25, B = 4.96, V= 5.7730 and la = 0 
Hydroquinone: E = 1.063, S = 1.27, A = 1.06, B = 0.57, V= 0.8338 and la = 0 
Metoprolol: E = 1.170, S = 1.33, A = 0.17, B = 1.76, V= 2.2604 and la = 0 
Oxeprenolol: E = 1.310, S = 1.49, A = 0.17, B = 1.62, V== 2.2174 and la = 0 
Practolol: E = 1.450, S = 1.90, A = 0.60, B = 1.84, V= 2.1763 and la = 0
Descriptors E, S, A, B, V and la for the rest of the solutes are found in table 21.0 (from chapter 21) 
and table 25.0 (from chapter 25).
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Table 25.0. Drug data set used in this model to obtain a model to predict blood (or plasma) to muscle distributions in rats.
SOLUTE NAME E S A B V I SAMPLE
MUSCLE
REF
LOG P 
(B:M) CALC
3,3',5,5'-Tetrachlorobiphenyl 1.960 1.44 0.00 0.11 1.8138 0 Blood 12, 0.00 0.18
4-Chlorobiphenyl 1.500 1.05 0.00 0.18 1.4466 0 Blood 13, 0.00 0.17
4,4'-Dichlorobiphenyl 1.640 1.18 0.00 0.16 1.5690 0 Blood 13, 0.30 0.17
2,2',4,5,5'-Pentachlorobiphenyl 2.040 1.61 0.00 0.13 1.9362 0 Blood 13, 0.00 0.19
2,2',4,4', 5,5 ’-Hexachlorobiphenyl 2.180 1.74 0.00 0.11 2.0586 0 Blood 13, 0.60 0.20
5-Methyl-5-ethyl barbituric acid 1.030 1.17 0.46 1.18 1.2330 0 Plasma 7, -0.22 0.09
5-Ethyl-5-ethyl barbituric acid (Barbital) 1.030 1.14 0.47 1.18 1.3739 0 Plasma 7, -0.09 0.10
5-Propyl-5-ethyl barbituric acid 1.030 1.14 0.47 1.18 1.5148 0 Plasma 7, 0.14 0.11
5-Butyl-5-ethyl barbituric acid (Butethal) 1.030 1.14 0.47 1.18 1.6557 0 Plasma 7, 0.12 0.13
5-Pentyl-5-ethyl barbituric acid 1.030 1.14 0.47 1.18 1.7966 0 Plasma 7, 0.29 0.15
5-Hexyl-5-ethyl barbituric acid 1.030 1.14 0.47 1.18 1.9375 0 Plasma 7, 0.31 0.16
5-Heptyl-5-ethyl barbituric acid 1.030 1.14 0.47 1.18 2.0784 0 Plasma 7, 0.16 0.18
5-Octyl-5-ethyl barbituric acid 1.030 1.14 0.47 1.18 2.2193 0 Plasma 7, -0.09 0.19
5-Nonyl-5-ethyl barbituric acid 1.030 1.14 0.47 1.18 2.3602 0 Plasma 7, 0.10 0.21
AI-2 (SCH442416) 3.988 3.20 0.25 1.69 2.7696 0 Blood 1, -0.05 0.17
AI-6 2.250 1.96 0.95 1.97 1.6648 0 Plasma 9, 0.43 -0.03
Biperiden 1.850 1.25 0.31 1.57 2.6196 0 Plasma 2 , 6 0.49 0.24
Cocaine 1.355 1.92 0.00 1.50 2.2977 0 Plasma 8 , 0.60 0.31
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Cefazolin 3.620 4.00 0.75 2.68 2.8265 1 Plasma 2 , 6 -0.94 -0.92
Clobazam 2.200 2.71 0.00 1.29 2.1326 0 Plasma 2 , 0.41 0.25
Cotinine 1.049 1.49 0.00 1.38 1.3867 0 Plasma 2 , -0.05 0.23
Daidzein 2.170 2.05 0.92 1.13 1.7871 0 Blood 15, 0.08 -0.03
Diazepam 2.078 1.55 0.00 1.28 2.0739 0 Plasma 2,3 0.15 0.24
2,3-Dideoxyinosine (Didanosine) 1.810 1.78 0.58 1.90 1.5951 0 Plasma 2 , -0.16 0.08
Digoxin 4.240 5.70 1.80 5.25 6.2117 0 Plasma 2 , 0.15 0.27
Dicloxacillin 2.900 3.05 0.70 2.04 3.0085 1 Plasma 2 , 6 -1.30 -0.87
Fentanyl 1.830 1.75 0.00 1.81 2.8399 0 Plasma 2 , 6 0.49 0.35
Fluoxetine 1.000 1.30 0.10 0.93 2.2403 0 Plasma 17, 0.44 0.28
Flurazepam 2.040 1.68 0.00 1.90 2.8959 0 Plasma 2 , 0.69 0.35
Glycyrrhetinic acid 1.560 2.17 0.93 1.60 3.8984 1 Plasma 2 , - 1.00 -0.77
Hexobarbital 1.500 1.37 0.17 1.37 1.7859 0 Plasma 2 , 6 -0.11 0.20
Medazepam 1.898 1.77 0.00 0.89 2.0582 0 Plasma 2 , 0.34 0.24
Methotrexate 4.000 3.70 1.60 3.37 3.2197 1 Plasma 10, -0.82 -1.09
Midazolam 2.570 2.01 0.00 1.38 2.2629 0 Plasma 4, 5,11 0.11 0.24
Midazolam 2.570 2.01 0.00 1.38 2.2629 0 Blood 5, 0.08 0.24
Morphine 2.120 1.88 0.49 1.83 2.0648 0 Plasma 6 , 0.40 0.13
Nalidixic acid 1.558 1.80 0.59 1.25 1.6999 1 Plasma 6 , -0.44 -0.94
Nicotine 0.865 0.88 0.00 1.09 1.3710 0 Plasma 2 , 0.19 0.22
o-Ethoxybenzamide (AI-5) 0.914 1.51 0.49 0.80 1.3133 0 Plasma 2 , -0.09 0.09
Pentazocine 1.400 1.15 0.60 1.25 2.4464 0 Plasma 2 , 6 0.77 0.16
PenicillinV 2.200 1.90 0.80 1.89 2.4358 1 Plasma 2 , 6 - 1.22 -0.93
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Pentobarbital (5-Ethyl-5-( 1 -methylbutyl)barbital) 1.030 1.11 0.47 1.23 1.7966 0 Plasma 2 , -0.10 0.15
Phenobarbital 1.630 1.80 0.73 1.15 1.6999 0 Plasma 2 , 6 0.06 0.04
Phenytoin 1.713 2.19 0.85 1.00 1.8693 0 Plasma 2 , 6 -0.16 0.02
p-Phenylbenzoic acid 1.480 1.30 0.59 0.50 1.5395 1 Plasma 2 , 6 - 1.10 -0.98
p,p'-Dichlorodiphenylsulfone 1.880 2.20 0.00 0.54 1.8499 0 Blood 16, 0.58 0.21
Propranolol (Propanolol) 1.840 1.43 0.44 1.31 2.1480 0 Plasma 3, 0.34 0.15
Procainamide 1.268 2.15 0.57 1.50 2.0178 0 Plasma 2 , 6 0.49 0.15
Prazepam 2.486 1.90 0.00 1.29 2.3880 0 Plasma 2 , 0.26 0.25
Pyrene 2.808 1.71 0.00 0.28 1.5846 0 Plasma 14, 0.20 0.11
R-Carvedilol 3.152 2.83 0.84 1.96 3.1032 0 Plasma 6 , -0.10 0.11
Salicylic acid (2-Hydroxybenzoic acid) 0.890 0.84 0.71 0.38 0.9904 1 Plasma 2 , 6 -0.85 -1.04
S-Carvedilol 3.152 2.83 0.84 1.96 3.1032 0 Plasma 6 , 0.20 0.11
Terbinafine 1.891 1.38 0.00 1.03 2.6061 0 Plasma 11, 0.00 0.30
Tetracycline 3.500 3.50 0.69 3.29 3.0992 0 Plasma 2 , 0.29 0.17
Theophylline (1,3-Dimethylxanthine) 1.500 1.60 0.54 1.34 1.2223 0 Plasma 2 , -0.22 0.05
Thiopental (Thiopentone) 1.480 1.36 0.55 1.04 1.9014 0 Plasma 2 , 6 -0.12 0.11
Thioridazine 2.700 2.10 0.00 1.30 2.9017 0 Plasma 17, 0.26 0.30
Thiobarbital 1.407 1.18 0.50 1.10 1.4787 0 Plasma 2 , -0.22 0.08
Valproic acid 0.140 0.57 0.60 0.50 1.3102 1 Plasma 6 , -0.80 -0.93
REF = reference
LOG P (rat data for blood and plasma to muscle distribution)
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Table 26.0. Drug data set used in this model to obtain a model to predict blood
(plasma or serum) to liver distributions in rats.
SOLUTE NAME SAMPLE
LIVER
REF
LOG P 
(B:L) CALC
1 -(3-Fhioropropyl)-2-nitroimidazole (FPN) Blood 15, 0.92 0.29
1 -(8-fluorooctyl)-2-nitroimidazole (FON) Blood 15, 0.47 0.43
3,3', 5,5 '-T etrachlorobiphenyl Blood 16, 0.78 0.48
4-Chlorobiphenyl Blood 17, 0.00 0.40
4,4'-Dichlorobiphenyl Blood 17, 0.48 0.42
2,2',4,5,5'-Pentachlorobiphenyl Blood 17, 0.78 0.51
2,2',4,4',5,5'-Hexachlorobiphenyl Blood 17, 1.08 0.53
5-Methyl-5-ethyl barbituric acid Plasma 9, 0.44 0.31
5-Ethyl-5-ethyl barbituric acid (Barbital) Plasma 9, 0.57 0.34
5-Propyl-5-ethyl barbituric acid Plasma 9, 0.47 0.37
5-Butyl-5-ethyl barbituric acid (Butethal) Plasma 9, 0.47 0.39
5-Pentyl-5-ethyl barbituric acid Plasma 9, 0.51 0.42
5-Hexyl-5-ethyl barbituric acid Plasma 9, 0.44 0.45
5-Heptyl-5-ethyl barbituric acid Plasma 9, 0.15 0.48
5-Octyl-5-ethyl barbituric acid Plasma 9, 0.21 0.50
5-Nonyl-5-ethyl barbituric acid Plasma 9, 0.33 0.53
AI-2 (SCH442416) Blood 1, 0.94 0.94
AI-6 Plasma 3, 0.58 0.46
AI-9 (YH1885) Plasma 7, 1.10 0.77
Azithromycin Serum 2 , 2.20 1.58
Cocaine Plasma 14, 19 0.08 0.68
Cefazolin Plasma 8 , -0.10 -0.02
Daidzein Blood 20 , 0.06 0.35
Dicloxacillin Plasma 8 , -0.37 -0.07
Doxorubicin Plasma 4, 0.64 1.06
Erythromycin Serum 2 , 1.43 1.57
Fentanyl Plasma 8 , 0.58 0.90
Fluoromisonidazole
(1 -(3-Fluoro-2-hydroxyproyl-2-nitroirnidazole) 
(FMISO) Blood 15, 0.28 0.35
Fluoxetine Plasma 22 , 0.77 0.56
Hexobarbital Plasma 8 , 0.78 0.57
Hydroquinone (1,4-Dihydroxybenzene) Blood 11, -0.12 -0.02
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Lorazepam Plasma 12, 1.08 0.72
Methotrexate Plasma 10, 0.48 0.00
Midazolam Plasma 5, 6 , 8 0.77 0.79
Midazolam Blood 6 , 0.57 0.79
Morphine Plasma 8 , 0.08 0.64
Nalidixic acid Plasma 8 , -0.23 -0.48
Olanzapine Plasma 23, 1.33 0.83
Pentazocine Plasma 8 , 0.36 0.57
PenicillinV Plasma 8 , -0.60 -0.23
Phenobarbital Plasma 8 , 0.26 0.35
Phenytoin Plasma 8 , 0.36 0.30
p-Phenylbenzoic acid Plasma 8 , -0.46 -0.59
Procainamide Plasma 8 , 0.51 0.44
Pyrene Plasma 18, 0.37 0.54
R-Etodolac Plasma 8 , -0.92 -0.52
R-Carvedilol Plasma 8 , 0.64 0.81
Salicylic acid (2-Hydroxybenzoic acid) Plasma 8 , -0.64 -0.78
S-Carvedilol Plasma 8 , 1.08 0.81
S-Etodolac Plasma 8 , -0.37 -0.52
Terbinafine Plasma 13, 0.18 0.77
Thiopental (Thiopentone) Plasma 8 , 0.36 0.44
Thioridazine Plasma 2 2 , 0.94 0.91
OUTLIERS
p,p'-Dichlorodiphenylsulfone Blood 2 1 , 1.34 0.52
Valproic acid Plasma 8 , 0.26 -0.57
REF = reference
LOG P (rat data for blood, plasma or serum to liver distribution)
Azithromycin: E = 2.242, S = 3.20, A = 1.19, B = 4.90, V= 5.9980 and la = 0
Doxorubicin: E = 3.630, S = 3.50, A : 1.30, B = 3.64, V= 3.7284 and la = 0
Erythromycin: E = 2.900, S = 3.73, A = 1.25, B = 4.96, V= 5.7730 and la = 0
Hydroquinone: E = 1.063, S = 1.27, A = 1.06, B = 0.57, V= 0.8338 and la = 0
Descriptors E, S, A, B, V and la for the rest of the solutes are found in table 21.0 (from chapter 21)
and table 25.0 (from chapter 25)
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Table 27.0. Data set used in this model to obtain model to predict drug blood (&
plasma) to skin distributions in rats
COMPOUND NAME SAMPLE REF
SKIN 
LOG BSa
CALC 
LOG BSa
2,2',4,4',5,5'-Hexachlorobiphenyl BLOOD 9 1.48 1.05
2,2',4,5,5'-Pentachlorobiphenyl BLOOD 9 0.85 1.00
3,3',5,5'-Tetrachlorobiphenyl BLOOD 10 0.85 0.98
4,4'-Dichlorobiphenyl BLOOD 9 1.00 0.87
4-Chlorobiphenyl BLOOD 9 1.00 0.83
5-Butyl-5-ethyl barbituric acid (Butethal) PLASMA 8 0.14 0.12
5-Heptyl-5-ethyl barbituric acid PLASMA 8 0.04 0.18
5-Hexyl-5-ethyl barbituric acid PLASMA 8 0.42 0.16
5-Methyl-5-ethyl barbituric acid PLASMA 8 0.05 0.07
5-Nonyl-5-ethyl barbituric acid PLASMA 8 0.31 0.21
5-Octyl-5-ethyl barbituric acid PLASMA 8 0.09 0.20
5-Pentyl-5-ethyl barbituric acid PLASMA 8 0.05 0.14
5-Propyl-5-ethyl barbituric acid PLASMA 8 0.19 0.10
Acrylic acid BLOOD 12 0.01 -0.49
Barbital
(5-Ethyl-5-ethyl barbituric acid) PLASMA 8 0.08 0.08
Biperiden PLASMA 2 ,7 0.60 0.20
Cefazolin PLASMA 2 ,7 -0.53 -0.84
Decane BLOOD 11 0.68 0.73
Diazepam PLASMA 2 ,4 0.54 0.46
Fentanyl PLASMA 7 0.32 0.30
Glycyrrhetinic acid PLASMA 2 -0.80 -0.55
Hexobarbital PLASMA 2 ,7 -0.03 0.24
Midazolam PLASMA
5, 6 , 
7 0.15 0.51
Midazolam BLOOD 6 , 0.11 0.51
Nalidixic acid PLASMA 7 -0.46 -0.55
Nicotine PLASMA 2 0.04 0.31
o-Ethoxybenzamide (AI-5) PLASMA 2 ,4 0.02 0.27
p,p'-Dichlorodiphenylsulfone BLOOD 1, 1.21 0.83
Pentazocine PLASMA 2, 7 0.67 0.16
Phenobarbital PLASMA 2,7 0.14 0.12
Phenytoin PLASMA 2,7 -0.03 0.20
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p-Phenylbenzoic acid PLASMA 7 -0.82 -0.25
Salicylic acid PLASMA 2,7 -0.58 -0.40
Thiopental (Thiopentone) PLASMA 2 ,7 0.07 0.23
Valproic acid PLASMA 7 -0.33 -0.44
OULIERS
Terbinafine PLASMA 3 1.61 0.75
a blood (or plasma) to skin distribution of drugs
Acrylic acid: E = 0.357, S = 0.58, A = 0.60, B = 0.43, V= 0.5627 and la = 1 
Decane: E = 0.00, S = 0.00, A = 0.00, B = 0.00, V= 1.5176 and la = 0
Descriptors E, S, A, B, V and la for the rest of the solutes are found in table 21.0 (from chapter 21) 
and table 25.0 (from chapter 25).
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Table 28.0. Drug data set used in this model to obtain a model to predict blood
(plasma or serum) to kidney distributions in rats.
SOLUTE NAME SAMPLE REF
KIDNEY 
LOG P (B:K) CALC
1 -(3-Fluoropropyl)-2-nitroimidazole (FPN) Blood 16, 0.61 0.37
1 -(8-fluorooctyl)-2-nitroimidazole (FON) Blood 16, 0.47 0.59
5-Methyl-5-ethyl barbituric acid Plasma 12, 0.10 0.31
5-Ethyl-5-ethyl barbituric acid (Barbital) Plasma 12, 0.25 0.35
5-Propyl-5-ethyl barbituric acid Plasma 12, 0.59 0.40
5-Butyl-5-ethyl barbituric acid (Butethal) Plasma 12, 0.64 0.44
5-Pentyl-5-ethyl barbituric acid Plasma 12, 0.46 0.49
5-Hexyl-5-ethyl barbituric acid Plasma 12, 0.32 0.53
5-Heptyl-5-ethyl barbituric acid Plasma 12, 0.31 0.58
5-Octyl-5-ethyl barbituric acid Plasma 12, 0.40 0.62
5-Nonyl-5-ethyl barbituric acid Plasma 12, 0.93 0.66
AI-2 (SCH442416) Blood 2 , 0.67 0.70
AI-9 (YH1885) Plasma 10, 1.23 0.75
Azithromycin Serum 3, 2.19 2.00
Biperiden Plasma 11, 1.04 0.88
Cefazolin Plasma 11, 0.45 0.19
Daidzein Blood 19, -0.06 0.12
Diazepam Plasma 6 , 0.38 0.75
Dicloxacillin Plasma 11, 0.11 0.27
Doxorubicin Plasma 5, 0.71 0.89
Erythromycin Serum 3, 1.42 1.83
Fentanyl Plasma 11, 1.08 1.09
Fluoromisonidazole (1 -(3-Fluoro-2- 
hydroxyproyl-2-n itroi midazole)(FM 1 SO) Blood 16, 0.23 0.37
Fluoxetine Plasma 1, 0.97 0.73
Hexobarbital Plasma 11, 0.18 0.63
Hydroquinone (1,4-Dihydroxybenzene) Blood 13, -0.16 -0.25
Lorazepam Plasma 14, 0.62 0.64
Methotrexate Plasma 18, 0.48 0.08
Midazolam Plasma 7, 8, 11 0.66 0.77
Midazolam Blood 8 , 0.64 0.77
Morphine Plasma 11, 0.98 0.59
Nalidixic acid Plasma 11, -0.27 -0.09
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Olanzapine Plasma 9, 0.76 0.85
Pentazocine Plasma 11, 1.30 0.63
PenicillinV Plasma 11, 0.57 0.15
Phenobarbital Plasma 11, -0.14 0.23
Phenytoin Plasma 11, 0.20 0.15
p-Phenylbenzoic acid Plasma 11, -0.52 -0.24
p,p'-Dichlorodiphenylsulfone Blood 2 0 , 0.67 0.45
Propranolol (Propanolol) Plasma 6 , 0.58 0.59
Procainamide Plasma 11, 0.81 0.45
Pyrene Plasma 17, 0.38 0.35
R-Etodolac Plasma 11, -0.92 -0.21
R-Carvedilol Plasma 11, 0.43 0.64
Salicylic acid (2-Hydroxybenzoic acid) Plasma 11, -0.36 -0.43
S-Carvedilol Plasma 11, 0.85 0.64
S-Etodolac Plasma 11, -0.41 -0.21
Terbinafme Plasma 15, 0.45 0.89
Thiopental (Thiopental) Plasma 11, 0.49 0.41
Thioridazine Plasma 1, 1.19 0.94
Valproic acid Plasma 11, 0.18 -0.20
OUTLIERS
AI-6 Plasma 4, 1.71 0.50
REF = reference
LOG P (rat data for blood, plasma or serum to kidney distribution)
Azithromycin: E = 2.242, S = 3.20, A = 1.19, B = 4.90, V= 5.9980 and la = 0
Doxorubicin: E = 3.630, S = 3.50, A = 1.30, B = 3.64, V= 3.7284 and la -  0
Erythromycin: E = 2.900, S = 3.73, A = 1.25, B = 4.96, V= 5.7730 and la = 0
Hydroquinone: E = 1.063, S = 1.27, A = 1.06, B = 0.57, V= 0.8338 and la = 0
Descriptors E, S, A, B, V and la for the rest of the solutes are found in table 21.0 (from chapter 21)
and table 25.0 (from chapter 25).
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Structures for trivial names
517
Structures for VOCs
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